AU2009248993A1 - Triazine compounds as PI3 kinase and mTOR inhibitors - Google Patents

Triazine compounds as PI3 kinase and mTOR inhibitors Download PDF

Info

Publication number
AU2009248993A1
AU2009248993A1 AU2009248993A AU2009248993A AU2009248993A1 AU 2009248993 A1 AU2009248993 A1 AU 2009248993A1 AU 2009248993 A AU2009248993 A AU 2009248993A AU 2009248993 A AU2009248993 A AU 2009248993A AU 2009248993 A1 AU2009248993 A1 AU 2009248993A1
Authority
AU
Australia
Prior art keywords
phenyl
triazin
urea
morpholin
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2009248993A
Other versions
AU2009248993B2 (en
AU2009248993C1 (en
Inventor
Semiramis Ayral-Kaloustian
Zecheng Chen
Kevin J. Curran
Christoph M. Dehnhardt
Efren Guillermo Delos Santos
Osvaldo Dos Santos
Ariamala Gopalsamy
Joshua Aaron Kaplan
Tarek S. Mansour
David J. Richard
Mengxiao Shi
Aranapakam M. Venkatesan
Jeroen C. Verheijen
Arie Zask
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009248993(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2009248993A1 publication Critical patent/AU2009248993A1/en
Publication of AU2009248993B2 publication Critical patent/AU2009248993B2/en
Application granted granted Critical
Publication of AU2009248993C1 publication Critical patent/AU2009248993C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Description

WO 2009/143313 PCT/US2009/044774 TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS FIELD OF THE INVENTION This invention relates to 2,4,6-substituted [1,3,5]triazine compounds in which one substituent is an optionally substituted morpholino, tetrahydropyranyl or dihydropyranyl group, 5 which inhibit P13 kinase and mTOR, to processes for preparing them, to methods of treatment using them and to pharmaceutical compositions containing them.. BACKGROUND OF THE INVENTION Phosphatidylinositol (hereinafter abbreviated as "PI") is one of the phospholipids in cell membranes. In recent years it has become clear that PI plays an important role also in 10 intracellular signal transduction. It is well recognized in the art that PI (4,5) bisphosphate (PI(4,5)P2 or PIP2) is degraded into diacylglycerol and inositol (1,4,5) triphosphate by phospholipase C to induce activation of protein kinase C and intracellular calcium mobilization, respectively [M. J. Berridge et al., Nature, 312, 315 (1984); Y. Nishizuka, Science, 225, 1365 (1984)]. 15 Phosphatidylinositol-3 kinase ("PI3K") is an enzyme that phosphorylates the 3-position of the inositol ring of phosphatidylinositol [D. Whitman et al., Nature, 332, 664 (1988)]. Pluralities of P13K subtypes exist. Three major subtypes of PI3Ks have now been identified on the basis of their in vitro substrate specificity, and these three are designated class I (a & b), class 11, and class III [B. Vanhaesebroeck, Trend in Biol. Sci., 22, 267(1997)]. 20 The class la P13K subtype has been most extensively investigated to date. Within the class la subtype there are three isoforms (a, 0, & 6) that exist as hetero dimers of a catalytic 110-kDa subunit and regulatory subunits of 50-85kDa. The regulatory subunits contain SH2 domains that bind to phosphorylated tyrosine residues within growth factor receptors or adaptor molecules and thereby localize P13K to the inner cell membrane. At the inner cell membrane 25 P13K converts PIP2 to PIP3 (phosphatidylinositol-3,4,5-trisphosphate) that serves to localize the downstream effectors PDK1 and Akt to the inner cell membrane where Akt activation occurs. Activated Akt mediates a diverse array of effects including inhibition of apoptosis, cell cycle progression, response to insulin signaling, and cell proliferation. Class la P13K subtypes also contain Ras binding domains (RBD) that allow association with activated Ras providing another 30 mechanism for P13K membrane localization. Activated, oncogenic forms of growth factor receptors, Ras, and even P13K kinase have been shown to aberrantly elevate signaling in the P13K/Akt/mTOR pathway resulting in cell transformation. As a central component of the PI3K/Akt/mTOR signaling pathway P13K (particularly the class la a isoform) has become a major therapeutic target in cancer drug discovery. 35 Substrates for class I P13Ks are PI, PI(4)P and PI(4,5)P2, with PI(4,5)P2 being the most favored. Class I P13Ks are further divided into two groups, class la and class Ib, because of 1 WO 2009/143313 PCT/US2009/044774 their activation mechanism and associated regulatory subunits. The class lb P13K is p1 10y that is activated by interaction with G protein-coupled receptors. Interaction between p1 1y and G protein-coupled receptors is mediated by regulatory subunits of 110, 87, and 84 kDa. PI and PI(4)P are the known substrates for class II PI3Ks; PI(4,5)P2 is not a substrate 5 for the enzymes of this class. Class 11 P13Ks include P13K C2a, C2p and C2y isoforms, which contain C2 domains at the C terminus, implying that their activity is regulated by calcium ions. The substrate for class III PI3Ks is PI only. A mechanism for activation of the class III PI3Ks has not been clarified. Because each subtype has its own mechanism for regulating activity, it is likely that activation mechanism(s) depend on stimuli specific to each respective 10 class of PI3K. The compound P1103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2 yl)phenol) inhibits PI3Ka and P13Kg as well as the mTOR enzymes with IC50 values of 2, 3, and 50-80 nM respectively. I.P. dosing in mice of this compound in human tumor xenograft models of cancer demonstrated activity against a number of human tumor models, including the 15 glioblastoma (PTEN null U87MG), prostate (PC3), breast (MDA-MB-468 and MDA-MB-435) colon carcinoma (HCT 116); and ovarian carcinoma (SKOV3 and IGROV-1); (Raynaud et al, Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases, Cancer Res. 2007 67: 5840-5850). The compound ZSTK474 (2-(2-difluoromethylbenzoimidazol-1-yl)-4, 6-dimorpholino-1, 20 3,5-triazine) inhibits PI3Ka and P13Kg but not the mTOR enzymes with an IC 50 values of 16, 4.6 and >10,000 nM respectively (Dexin Kong and Takao Yamori, ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms, Cancer Science, 2007, 98:10 1638 1642). Chronic oral administration of ZSTK474 in mouse human xenograft cancer models, completely inhibited growth which originated from a non-small-cell lung cancer (A549), a 25 prostate cancer (PC-3), and a colon cancer (WiDr) at a dose of 400 mg/kg. (Yaguchi et al, Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor, J. NatI. Cancer Inst. 98: 545-556). The compound NVP-BEZ-235 (2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3 dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile) inhibits both PI3Ka and P13Kg as 30 well as the mTOR enzymes with IC5o values 4, 5, and "nanomolar". Testing in human tumor xenograft models of cancer demonstrated activity against human tumor models of prostrate (PC-3) and glioblastoma (U-87) cancer. It entered clinical trials in December of 2006 (Verheijen, J.C. and Zask, A., Phosphatidylinositol 3-kinase (P13K) inhibitors as anticancer drugs, Drugs Fut. 2007, 32(6): 537-547). 35 The compound SF-1126 (a prodrug form of LY-294002, which is 2-(4-morpholinyl)-8 phenyl-4H-1-benzopyran-4-one) is "a pan-PI3K inhibitor". It is active in preclinical mouse cancer models of prostrate, breast, ovarian, lung, multiple myeloma, and brain cancers. 2 WO 2009/143313 PCT/US2009/044774 (Verheijen, J.C. and Zask, A., Phosphatidylinositol 3-kinase (P13K) inhibitors as anticancer drugs, Drugs Fut. 2007, 32(6): 537-547). Although it seems clear that inhibition of the a isoform is essential for the antitumor activity of P13K inhibitors, it is not clear whether a more selective inhibitor of a particular P13K 5 isoform may lead to fewer unwanted biological effects. It has recently been reported that non PI3Ka class I isoforms (P13KP, 5 and y) have the ability to induce oncogenic transformation of cells, suggesting that nonisoform- specific inhibitors may offer enhanced therapeutic potential over specific inhibitors. Selectivity versus other related kinases is also an important consideration for the 10 development of P13K inhibitors. While selective inhibitors may be preferred in order to avoid unwanted side effects, there have been reports that inhibition of multiple targets in the PI3K/Akt pathway (e.g., PI3Ka and mTOR [mammalian target of rapamycin]) may lead to greater efficacy. It is possible that lipid kinase inhibitors may parallel protein kinase inhibitors in that nonselective inhibitors may also be brought forward to the clinic. 15 Mammalian Target of Rapamycin, mTOR, is a cell-signaling protein that regulates the response of tumor cells to nutrients and growth factors, as well as controlling tumor blood supply through effects on Vascular Endothelial Growth Factor, VEGF. Inhibitors of mTOR starve cancer cells and shrink tumors by inhibiting the effect of mTOR. All mTOR inhibitors bind to the mTOR kinase. This has at least two important effects. First, mTOR is a downstream 20 mediator of the PI3K/Akt pathway. The PI3K/Akt pathway is thought to be over activated in numerous cancers and may account for the widespread response from various cancers to mTOR inhibitors. The over-activation of the upstream pathway would normally cause mTOR kinase to be over activated as well. However, in the presence of mTOR inhibitors, this process is blocked. The blocking effect prevents mTOR from signaling to downstream pathways that 25 control cell growth. Over-activation of the PI3K/Akt kinase pathway is frequently associated with mutations in the PTEN gene, which is common in many cancers and may help predict what tumors will respond to mTOR inhibitors. The second major effect of mTOR inhibition is anti angiogenesis, via the lowering of VEGF levels. In lab tests, certain chemotherapy agents were found to be more effective in the 30 presence of mTOR inhibitors. George, J.N., et al., Cancer Research, 61, 1527-1532, 2001. Additional lab results have shown that some rhabdomyosarcoma cells die in the presence of mTOR inhibitors. There are three mTOR inhibitors, which have progressed into clinical trials. These compounds are Wyeth's Torisel, also known as 42-(3-hydroxy-2-(hydroxymethyl)-rapamycin 2 35 methylpropanoate, CCI-779 or Temsirolimus; Novartis' Everolimus, also known as 42-0-(2 hydroxyethyl)-rapamycin, or RAD 001; and Ariad's AP23573 also known as 42 (dimethylphopsinoyl)-rapamycin. The FDA has approved Torisel for the treatment of advanced 3 WO 2009/143313 PCT/US2009/044774 renal cell carcinoma. In addition, Torisel is active in a NOS/SCID xenograft mouse model of acute lymphoblastic leukemia [Teachey et al, Blood, 107(3), 1149-1155, 2006]. On March 30, 2009, the U. S. Food and Drug Administration (FDA) approved Everolimus (AFINITOR
TM
) for the treatment of patients with advanced renal cell carcinoma. AP23573 has been given orphan 5 drug and fast-track status by the FDA for treatment of soft-tissue and bone sarcomas. The three mTOR inhibitors have non-linear, although reproducible pharmacokinetic profiles. Mean area under the curve (AUC) values for these drugs increase at a less than dose related way. The three compounds are all semi-synthetic derivatives of the natural macrolide antibiotic rapamycin. It would be desirable to find fully synthetic compounds, which inhibit 10 mTOR that are more potent and exhibit improved pharmacokinetic behaviors. 4 WO 2009/143313 PCT/US2009/044774 SUMMARY OF THE INVENTION This invention provides compounds of formula I R1 N N R 4 N R 2 wherein: 5 R'is R7 0 R 8 R7 R8 R N R 9 R R 9 IIv I or I and R 2 , R 4 , and R 6
-
9 are defined below, and pharmaceutically acceptable salts and esters thereof. These compounds are useful as inhibitors of mTOR and P13 kinases. This invention further provides compositions containing one or more of the 10 aforementioned compounds, which compositions may contain a pharmaceutically acceptable carrier. The present invention provides methods for making the compounds of the invention, as described below. Methods of using the invention are also provided, for example: a method for inhibiting mTOR, a method for inhibiting a P13 kinase, and methods for treating various forms of 15 cancer. 5 WO 2009/143313 PCT/US2009/044774 DETAILED DESCRIPTION OF THE INVENTION In one aspect, the present invention provides compounds of formula I R1 N N R 4 N R 2 wherein: 5 R'is R7 0 R 8 R7 R8 R N R 9 R R 9 IIv or I wherein:
R
6 , R 7 , R , R 9 are each independently selected from the group consisting of a hydrogen atom, and a C 1
-C
6 alkyl optionally substituted with C 2
-C
6 alkenyl, C 4
-C
6 alkadienyl, C 2
-C
6 alkynyl or 10 C 4
-C
6 alkadiynyl; or one of R 6 and R 7 or R 8 and R 9 , together with the carbon atoms to which they are attached form an optionally substituted 5-8 membered saturated or unsaturated ring containing 0, 1 or 2 atoms independently selected from 0, NH and S; the dashed line ----- represents an optional second bond; 15 R 2 is optionally substituted C 6
-C
1 4 aryl-NH-COR 3 , optionally substituted C 1 -Coheteroaryl
NH-COR
3 , -CH=CH-C 6
-C
1 0 aryl-NH-COR 3 or -CH=CH-C 1 -Coheteroaryl-NH-COR 3 ;
R
3 is OR 5 , NR 5
R
5 or NHR 5 ;
R
5 is independently selected from the group consisting of C 1
-C
6 alkyl, C 3
-C
6 alkenyl, C3
C
6 alkynyl, optionally substituted C 6 -Cloaryl, Cl-C 6 haloalkyl, optionally substituted Cj 20 COgheteroaryl, C 1
-C
6 hydroxylalkyl-, C 3
-C
1 osaturated or unsaturated mono or bicyclic C3 Clacycloalkyl optionally substituted with OH, NR 11
R
1 1 or 3-7 membered C 1
-C
6 heterocyclyl, and 3-10 membered saturated or unsaturated mono or bicyclic C 1 -Coheterocyclyl, with the proviso that three-membered cycloalkyl and heterocyclyl rings are saturated; or two R 5 groups taken together with the nitrogen atom to which they are attached form a 25 3 to 8 membered ring system optionally substituted with C 1
-C
6 alkyl, which ring system is 6 WO 2009/143313 PCT/US2009/044774 saturated or unsaturated and has, in addition to said nitrogen atom, 0 to 2 heteroatom ring members selected from 0, S, S(O), S(0) 2 and NR 10 ;
R
10 is selected from the group consisting of H, C 1
-C
6 alkyl, -S0 2
(C
1
-C
6 alkyl), -COO(Cl
C
6 alkyl), -CONH(C 1
-C
6 alkyl), -CON(C 1
-C
6 alkyl) 2 , -CO(C 1
-C
6 alkyl), and -SO 2
NHR
11 ; 5 R" is selected from the group consisting of H, C 1
-C
6 alkyl optionally substituted with OH,
NR
11
R
1 1 or a 3-7 membered C 1
-C
6 heterocyclyl, -CO(C 1
-C
6 alkyl), optionally substituted C6 Cloaryl, and optionally substituted C 1 -Coheteroaryl;
R
4 is selected from the group consisting of: a) C 1
-C
6 alkyl'optionally substituted with: i) 3 10 membered C 1 -Coheterocyclyl optionally substituted with C 1
-C
6 alkyl-, ii) H 2 N-, iii) (Cl 10 C 6 alkyl)NH-, iv) (C 1
-C
6 alkyl) 2 N-, v) NH(CH 2
)
2
N(C
1
-C
6 alkyl) 2 wherein a is 2, 3 or 4, and vi) CHO, b) C 3
-C
6 alkenyl, c) C 3
-C
6 alkynyl, d) -O-C 1
-C
8 alkyl optionally substituted with -O-C 1
-C
8 alkyl, e) O-C 3
-C
8 alkenyl, f) -O-C 3
-C
8 alkynyl, g) saturated or unsaturated mono or bicyclic C 3
-C
8 cycloalkyl, and h) saturated or unsaturated mono or bicyclic -O-C 3
-C
12 cycloalkyl, all the above optionally substituted with OH, NR 11
R
1 1 or a 3-7 membered C 1
-C
6 heterocyclyl optionally substituted with 15 C 1
-C
6 alkyl-, provided that an OH or NR 11
R
11 is not directly bonded to a carbon atom that is double- or triple-bonded to another carbon atom; i) -CH=CH-C 6
-C
10 aryl; j) -CH=CH-C 1 Coheteroaryl; k) optionally substituted C 6
-C
1 0 aryl; I) optionally substituted 5-10 membered Cj Coheteroaryl attached to the triazine moiety via a carbon atom; m) 3-10 membered saturated or unsaturated monocyclic C 1 -Coheterocyclyl attached to the triazine moiety through a carbon or 20 nitrogen atom and optionally substituted with from 1 to 3 substituents independently selected from: OH, NR 1 1
R
11 , C 1
-C
6 alkyl, (C 1
-C
6 alkyl)amido-, (C 1
-C
6 alkyl)C(O)-, (C 1
-C
6 alkoxy)carbonyl-, adamantyl, C 1
-C
6 hydroxylalkyl-, (C 1
-C
6 alkyl)amido-; or a 3-7 membered C 1
-C
6 heterocyclyl, with the proviso that 3 membered heterocyclyl is saturated and attached to the triazine moiety through a nitrogen atom, and 5 membered bicyclic heterocyclyl is saturated; n) optionally 25 substituted -O-C 6 -Cloaryl; o) optionally substituted -O-C 1 -Coheteroaryl; p) -O-(3-12 membered saturated or unsaturated mono or bicyclic)Ci-Cgheterocyclyl optionally substituted with (Cl
C
6 alkoxy)carbonyl-, H 2 NS(0) 2 -, or C 1
-C
6 alkyl further optionally substituted with OH, NR 1 1
R
11 or a 3-7 membered C 1
-C
6 heterocyclyl, with the proviso that three membered heterocyclyl is saturated; q) -NHC 6 -Cloaryl, r) -NHC 1 -Coheteroaryl, s) -NHNH 2 , t) -NHNHC 1
-C
6 alkyl, u) 30 NHN(C 1
-C
6 alkyl) 2 , v) -NHOH, w) -COOH, x) -COO-C 1
-C
6 alkyl, y) -CONR R , z) -NR R, 7 WO 2009/143313 PCT/US2009/044774
R
6
R
7
R
6
R
7 aa) N-N bb) -- N cc) _N-N Z dd) N Z
R
9
R
8
R
9
R
8 wherein Z is CH 2 , 0, S(O), or NR 1 0 and n is 0, 1 or 2; ee) halogen, ff) C 6
-C
14 aryl-S(0) 2 -NH-, gg) R 1 NHC(O)NH-O-, and hh) optionally substituted 5 membered monocyclic C 1
-C
4 heteroaryl attached to the triazine moiety via a nitrogen atom;
R
12 and R 1 3 are each independently selected from H, optionally mono or disubstituted 5 C 1
-C
8 alkyl, optionally substituted C 3
-C
8 alkenyl, and optionally substituted C 3
-C
8 alkynyl, the optional substituents being selected from C 1
-C
6 alkoxy, OH, NR 11
R
11 , and 3-7 membered Cj
C
6 heterocyclyl, provided that an OH or NR 1 1
R
11 is not directly bonded to a carbon atom that is double- or triple-bonded to another carbon atom; or R 1 2 and R 1 3 taken together with the nitrogen atom to which they are attached form a 3 10 to 8 membered monocyclic ring system optionally substituted with C 1
-C
6 alkyl, which ring system is saturated or unsaturated and has, in addition to said nitrogen atom, 0 to 2 heteroatom ring members selected from 0, S(O), and NR 1 0 ; or R 1 2 and R 13 taken together with the nitrogen atom to which they are attached form (CH2)xNH R9a b R8 R~ N 0 FK-F]hR'O R8 N N NQN or N N
R
6 N R 7 R 6 N R 7 R N:i wherein a and b are each independently -CH 2 -, 0, S, or NR 1 0 , and x is 1-3; 15 C 1 -Coheteroaryl refers to a 5-10 membered aromatic ring system having one or more rings and 1, 2, 3 or 4 ring members independently selected from 0, NR 1 0 , and S(O),;
C
1 -Coheterocyclyl refers to a 3-10 membered ring system having one or more rings and 1, 2, 3 or 4 ring members independently selected from 0, NR 1 0 , and S(O),; and optionally substituted aryl and heteroaryl groups are unsubstituted or are substituted with 20 1 or 2 moieties selected from the group consisting of: a) C 1
-C
6 alkyl optionally substituted with OH, NH 2 , NH(C 1
-C
6 alkyl), N(C 1
-C
6 alkyl) 2 , -NH(CH 2 )wN(C 1
-C
6 alkyl) 2 wherein w is 2, 3 or 4, or 3 10 membered C 1 -Coheterocyclyl optionally substituted with from 1 to 3 independently selected
C
1
-C
6 alkyl- substituents; b) halogen; c) hydroxy; d) NH 2 ; e) NO 2 ; f) SO 2
NH
2 ; g) COOH; h)
COO(C
1 -Cealkyl); i) NHCOO(C 1
-C
6 alkyl); j) NH(C 1
-C
6 alkyl); k) N(C 1
-C
6 alkyl) 2 ; I) C(O)NR"R , 25 wherein R" is H or C 1
-C
6 alkyl, and Rb is H, C 1
-C
6 alkyl, (C 6 -Cl 4 aryl)alkyl-, or (Cl Cgheteroaryl)alkyl-; m) -Y-Q, wherein Y is: i) 0, ii) NH, iii) N(C 1 -Cealkyl), iv) NHSO 2 , v) SO 2 NH, vi) NHCONH, vii) NHCON(C 1
-C
6 alkyl), viii) S(O)q, q is 0, 1 or 2, ix) -C(O)NH-, x) -NHC(O)- xi) C(O)N(CH 3 )-, xii) C(O), or xiii) absent, and Q is selected from: i) C 6
-C
10 aryl, optionally substituted with from 1 to 3 substituents independently selected from: A) C 1
-C
6 alkoxy- optionally 30 substituted with 1) H 2 N-, 2) (C 1 -Cealkyl)amino-, 3) di(C 1
-C
6 alkyl)amino-, 4) C 1 -Coheterocyclyl 8 WO 2009/143313 PCT/US2009/044774 optionally substituted by C 1
-C
6 alkyl-, or 5) hydroxyl, B) (C 1
-C
6 alkoxy)carbonyl-, C) (Cl
C
6 alkoxy)C(O)NH-, D) C 1
-C
6 alkyl- optionally substituted with 1) H 2 N-, 2) (Cl-C 6 alkyl)amino-, or 3) di(C 1
-C
6 alkyl)amino-, E) (C 1
-C
6 alkyl)amino-, F) di(C 1
-C
6 alkyl)amino-, G) (C 1
-C
6 alkyl)amido optionally substituted with 1) H 2 N-, 2) (C 1
-C
6 alkyl)amino-, or 3) di(C 1
-C
6 alkyl)amino-, H) (Cl 5 C 6 alkyl)carboxyamido-, I) C 1 -Coheterocyclyl- optionally substituted by C 1
-C
6 alkyl- or Cj
C
6 hydroxylalkyl-, J) heterocyclyl(C 1
-C
6 alkyl)- optionally substituted by C 1
-C
6 alkyl-, K) halogen, L) hydroxyl, M) C 1
-C
6 hydroxylalkyl-, N) perfluoro(C 1
-C
6 )alkyl-, 0) H 2 N-, P) 0 2 N-, Q) H 2
NSO
2 -, R)
HO
2 C-, and S) NC-, ii) 5-10 membered C 1 -Coheteroaryl, optionally substituted with from 1 to 3 substituents independently selected from: A) C 1
-C
6 alkoxy- optionally substituted with 1) H 2 N-, 2) 10 (C 1
-C
6 alkyl)amino-, 3) di(C 1
-C
6 alkyl)amino-, 4) C 1 -Cgheterocyclyl- optionally substituted by Cj
C
6 alkyl-, or 5) hydroxyl, B) (C 1
-C
6 alkoxy)carbonyl-, C) (C 1
-C
6 alkoxy)C(O)NH-, D) C 1
-C
6 alkyl optionally substituted with 1) H 2 N-, 2) (C 1
-C
6 alkyl)amino-, or 3) di(C 1
-C
6 alkyl)amino-, E) (Cl
C
6 alkyl)amino-, F) di(C 1
-C
6 alkyl)amino-, G) (C 1
-C
6 alkyl)amido- optionally substituted with 1)
H
2 N-, 2) (C 1
-C
6 alkyl)amino-, or 3) di(C 1
-C
6 alkyl)amino-, H) (C 1
-C
6 alkyl)carboxyamido-, I) Cj 15 Coheterocyclyl- optionally substituted by C 1
-C
6 alkyl- or C 1
-C
6 hydroxylalkyl-, J) heterocyclyl(C 1 C 6 alkyl)- optionally substituted by C 1
-C
6 alkyl-, K) halogen, L) hydroxyl, M) C 1
-C
6 hydroxylalkyl-, N) perfluoro(C 1
-C
6 )alkyl-, 0) H 2 N-, P) 0 2 N-, Q) H 2
NSO
2 -, R) HO 2 C-, and S) NC-, iii) 3-10 membered C 1 -Coheterocyclyl, optionally substituted with from 1 to 3 substituents independently selected from: A) C 1
-C
6 alkyl-, B) heterocyclyl(C 1
-C
6 alkyl)-, C) (C 6
-C
1 4 aryl)alkyl-, D) C 1
-C
8 acyl-, 20 E) (C 1
-C
6 alkoxy)carbonyl-, F) (C 1
-C
6 alkyl)carboxyl- , G) halogen, H) C 1
-C
6 haloalkyl-, I) hydroxyl, J) C 1
-C
6 hydroxyalkyl-, K) H 2 N-, L) (C 1
-C
6 alkyl)amino-, M) di(C 1
-C
6 alkyl)amino-, N) HO 2 C-, 0)
(C
1
-C
6 alkoxy)carbonyl-, P) (C 1
-C
6 alkyl)carboxyl-, Q) (C 1
-C
6 alkyl)amido-, R) H 2 NC(O)-, S) (Ci
C
6 alkyl)carboxyamido-, T) 5-10 membered C 1 -Cgheteroaryl, U) C 6
-C
14 ary, V) C 3
-C
8 cycloalkyl W) 3-10 membered C 1 -Coheterocyclyl, X) NC-; and Y) -NO 2 ; iv) C 3
-C
10 cycloalkyl, v) C 1
-C
6 alkyl, vi) 25 C 2
-C
6 alkenyl, vii) C 2
-C
6 alkynyl, viii) C 1
-C
6 hydroxyalkyl-, ix) (CH 2 )vO(C 1 -Cealkyl), x) (CH 2 )vNH 2 , xi)
(CH
2 )vNH(C 1
-C
6 alkyl), xii) (CH 2 )vN(C 1
-C
6 alky) 2 , xiii) O(CH 2 )vN(C 1
-C
6 alky) 2 , xiv) (CH 2 )vC 6
-C
1 Oaryl, xv) -CN, xvi) (CH 2 )v 5-10 membered C 1 -Coheteroaryl, xvii) (CH 2 )v 3-10 membered Cj Coheterocyclyl, optionally substituted by C 1
-C
6 alkyl-, wherein v is 1, 2, 3 or 4, and xviii) Cj
C
6 perfluoroalkyl- ; and n) C(O)R wherein R' is: i) H, ii) C 1
-C
6 alkyl, or iii) C 3
-C
6 cycloalkyl, 30 and pharmaceutically acceptable salts and esters thereof. In some embodiments of the invention, R 1 and/or R 4 is 0 N 9 WO 2009/143313 PCT/US2009/044774 In some embodiments, R 1 and/or R 4 is o 0 aJvvvP or ~ Avv In some embodiments, one of R 1 or R 4 is 0 N 5 and the other is o 0 ~Avv' or aivvv' In some embodiments, R 2 is optionally substituted C 6
-C
1 4 aryI-NH-COR 3 ; in others R 2 is optionally substituted phenyl-NH-COR 3 In some embodiments, R 3 is NHR 5 or OR 5 . In some embodiments, R 5 is optionally 10 substituted C 6
-C
1 0 aryl, such as optionally substituted phenyl or C 1 -Coheteroaryl. In some embodiments, the optionally substituted C 6
-C
1 0 aryl or phenyl is substituted with -Y-Q, C(O)NR"Rb or C(O)Rc. In some embodiments, R 5 is phenyl substituted with -Y-Q. The following compounds exemplify illustrative compounds of Formula I: 15 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-3-ylurea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-phenylurea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-thiophen-2-ylurea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-methylphenyl)urea; 20 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-fluorophenyl)urea; 1-(2,4-dimethoxyphenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-urea; 10 WO 2009/143313 PCT/US2009/044774 1-(4-chlorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-methoxyphenyl)urea; (4-chlorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; (2,4-difluorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; 5 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-ethylurea; tert-butyl 3-{[4-(4-{[(4-fluorophenyl)carbamoyl]amino}phenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]amino}azetidine-1 -carboxylate; tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(phenylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)amino]azetidine-1 -carboxylate; 10 tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridine-3-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)amino]azetidine-1 -carboxylate; tert-butyl 3-{[4-(4-{[(4-methylphenyl)carbamoyl]amino}phenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]amino}azetidine-1 -carboxylate; 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yI]phenyl}-3-phenylurea; 15 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yI]phenyl}-3-(4-fluorophenyl)urea; 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(4-methylphenyl)urea; tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridine-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)amino]azetidine-1 -carboxylate; 20 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea 1-[2-(dimethylamino)ethyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}urea; 1 -[4-(4,6-dimorpholin-4-yl- 1,3,5-triazin-2-yl)phenyl]-3-(2-methylpyridin-4-yl)urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(2-hydroxyethyl)phenyl]urea; 25 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(hydroxymethyl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-hydroxyphenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(1 -hydroxyethyl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(trifluoromethyl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-hydroxyphenyl)urea; 30 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[5-(trifluoromethyl)pyridin-2-yl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[2,2,2-trifluoro-1 -hydroxy- 1 (trifluoromethyl)ethyl]phenyl}urea; 11 WO 2009/143313 PCT/US2009/044774 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[3-(1 -hydroxyethyl)phenyl]urea; methyl 4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate; 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4 ylurea; 5 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)- 1,3,5-triazin-2-yl]phenyl}-3-phenylurea; 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3 ylurea; 1 -[4-(hydroxymethyl)phenyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1, 3,5 triazin-2-yl]phenyl}urea; 10 1 -(2-methylpyrid in-4-yl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)- 1,3,5-triazin-2 yl]phenyl}urea; 1-[2-(methylamino)ethyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2 yl]phenyl}urea; 1-(3-acetylphenyl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2 15 yl]phenyl}urea; 1-[4-(dimethylamino)phenyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5 triazin-2-yl]phenyl}urea; 4-[3-{4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl}ureido]benzoic acid; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2 20 yl)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)ureido)benzamide HCI salt; 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazine-1 carbonyl)phenyl)urea; 25 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N-methylbenzamide; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N methylbenzamide; 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-morpholinopiperidine-1 carbonyl)phenyl)urea; 30 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N-(quinuclidin-3-yl)benzamide; 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-(pyrrolidin-1-yl)piperidine-1 carbonyl)phenyl)urea; 1-(4-(1,4'-bipiperidine-1'-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2 35 yl)phenyl)urea; 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 -carbonyl)phenyl)urea; 12 WO 2009/143313 PCT/US2009/044774 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(2-(pyridin-2-yl)acetyl)phenyl)urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(1 -hydroxyethyl)phenyl]urea; 1 -[4-(4,6-dimorpholin-4-yl- 1,3,5-triazin-2-yl)phenyl]-3-(2-methylpyridin-4-yl)urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(hydroxymethyl)phenyl]urea; 5 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(trifluoromethyl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[2,2,2-trifluoro-1 -hydroxy- 1 (trifluoromethyl)ethyl]phenyl}urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[5-(trifluoromethyl)pyridin-2-yl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[3-(1 -hydroxyethyl)phenyl]urea; 10 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1,3,5-triazin-2-yl}phenyl)-3-pyridin-4 ylurea; 1 -[4-(2-hydroxyethyl)phenyl]-3-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1, 3,5-triazin 2-yl}phenyl)urea; 1-[4-(2-hydroxymethyl)phenyl]-3-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5 15 triazin-2-yl}phenyl)urea; 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1,3,5-triazin-2-yl}phenyl)-3-(2 methylpyrid in-4-yl)urea; 1-[4-(1 -hydroxyethyl)phenyl]-3-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1, 3,5-triazin 2-yl}phenyl)urea; 20 1-[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; methyl 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl} amino)benzoate; 1 -[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; 25 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-( 1 methylpiperidin-4-yl)benzamide; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(1 -methylpiperidin-4-yl)urea; 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1,3,5-triazin-2-yl}phenyl)-3-( 1 methylpiperidin-4-yl)urea; 30 1 -{4-[4-(3,6-Dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-[1,3,5]triazin-2-yl]-phenyl}-3-pyridin-4-yl urea; 1 -{4-[4-Morpholin-4-yl-6-(tetrahydro-pyran-4-yl)-[1,3,5]triazin-2-yl]-phenyl}-3-pyrid in-4-yl-urea; 3-({4-Morpholin-4-yl-6-[4-(3-pyridin-4-yl-ureido)-phenyl]-[1,3,5]triazin-2-ylamino}-methyl) azetidine-1-carboxylic acid tert-butyl ester; 13 WO 2009/143313 PCT/US2009/044774 1-(4-{4-[(azetidin-3-ylmethyl)-amino]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-phenyl)-3-pyridin-4-yl urea; 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin 4-ylurea; 5 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin 3-ylurea; 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3 phenylurea; 1-[4-(dimethylamino)phenyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 10 triazin-2-yl]phenyl}urea; 1-(4-cyanophenyl)-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}urea; 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(2 methylpyrid in-4-yl)urea; 15 1-[2-(dimethylamino)ethyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}urea; 1-[4-(4-morpholin-4-yl-6-quinolin-3-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; 1-[4-(4-azetidin-1 -yl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; methyl 4-({[4-(4-azetidin-1-yl-6-morpholin-4-yl-1,3,5-triazin-2 20 yl)phenyl]carbamoyl}amino)benzoate; 1 -[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-( 1 methylpiperidin-4-yl)benzamide; 25 4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-(2-piperidin- 1 ylethyl)benzamide; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(morpholin-4-ylcarbonyl)phenyl]urea; 1-[4-(4-methyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; 4-({[4-(4-methyl-6-morpholin-4-yl- 1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate; 30 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-{4-[(4 methylpiperazin-1-yl)carbonyl] phenyl}urea; 4-({[4-(4-methyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-(1 methylpiperidin-4-yl)benzamide; N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4-methyl-6-morpholin-4-yl-1,3,5-triazin-2 35 yl)phenyl]carbamoyl}amino)benzamide; 1-[4-(4-methyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; 14 WO 2009/143313 PCT/US2009/044774 1-(4-{[3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin 2-yl)phenyl]urea; 1-[4-({4-[2-(dimethylamino) ethyl]piperazin- 1-yl}carbonyl)phenyl]-3-[4-(4,6-dimorpholin-4-yl 1,3,5-triazin-2-yl)phenyl]urea; 5 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-pyrrolidin-1 -ylpiperidin-1 yl)carbonyl]phenyl}urea; 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoic acid; N-[2 (dimethylamino)ethyl]-4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-methylbenzamide; 10 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzamide; 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate; 4-({[4-(4-azetidin-1-yl-6-morpholin-4-yl-1,3,5-triazin-2yl)pheny] carbamoyl} amino) benzoic acid; 15 mp 204 C; 1-[4-(4-azetidin-1 -yl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; mp 170 0C; 4-({[4-(4-azetidin-1 -yl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-[2 (dimethylamino)ethyl]-N-methylbenzamide; 20 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-[2 (dimethylamino)ethyl]-N-methylbenzamide; 1 -{4-[4-(1 -ethoxyvinyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 1 -{4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 1-[4-(4-acetyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; 25 methyl 4-[({4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate; 1-{4-[4-(1-hydroxyethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; methyl 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate; 30 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoic acid; 1-(4-{4-morpholin-4-yl-6-[2-(pyridin-4-ylamino)ethyl]-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea; 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-[2 (dimethylamino)ethyl]benzamide; 35 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; 15 WO 2009/143313 PCT/US2009/044774 1 -[4-(4-ethyl-6-mo rphoi n-4-y- 1, ,3,5-tri azi n-2-yI)p he nyl]-3-{4- [(4-m ethyl p ipe razi n- 1 yI)carbonyl]phenyllurea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-ethyl-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 5 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-[4-(4-ethyl-6-morpholin-4-y- 1,3,5 triazin-2-yI)phenyl]urea; 1 -[4-(4-butyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-[4-(hydroxymethyl)phenyl]urea; 4-[({4-[4-(3,6-dihydro-2H-pyran-4-y)-6-morpholin-4-y-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]-N-[2-(dimethylamino)ethyl]-N-methylbenzamide; 10 1 -[4-(4-butyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-(4-{[4-(dimethylamino)piperidin- 1 yI]carbonyllphenyl)urea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-ethyl-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)-N-methylbenzamide; N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-y- 1,3,5-triazin-2 15 yI)phenyl]carbamoyllamino)-N-methylbenzamide; N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 4-({[4-(4-methoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-methyl-N-[2 (methylamino)ethyl]benzamide; 20 1 -[4-(4-methoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-{4-[(4-methylpiperazin- 1 yI)carbonyl]phenyllurea; 1 -{4-[(3,3-dimethylpiperazin- 1 -yI)carbonyl]phenyl}-3-[4-(4-methoxy-6-morpholin-4-y- 1,3,5 triazin-2-yI)phenyl]urea; 4-({[4-(4-methoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(2-piperidin- 1 25 ylethyl)benzamide; 4-({[4-(4-ethyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-[4-(4 methylpiperazin-1 -yI)phenyl]benzamide; 1 -[4-(4-butyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]-3-[4-({[2 (dimethylamino)ethyl]aminolmethyl)phenyl]urea; 30 4-({[4-(4-butyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-[4-(4 methylpiperazin-1 -yI)phenyl]benzamide; 1 -[4-(4-butyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-{4-[(4-methylpiperazin- 1 yI)m ethyl] phenyllu rea; 1 -[4-(4-butyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]-3-(4-formylphenyl)urea; 35 4-({[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(pyridin-2 ylmethyl)benzamide; 1 -(4-{4-[2-( 1,3-dioxan-2-yI)ethyl]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3-pyridin-4-ylurea; 16 WO 2009/143313 PCT/US2009/044774 1-(4-{4-[2,5-bis(hydroxymethyl)pyrrolidin-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3 pyridin-4-ylurea; 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-{4-[2 (dimethylamino)ethoxy]phenyl}benzamide; 5 1 -{4-[(4-benzylpiperidin-1 -yl)carbonyl]phenyl}-3-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-(1 -methylpiperidin 4-yl)benzamide; 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-(1 -methylpiperidin 10 4-yl)benzamide; 1-(4-{4-[3-(dimethylamino)propyl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea; 1-[4-(4-{3-[(1 -methylethyl)amino]propyl}-6-morpholin-4-yl- 1,3,5-triazin-2-yl)phenyl]-3-pyridin-4 ylurea; 1 -{4-[4-morpholin-4-yl-6-(3-pyrrolidin-1 -ylpropyl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 15 1-(4-{4-[3-(4-methylpiperazin-1 -yl)propyl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4 ylurea; 1 -{4-[4-(3-{[2-(dimethylamino)ethyl]amino}propyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3 pyridin-4-ylurea; 1 -{4-[4-(3-hydroxypropyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 20 1 -{4-[4-morpholin-4-yl-6-(3-oxopropyl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2-y]phenyl}-3-(4-{[4 (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)urea; 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl} carbamoyl)amino]-N-[2-(dimethylamino)ethyl]benzamide; 25 1-[4-(4-methylpiperazin-1 -yl)phenyl]-3-[4-(4-morpholin-4-yl-6-propyl-1,3,5-triazin-2 yl)phenyl]urea; 1 -{4-[2-(dimethylamino)ethoxy]phenyl}-3-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 1 -[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(4-methylpiperazin-1 -yl)phenyl]urea; 30 1-[4-(4-methylpiperazin-1 -yl)phenyl]-3-{4-[4-(2-methylpropyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}urea; 1 -{4-[(3,3-dimethylpiperazin-1 -yl)carbonyl]phenyl}-3-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-(1 -methylazetidin 35 3-yl)benzamide; methyl 4-[({4-[4-(1-methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate 17 WO 2009/143313 PCT/US2009/044774 N-[2-(dimethylamino)ethyl]-4-[({4-[4-(1 -methylethyl)-6-morpholin-4-yl- 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; 5 N-(1 -methylazetidin-3-yl)-4-[({4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; 1-(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-{4-[4-(1 -methylethyl)-6-morpholin-4-yl 1,3,5-triazin-2-yl]phenyl}urea; 4-[({4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]-N-pyridin 10 4-ylbenzamide; 4-[({4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]-N-pyridin 3-ylbenzamide; N-cyclobutyl-4-[({4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; 15 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-phenylpiperidin-1 yl)carbonyl]phenyl}urea; 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-(pyridin-4 ylmethyl)benzamide; 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-{4-[4-(2-methylpropyl)-6-morpholin-4-yl-1, 3,5 20 triazin-2-yl]phenyl}urea; 1-(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-{4-[4-(2-methylpropyl)-6-morpholin-4 yl-1,3,5-triazin-2-yl]phenyl}urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-(2-methylpropyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; 25 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl- 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; 1 -{4-[4-(dimethylamino)piperidin-1 -yl]phenyl}-3-{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5 30 triazin-2-yl]phenyl}urea; 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl- 1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 1 -{4-[4-(dimethylamino)piperidin-1 -yl]phenyl}-3-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoic 35 acid; 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl- 1,3,5-triazin-2-yl]phenyl}-3-[4-(4-methylpiperazin-1 yl)phenyl]urea; 18 WO 2009/143313 PCT/US2009/044774 methyl 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yI-l ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzoate; 1 -{4-[4-(dimethylamino)piperid in-i -yI]phenyl}-3-[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2 yI)phenyl] urea; 5 1 -[4-(4-morpholin-4-yI-6-phenyl- 1,3,5-triazin-2-yI)phenyl]-3-pyridin-4-ylurea; 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]ca rbo nyllp he nyl)-3-{4-[4- mo rpholIi n-4-yI-6- (tetra hyd ro-2 H pyran-4-yI)- 1,3,5-triazin-2-yI]phenyllurea; 1 -(4-(4,6- bis ((R)-3- methyl mo rphoIi no)-1, ,3,5-triazi n-2-yI) ph enyl)-3-(pyrid in-4-yI)u rea; 1 -(4-(4,6- bis ((R)-3- methyl mo rphoIi no)-1, ,3,5-triazi n-2-yI) ph enyl)-3-(pyrid in-3-yI)u rea; 10 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-methylpiperazin-1 yI)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(6-(4-methylpiperazin-1 yI)pyrid in-3-yI)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4 15 ((dimethylamino)methyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 (dimethylamino)ethoxy)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2-(pyrrolidin-1 yI)ethoxy)phenyl)u rea; 20 (R)-1 -(4-(4-(3- methyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4-y)- 1, 3,5-triazi n-2-yI)p he nyl)-3 (pyridin-3-yI)urea; (R)-1 -(4-(4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(4-(4 methylpiperazin-1 -yI)phenyl)urea; (R)-1 -(4-(4-(3- methyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4-y)- 1, 3,5-triazi n-2-yI)p he nyl)-3-(4 25 (piperazin-1 -yI)phenyl)urea; 1 -(4-(4-((R)-3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(4 ((S)-3-methylpiperazin-1 -yI)phenyl)urea; 1 -(4-(4-((R)-3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(4 ((R)-3-methylpiperazin-1 -yI)phenyl)urea; 30 1 -(4-((3R,5S)-3,5-dimethylpiperazin-1 -yI) ph enyl)-3- (4-(4-((R)-3-m ethyl mo rpholIi no)-6-(tetra hyd ro 2H-pyran-4-y)-1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(2-(dimethylamino)ethoxy)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(4-ethylpiperazin-1 -yI) ph enyl)-3-(4-(4-(3- methyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4 35 yI)-l ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(4-isopropylpiperazin-1 -yI)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 19 WO 2009/143313 PCT/US2009/044774 (R)-1 -(4-(4-(dimethylamino)piperidin-1 -yI)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro 2H-pyran-4-y)-1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 5 (R)-1 -(4-(4-isopropylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro 2H-pyran-4-y)-1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4- (4-(3-m ethyl mo rphoIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(6-(4 methylpiperazin- 1 -yI)pyridin-3-yI)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)- 1,3,5-triazin-2-yI)phenyl)-3-(4-(4-ethylpiperazin-1 10 yI)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-isopropylpiperazin-1 yI)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4 (dimethylamino)piperidin-1 -yI)phenyl)urea; 15 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-methylpiperazine-1 carbonyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-isopropylpiperazine-1 carbonyl)phenyl)urea; 4- (3-(4-(4,6- bis((R)-3-m ethyl mo rphoIi no)- 1, 3,5-tri azi n-2-yI)p he nyl)u re ido)-N, N 20 dimethylbenzamide; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(pyrrolidin-1 ylmethyl)phenyl)u rea; 4-({[4-(4-{4-[(methylcarbamoyl)amino]phenyl}-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 25 1 -{4-[4-(3,5-dimethylmorpholin-4-yI)-6-{4-[(methylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 yI]phenyl}-3-pyridin-3-ylu rea; 3-({[4-(4-{4-[(methylcarbamoyl)amino]phenyl}-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 1 -methyl-3-[4-(4-morpholin-4-yI-6-{4-[(pyridin-3-ylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 30 yI)phenyl]urea; 1 -methyl-3-[4-(4-morpholin-4-yI-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 yI)phenyl] urea; 3- [({4- [4-(3,5-d im ethyl mo rpholIi n-4-yI)-6-{4-[(methyl ca rba moyl)a m ino] ph enyl- 1, ,3,5-tri azi n-2 yI]phenyllcarbamoyl)amino]benzamide; 35 4- [({4- [4-(3,5-d im ethyl mo rpholIi n-4-yI)-6-{4-[(methyl ca rba moyl)a m ino] ph enyl- 1, ,3,5-tri azi n-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[4-(3,5-dimethylmorpholin-4-yI)-6-{4-[(methylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 yI]phenyl}-3-pyridin-4-ylu rea; 20 WO 2009/143313 PCT/US2009/044774 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-methylurea; 1-(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-(4-{4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3 5 yloxy]-1,3,5-triazin-2-yl}phenyl)urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridazin-4-ylurea; 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-{4-[4-morpholin-4-yl-6-(oxetan-3-yloxy)-1,3,5 triazin-2-yl]phenyl}urea; 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5 10 triazin-2-yl)phenyl]urea; 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea; 1-[4-(4-isopropyl-6-morpholin-4-yl-1,3,5-triazin-2-yI)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; 15 1 -{4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(4-pyrimidin-5-ylphenyl)urea; 1-(4-{4-[(2,2-dimethoxyethyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3 ylurea; 1 -{4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(4-pyridin-4-ylphenyl)urea; 1-(4-iodophenyl)-3-{4-[4-(1 -methylethyl)-6-morpholin-4-yl- 1,3,5-triazin-2-yl]phenyl}urea; 20 1 -{4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(4-{[4-( 1 methylethyl)piperazin-1 -yl]carbonyl}phenyl)urea; 1-[4-(4-azetidin-1 -yl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-{[4-(1 -methylethyl)piperazin 1 -yl]carbonyl}phenyl)urea; 1 -{4-[2-(dimethylamino)pyrimidin-5-yl]phenyl}-3-{4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5 25 triazin-2-yl]phenyl}urea; tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)oxy]azetidine-1 -carboxylate; 1-(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 30 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-nitrophenyl)urea; 1-(4-aminophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; N-[4-({[4-(4, 6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)phenyl]-4 methylpiperazine-1 -carboxamide; 4-(dimethylamino)-N-[4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 35 yl)phenyl]carbamoyl}amino)phenyl]piperidine-1-carboxamide; 21 WO 2009/143313 PCT/US2009/044774 1 -[2-(dimethylamino)ethyl]-3-[4-({[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2 yI)phenyl]carbamoyllamino)phenyl]-1 -methylurea; 1 -[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-(4-{[(2-piperidin-1 ylethyl)carbamoyl]aminolphenyl)urea; 5 N-[4-({[4-(4, 6-dimorpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)phenyl]-4-methyl- 1,4 diazepane-1 -carboxamide; N-[4-({[4-(4, 6-dimorpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)phenyl]-4 ethylpiperazine-1 -carboxamide; 1 -{4-[(dimethylcarbamoyl)amino]phenyl}-3-[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2 10 yI)phenyl]urea; 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yI)-6-morpholin-4-yI- 1,3,5-triazin-2-yI]phenyl}-3-(4-{[4 (dimethylamino)piperidin-1 -yI]carbonyllphenyl)urea; 4-[({4-[4-(3,6-dihydro-2H-pyran-4-y)-6-morpholin-4-y-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]-N-[2-(dimethylamino)ethyl]-N-methylbenzamide; 15 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yI)-6-morpholin-4-yI- 1,3,5-triazin-2-yI]phenyl}-3-{4-[(4 methylpiperazin- 1 -yI)carbonyl]phenyllurea; 4-[({4-[4-(3,6-dihydro-2H-pyran-4-y)-6-morpholin-4-y-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]-N-[2-(dimethylamino)ethyl]benzamide; 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]ca rbo nyllp he nyl)-3-{4-[4- mo rpholIi n-4-yI-6- (tetra hyd ro-2 H 20 pyran-4-yI)- 1,3,5-triazin-2-yI]phenyllurea; N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-yI-6-(tetrahydro-2H-pyran-4-y)- 1,3, 5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 4-[({4-[4-morpholin-4-yI-6-(tetrahydro-2H-pyran-4-y)-1 ,3,5-triazin-2-yI]phenyllcarbamoyl)amino] N-(2-pyrrolidin-1 -ylethyl)benzamide; 25 4-[({4-[4-morpholin-4-yI-6-(tetrahydro-2H-pyran-4-y)- ,3,5-triazin-2-yI]phenyllcarbamoyl)amino] N-(2-piperidin- 1 -ylethyl)benzamide; 1 -[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-(4-{[4-( 1 -methylethyl)piperazin- 1 yI]carbonyllphenyl)urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4-morpholin-4-yI-6-[(3S)-tetrahydrofuran-3-yloxy] 30 1 ,3,5-triazin-2-yIlphenyl)carbamoyl]aminolbenzamide; 4-{[(4-{4-morpholin-4-yI-6-[(3S)-tetrahydrofuran-3-yloxy]-1 ,3,5-triazin-2 yIlphenyl)carbamoyl]amino}-N-(2-piperidin-1 -ylethyl)benzamide; 4-{[(4-{4-morpholin-4-yI-6-[(3S)-tetrahydrofuran-3-yloxy]-1 ,3,5-triazin-2 yIlphenyl)carbamoyl]amino}-N-(2-pyrrolid in-i -ylethyl)benzamide; 35 1 -(4-{[4-(l1 -methylethyl)piperazin-1 -yI]carbonyllphenyl)-3-(4-{4-morpholin-4-y-6-[(3S) tetra hyd rofu ra n-3-yloxy]- 1, 3,5-tri azi n-2-yIlp he nyl)u rea; 1 -(4-{[4-(l1 -methylethyl)piperazin-1 -yI]carbonyllphenyl)-3-{4-[4-morpholin-4-yI-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI]phenyllurea; 22 WO 2009/143313 PCT/US2009/044774 N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5 triazin-2-yl]phenyl}carbamoyl)amino]benzamide; 4-[({4-[4-(2-methylpropyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoic acid; 5 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl- 1,3,5-triazin-2-yl]phenyl}-3-[4-(4-methylpiperazin-1 yl)phenyl]urea; 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoic acid; methyl 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2 10 yl]phenyl}carbamoyl)amino]benzoate; 1-{4-[4-(dimethylamino)piperidin-1-yl]phenyl}-3-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl- 1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 1-{4-[4-(dimethylamino)piperidin-1-yl]phenyl}-3-{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5 15 triazin-2-yl]phenyl}urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl- 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; 1-{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; 20 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-pyridin-2-ylpiperazin-1 yl)carbonyl]phenyl}urea; 1 -{4-[4-(dimethylamino)piperidin-1 -yl]phenyl}-3-[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2 yl)phenyl]urea; 1 -[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin- 1 25 yl)carbonyl]phenyl}urea; 1-[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; methyl 4-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate; N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzamide; 30 methyl 4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoate; 4-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoic acid; N-[2-(dimethylamino)ethyl]-4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl- 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; 35 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2 yl)phenyl]urea; 23 WO 2009/143313 PCT/US2009/044774 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-[4-(4-morpholin-4-yI-6-phenyl-1,3,5 triazin-2-yI)phenyl]urea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 5 4-{[(4-{4,6-b is[(3S)-3- methyl mo rphoi n-4-y]-1, ,3,5-triazi n-2-yIl ph enyl)ca rba moyl] am ino}-N- [2 (dimethylamino)ethyl]benzamide; 1 -{4-[(4-isopropylpiperazin-1 -yI)ca rbo nyl] ph enyl}-3-{4-[4-(4-m ethyl ph enyl)-6-mo rphoIi n-4-y 1 ,3,5-triazin-2-yI]phenyllurea; 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-y-1 3, 5-triazin-2-yI]phenyllcarbamoyl)amino]-N-(2 10 pyrrolidin-1 -ylethyl)benzamide; 4-{[(4-{4,6-b is[(3S)-3- methyl mo rphoi n-4-y]-1, ,3,5-triazi n-2-yIlp he nyl)ca rba moyl] am inolbe nzo ic acid; N-(2-methoxyethyl)-4-[({4-[4-(4-methylphenyl)-6-morpholin-4-y-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 15 N-(2-methoxyethyl)-4-({[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 4-({[4-(4-morpholin-4-yI-6-phenyl- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(2-pyrrolid in-i ylethyl)benzamide; 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5-triazin-2-yI]phenyl}-3-[4-(pyrrolid in-i 20 ylcarbonyl)phenyl]urea; N-[3-(dimethylamino)propyl]-4-[({4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5-triazin-2-yI]phenyl}-3-[4-(piperidin-1 ylcarbonyl)phenyl]urea; 25 N-[3-(dimethylamino)propyl]-4-({[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 1 -{4-[4-morpholin-4-yI-6-(2-thienyl)-1 ,3,5-triazin-2-yI]phenyl}-3-pyrid in-4-ylurea; 4-[({4-[4-morpholin-4-yI-6-(2-thienyl)-1 ,3,5-triazin-2-yI]phenyllcarbamoyl)amino]benzoic acid; 1 -{4-[(4-methylpiperazin-1 -yI)carbonyl]phenyl}-3-{4-[4-morpholin-4-y-6-(2-thienyl)-1,3,5-triazin 30 2-yI]phenyllurea; methyl 4-[({4-[4-morpholin-4-yI-6-(2-thienyl)-1 ,3,5-triazin-2-yI]phenyllcarbamoyl)amino]benzoate; N-(2-methoxyethyl)-4-[({4-[4-morpholin-4-y-6-(2-thienyl)-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-y-6-(2-thienyl)-1 ,3,5-triazin-2 35 yI]phenyllcarbamoyl)amino]benzamide; N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-y-6-(2-thienyl)-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 24 WO 2009/143313 PCT/US2009/044774 4-{[(4-{4,6-b is[(3S)-3- methyl mo rphoi n-4-y]-1, ,3,5-triazi n-2-yIl ph enyl)ca rba moyl] am ino}-N- [2 (dimethylamino)ethyl]-N-methylbenzamide; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-{4-[(4- methyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 5 1 -{4-[4-morpholin-4-yI-6-( 1,4-oxazepan-4-y)-1,3, 5-triazin-2-yI]phenyl}-3-pyrid in-4-ylurea; methyl 4-[({4-[4-morpholin-4-yI-6-( 1,4-oxazepan-4-y)- 1,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzoate; 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-{4-[4-morpholin-4-yI-6-(2-thienyl) 1 ,3,5-triazin-2-yI]phenyllurea; 10 4-[({4-[4-morpholin-4-yI-6-( 1,4-oxazepan-4-y)- 1,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzoic acid; N- [3-(d im ethyl am ino) pro pyl]-4- [({4-[4-mo rphoi n-4-y-6-(2-th ie nyl)-1, ,3,5-triazi n-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-[4- (pyrroIid in- 1 15 ylcarbonyl)phenyl]urea; N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-y-6-( 1,4-oxazepan-4-y)-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[(4-methylpiperazin-1 -yI)carbonyl]phenyl}-3-{4-[4-morpholin-4-y-6-( 1,4-oxazepan-4-y) 1 ,3,5-triazin-2-yI]phenyllurea; 20 N-(2-methoxyethyl)-4-[({4-[4-morpholin-4-y-6-( 1,4-oxazepan-4-y)-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[4-ethylpiperazin-1 -yI)carbonyl]phenyl}-3-{4-[4-morpholin-4-yI-6-(2-thienyl)-1 ,3,5-triazin-2 yI] phenyllu rea; 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5-triazin-2-yI]phenyl}-3-{3-[(4-methylpiperazin-1 25 yI)carbonyl]phenyllurea; 3-[({4-[4-(4-methylphenyl)-6-morpholin-4-y-1 ,3,5-triazin-2-yI]phenyllcarbamoyl)amino]benzoic acid; methyl 3-[({4-[4-(4-methylphenyl)-6-morpholin-4-y-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzoate; 30 1 -(3-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-{4-[4-(4-methylphenyl)-6-morpholin-4 yI-l ,3,5-triazin-2-yI]phenyllurea; N- [2-(d im ethyla m ino)ethyl]- N-m ethyl-3-[({4-[4-(4- methyl ph enyl)-6- mo rphoi n-4-y- 1, 3,5-triazi n-2 yI]phenyllcarbamoyl)amino]benzamide; methyl 3-({[4-(4-ethyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)benzoate; 35 methyl 3-({[4-(4-morpholin-4-yl-6-thiophen-2-yl-1 ,3,5-triazin-2 yl)phenyl]carbamoyllamino)benzoate; N- [2-(d im ethyla m ino)ethyl]-3-[({4-[4- (4- methyl ph enyl)-6-mo rphoi n-4-yl- 1, 3,5-triazi n-2 yl]phenyllcarbamoyl)amino]benzamide; 25 WO 2009/143313 PCT/US2009/044774 N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-yl-6-(1,4-oxazepan-4-yl)-1,3,5-triazin 2-yl]phenyl}carbamoyl)amino]benzamide; 3-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoic acid; methyl 3-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate; 5 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{3-[(4-pyridin-2-ylpiperazin-1 yl)carbonyl]phenyl}urea; N-[2-(dimethylamino)ethyl]-3-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-methylbenzamide; 1 -[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{3-[(4-methylpiperazin- 1 10 yl)carbonyl]phenyl}urea; 3-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoic acid; methyl 4-({[4-(4-morpholin-4-yl-6-piperidin-1-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzoate; 1-[4-(4-morpholin-4-yl-6-piperidin-1-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; 15 4-({[4-(4-morpholin-4-yl-6-piperidin-1-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoic acid; methyl 4-({[4-(4-morpholin-4-yl-6-pyrrolidin-1-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzoate; 1-(4-{[4-(1 -methylethyl)piperazin-1 -yl]carbonyl}phenyl)-3-[4-(4-morpholin-4-yl-6-piperidin-1 -yl 1,3,5-triazin-2-yl)phenyl]urea; 20 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-[4-(4-morpholin-4-yl-6-piperidin-1 -yl-1,3,5-triazin 2-yl)phenyl]urea; 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-[4-(4-morpholin-4-yl-6-piperidin-1 -yl-1,3,5 triazin-2-yl)phenyl]urea; 1-(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4-morpholin-4-yl-6-piperidin-1 -yl 25 1,3,5-triazin-2-yl)phenyl]urea; 4-({[4-(4-morpholin-4-yl-6-pyrrolidin-1-yl-l,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoic acid; 1-[4-(4-morpholin-4-yl-6-pyrrolidin-1 -yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-morpholin-4-yl-6-piperidin-1 -yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzamide; 30 1-(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4-morpholin-4-yl-6-pyrrolid in- 1-yl 1,3,5-triazin-2-yl)phenyl]urea; 1-(4-{[4-(1 -methylethyl)piperazin-1 -yl]carbonyl}phenyl)-3-[4-(4-morpholin-4-yl-6-pyrrolidin-1 -yl 1,3,5-triazin-2-yl)phenyl]urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4-morpholin-4-yl-6-pyrrolidin-1 -yl-1,3,5-triazin-2 35 yl)phenyl]carbamoyl}amino)benzamide; 26 WO 2009/143313 PCT/US2009/044774 N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4-morpholin-4-yI-6-piperidin- -yI-l ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 1 -{4-[4-ethylpiperazin-1 -yI)carbonyl]phenyl}-3-[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI-l 3,5-triazin 2-yI)phenyl]urea; 5 1 -{4-[(4-methylpiperazin-1 -yI)carbonyl]phenyl}-3-[4-(4-morpholin-4-y-6-pyrrolid in-i -yI-l 3,5 triazin-2-yI)phenyl]urea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI-l ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-pyrid in-4-yl ure a; 10 N-[3-(dimethylamino)propyl]-4-({[4-(4-morpholin-4-y-6-piperidin-1 -yI-l 3, 5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; N-(2-methoxyethyl)-4-({[4-(4-morpholin-4-y-6-piperidin-1 -yI-l ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 1 -[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI-l ,3,5-triazin-2-yI)phenyl]-3-[4-(pyrrolidin- 1 15 ylcarbonyl)phenyl]urea; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-{4-[(4-ethyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-(4-{[4-(1 1 methylethyl)piperazin- 1 -yI]carbonyllphenyl)urea; 20 methyl 4-{[(4-{4- [(3S)-3- methyl mo rpholIi n-4-yI]-6-mo rphoIi n-4-y- 1, 3,5-tri azi n-2 yIlphenyl)carbamoyl]aminolbenzoate; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-(4-{[4 (dimethylamino)piperidin-1 -yI]carbonyllphenyl)urea; 1 -(4-{4-[(3S)-3-m ethyl mo rphoIi n-4-yI]-6-mo rphoIi n-4-y- 1, 3,5-triazi n-2-yIlp he nyl)-3-{4-[(4 25 methylpiperazin-1 -yI)carbonyl]phenyllurea; 1 -(4-{[4-(l1 -methylethyl)piperazin-1 -yI] ca rbo nyllp he nyl)-3-(4-{4- [(3S)-3- methyl mo rphoIi n-4-y]-6 morpholin-4-yI- 1,3,5-triazin-2-yIlphenyl)urea; 4-{[(4-{4-[(3S)-3-methylmorpholin-4-y]-6-morpholin-4-y-1,3, 5-triazin-2 yIlphenyl)carbamoyl]aminolbenzoic acid; 30 1 -{4-[(4-ethylpiperazin- 1-yI)carbonyl]phenyl}-3-(4-{4-[(3S)-3-methylmorpholin-4-yI]-6-morpholin 4-yI-l ,3,5-triazin-2-yIlphenyl)urea; N- [3-(d im ethyla m ino)p ro pyl]-4-{[(4-{4-[(3S)-3-m ethyl mo rphoIi n-4-y]-6- mo rphoIi n-4-y- 1, 3,5 triazin-2-yIlphenyl)carbamoyl]aminolbenzamide; 4-{[(4-{4-[(3S)-3-methylmorpholin-4-y]-6-morpholin-4-y-1,3, 5-triazin-2 35 yIlphenyl)carbamoyl]amino}-N-(2-pyrrolid in-i -ylethyl)benzamide; 1 -(4-{4-[(3R)-3-methylmorpholin-4-y]-6-[(3S)-3-methylmorpholin-4-y]-1 ,3,5-triazin-2-yIlphenyl) 3-{4-[(4-methylpiperazin- 1-yI)carbonyl]phenyllurea; 27 WO 2009/143313 PCT/US2009/044774 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIl ph enyl)-3- (4-{[4 (dipropylamino)piperidin-1 -yI]carbonyllphenyl)urea; 1 -{4-[4-ethylpiperazin- 1 -yI)carbonyl]phenyl}-3-(4-{4-[(3R)-3-methylmorpholin-4-yI]-6-[(3S)-3 m ethyl mo rphoIi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)u rea; 5 4-{[(4-{4-[(3 R)-3- methyl mo rpholIi n-4-yI]-6- [(3S)-3- methyl mo rphoi n-4-y]- 1, 3,5-tri azi n-2 yIlphenyl)carbamoyl]aminolbenzoic acid; 1 -{4-[(4-butylpiperazin- 1-yI)carbonyl]phenyl}-3-(4-{4-[(3R)-3-methylmorpholin-4-yI]-6-[(3S)-3 m ethyl mo rphoIi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)u rea; methyl 4-{[(4-{4- [(3 R)-3-m ethyl mo rpholIi n-4-yI]-6-[(3S)-3- methyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2 10 yIlphenyl)carbamoyl]aminolbenzoate; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-{4-[(4- butyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 1 -(4-{[4-(l1 -methylethyl)piperazin-1 -yI] ca rbo nyllp he nyl)-3-(4-{4- [(3 R)-3-m ethyl mo rphoi n-4-y]-6 [(3S)-3-methylmorpholin-4-y]- 1,3,5-triazin-2-yIlphenyl)urea; 15 1- (4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-(4-{[4- (2 methylpropyl)piperazin-1 -yI]carbonyllphenyl)urea; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-(4-{[4-(1 1 methylpropyl)piperazin-1 -yI]carbonyllphenyl)urea; 4-{[(4-{4,6-b is[(3S)-3- methyl mo rphoi n-4-y]-1, ,3,5-triazi n-2-yIlp he nyl)ca rba moyl] amin o}-N- [2-(4 20 methylpiperazin- 1 -yI)ethyl]benzamide; N- [2-(d im ethyla m ino)ethyl]-4-{[(4-{4-[(3 R)-3- methyl mo rpholIi n-4-yI]-6-[(3S)-3- methyl mo rphoi n-4 yI]-l ,3,5-triazin-2-yIlphenyl)carbamoyl]aminolbenzamide; 4-{[(4-{4,6-b is[(3S)-3- methyl mo rphoi n-4-y]-1, ,3,5-triazi n-2-yIlp he nyl)ca rba moyl] amin o}-N- (2 pyrrolidin- 1 -ylethyl)benzamide; 25 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-{4-[(4-p ro pyl p ipe rid in- 1 yI)carbonyl]phenyllurea; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-[4- (p ipe rid in- 1 ylcarbonyl)phenyl]urea; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-{4-[(4-p ro pyl p ipe razi n- 1 30 yI)carbonyl]phenyllurea; 4-{[(4-{4,6-b is[(3S)-3- methyl mo rphoi n-4-y]-1, ,3,5-triazi n-2-yIlp he nyl)ca rba moyl] amin o}-N- (2 methoxyethyl)benzamide; 1 -{4-[4-morpholin-4-yI-6-(4-tricyclo[3.3. 1.1 3,7]dec-1 -ylpiperazin-1 -yI)-l ,3,5-triazin-2-yI]phenyl}-3 pyridin-4-ylurea; 35 methyl 4-{[(4-{4-[4-(dimethylcarbamoyl)piperazin- 1-yI]-6-morpholin-4-yI- 1,3,5-triazin-2 yIlphenyl)carbamoyl]aminolbenzoate; N, N-dimethyl-4-(4-morpholin-4-yI-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 yI)piperazine-1 -carboxamide; 28 WO 2009/143313 PCT/US2009/044774 N,N-dimethyl-4-(4-{4-[({4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}carbamoyl)amino]phenyl}-6 morpholin-4-yl-1,3,5-triazin-2-yl)piperazine-1 -carboxamide; N,N-dimethyl-4-{4-morpholin-4-yl-6-[4-({[4-(pyridazin-4 ylcarbamoyl)phenyl]carbamoyl}amino)phenyl]-1,3,5-triazin-2-yl}piperazine-1 -carboxamide; 5 N,N-dimethyl-4-(4-morpholin-4-yl-6-{4-[({4-[(4-propylpiperidin-1 yl)carbonyl]phenyl}carbamoyl)amino]phenyl}-1,3,5-triazin-2-yl)piperazine-1 -carboxamide; 4-{[(4-{4-[4-(dimethylcarbamoyl)piperazin-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoic acid; 4-(4-{4-[({4-[(2-methoxyethyl)carbamoyl]phenyl}carbamoyl)amino]phenyl}-6-morpholin-4-yl 10 1,3,5-triazin-2-yl)-N,N-dimethylpiperazine-1-carboxamide; 4-[4-(4-{[(4-{[2-(dimethylamino)ethyl](methyl)carbamoyl}phenyl)carbamoyl]amino}phenyl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]-N,N-dimethylpiperazine-1-carboxamide; 4-(4-{4-[({4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}carbamoyl)amino]phenyl}-6-morpholin-4-yl 1,3,5-triazin-2-yl)-N,N-dimethylpiperazine-1 -carboxamide; 15 1-(4-{4-[4-(ethylsulfonyl)piperazin-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4 ylurea; methyl 4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoate; 4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2 20 yl}phenyl)carbamoyl]amino}benzoic acid; N-[3-(dimethylamino)propyl]-4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5 triazin-2-yl}phenyl)carbamoyl]amino}benzamide; N-[2-(dimethylamino)ethyl]-4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5 triazin-2-yl}phenyl)carbamoyl]amino}benzamide; 25 4-{[(4-{4-[4-(1-methylethyl)-1,4-diazepan-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoic acid; methyl 4-{[(4-{4-[4-(acetylamino)piperidin-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoate; 1-(4-{4-[4-(1 -methylethyl)- 1,4-diazepan-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-{4-[(4 30 methylpiperazin-1-yl)carbonyl]phenyl}urea; N-[1 -(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2-yl)piperidin-4 yl]acetamide; 4-{[(4-{4-[4-(acetylamino)piperidin-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoic acid; 35 N-[2-(dimethylamino)ethyl]-4-{[(4-{4-[4-(1 -methylethyl)-1,4-d iazepan- 1 -yl]-6-morpholin-4-yl 1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; N-{1-[(4-{[(4-{4-[4-(1-methylethyl)-1,4-diazepan-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}phenyl)carbonyl]piperidin-4-yl}acetamide; 29 WO 2009/143313 PCT/US2009/044774 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-(4-{4-[4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)urea; 1-(4-{4-[4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-(4-{[4 (1 -methylethyl)piperazin-1 -yl]carbonyl}phenyl)urea; 5 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-(4-{[(3S)-3 methylmorpholin-4-yl]carbonyl}phenyl)urea; 1 -{4-[(4-butylpiperazin-1 -yl)carbonyl]phenyl}-3-(4-{4-[4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)urea; 1-(4-{4-[(4-methylpiperazin-1 -yl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-phenylurea; 10 1-(4-{4-[(1 -methylpiperidin-4-yl)oxy]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4 ylurea; 1 -{4-[4-morpholin-4-yl-6-(piperidin-4-yloxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; ethyl 4-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)oxy]piperidine-1-carboxylate; 15 N-ethyl-4-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)oxy]piperidine-1 -carboxamide; tert-butyl 4-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)oxy]piperidine-1-carboxylate; 4-[(4-morpholin-4-yl-6-{4-[(pyrid in-4-ylcarbamoyl)amino]phenyl}- 1,3,5-triazin-2-yl)oxy]piperidine 20 1-sulfonamide; 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin 4-ylurea; 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin 3-ylurea; 25 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3 phenylurea; 1-[4-(dimethylamino)phenyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}urea; 1-(4-cyanophenyl)-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2 30 yl]phenyl}urea; 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(2 methylpyrid in-4-yl)urea; 1-[2-(dimethylamino)ethyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}urea; 35 1-[4-(4-morpholin-4-yl-6-quinolin-3-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; 1 -{4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 30 WO 2009/143313 PCT/US2009/044774 methyl 4-[({4-[4-(2-methoxyethoxy)-6-morpholin-4-y- 1,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzoate; 1 -(4-{4-morpholin-4-yI-6-[2-(pyridin-4-ylamino)ethyl]- 1,3,5-triazin-2-yIlphenyl)-3-pyridin-4-ylurea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-y- 1,3,5-triazin-2 5 yI)phenyl]carbamoyllamino)-N-methylbenzamide; N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 4-({[4-(4-methoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-methyl-N-[2 (methylamino)ethyl]benzamide; 10 1 -[4-(4-methoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-{4-[(4-methylpiperazin- 1 yI)carbonyl]phenyllurea; 1 -{4-[(3,3-dimethylpiperazin- 1-yI)carbonyl]phenyl}-3-[4-(4-methoxy-6-morpholin-4-y- 1,3,5 triazin-2-yI)phenyl]urea; 4-({[4-(4-methoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(2-piperidin- 1 15 ylethyl)benzamide; 1 -(4-{4-[2,5-bis(hydroxymethyl)pyrrolidin-1 -yI]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3 pyridin-4-ylurea; 1 -(4-{4-[2-( 1,3-dioxan-2-yI)ethyl]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3-pyridin-4-ylurea; 1 -(4-{4-[3-(dimethylamino)propyl]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3-pyridin-4-ylurea; 20 1 -[4-(4-{3-[(l1 -m ethyl ethyl)a m ino]pro pyl}-6-mo rphoIi n-4-y- 1, 3,5-triazi n-2-yI)p hen yl]-3-pyrid in-4 ylu rea; 1 -{4-[4-morpholin-4-yI-6-(3-pyrrolidin-1 -ylpropyl)-1 ,3,5-triazin-2-yI]phenyl}-3-pyridin-4-ylurea; 1 -(4-{4-[3-(4-methylpiperazin-1 -yI)propyl]-6-morpholin-4-y- 1,3,5-triazin-2-yIlphenyl)-3-pyridin-4 ylu rea; 25 1 -{4-[4- (3-{[2-(d im ethyl am ino)ethyl] am inolp ropyl)-6-mo rp hol in-4-y- 1, ,3,5-tri azi n-2-yI] ph enyl}-3 pyridin-4-ylurea; 1 -{4-[4-(3-hydroxypropyl)-6-morpholin-4-y-1 ,3,5-triazin-2-yI]phenyl}-3-pyridin-4-ylurea; 1 -{4-[4-morpholin-4-yI-6-(3-oxopropyl)-1 ,3,5-triazin-2-yI]phenyl}-3-pyridin-4-ylurea; N-(4-morpholin-4-yI-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 30 yI)benzenesulfonamide; N-{4-[4-({[4-(4-methylpiperazin-1 -yI)phenyl]carbamoyllamino)phenyl]-6-morpholin-4-y- 1,3,5 triazin-2-yIlbenzenesulfonamide; N-(4-{4-[({4-[2-(dimethylamino)ethoxy]phenyllcarbamoyl)amino]phenyl-6-morpholin-4-y-1,3,5 triazin-2-yI)benzenesulfonamide; 35 N-(4-{4-[({4-[(4-methylpiperazin- 1 -yI)carbonyl]phenyllcarbamoyl)amino]phenyl}-6-morpholin-4 yI-l ,3,5-triazin-2-yI)benzenesulfonamide; 31 WO 2009/143313 PCT/US2009/044774 N-{4-morpholin-4-yI-6-[4-({[4-(piperazin- 1 -ylcarbonyl)phenyl]carbamoyllamino)phenyl]-1,3,5 triazin-2-yIlbenzenesulfonamide; N-[4-(4-{[(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)carbamoyl]aminolphenyl)-6 morpholin-4-yI- 1,3,5-triazin-2-yI]benzenesu Ifonamide; 5 N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4-morpholin-4-yI-6-[(phenylsulfony)amino]-1,3,5 triazin-2-yIlphenyl)carbamoyl]aminolbenzamide; N-[2-(dimethylamino)ethyl]-4-{[(4-{4-morpholin-4-yI-6-[(phenylsulfonyl)amino]-1 ,3,5-triazin-2 yIlphenyl)carbamoyl]aminolbenzamide; methyl 4-{[(4-{4-morpholin-4-yI-6-[(phenylsu Ifonyl)amino]- 1,3,5-triazin-2 10 yIlphenyl)carbamoyl]aminolbenzoate; 4-{[(4-{4-morpholin-4-yI-6-[(phenylsu Ifonyl)amino]-1 ,3,5-triazin-2 yIlphenyl)carbamoyl]aminolbenzoic acid; 1 -{4-[(4-methylpiperazin- 1-yI)carbonyl]phenyl}-3-[4-(6-morpholin-4-yI-4-oxo-4,5-dihyd ro-1,3,5 triazin-2-yI)phenyl]urea; 15 1 -(4-(2,4-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-isopropyl-2-methylpiperazine-1 carbonyl)phenyl)urea; 1 -(4-(4-cyclobutyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 20 yI)phenyl)urea; 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-isopropyl-3-methylpiperazine-1 carbonyl)phenyl)urea; 1 -(4-(3,4-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 25 1 -(4-(4-cyclobutyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 1 -(4-(4-cyclobutylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 1 -(4-(2,4-dimethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4 30 yI)-l ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-isopropyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-cyclobutyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 35 1 -(4-(4-isopropyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(3,4-dimethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4 yI)-l ,3,5-triazin-2-yI)phenyl)urea; 32 WO 2009/143313 PCT/US2009/044774 1-(4-(4-cyclobutyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-cyclobutylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4 yl)-1,3,5-triazin-2-yl)phenyl)urea; 5 1-(4-(2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4-yl) 1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4-yl) 1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(3-methylpiperazine-1 10 carbonyl)phenyl)urea; 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(2-methylpiperazine-1 carbonyl)phenyl)urea; 1-(4-(3,3-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2 yl)phenyl)urea; 15 1-(4-(3,3-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4 yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(3,3,4 trimethylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(3,3,4-trimethylpiperazine-1 20 carbonyl)phenyl)urea; 1-(4-(2,4-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4 yl)-1,3,5-triazin-2-yl)phenyl)urea; 1 -(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl)- 1,3,5-triazin-2-yl)phenyl)-3-(4-(2 methylpiperazine-1 -carbonyl)phenyl)urea; 25 1-(4-(4-isopropyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-cyclobutyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-isopropyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6 30 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(3,4-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-cyclobutyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea; 35 1-(4-(4-cyclobutylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(3,3,4 trimethylpiperazine-1 -carbonyl)phenyl)urea; 33 WO 2009/143313 PCT/US2009/044774 1 -(4-(3,3-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; N- (2-(d im ethyla m ino)ethyl)-N-m ethyl-4- (3- (4- (4-(3-m ethyl mo rphol ino)-6- (tetra hyd ro-2 H-pyra n-4 yI)-l ,3,5-triazin-2-yI)phenyl)ureido)benzamide; 5 N- (2-(d im ethyla m ino)ethyl)-4- (3-(4-(4- (3-m ethyl mo rphoIi no)-6- (tetra hyd ro-2 H-pyra n-4-y)-1, 3,5 triazin-2-yI)phenyl)ureido)benzamide; 1 -(4-(4-(dimethylamino)piperidine-i -ca rbo nyl)p he nyl)-3-(4-(4- (3-m ethyl mo rphoIi no)-6 (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2-yI) ph enyl)u rea; 1 -(4-(2,4-dimethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 10 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(2,4-dimethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-isopropyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 15 1 -(4-(4-cyclobutyl-2-methylpiperazine- 1 -ca rbo nyl)p he nyl)-3-(4- (4-(2-m ethyl mo rphoIi no)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(4-(2-methylmorpholino)-6-morpholino-1,3,5 triazin-2-yI)phenyl)ureido)benzamide; 1 -(4-(4-isopropyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6 20 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-(2-methylmorpholino)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(4-(3-methylpiperazine-1 carbonyl)phenyl)urea; 1 -(4-(3,4-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 1 ,3,5-triazin-2-yI)phenyl)urea; 25 1 -(4-(4-cyclobutyl-3-methylpiperazine- 1 -ca rbo nyl)p he nyl)-3-(4- (4-(2-m ethyl mo rphoIi no)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(3,3-dimethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4- (2-m ethyl mo rpholIi no)-6- mo rpholIi no- 1, 3,5-triazi n-2-yI)p he nyl)-3-(4-(3,3,4 30 trimethylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-cyclobutylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 1 ,3,5-triazin-2-yI)phenyl)urea; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4-(2-methylmorpholino)-6-morpholino-1 ,3,5-triazin-2 yI)phenyl)ureido)benzamide; 35 1 -(4-(4-(dimethylamino)piperidine-i -ca rbo nyl)p he nyl)-3-(4-(4- (2-m ethyl mo rphoi no)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(3-(dimethylamino)pyrrolidine-1 -ca rbo nyl)p he nyl)-3-(4-(4- (2-m ethyl mo rphoIi no)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 34 WO 2009/143313 PCT/US2009/044774 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea; 5 1-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2 yl)phenyl)-3-(4-(4-methylpiperazin-1 -yl)phenyl)urea; 1-(4-(4-(dimethylamino)piperidin-1 -yl)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6 ((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2 10 yl)phenyl)-3-(4-(quinuclidin-4-yl)phenyl)urea; 1-(4-(4-cyclopropylpiperazin-1 -yl)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(cyclopropylmethyl)piperazin-1 -yl)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6 ((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)urea; 15 1-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2 yl)phenyl)-3-(4-(4-ethylpiperazin-1 -yl)phenyl)urea; 1-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2 yl)phenyl)-3-(4-(4-isopropylpiperazin-1 -yl)phenyl)urea; 1-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2 20 yl)phenyl)-3-(4-(4-methylpiperazine-1-carbonyl)phenyl)urea; 1-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2 yl)phenyl)-3-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)urea; 25 1-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2 yl)phenyl)-3-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-cyclopropylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yl)-6 ((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(cyclopropylmethyl)piperazine-1 -carbonyl)phenyl)-3-(4-(4-((2R,5S)-2,5 30 dimethylpyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)- 1, 3,5-triazin 2-yl)phenyl)-3-(4-(4-methylpiperazin-1 -yl)phenyl)urea; 1-(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)- 1, 3,5-triazin 2-yl)phenyl)-3-(4-(4-(dimethylamino)piperidin-1 -yl)phenyl)urea; 35 1-(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)- 1, 3,5-triazin 2-yl)phenyl)-3-(4-(quinuclidin-4-yl)phenyl)urea; 1-(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidin-1 -yl)-6-((R)-3-methylmorpholino)- 1, 3,5-triazin 2-yl)phenyl)-3-(4-(4-cyclopropylpiperazin-1 -yl)phenyl)urea; 35 WO 2009/143313 PCT/US2009/044774 1 -(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidi n-i -yI)-6-((R)-3- methyl mo rpholIi no)- 1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-(cyclopropylmethyl)piperazin-1 -yI)phenyl)urea; 1 -(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidi n-i -yI)-6-((R)-3- methyl mo rpholIi no)- 1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-ethylpiperazin-1 -yI)phenyl)urea; 5 1 -(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidi n-i -yI)-6-((R)-3- methyl mo rpholIi no)- 1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-isopropylpiperazin-1 -yI)phenyl)urea; 1 -(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidi n-i -yI)-6-((R)-3- methyl mo rpholIi no)- 1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-methylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidi n-i -yI)-6-((R)-3- methyl mo rpholIi no)- 1, 3,5-triazi n 10 2-yI)phenyl)-3-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid in- 1 -yI)-6-((R)-3- methyl mo rpholIi no)- 1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)urea; 1 -(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidi n-i -yI)-6-((R)-3- methyl mo rpholIi no)- 1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-ethylpiperazine- 1 -carbonyl)phenyl)urea; 15 1 -(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidi n-i -yI)-6-((R)-3- methyl mo rpholIi no)- 1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-cyclopropylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-((2S,5R)-2,5-bis(hydroxymethyl)pyrrolidi n-i -yI)-6-((R)-3- methyl mo rpholIi no)- 1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-(cyclopropylmethyl)piperazine- 1 -carbonyl)phenyl)urea; 1 -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 20 1 -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-3-yI)urea; 1 -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4-yI)urea; 1 -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)- 1,3,5-triazin-2-yI)phenyl)-3-(pyrimid in-5-yI)urea; 4-(3-(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yI)phenyl)ureido)benzamide; N- (2-(d im ethyla m ino)ethyl)-4- (3-(4-(4- mo rpholIi no-6- (tetra hyd rofu ra n-3-yloxy)-1, ,3,5-triazi n-2 25 yI)phenyl)ureido)benzamide; N- (2-(d im ethyla m ino)ethyl)-N-m ethyl-4- (3-(4- (4- mo rpholIi no-6- (tetra hyd rofu ra n-3-yloxy)- 1, 3,5 triazin-2-yI)phenyl)ureido)benzamide; N- (2-(m ethyl am ino)eth yl)-4-(3- (4-(4- mo rpholIi no-6- (tetra hyd rofu ra n-3-yloxy)-1, ,3,5-triazi n-2 yI)phenyl)ureido)benzamide; 30 N- methyl-N- (2-(m ethyla m ino)eth yl)-4- (3-(4-(4- mo rphoIi no-6- (tetra hyd rofu ra n-3-yloxy)-1, 3,5 triazin-2-yI)phenyl)ureido)benzamide; 1 -(4-((R)-3-(dimethylamino)pyrrolidine- 1 -carbonyl)phenyl)-3-(4-(4-morpholino-6 (tetra hyd rofu ra n-3-yloxy)- 1, 3,5-tri azi n-2-yI) ph enyl) urea; 1 -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(piperazine-1 35 carbonyl)phenyl)urea; 1 -(4-(4-methylpiperazine-1 -ca rbo nyl)p he nyl)-3-(4- (4-mo rphoIi no-6- (tetra hyd rofu ra n-3-yloxy) 1 ,3,5-triazin-2-yI)phenyl)urea; 36 WO 2009/143313 PCT/US2009/044774 1-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)- 1,3,5 triazin-2-yl)phenyl)urea; 1-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy) 1,3,5-triazin-2-yl)phenyl)urea; 5 1 -(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran-3-yloxy)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea; 1 -(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran-3-yloxy)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-3-yl)urea ; 1 -(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran-3-yloxy)-1,3,5-triazin-2-yl)phenyl)-3 10 (pyridazin-4-yl)urea; 1 -(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran-3-yloxy)-1,3,5-triazin-2-yl)phenyl)-3 (pyrimidin-5-yl)urea; 4-(3-(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran-3-yloxy)- 1,3,5-triazin-2 yl)phenyl)ureido)benzamide; 15 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-((S)-3-methylmorpholino)-6 (tetrahydrofuran-3-yloxy)- 1,3,5-triazin-2-yl)phenyl)urea; 1 -(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran-3-yloxy)-1,3,5-triazin-2-yl)phenyl)-3-(4 (piperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yl)phenyl)-3-(4-(4 20 methylpiperazine-1-carbonyl)phenyl)urea; 1-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran 3-yloxy)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-((S)-3-methylmorpholino)-6 (tetrahydrofuran-3-yloxy)- 1,3,5-triazin-2-yl)phenyl)urea; 25 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4-yl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5-yl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 30 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-chlorophenyl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-fluorophenyl)urea; methyl4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2yl)phenyl)ureido) benzoate; 4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)benzoic acid; 4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N-(2 35 (dimethylamino)ethyl)benzamide; 37 WO 2009/143313 PCT/US2009/044774 4-(3-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N-(2 (dimethylamino)ethyl)-N-methylbenzamide; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(3 (dimethylamino)pyrrolidine-1 -carbonyl)phenyl)urea; 5 4-(3-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)benzamide; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-ethylpiperazine-1 carbonyl)phenyl)urea; 10 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-isopropylpiperazine-1 carbonyl)phenyl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 (dimethylamino)piperidine-1 -carbonyl)phenyl)urea; 1-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-(4-methyl-1,4-diazepan- 1-yl)-6 15 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine- 1 carbonyl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 20 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 ethylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-n propylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 25 isopropylpiperazine-1-carbonyl)phenyl)urea; 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(4-methyl-1,4-diazepan- 1-yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)ureido)benzamide; 30 N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino 1,3,5-triazin-2-yl)phenyl)ureido)benzamide; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 1-(4-chlorophenyl)-3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 35 1-(4-fluorophenyl)-3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 38 WO 2009/143313 PCT/US2009/044774 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4 yl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5 5 yl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 10 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 ethylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-n propylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 15 isopropylpiperazine-1-carbonyl)phenyl)urea; 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(4-ethyl-1,4-diazepan- 1-yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)ureido)benzamide; 20 N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5 triazin-2-yl)phenyl)ureido)benzamide; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 1-(4-chlorophenyl)-3-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 25 1-(4-fluorophenyl)-3-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4-yl)urea; 30 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5-yl)urea; 1-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 1-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 35 1-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 ethylpiperazine-1 -carbonyl)phenyl)urea; 39 WO 2009/143313 PCT/US2009/044774 1 -(4-(4-(4-propyl-1 ,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-n propylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-(4-propyl-1 ,4-d iazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4 isopropylpiperazine-1 -carbonyl)phenyl)urea; 5 1 -(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(4-propyl- 1,4-diazepan-1 -yI)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4-(4-propyl- 1,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2 yI)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(4-(4-propyl- 1,4-diazepan- 1 -yI)-6-morpholino-1,3,5 10 triazin-2-yI)phenyl)ureido)benzamide; 1 -(4-(4-(4-propyl-1 ,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-phenylurea; 1 -(4-chlorophenyl)-3-(4-(4-(4-propyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 1 -(4-fluorophenyl)-3-(4-(4-(4-propyl- 1,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2 15 yI)phenyl)urea; 1 -(4-(4-(4-propyl- 1,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-3-yI)urea; 1 -(4-(4-(4-propyl- 1,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 1 -(4-(4-(4-propyl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4 yI)u rea; 20 1 -(4-(4-(4-propyl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyrimidin-5 yI)u rea; 1 -(4-(4-(4-isopropyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-3 yI)u rea; 1 -(4-(4-(4-isopropyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4 25 yI)urea; 1 -(4-(4-(4-isopropyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4 yI)u rea; 1 -(4-(4-(4-isopropyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyrimidin-5 yI)u rea; 30 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridin-3-yI)urea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4 yI)u rea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyrimidin-5 35 yI)urea ; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-phenylurea; 40 WO 2009/143313 PCT/US2009/044774 1-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4 chlorophenyl)urea; 1-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4 fluorophenyl)urea; 5 Methyl-4-(3-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)ureido)benzoate; 4-(3-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)benzoic acid; 4-(3-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N-(2 10 (dimethylamino)ethyl)benzamide; 4-(3-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N-(2 (dimethylamino)ethyl)-N-methylbenzamide; 1-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(3 (dimethylamino)pyrrolidine-1 -carbonyl)phenyl)urea; 15 4-(3-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)benzamide; 1-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 ethylpiperazine-1 -carbonyl)phenyl)urea; 20 1-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-n propylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 isopropylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 25 carbonyl)phenyl)urea; 1-(4-(4-(4-acetyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 (dimethylamino)piperidine-1 -carbonyl)phenyl)urea; 1-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 30 1-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine 1 -carbonyl)phenyl)urea; 1-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6 35 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 isopropylpiperazine-1 -carbonyl)phenyl)urea; 41 WO 2009/143313 PCT/US2009/044774 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 1-(4-chlorophenyl)-3-(4-(4-(4-isobutyryl-1,4-d iazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 5 yl)phenyl)urea; 1-(4-fluorophenyl)-3-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 1-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4 yl)urea; 10 1-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4 yl)urea; 1-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3 yl)urea; 1-(4-(4-(4-isobutyryl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5 15 yl)urea; tert-butyl 4-(4-(4-(3-(4-(methoxycarbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2-yl) 1,4-diazepane-1-carboxylate; methyl4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl) ureido)benzoate; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 20 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-chlorophenyl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-fluorophenyl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4-yl)urea; 25 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5-yl)urea; N-methyl-4-(4-morpholino-6-(4-(3-phenylureido)phenyl)-1,3,5-triazin-2-yl)-1,4-diazepane-1 carboxamide (M+H) 532.2; 4-(4-(4-(3-(4-chlorophenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2-yl)-N-methyl-1,4 diazepane-1 -carboxamide; 30 4-(4-(4-(3-(4-fluorophenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2-yl)-N-methyl-1,4 diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(2-(dimethylamino)ethylcarbamoyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5 triazin-2-yl)-N-methyl-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-((2-(dimethylamino)ethyl)(methyl)carbamoyl)phenyl)ureido)phenyl)-6-morpholino 35 1,3,5-triazin-2-yl)-N-methyl- 1,4-diazepane- 1 -carboxamide; 42 WO 2009/143313 PCT/US2009/044774 4-(4-(4-(3-(4-carbamoylphenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2-yl)-N-methyl-1,4 diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino 1,3,5-triazin-2-yl)-N-methyl- 1,4-diazepane- 1 -carboxamide; 5 N-methyl-4-(4-morpholino-6-(4-(3-(4-(piperazine-1 -carbonyl)phenyl)ureido)phenyl)-1,3,5-triazin 2-yl)-1,4-diazepane-1-carboxamide; N-methyl-4-(4-(4-(3-(4-(4-methylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino 1,3,5-triazin-2-yl)-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2 10 yl)-N-methyl-1,4-diazepane-1-carboxamide; 4-(4-(4-(3-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5 triazin-2-yl)-N-methyl-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5 triazin-2-yl)-N-methyl-1,4-diazepane-1 -carboxamide; 15 4-(4-(4-(3-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5 triazin-2-yl)-N-isopropyl-1,4-diazepane-1 -carboxamide; N-isopropyl-4-(4-(4-(3-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino 1,3,5-triazin-2-yl)-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2 20 yl)-N-isopropyl-1,4-diazepane-1-carboxamide; N-isopropyl-4-(4-(4-(3-(4-(4-methylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino 1,3,5-triazin-2-yl)-1,4-diazepane-1 -carboxamide; N-isopropyl-4-(4-morpholino-6-(4-(3-(4-(piperazine-1 -carbonyl)phenyl)ureido)phenyl)-1,3,5 triazin-2-yl)-1,4-diazepane-1 -carboxamide; 25 N-isopropyl-4-(4-morpholino-6-(4-(3-pyridin-4-ylureido)phenyl)-1,3,5-triazin-2-yl)-1,4-diazepane 1-carboxamide; N-isopropyl-4-(4-morpholino-6-(4-(3-pyridazin-4-ylureido)phenyl)-1,3,5-triazin-2-yl)-1,4 diazepane-1 -carboxamide; N-isopropyl-4-(4-morpholino-6-(4-(3-pyrimidin-5-ylureido)phenyl)-1,3,5-triazin-2-yl)-1,4 30 diazepane-1-carboxamide; N-isopropyl-4-(4-morpholino-6-(4-(3-pyridin-3-ylureido)phenyl)-1,3,5-triazin-2-yl)-1,4-diazepane 1-carboxamide; 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 35 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4-yl)urea; 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5-yl)urea; 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 43 WO 2009/143313 PCT/US2009/044774 1 -(4-chlorophenyl)-3-(4-(4-morpholino-6-( 1 H-pyrazol-1 -yI)-l ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-fluorophenyl)-3-(4-(4-morpholino-6-( 1 H-pyrazol-1 -yI)-l ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-(2-methyl-1 H-imidazol-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-phenylurea; 1 -(4-chlorophenyl)-3-(4-(4-(2-methyl-1 H-imidazol-1 -yI)-6-morpholino-1 ,3,5-triazin-2 5 yI)phenyl)urea; 1 -(4-fluorophenyl)-3-(4-(4-(2-methyl- 1 H-imidazol- 1 -yI)-6-morpholino- 1,3,5-triazin-2 yI)phenyl)urea; 1 -(4-(4-(2-methyl-1 H-imidazol- 1 -yI)-6-morpholino-1 ,3 ,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 1 -(4-(4-(2-methyl-1 H-imidazol- 1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4 10 yI)urea; 1 -(4-(4-(2-methyl-1 H-imidazol-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyrimidin-5 yI)u rea; 1 -(4-acetyl phe nyl)-3-(4-(4,6-b is ((R)-3-m ethyl mo rphoi no)- 1, 3,5-tri azi n-2-yI)p he nyl)u rea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(piperazin-1 -yI)phenyl)urea; 15 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 (dimethylamino)acetyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 morpholinoacetyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 20 hydroxyacetyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4 (methoxymethyl )phenyl)u rea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 methoxyethyl)phenyl)urea; 25 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(1 hydroxyethyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2-hydroxypropan-2 yI)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 30 hydroxypropyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2-hydroxy-2 methylpropyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4 (dimethylamino)piperidine-1 -carbonyl)phenyl)urea; 35 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-cyanophenyl)urea; 4-(3-(4-(4,6-bis((R)-3-methylmorpholino)- 1,3,5-triazin-2-yI)phenyl)ureido)-N-methylbenzamide; 44 WO 2009/143313 PCT/US2009/044774 4-(3-(4-(4,6-bis((R)-3-methylmorpholino)- 1,3,5-triazin-2-yI)phenyl)ureido)-NN dimethylbenzamide; 4- (3-(4-(4,6- bis((R)-3-m ethyl mo rphol ino)-1, ,3,5-tri azi n-2-yI)p he nyl)u re ido) be nza mid e; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(6-(4-methylpiperazine-1 5 carbonyl)pyridin-3-yI)urea; (R)-1 -(4-((dimethylamino)methyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran 4-yI)-l ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3 (pyridin-4-yI)urea; 10 (R)-1 -(4-acetyl ph enyl)-3- (4- (4-(3-m ethyl mo rphoi no)-6- (tetra hyd ro-2 H-pyra n-4-y)-1, ,3,5-tri azi n-2 yI)phenyl)urea; (R)- 1 -(4- (2-(d im ethyla m ino)acetyl)p he nyl)-3-(4- (4-(3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H-pyra n 4-yI)-l ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(4-(2 15 morpholinoacetyl)phenyl)urea; (R)-1 -(4-(2-hyd roxyacetyl) ph enyl)-3-(4- (4-(3-m ethyl mo rphoi no)-6- (tetra hyd ro-2 H-pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(m ethoxym ethyl)p he nyl)-3-(4- (4-(3-m ethyl mo rphoi no)-6-(tetra hyd ro-2 H-pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; 20 (R)-1 -(4-(2- methoxyeth yl) ph enyl)-3- (4-(4-(3- methyl mo rphoi no)-6-(tetra hyd ro-2 H- pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(l1 -hyd roxyethyl)p he nyl)-3-(4- (4- ((R)-3- methyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(2- hyd roxyp ropa n-2-yI) ph enyl)-3- (4-(4- (3-m ethyl mo rphoIi no)-6-(tetra hyd ro-2 H- pyra n-4 25 yI)-l ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(2-hyd roxyp ro pyl) ph enyl)-3-(4- (4-((R)-3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H- pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(2-hydroxy-2-methylpropyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 30 (R)-1 -(4-(4-(dimethylamino)piperidine-i -ca rbo nyl)p he nyl)-3-(4-(4-(3-m ethyl mo rphoIi no)-6 (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2-yI) ph enyl)u rea; (R)-1 -(4-cyanophenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-y)- 1,3,5-triazin-2 yI)phenyl)urea; (R)- N-m ethyl-4-(3-(4- (4-(3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H-pyra n-4-y)- 1, 3,5-tri azi n-2 35 yI)phenyl)ureido)benzamide; (R)-N, N-d im ethyl-4-(3- (4- (4-(3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H-pyra n-4-y)-1, ,3,5-triazi n-2 yI)phenyl)ureido)benzamide; 45 WO 2009/143313 PCT/US2009/044774 (R)-4-(3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-y)- 1,3,5-triazin-2 yI)phenyl)ureido)benzamide; (R)-1 -(4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(6-(4 methylpiperazine-1 -carbonyl)pyridin-3-yI)urea; 5 1 -(4-(4-(3-methyl-1 H-pyrazol- 1 -yI)-6-morpholi no-1, ,3,5-triazi n-2-yI)phenyl)-3-(pyri mid in-5-yI)u rea; 1 -(4-(4-(3-methyl-1 H-pyrazol- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-3-yI)urea; I -(4-(4-(3-methyl-1 H-pyrazol-1I-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 1 -(4-(4-(3-methyl-1 H-pyrazol- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4-yI)urea; 1 -(4-(4-(3-methyl- 1 H-pyrazol- 1-yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-phenylurea; 10 1 -(4-chlorophenyl)-3-(4-(4-(3-methyl-1 H-pyrazol-1 -yI)-6-morpholino- 1,3,5-triazin-2 yI)phenyl)urea; 1 -(4-fluorophenyl)-3-(4-(4-(3-methyl- 1 H-pyrazol-1 -yI)-6-morpholino- 1,3,5-triazin-2 yI)phenyl)urea; methyl 4- (3- (4-(4- (3-m ethyl- 1 H-pyrazol-1 -yI)-6-morpholino- 1,3,5-triazin-2 15 yI)phenyl)ureido)benzoate; 4- (3-(4- (4-(3-m ethyl- 1 H-pyrazol-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)ureido)benzoic acid; 4- (3-(4- (4-(3-m ethyl- 1 H-pyrazol-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)ureido)benzamide; 1 -(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(3-methyl-1 H-pyrazol- l-yI)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 20 1 -(4-(4-(3-methyl-1 H-pyrazol- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 1 -(4-(4-(3-methyl-1 H-pyrazol- 1-yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-ethylpiperazine-1 -ca rbo nyl) ph enyl)-3-(4- (4-(3-m ethyl- 1 H-pyrazol-1 -yI)-6-morpholino 25 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-isopropylpiperazine-l1-carbonyl)phenyl)-3-(4-(4-(3-methyl-1 H-pyrazol-1 -yI)-6-morpholino 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-(3-methyl-1 H-pyrazol- l-yI)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 30 1 -{4-[(4-butylpiperazin-1 -yI)carbonyl]phenyl}-3-(4-{4-[4-(l1-methylethyl)-l1,4-diazepan- l-yI]-6 morpholin-4-yI- 1,3,5-triazin-2-yIlphenyl)urea; 1 -(4-{4-[4-(l1-methylethyl)- 1,4-diazepan-1 -yI]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3-(4-{[4 (1 -methylethyl)piperazin-1 -yI]carbonyllphenyl)urea; 1 -{4-[4-ethylpiperazin-1 -yI)carbonyl]phenyl}-3-(4-{4-[4-( 1 -methylethyl)- 1,4-diazepan-1 -yI]-6 35 morpholin-4-yI- 1,3,5-triazin-2-yIlphenyl)urea; 46 WO 2009/143313 PCT/US2009/044774 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4 yl)-1,3,5-triazin-2-yl]phenyl}urea; 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea; 5 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea; 1-(4-{[4-(1 -methylethyl)piperazin-1 -yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5 10 triazin-2-yl]phenyl}carbamoyl)amino]benzamide; 1 -{4-[4-(azetidin-3-yloxy)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; N-(1 -methylethyl)-3-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin 2-yl)oxy]azetidine-1 -carboxamide; N-{1 -[(4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1,3,5-triazin-2 15 yl}phenyl)carbamoyl]amino}phenyl)carbonyl]piperidin-4-yl}acetamide; 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1,3,5-triazin-2-yl}phenyl)-3-(4-{[4- (1 -methylethyl)-1,4 diazepan-1 -yl]carbonyl}phenyl)urea; 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-[4-(3-oxa-8 azabicyclo[3.2. 1 ]oct-8-ylcarbonyl)phenyl]urea; 20 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1,3,5-triazin-2-yl}phenyl)-3-{4-[(4-cyanopiperidin-1 yl)carbonyl]phenyl}urea; 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-(4-{[(3S)-3 (dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)urea; 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-(4-{[(3R)-3 25 (dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)urea; 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-(4-{4-(morpholin-4-yl)-6-[4 (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-(4-{4-(morpholin-4-yl)-6-[4 (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; 30 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-{4-[(2-methylpiperazin-1 yl)carbonyl]phenyl}urea; 1-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)-3-[4 (piperazin-1 -ylcarbonyl)phenyl]urea; 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-(4-{4-(morpholin-4-yl)-6-[4 35 (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-{4-[(3,3,4-trimethylpiperazin-1 yl)carbonyl]phenyl}urea; 47 WO 2009/143313 PCT/US2009/044774 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-(4-{[(3R)-3-methylpiperazin- 1 yl]carbonyl}phenyl)urea; 1-(4-{[(3R)-3,4-dimethylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin 2-yl]phenyl}urea; 5 1-(4-{[(3R)-4-cyclobutyl-3-methylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl) 1,3,5-triazin-2-yl]phenyl}urea; 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-(4-{[(3R)-3-methyl-4-(propan-2 yl)piperazin-1 -yl]carbonyl}phenyl)urea; 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-(4-{[(3S)-3-methylpiperazin-1 10 yl]carbonyl}phenyl)urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-[4-(propan-2-yl) 1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-[4-(propan-2-yl)- 1,4-diazepan-1 -yl]-1,3,5-triazin-2 yl}phenyl)-3-{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}urea; 15 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-(4-{4-[(3S)-3-methylmorpholin-4 yl]-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; N-[3-(dimethylamino)propyl]-4-{[(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl] 1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan 20 1-yl]-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; 1-[4-(morpholin-4-ylcarbonyl)phenyl]-3-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 yl]-1,3,5-triazin-2-yl}phenyl)urea; N-(2-methoxyethyl)-4-{[(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)- 1,4-diazepan- 1-yl]-1,3,5-triazin 2-yl}phenyl)carbamoyl]amino}benzamide; 25 1-[4-(1,4-diazepan-1 -ylcarbonyl)phenyl]-3-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4 diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; 1-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)-3-(4-{[4 (propan-2-yl)-1,4-diazepan-1-yl]carbonyl}phenyl)urea; 1 -(4-{[(3S)-4-cyclobutyl-3-methylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl) 30 1,3,5-triazin-2-yl]phenyl}urea; 1-(4-{[(3S)-3,4-dimethylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin 2-yl]phenyl}urea; 1 -{4-[4-(morpholin-4-yl)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-{4-[(3,3,4 trimethylpiperazin-1 -yl)carbonyl]phenyl}urea; 35 1-(4-{[(3S)-3,4-dimethylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4-(morpholin-4-yl)-6-(tetrahydro 2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; 1-(4-{[(3S)-3-methylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4-(morpholin-4-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; 48 WO 2009/143313 PCT/US2009/044774 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; and 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea. 5 The invention also includes pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable carrier. The invention includes a compound of formula I when provided as a pharmaceutically acceptable prodrug, hydrated salt, such as pharmaceutically acceptable salt, or mixtures thereof. In other aspects, the invention provides that the pharmaceutically acceptable carrier 10 suitable for oral administration and the composition comprises an oral dosage form. In other aspects, the invention provides a composition comprising a compound of Formula I, a second compound selected from the group consisting of a topoisomerase I inhibitor, a MEK 1/2 inhibitor, a HSP90 inhibitor, procarbazine, dacarbazine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, 15 cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epirubicin, 5-fluorouracil, docetaxel, paclitaxel, leucovorin, levamisole, irinotecan, estramustine, etoposide, nitrogen mustards, BCNU, carmustine, lomustine, vinblastine, vincristine, vinorelbine, 20 cisplatin, carboplatin, oxaliplatin, imatinib mesylate, Avastin (bevacizumab), hexamethylmelamine, topotecan, tyrosine kinase inhibitors, tyrphostins, herbimycin A, genistein, erbstatin, hydroxyzine, glatiramer acetate, interferon beta-la, interferon beta-1b, natalizumab and lavendustin A; and a pharmaceutically acceptable carrier. In other aspects, the second compound is Avastin. 25 In other aspects, the invention provides a method of treating a P13K-related disorder, comprising administering to a mammal in need thereof a compound of Formula I in an amount effective to treat a P13K-related disorder. In other aspects, the P13K-related disorder is selected from restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, 30 atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, and cancer. In other aspects, the P13K-related disorder is cancer. In other aspects, the cancer is selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung 35 cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and brain cancer. In other aspects, the invention provides a method of treating an mTOR-related disorder, comprising administering to a mammal in need thereof a compound of Formula I in an amount effective to treat an mTOR-related disorder. 49 WO 2009/143313 PCT/US2009/044774 In other aspects, the mTOR-related disorder is selected from restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, and cancer. 5 In other aspects, the mTOR-related disorder is cancer. In other aspects, the cancer is selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and brain cancer. In other aspects, the invention provides a method of treating a hSMG-1-related disorder, 10 comprising administering to a mammal in need thereof a compound of Formula I in an amount effective to treat a hSMG-1-related disorder. In other aspects, the hSMG-1-related disorder is selected from restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, 15 kidney disease, and cancer. In other aspects, the hSMG-1-related disorder is cancer. In other aspects, the cancer is selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and brain cancer. 20 In other aspects, the invention provides a method of treating advanced renal cell carcinoma, comprising administering to a mammal in need thereof a compound of Formula I in an amount effective to treat advanced renal cell carcinoma. In other aspects, the invention provides a method of treating acute lymphoblastic leukemia, comprising administering to a mammal in need thereof a compound of Formula I in an 25 amount effective to treat acute lymphoblastic leukemia. In other aspects, the invention provides a method of treating acute malignant melanoma, comprising administering to a mammal in need thereof a compound of Formula I in an amount effective to treat malignant melanoma. In other aspects, the invention provides a method of treating soft-tissue or bone 30 sarcoma, comprising administering to a mammal in need thereof a compound of Formula I in an amount effective to treat soft-tissue or bone sarcoma. In other aspects, the invention provides a method of treating a cancer selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric 35 cancer, and brain cancer comprising administering to a mammal in need thereof a composition comprising a compound of Formula I; a second compound selected from the group consisting of a topoisomerase I inhibitor, a MEK 1/2 inhibitor, a HSP90 inhibitor, procarbazine, dacarbazine, 50 WO 2009/143313 PCT/US2009/044774 R N R 9 N N gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, 5 doxorubicin, epirubicin, 5-fluorouracil, docetaxel, paclitaxel, leucovorin, levamisole, irinotecan, estramustine, etoposide, nitrogen mustards, BCNU, carmustine, lomustine, vinblastine, vincristine, vinorelbine, cisplatin, carboplatin, oxaliplatin, imatinib mesylate, Avastin (bevacizumab), hexamethylmelamine, topotecan, tyrosine kinase inhibitors, tyrphostins, herbimycin A, genistein, erbstatin, and lavendustin A; and a pharmaceutically acceptable 10 carrier. in an amount effective to treat the cancer. In other aspects, the invention provides a method of inhibiting mTOR in a subject, comprising administering to a subject in need thereof a compound of Formula I in an amount effective to inhibit mTOR. In other aspects, the invention provides a method of inhibiting P13K in a subject, 15 comprising administering to a subject in need thereof a compound of Formula I in an amount effective to inhibit P13K. In other aspects, the invention provides a method of inhibiting hSMG-1 in a subject, comprising administering to a subject in need thereof a compound of Formula I in an amount effective to inhibit hSMG-1. 20 In other aspects, the invention provides a method of inhibiting mTOR, P13K, and hSMG 1 together in a subject, comprising administering to a subject in need thereof a compound of Formula I in an amount effective to inhibit mTOR, P13K, and hSMG-1. In another aspect, the invention provides a method of synthesizing compounds of the Formula I, which are: 25 said method comprising reacting 2,4,6-trichloro[1,3,5]triazine with
R
7 0 R 8 R6 N R 9 H 51 WO 2009/143313 PCT/US2009/044774 to form the intermediate dichlorotriazine compound
R
7 0 R 8 R N R 9 N N Cl N Cl The method of synthesizing compounds of the Formula I further comprising reacting the intermediate dichlorotriazine compound with 0 5 Sn(butyl) 3 to form the intermediate compound R7 0 R 8 R N R 9 N N CI N 0 52 WO 2009/143313 PCT/US2009/044774 The method of synthesizing compounds of the Formula I further comprising reacting the intermediate dichlorotriazine compound with
R
7 0 R 8 R N R 9 H to form the intermediate compound
R
7 0 R 8 69 R N R9 N N R Cl N N R 0
R
9
R
8 5 wherein each R 6 , R 7 , R 8 and R 9 is independently selected and defined according to formula 1. 53 WO 2009/143313 PCT/US2009/044774 The method of synthesizing compounds of the Formula I wherein the reacting moiety
R
7 0 R 8 R6 N R 9 H is N 5 Procedures used to synthesize the compounds of the present invention are described in Schemes 1-12 and are illustrated in the examples. Reasonable variations of the described procedures are intended to be within the scope of the present invention: 54 WO 2009/143313 PCT/US2009/044774 Scheme 1
R
7 0 R 8
R
7 0 R 8 R 7 0 R 8 CI R 6 N R 9
R
6 N R 9 Amine/ Et 3 N R 6 N R 9 N N a N _N N N CI N CI CI N CI OC/ Acetone R N N2CI 1 2 R 33 c d\b
R
7 0 R 8
R
7 0 R 8 R O RX R = Alkyl, Alkene, Alkyne R 6 N R 9
R
6 N R 9 Aryl, Heteroaryl, Cycloalkyl, R 6 N R 9 N N N N Cycloalkyl with one or two I R12 N heteroatoms selected from N N R'O N C N N O, S(O)",
N-R
1 0 , R iN C 5 R NH2 6 4 e
RR
7 0 R8 R 0 R8 Xx xxRy 0 R 8
R
6 N R 9
R
6 N R 9 e N N N N R 6 N R 9 R N ~ N NN
NH
2 N NH 2 R 2 N il e N 9 H 9 (a) Acetone/ H 2 0/ Et 3 N/ -10 0C; (b) 4-aminophenyl boronic acid/ (Ph 3
)
4 P(Pd)/ Na 2 CO3/ DME/ Reflux or m Wave (c) Corresponding alcohol/ n-BuLi or NaH/ THF/ RT or Reflux; (d) When R = alky RMgBr/ Pd (0)/ THF; when R = Alkene or cycloalkyl or cycloalkyl with one or two heteroatoms the transformation is via vinyl stanane/ Pd(0)/ Organic solvent/ Reflux (Stille coupling); When R = aryl or heteroaryl the transformation is via Aryl bornate/ (Ph 3
)
4 P(Pd)/ Na 2 CO3/ DME/ Reflux or m Wave (Suzuki coupling); (e) When R 3 is -OR 5 , DCM/ CICOOR 5 / Et 3 N/ 0 0 C-RT; When R 5 is NHR 5 , DMAP/ DCM/ R 5 NCO or (COC12)3/ Et 3
N/R
5
NH
2 Compounds of the present inventions were prepared by a multi-step sequence as depicted in Scheme 1. One chlorine atom at a time was selectively replaced at different 5 temperatures. The commercially available cyanuric acid chloride 1 was reacted with morpholine or substituted morpholine derivatives at -10 0C to give the mono morpholine derivative 2. This pivotal intermediate 2 can be reacted with different nucleophiles. In this present invention, intermediates 2 were reacted with different amines and alcohols to give 3 and 5 respectively. 55 WO 2009/143313 PCT/US2009/044774 The third chlorine atom in intermediates 3 and 5 was replaced with 4-aminoaryl and aminoheteroaryl boronic acid in the presence of (Ph 3
)
4 P(Pd)/ Na 2 CO3/ DME/ Reflux or microwave condition to yield 4 and 8 respectively. The amino group was converted to the urea derivatives by different two procedures depending upon the availability of the starting material. 5 Some of the examples reported here were transformed into the urea derivative by reacting 4 or 8 with an appropriately substituted isocyanate derivative. Many of the urea derivatives reported here were prepared by reacting intermediates 4 or 8 with triphosgene/ Et 3 N and an appropriately substituted primary amine derivative. The corresponding carbamate derivatives were prepared by reacting intermediates 4 or 8 with an appropriately substituted chloroformate reagents. The 10 intermediates 2 were also used to prepare derivatives of 6, where in R is a alkyl, alkene, alkyne, aryl or heteroaryl. Reacting 6 with the appropriately substituted alkyl introduced alkyl or cycloalkyl groups in intermediate 6 or cycloalkyl magnesium bromide or the corresponding appropriately substituted organo- zinc reagent. Alkenes can be introduced in compound 6 by a Pd catalyzed appropriately substituted vinyl tin derivatives. Similarly, aryl or heteroaryl 15 substituents can be introduced either by reacting 6 with the corresponding boronic acid (Suzuki coupling) or aryl or heteroaryl magnesium bromide. Alkynes can be introduced by reacting compound 6 with an appropriately substitute alkyne and Pd(O). The alkyne and the alkene introduced can also be functionally converted into other derivatives such as alkyl, alcohol and amine moieties. Detailed procedures are described in the experimental section for each 20 derivative prepared. 56 WO 2009/143313 PCT/US2009/044774 Scheme 2 Scheme 2
HK
2
CO
3 /DMF N N N N a N N N N C<N<CI Cl< CI N CIN CI 1 10 CHF 2 aO HH H 0 N N N Iii NN 0 ~~ NIINAIi"N
CHF
2 N \CHF2 (a) Acetone/ H 2 0/ Et 3 N/ -10 OC to Room temperature Certain compounds of the invention were prepared by the methods outlined in Scheme 2. 57 WO 2009/143313 PCT/US2009/044774 Scheme 3 Scheme 3 CIN 0 N N a N N SnBu 3 N Al' a) N -N N_ _ N A K (P), ) 2 dC 2 NNB CI N CI CI N CI (Ph3P)2P Dioxanel CI N (hReflux 01I (Ph 3
P)
2 PdCI 2 Dioxanel b NH 2 Reflux N N N N c N N NR H 2 N N CI 'a~ 0 H H Id N b N - N 0'0N N0 c d N 'N NN'N NNN O N N2N N N. O0 N N0. H H H H (a) 1 Eq. of morpholine/ Et 3 N/ Acetone/ Water/ -20 0C; (b) (Ph 3
P)
4 Pd, DME, Na 2
CO
3 , Reflux; (c) RNCO, CH 2
CI
2 , RT or (COC12)3, RNH 2 , Et 3 N, CHC1 3 ; (d) H 2 / Pd (0) Compounds of the invention were also prepared according to the method illustrated in Scheme 3. 58 WO 2009/143313 PCT/US2009/044774 Scheme 4 The benzene-1,4-diamine intermediates were prepared from 4-fluoronitrobenzene and I NI 0 2 N F a 0 2 N NR b H 2 N N'R (a) NHR'R"/ toluene; (b) H 2 /palladium on carbon, ethyl acetate, methanol. NOTE: If either R' or R" = H or contain a nucleophilic amine, that amine was converted to its Boc derivative. Deprotection was accomplished following the final step of urea formation. the appropriate amine as shown in Scheme 4. Scheme 5 a b 0 2 N F a 0 2 N
H
2 N (a) ROH/ NaH/ toluene; (b) H 2 /palladium on carbon, ethyl acetate, methanol. NOTE: If R contains a nucleophilic amine, that amine was converted to its Boc derivative. Deprotection was accomplished following the final step of urea formation. 5 The 4-(alkoxy)aniline intermediates were prepared from 4-fluoronitrobenzene and the appropriate alcohol as shown in Scheme 5. 59 WO 2009/143313 PCT/US2009/044774 Scheme 6 R7' O R8
R
7 0 R 8 CI
R
6 N R 9 R6 N R9 N N H N N N CI a N C 0 2 N 0 2 N S R 7 0 R 8
R
7 0 R 8 N R 6 N R 9
R
6 N R 9 HN N c N N b 02N N N H N N 0 2 N S11 H 2 NO -' S R7 O R8 R7 O 0 R8 R6 N R9 R6 N R 9 d N N e N N O N N O N N R' NS R'N N H H H H (a) Na 2
CO
3 , acetone, water; (b) NaHCO 3 , acetone, water (c) SnCl 2 , pyridine, DMF; (d) triphosgene, Et 3 N, CH 2
CI
2 , then RNH 2 (e) oxone, acetonitrile, water. The thiomorpholine and bis morpholine compounds were prepared from 2,4-dichloro-6 (4-nitrophenyl)-1,3,5-triazine and the appropriate morpholine and thiomorpholine reagents as shown in Scheme 6. 60 WO 2009/143313 PCT/US2009/044774 Scheme 7
R
7 O R 8
R
7 0 R 8 CI R 6 N R 9 Bu 3 Sn *. 'J" R 3 N R9 N N H N N O N Cl a N CI b 0 2 N 0 2 N
R
7 0 R 8 R 7 0 R 8
R
6 N R 9 R, N R 9 N NN N N NN N N N O 0 2 N H- 2 NJC - N-'C d H H
R
7 0 R 8 R 7 0 R 8
R
6 A R Rj 6 N R 9 RN R 9 A N N NN 'C'N': 0 j[) N -C
H
2 N 0 N N H H H H
R
7 1 0 R 8
R
6 N R 9 N lj- N 0~ 1 'a
N"
RN ' N H H (a) Na 2 00 3 , acetone, water; (b) Pd(PPh 3
)
4 , toluene (c) Fe, acetic acid, ethyl acetate, water (d) triphosgene, Et 3 N, CH 2
CI
2 , then RNH 2 (e) H 2 /Pd-C, ethyl acetate, methylene chloride, methanol. The dihydropyran and tetrahydropyran compounds were prepared from 2,4-dichloro-6 (4-nitrophenyl)-1,3,5-triazine, tributyl(3,6-dihydro-2H-pyran-4-yl)stannane, and the appropriate morpholine as shown in Scheme 7. 61 WO 2009/143313 PCT/US2009/044774 Scheme 8 0 0 0 S Cl ~ . N'~N O O 0 2 NC a O2N&R' b H 2 N R' (a) NHR'R", Et 3 N, CH 2 Cl2 (b) H 2 ,/palladium on carbon, ethyl acetate, methanol. NOTE: If R 1 or R 2 contain a nucleophilic amine, that amine was converted to its Boc derivative. Deprotection was accomplished following the final step of urea formation. The (4-aminophenyl)(piperazin-1-yl)methanone intermediates were prepared from 4 nitrobenzoyl chloride and the appropriate amine as shown in Scheme 8. 62 WO 2009/143313 PCT/US2009/044774 Scheme 9 CI NN N llNI N 'IINH 0 N Cl a 0 N Cl b 0 2 N 0 2 N N IN N N N -1j, 1* cJ) w 0 2 N N N c H 2 N N N d 00 N N R'0 N " N H H (a) Na 2
CO
3 , acetone, water; (b) NaHCO 3 , acetone, water (c) H 2 -Pd-C, ethyl acetate, methylene chloride, methanol (d) triphosgene, Et 3 N, CH 2
CI
2 , then RNH 2 The 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-((R)-3-methylmorpholino)-1, 3,5 triazin-2-yl)phenyl)-3-urea compounds were prepared from 2,4-dichloro-6-(4-nitrophenyl)-1,3,5 triazine, (R)-3-methylmorpholine, 3-oxa-8-azabicyclo[3.2.1]octane-hydrochloride, and the 5 appropriate amine as shown in Scheme 9. 63 WO 2009/143313 PCT/US2009/044774 Scheme 10 LiTMP 0 0 Li/DBBITHF 0 0 CLC0 2 Me 2,6-di-tflu-phenol0 -N078 0 C 0N - - 78 0 C IN 0 0 0 0 TB SCL/Im-idazole 0 LiH/H/tDMF, 80 0 C 1. BHDMS/THF I N_____ 30 min, MW 2. aH 20 -jp. NaHH0 HO 0 lBs 0NaH/THF 0- TBAF/THF/rt
HO,,
1 0 BnBr, rt ", N- - -N- l0 0 lBs - ~ HO NaH(3 eq)/THF \ / NTsCl (Ieq) H 0 H/0 0
P
EN-K. 0 0 C-rt__ HO 64 WO 2009/143313 PCT/US2009/044774 H OH Swern Oxidation 0 N O2 O N O O O DAST INaBH 4 OO DAST H ~ HO ~ N~' 0 0 The preparation of both the (6S') and (6R') isomers of tert-butyl 6-hydroxy-3-oxa-8 azabicyclo[3.2.1]octane-8-carboxylate from tert-butyl 1H-pyrrole-1-carboxylate is shown in Scheme 10. 65 WO 2009/143313 PCT/US2009/044774 Scheme 11 O
RNH
2 /NaCNBH 4 R RMgCl O R DAST F R HOJO R = Alkyl, aryl or heteroaryl The (6S')-tert-butyl 6-amino-3-oxa-8-azabicyclo[3.2.1]octane-8-carboxylate and (6R') tert-butyl 6-fluoro-6-(alkyl, aryl, or heteroaryl)-3-oxa-8-azabicyclo[3.2.1]octane-8-carboxylate compounds could be prepared from tert-butyl 6-oxo-3-oxa-8-azabicyclo[3.2.1]octane-8 5 carboxylate (Scheme 10) and the appropriate amine or Grignard reagent as shown in Scheme 11. Scheme 12 CI R1 1 N N R1-H N N R 4 -H CI N CI or R 1 -SnBu 3 CI N CI C<N<R4 Stille coupling
R
2
-B(OR)
2 R1 , N N Suzuki coupling
R
2 N R 4 Compounds of formula I can be prepared from cyanuric chloride as shown in Scheme 12. 66 WO 2009/143313 PCT/US2009/044774 DEFINITIONS The following definitions are used in connection with the compounds of the present invention unless the context indicates otherwise. In general, the number of carbon atoms present in a given group is designated "Cx-C y", where x and y are the lower and upper limits, 5 respectively. For example, a group designated as "C1-C6" contains from 1 to 6 carbon atoms. The carbon number as used in the definitions herein refers to carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like. Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming from left to right the terminal portion of the functionality 10 followed by the adjacent functionality toward the point of attachment. For example, the substituent "arylalkyloxycabonyl" refers to the group (C 6
-C
1 4 aryl)-(C 1
-C
6 alkyl)-O-C(O)-. Terms not defined herein have the meaning commonly attributed to them by those skilled in the art. "Acyl-" refers to a group having a straight, branched, or cyclic configuration or a combination thereof, attached to the parent structure through a carbonyl functionality. Such 15 groups may be saturated or unsaturated, aliphatic or aromatic, and carbocyclic or heterocyclic. Examples of a C 1
-C
8 acyl- group include acetyl-, benzoyl-, nicotinoyl-, propionyl-, isobutyryl-, oxalyl-, and the like. Lower-acyl refers to acyl groups containing one to four carbons. An acyl group can be unsubstituted or substituted with one or more of the following groups: halogen,
H
2 N-, (C 1
-C
6 alkyl)amino-, di(C 1
-C
6 alkyl)amino-, (C 1
-C
6 alkyl)C(O)N(C 1
-C
3 alky)-, (Cl 20 C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C 1
-C
6 alkyl)NHC(O)-, di(C 1
-C
6 alkyl)NC(O)-, -CN, hydroxyl, C 1
-C
6 alkoxy-, C 1
-C
6 alkyl-, HO 2 C-, (Cl-C 6 alkoxy)carbonyl-, (C 1
-C
6 alkyl)C(O)-, C6
C
1 4 aryl-, C 1 -Coheteroaryl-, or C 3
-C
8 cycloalkyl-. "Alkyl" refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms, for example, a C 1 -Cl 2 alkyl group may have 25 from 1 to 12 (inclusive) carbon atoms in it. Examples of C 1
-C
6 alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl. Examples of C 1
-C
8 alkyl groups include, but are not limited to, methyl, propyl, pentyl, hexyl, heptyl, 3-methylhex-1-yl, 2,3-dimethylpent-2-yl, 3-ethylpent-1-yl, octyl, 2-methylhept-2-yl, 2,3-dimethylhex-1-yl, and 2,3,3-trimethylpent-1-yl. An alkyl group can 30 be unsubstituted or substituted with one or more groups, including: halogen, -NH 2 , (C
C
6 alkyl)NH, (C 1
-C
6 alkyl)( C 1
-C
6 alkyl)N-, -N(C 1
-C
3 alkyl)C(O)( C 1
-C
6 alkyl), -NHC(O)( C 1
-C
6 alkyl), NHC(O)H, -C(O)NH 2 , -C(O)NH(C 1
-C
6 alkyl), -C(O)N(C 1
-C
6 alkyl)( C 1
-C
6 alkyl), -CN, hydroxyl, Ci
C
6 alkoxy, C 1
-C
6 alkyl, -C(O)OH, -C(O)O(C 1
-C
6 alkyl), -C(O)( C 1
-C
6 alkyl), C 6
-C
14 aryl, Cl COgheteroaryl, C 3
-C
8 cycloalkyl, C 1
-C
6 haloalkyl-, C 1
-C
6 aminoalkyl-, -OC(O)( C 1
-C
6 alkyl), Ci 35 C 6 carboxyamidoalkyl-, and -NO 2 . "Alkadienyl" refer to a straight or branched chain unsaturated hydrocarbon containing at least two double bonds, and either may exist in the E or Z conformation. Examples of a C4 67 WO 2009/143313 PCT/US2009/044774
C
6 alkadienyl group include, but are not limited to, buta-1,3-dienyl, buta-2,3-dienyl, isoprenyl, penta-1,3-dienyl, and penta-2,4-dien-2-yl. "Alkadiynyl" refer to a straight or branched chain unsaturated hydrocarbon containing at least two triple bonds. Examples of a C 4
-C
6 alkadiynyl group include, but are not limited to, buta 5 1,3-diynyl, buta-2,3-diynyl, penta-1,3-diynyl, and penta-2,4-diynyl. "Alkenyl" refer to a straight or branched chain unsaturated hydrocarbon containing at least one double bond, and may exist in the E or Z conformation. Examples of a C 2
-C
8 alkenyl group include, but are not limited to, ethylene, propylene, 1-butylene, 2-butylene, isobutylene, sec-butylene, 1-pentene, 2-pentene, isopentene, 1-hexene, 2-hexene, 3-hexene, isohexene, 1 10 heptene, 2-heptene, 3-heptene, 1-octene, 2-octene, 3-octene, and 4-octene. Examples of a C2
C
6 alkenyl group include, but are not limited to, ethylene, propylene, 1-butylene, 2-butylene, isobutylene, sec-butylene, 1-pentene, 2-pentene, isopentene, 1-hexene, 2-hexene, 3-hexene, and isohexene. Examples of a C 3
-C
8 alkenyl group include, but are not limited to, propylene, 1 butylene, 2-butylene, isobutylene, sec-butylene, 1-pentene, 2-pentene, isopentene, 1-hexene, 15 2-hexene, 3-hexene, isohexene, 1-heptene, 2-heptene, 3-heptene, 1-octene, 2-octene, 3 octene, and 4-octene. Examples of a C 3
-C
6 alkenyl group include, but are not limited to, prop-2 enyl, but-3-enyl, but-2-enyl, 2-methyallyl, pent-4-enyl, and hex-5-enyl. An alkenyl group can be unsubstituted or substituted with one or more groups, including: halogen, -NH 2 , (C 1
-C
6 alkyl)NH-,
(C
1
-C
6 alkyl)( C 1
-C
6 alkyl)N-, -N(C 1
-C
3 alkyl)C(O)( C 1
-C
6 alkyl), -NHC(O)( C 1
-C
6 alkyl), -NHC(O)H, 20 C(O)NH2, -C(O)NH(C 1
-C
6 alkyl), -C(O)N(C 1
-C
6 alkyl)( C 1
-C
6 alkyl), -CN, hydroxyl, C 1
-C
6 alkoxy,
C
1
-C
6 alkyl, -C(O)OH, -C(O)O(C 1 -Cealkyl), -C(O)( C 1
-C
6 alkyl), C 6
-C
14 aryl, C 1 -Coheteroaryl, and
C
3
-C
8 cycloalkyl. "Alkynyl" refers to a straight or branched chain unsaturated hydrocarbon containing at least one triple bond. Examples of a C 2
-C
6 alkynyl group include, but are not limited to, 25 acetylene, propyne, 1-butyne, 2-butyne, isobutyne, sec-butyne, 1-pentyne, 2-pentyne, isopentyne, 1-hexyne, 2-hexyne, 3-hexyne, and isohexyne. Examples of a C 3
-C
6 alkynyl group include, but are not limited to, prop-2-ynyl, but-3-ynyl, but-2-ynyl, pent-4-ynyl, and hex-5-ynyl. Examples of a C 3
-C
8 alkynyl group include, but are not limited to, prop-2-ynyl, but-3-ynyl, but-2 ynyl, pent-4-ynyl, hex-5-ynyl, hept-3-ynyl, 2-methylhex-3-ynyl, oct-4-ynyl, and 2-methylhept-3 30 ynyl. An alkynyl group can be unsubstituted or substituted with one or more groups, including: halogen, -NH 2 , (C 1
-C
6 alkyl)NH, (C 1
-C
6 alkyl)( C 1
-C
6 alkyl)N-, -N(C 1
-C
3 alkyl)C(O)( C 1
-C
6 alkyl), NHC(O)( C 1
-C
6 alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C 1
-C
6 alkyl), -C(O)N(C 1
-C
6 alkyl)( Cj
C
6 alkyl), -CN, hydroxyl, C 1
-C
6 alkoxy, C 1
-C
6 alkyl, -C(O)OH, -C(O)O(C 1 -Cealkyl), -C(O)( Cj
C
6 alkyl), C 6
-C
1 4 aryl, C-COgheteroaryl, and C 3
-C
8 cycloalkyl. 35 "Alkoxy-" refers to the group R-0- where R is an alkyl group, as defined above. Exemplary C 1
-C
6 alkoxy- groups include but are not limited to methoxy, ethoxy, n-propoxy, 1 propoxy, n-butoxy and t-butoxy. An alkoxy group can be unsubstituted or substituted with one or 68 WO 2009/143313 PCT/US2009/044774 more of the following groups: halogen, hydroxyl, C 1
-C
6 alkoxy-, H 2 N-, (C 1
-C
6 alkyl)amino-, di(C 1 C 6 alkyl)amino-, (C1-C 6 alkyl)C(O)N(Cj-C 3 alkyl)-, (Cl-C 6 alkyl)carboxyamido-, HC(O)NH-,
H
2 NC(O)-, (C 1
-C
6 alkyl)NHC(O)-, di(C 1
-C
6 alkyl)NC(O)-, NC-, C 1
-C
6 alkoxy-, HO 2 C-, (Cl
C
6 alkoxy)carbonyl-, (Cl-C 6 alkyl)C(O)-, C 6
-C
14 aryl-, C 1 -Coheteroaryl-, C 3
-C
8 cycloalkyl-, Cj 5 C 6 haloalkyl-, amino(C 1
-C
6 alkyl)-, (C 1
-C
6 alkyl)carboxyl-, C 1
-C
6 carboxyamidoalkyl-, or 0 2 N-. "(Alkoxy)carbonyl-" refers to the group alkyl-O-C(O)-. Exemplary (C 1
-C
6 alkoxy)carbonyl groups include but are not limited to methoxy, ethoxy, n-propoxy, 1-propoxy, n-butoxy and t butoxy. An (alkoxy)carbonyl group can be unsubstituted or substituted with one or more of the following groups: halogen, hydroxyl, H 2 N-, (C 1
-C
6 alkyl)amino-, di(C 1
-C
6 alkyl)amino-, (Cl 10 C 6 alkyl)C(O)N(Cj-C 3 alkyl)-, (Cl-C 6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (Ci
C
6 alkyl)NHC(O)-, di(Cl-C 6 alkyl)NC(O)-, NC-, C 1
-C
6 alkoxy-, HO 2 C-, (Cl-C 6 alkoxy)carbonyl-, (Ci
C
6 alkyl)C(O)-, C 6
-C
14 aryl-, Cl-Coheteroaryl-, C 3
-C
8 cycloalkyl-, Cl-C 6 haloalkyl-, amino(Ci
C
6 alkyl)-, (Cl-C 6 alkyl)carboxyl-, C 1
-C
6 carboxyamidoalkyl-, or 0 2 N-. "(Alkyl)amido-" refers to a -C(O)NH- group in which the nitrogen atom of said group is 15 attached to a C 1
-C
6 alkyl group, as defined above. Representative examples of a (Ci
C
6 alkyl)amido- group include, but are not limited to, -C(O)NHCH 3 , -C(O)NHCH 2
CH
3 , C(O)NHCH 2
CH
2
CH
3 , -C(O)NHCH 2
CH
2
CH
2
CH
3 , -C(O)NHCH 2
CH
2
CH
2
CH
2
CH
3 , C(O)NHCH(CH 3
)
2 , -C(O)NHCH 2
CH(CH
3
)
2 , -C(O)NHCH(CH 3
)CH
2
CH
3 , -C(O)NH-C(CH 3
)
3 and C(O)NHCH 2
C(CH
3
)
3 . 20 "(Alkyl)amino-" refers to an -NH group, the nitrogen atom of said group being attached to a alkyl group, as defined above. Representative examples of an (C 1
-C
6 alkyl)amino- group include, but are not limited to CH 3 NH-, CH 3
CH
2 NH-, CH 3
CH
2
CH
2 NH-, CH 3
CH
2
CH
2
CH
2 NH-,
(CH
3
)
2 CHNH-, (CH 3
)
2
CHCH
2 NH-, CH 3
CH
2
CH(CH
3 )NH- and (CH 3
)
3 CNH-. An (alkyl)amino group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, 25 (C 1
-C
6 alkyl)amino-, di(C 1
-C
6 alkyl)amino-, (C 1
-C
6 alkyl)C(O)N(C 1
-C
3 alkyl)-, (Cl
C
6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C 1
-C
6 alkyl)NHC(O)-, di(C 1
-C
6 alkyl)NC(O)-, NC-, hydroxyl, C 1
-C
6 alkoxy-, C 1
-C
6 alkyl-, HO 2 C-, (Ci-C 6 alkoxy)carbonyl-, (C 1
-C
6 alkyl)C(O)-, C6
C
1 4 aryl-, C 1 -Coheteroaryl-, C 3
-C
8 cycloalkyl-, C 1
-C
6 haloalkyl-, amino(C 1
-C
6 alkyl)-, (Cl
C
6 alkyl)carboxyl-, Cl-C 6 carboxyamidoalkyl-, or 0 2 N-. 30 "Aminoalkyl-" refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with -NH 2 ; one or both H of the NH 2 may be replaced by a substituent. "Alkylcarboxyl-" refers to an alkyl group, defined above that is attached to the parent structure through the oxygen atom of a carboxyl (C(O)-O-) functionality. Examples of (Ci 35 C 6 alkyl)carboxyl- include acetoxy, propionoxy, propylcarboxyl, and isopentylcarboxyl. "(Alkyl)carboxyamido-" refers to a -NHC(O)- group in which the carbonyl carbon atom of said group is attached to a C1-C 6 alkyl group, as defined above. Representative examples of a 69 WO 2009/143313 PCT/US2009/044774
(C
1
-C
6 alkyl)carboxyamido- group include, but are not limited to, -NHC(O)CH 3 , -NHC(O)CH 2
CH
3 ,
-NHC(O)CH
2
CH
2
CH
3 , -NHC(O)CH 2
CH
2
CH
2
CH
3 , -NHC(O)CH 2
CH
2
CH
2
CH
2
CH
3 , NHC(O)CH(CH 3
)
2 , -NHC(O)CH 2
CH(CH
3
)
2 , -NHC(O)CH(CH 3
)CH
2
CH
3 , -NHC(O)-C(CH 3
)
3 and NHC(O)CH 2
C(CH
3
)
3 . 5 "Alkylene", "alkenylene", and "alkynylene" refers to alkyl, alkenyl and alkynyl groups, as defined above, having two points of attachment within a chemical structure. Examples of Cj
C
6 alkylene include ethylene, propylene, and dimethylpropylene. Likewise, examples of C2
C
6 alkenylene include ethenylene and propenylene. Examples of C 2
-C
6 alkynylene include ethynylene and propynylene. 10 Aryl refers to an aromatic hydrocarbon group. Examples of a C 6
-C
14 aryl group include, but are not limited to, phenyl, a-naphthyl, p-naphthyl, biphenyl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl, and acenanaphthyl. Examples of a C 6
-C
1 0 aryl group include, but are not limited to, phenyl, a-naphthyl, p-naphthyl, biphenyl, and tetrahydronaphthyl. An aryl group can be unsubstituted or substituted with one or more groups, including: C 1
-C
6 alkyl, halo, 15 haloalkyl-, hydroxyl, hydroxyl(C 1
-C
6 alkyl)-, -NH 2 , aminoalkyl-, dialkylamino-, -COOH, -C(0)0
(C
1
-C
6 alkyl), -OC(O)(C 1
-C
6 alkyl), N-alkylamido-, -C(O)NH 2 , (C 1
-C
6 alkyl)amido-, or -NO 2 . "(Aryl)alkyl" refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with an aryl group as defined above. (C6
C
1 4 Aryl)alkyl- moieties include benzyl, benzhydryl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 20 2-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl and the like. An (aryl)alkyl group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, hydroxyl,
(C
1
-C
6 alkyl)amino-, di(C 1
-C
6 alkyl)amino-, (C 1
-C
6 alkyl)C(O)N(C 1
-C
3 alkyl)-, (Ci
C
6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C 1
-C
6 alkyl)NHC(O)-, di(C 1
-C
6 alkyl)NC(O)-, NC-, hydroxyl, C 1
-C
6 alkoxy-, C 1
-C
6 alkyl-, HO 2 C-, (C 1
-C
6 alkoxy)carbonyl-, (C 1
-C
6 alkyl)C(O)-, C6 25 C 1 4 aryl-, C 1 -Coheteroaryl-, C 3
-C
8 cycloalkyl-, C 1
-C
6 haloalkyl-, amino(C 1
-C
6 alkyl)-, (Cl
C
6 alkyl)carboxyl-, Cl-C 6 carboxyamidoalkyl-, or 0 2 N-. "(Aryl)amino" refers to a radical of formula (aryl)-NH-, wherein aryl is as defined above. "(Aryl)oxy" refers to the group Ar-O- where Ar is an aryl group, as defined above. "Cycloalkyl" refers to a non-aromatic, saturated, monocyclic, bicyclic or polycyclic 30 hydrocarbon ring system. Representative examples of a C 3
-C
12 cycloalkyl include, but are not limited to, cyclopropyl, cyclopentyl, cycloheptyl, cyclooctyl, decahydronaphthalen-1-yl, octahydro-1 H-inden-2-yl, decahydro-1 H-benzo[7]annulen-2-yl, and dodecahydros-indacen-4-yl. Representative examples of a C 3
-C
10 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, decahydronaphthalen-1-yl, and 35 octahydro-1 H-inden-2-yl. Representative examples of a C 3
-C
8 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and octahydropentalen-2-yl. A cycloalkyl can be unsubstituted or substituted with one or more 70 WO 2009/143313 PCT/US2009/044774 groups, including: halogen, -NH 2 , (C 1
-C
6 alkyl)NH, (C 1
-C
6 alkyl)( C 1
-C
6 alkyl)N-, -N(C 1 C 3 alkyl)C(O)( C1-C 6 alkyl), -NHC(O)( C1-C 6 alkyl), -NHC(O)H, -C(O)NH 2 , -C(O)NH(C1-C 6 alkyl), C(O)N(C 1
-C
6 alkyl)( C 1
-C
6 alkyl), -CN, hydroxyl, C 1
-C
6 alkoxy, C 1
-C
6 alkyl, -C(O)OH, -C(O)O(Cl
C
6 alkyl), -C(O)( C 1
-C
6 alkyl), C 6
-C
14 aryl, C 1 -Coheteroaryl, C 3
-C
8 cycloalkyl, C 1
-C
6 haloalkyl-, Cj 5 C 6 aminoalkyl-, -OC(O)( C 1
-C
6 alkyl), C 1
-C
6 carboxyamidoalkyl-, and -NO 2 .Additionally, each of any two hydrogen atoms on the same carbon atom of the carbocyclic ring can be replaced by an oxygen atom to form an oxo (=0) substituent. "Cycloalkenyl" refers to a non-aromatic, unsaturated, monocyclic, bicyclic or polycyclic hydrocarbon ring system containing at least one double bond connecting two ring carbon atoms. 10 Representative examples of a C 5
-C
8 cycloalkenyl include, but are not limited to, cyclopentenyl, cyclohexenyl, 4,4a-octalin-3-yl, and cyclooctenyl. A cycloalkenyl can be unsubstituted or substituted with one or more groups, including: halogen, -NH 2 , (C 1
-C
6 alkyl)NH, (C 1
-C
6 alkyl)( Cj
C
6 alkyl)N-, -N(C 1
-C
3 alkyl)C(O)( C 1
-C
6 alkyl), -NHC(O)( C 1
-C
6 alkyl), -NHC(O)H, -C(O)NH 2 , C(O)NH(C 1
-C
6 alkyl), -C(O)N(C 1
-C
6 alkyl)( C 1
-C
6 alkyl), -CN, hydroxyl, C 1
-C
6 alkoxy, C 1
-C
6 alkyl, 15 C(O)OH, -C(O)O(C 1 -Cealkyl), -C(O)( C 1
-C
6 alkyl), C 6
-C
14 aryl, C 1 -Coheteroaryl, and C3
C
8 cycloalkyl. Additionally, each of any two hydrogen atoms on the same carbon atom of the carbocyclic ring can be replaced by an oxygen atom to form an oxo (=0) substituent. "Di(alkyl)amino-" refers to a nitrogen atom attached to two alkyl groups, as defined above. Each alkyl group can be independently selected. Representative examples of an di(C 1 20 C 6 alkyl)amino- group include, but are not limited to, -N(CH 3
)
2 , -N(CH 2
CH
3
)(CH
3 ), -N(CH 2
CH
3
)
2 , N(CH 2
CH
2
CH
3
)
2 , -N(CH 2
CH
2
CH
2
CH
3
)
2 , -N(CH(CH 3
)
2
)
2 , -N(CH(CH 3
)
2
)(CH
3 ), -N(CH 2
CH(CH
3
)
2
)
2 , NH(CH(CH 3
)CH
2
CH
3
)
2 , -N(C(CH 3
)
3
)
2
-N(C(CH
3
)
3
)(CH
3 ), and -N(CH 3
)(CH
2
CH
3 ). The two alkyl groups on the nitrogen atom, when taken together with the nitrogen to which they are attached, can form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon 25 atoms of the heterocycle can be replaced with -N(H)-, -N(C 1
-C
6 alkyl)-, -N(C 3
-C
8 cycloalkyl)-, N(C 6
-C
1 4 aryl)-, -N(C 1 -Cgheteroaryl)-, -N(amino(C 1
-C
6 alkyl))-, -N(C 6
-C
14 arylamino)-, -0-, -S-, S(O)-, or -S(O) 2 -. "Halo" or "halogen" refers to -F, -Cl, -Br and -1.
"C
1
-C
6 Haloalkyl-" refers to a C 1
-C
6 alkyl group, as defined above, wherein one or more of 30 the C 1
-C
6 alkyl group's hydrogen atoms has been replaced with -F, -Cl, -Br, or -1. Each substitution can be independently selected from -F, -Cl, -Br, or -1. Representative examples of an C 1
-C
6 haloalkyl- group include, but are not limited to, -CH 2 F, -CC13, -CF 3 , CH 2
CF
3 , -CH 2 CI, CH 2
CH
2 Br, -CH 2
CH
2 1, -CH 2
CH
2
CH
2 F, -CH 2
CH
2
CH
2 CI, -CH 2
CH
2
CH
2
CH
2 Br, -CH 2
CH
2
CH
2
CH
2 1, CH 2
CH
2
CH
2
CH
2
CH
2 Br, -CH 2
CH
2
CH
2
CH
2
CH
2 1, -CH 2 CH(Br)CH 3 , -CH 2
CH(CI)CH
2
CH
3 , 35 CH(F)CH 2
CH
3 and -C(CH 3
)
2
(CH
2 CI). "Heteroaryl" refers to a monocyclic, bicyclic, or polycyclic aromatic ring system containing at least one ring atom selected from the heteroatoms oxygen, sulfur and nitrogen. 71 WO 2009/143313 PCT/US2009/044774 Examples of C 1 -Coheteroaryl groups include furan, thiophene, indole, azaindole, oxazole, thiazole, isoxazole, isothiazole, imidazole, N-methylimidazole, pyridine, pyrimidine, pyrazine, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, 1,3,4-oxadiazole, 1,2,4-triazole, 1-methyl 1,2,4-triazole, 1 H-tetrazole, 1-methyltetrazole, benzoxazole, benzothiazole, benzofuran, 5 benzisoxazole, benzimidazole, N-methylbenzimidazole, azabenzimidazole, indazole, quinazoline, quinoline, and isoquinoline. Bicyclic C 1 -Cohetroaryl groups include those where a phenyl, pyridine, pyrimidine or pyridazine ring is fused to a 5 or 6-membered monocyclic heteroaryl ring having one or two nitrogen atoms in the ring, one nitrogen atom together with either one oxygen or one sulfur atom in the ring, or one 0 or S ring atom. Examples of 10 monocyclic C 1
-C
4 heteroaryl groups include 2H-tetrazole, 3H-1,2,4-triazole, furan, thiophene, oxazole, thiazole, isoxazole, isothiazole, imidazole, and pyrrole. A heteroaryl group can be unsubstituted or substituted with one or more groups, including: C 1
-C
6 alkyl, halo, haloalkyl-, hydroxyl, hydroxyl(C 1
-C
6 alkyl)-, -NH 2 , aminoalkyl-, dialkylamino-, -COOH, -C(O)O-(C 1
-C
6 alkyl), OC(O)(C 1 -Cealkyl), N-alkylamido-, -C(O)NH 2 , (C 1
-C
6 alkyl)amido-, or -NO 2 . 15 "(Heteroaryl)alkyl-" refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a heteroaryl- group as defined above. Examples of (C 1 -Cgheteroaryl)alkyl- moieties include 2-pyridylmethyl, 2-thiophenylethyl, 3 pyridylpropyl, 2-quinolinylmethyl, 2-indolylmethyl, and the like. A (heteroaryl)alkyl group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, hydroxyl, 20 (C 1
-C
6 alkyl)amino-, di(C 1
-C
6 alkyl)amino-, (C 1
-C
6 alkyl)C(O)N(C 1
-C
3 alkyl)-, (Ci
C
6 alkyl)carboxyamido-, HC(O)NH-, H 2 NC(O)-, (C 1
-C
6 alkyl)NHC(O)-, di(C 1
-C
6 alkyl)NC(O)-, NC-, hydroxyl, C 1
-C
6 alkoxy-, C 1
-C
6 alkyl-, HO 2 C-, (Cl-C 6 alkoxy)carbonyl-, (C 1
-C
6 alkyl)C(O)-, C6
C
1 4 aryl-, C 1 -Cgheteroaryl-, C 3
-C
8 cycloalkyl-, C 1
-C
6 haloalkyl-, amino(C 1
-C
6 alkyl)-, (Cl
C
6 alkyl)carboxyl-, Cl-C 6 carboxyamidoalkyl-, or 0 2 N-. 25 The term "heteroatom" refers to a sulfur, nitrogen, or oxygen atom. "Heterocycle" or "heterocyclyl" refers to monocyclic, bicyclic and polycyclic groups in which at least one ring atom is a heteroatom. A heterocycle may be saturated or partially saturated. Exemplary C 1 -Coheterocyclyl- groups include but are not limited to aziridine, oxirane, oxirene, thiirane, pyrroline, pyrrolidine, dihydrofuran, tetrahydrofuran, dihydrothiophene, 30 tetrahydrothiophene, dithiolane, piperidine, 1,2,3,6-tetrahydropyridine-1-yl, tetrahydropyran, pyran, thiane, thiine, piperazine, oxazine, 5,6-dihydro-4H-1,3-oxazin-2-yl, 2,5 diazabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.2]octane, 3,6-diazabicyclo[3.1.1]heptane, 3,8 diazabicyclo[3.2. 1 ]octane, 6-oxa-3,8-diazabicyclo[3.2. 1 ]octane, 7-oxa-2,5 diazabicyclo[2.2.2]octane, 2,7-dioxa-5-azabicyclo[2.2.2]octane, 2-oxa-5 35 azabicyclo[2.2.1]heptane-5-yl, 2-oxa-5-azabicyclo[2.2.2]octane, 3,6-dioxa-8 azabicyclo[3.2. 1 ]octane, 3-oxa-6-azabicyclo[3.1.1]heptane, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 5,7-dioxa-2-azabicyclo[2.2.2]octane, 6,8-dioxa-3-azabicyclo[3.2. 1 ]octane, 6-oxa-3 72 WO 2009/143313 PCT/US2009/044774 azabicyclo[3.1.1]heptane, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, 2-methyl-2,5 diazabicyclo[2.2.1]heptane-5-yl, 1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl, 3-hydroxy-8 azabicyclo[3.2.1]octan-8-yl-, 7-methyl-3-oxa-7,9-diazabicyclo[3.3.1]nonan-9-yl, 9-oxa-3 azabicyclo[3.3.1]nonan-3-yl, 3-oxa-9-azabicyclo[3.3.1]nonan-9-yl, 3,7-dioxa-9 5 azabicyclo[3.3.1]nonan-9-yl, 4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl, thiazine, dithiane, and dioxane. The contemplated heterocycle rings or ring systems have a minimum of 3 members. Therefore, for example, C 1 heterocyclyl- radicals would include but are not limited to oxaziranyl, diaziridinyl, and diazirinyl, C 2 heterocyclyl- radicals include but are not limited to aziridinyl, oxiranyl, and diazetidinyl, Coheterocyclyl- radicals include but are not limited to 10 azecanyl, tetrahydroquinolinyl, and perhydroisoquinolinyl. A heterocyclyl group can be unsubstituted or substituted with one or more groups, including: C 1
-C
6 alkyl, halo, haloalkyl-, hydroxyl, hydroxyl(C 1
-C
6 alkyl)-, -NH 2 , aminoalkyl-, dialkylamino-, -COOH, -C(O)O-(C 1
-C
6 alkyl), OC(O)(C 1 -Cealkyl), N-alkylamido-, -C(O)NH 2 , (C 1
-C
6 alkyl)amido-, or -NO 2 . "Heterocyclyl(alkyl)-" refers to an alkyl group, as defined above, wherein one or more of 15 the alkyl group's hydrogen atoms has been replaced with a heterocycle group as defined above. Heterocyclyl(C 1
-C
6 alkyl)- moieties include 2-pyridylmethyl, 1-piperazinylethyl, 4 morpholinylpropyl, 6-piperazinylhexyl, and the like. A heterocyclyl(alkyl) group can be unsubstituted or substituted with one or more of the following groups: halogen, H 2 N-, (Cl
C
6 alkyl)amino-, di(C 1
-C
6 alkyl)amino-, (C 1
-C
6 alkyl)C(O)N(C 1
-C
3 alkyl)-, (C 1
-C
6 alkyl)carboxyamido 20 , HC(O)NH-, H 2 NC(O)-, (C 1
-C
6 alkyl)NHC(O)-, di(C 1
-C
6 alkyl)NC(O)-, NC-, hydroxyl, C 1
-C
6 alkoxy-,
C
1
-C
6 alkyl-, HO 2 C-, (C 1
-C
6 alkoxy)carbonyl-, (C 1
-C
6 alkyl)C(O)-, 4- to 7-membered monocyclic heterocycle, C 6 -Cl 4 aryl-, C 1 -Coheteroaryl-, or C 3
-C
8 cycloalkyl-. "Hydroxylalkyl-" refers to a alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with hydroxyl groups. Examples of Cj 25 C 6 hydroxylalkyl- moieties include, for example, -CH 2 OH, -CH 2
CH
2 OH, -CH 2
CH
2
CH
2 OH, CH 2
CH(OH)CH
2 OH, -CH 2
CH(OH)CH
3 , -CH(CH 3
)CH
2 OH and higher homologs. "Monocyclic heterocyclyl" refers to monocyclic groups in which at least one ring atom is a heteroatom. A heterocycle may be saturated or partially saturated. Exemplary monocyclic Cj Coheterocyclyl- groups include but are not limited to aziridine, oxirane, oxirene, thiirane, 30 pyrroline, pyrrolidine, dihydrofuran, tetrahydrofuran, dihydrothiophene, tetrahydrothiophene, dithiolane, piperidine, 1,2,3,6-tetrahydropyridine-1-yl, tetrahydropyran, pyran, thiane, thiine, piperazine, oxazine, 5,6-dihydro-4H-1,3-oxazin-2-yl, 4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7 yl, thiazine, dithiane, and dioxane. The contemplated heterocycle ring systems have a minimum of 3 members. Therefore, for example, C 1 heterocyclyl- radicals would include but are not limited 35 to oxaziranyl, diaziridinyl, and diazirinyl, C 2 heterocyclyl- radicals include but are not limited to aziridinyl, oxiranyl, and diazetidinyl, Coheterocyclyl- radicals include but are not limited to azecanyl. A heterocyclyl group can be unsubstituted or substituted with one or more groups, 73 WO 2009/143313 PCT/US2009/044774 including: C 1
-C
6 alkyl, halo, haloalkyl-, hydroxyl, hydroxyl(C 1
-C
6 alkyl)-, -NH 2 , aminoalkyl-, dialkylamino-, -COOH, -C(O)O-(C 1
-C
6 alkyl), -OC(O)(C 1
-C
6 alkyl), N-alkylamido-, -C(O)NH 2 , (Cl
C
6 alkyl)amido-, or -NO 2 . "Perfluoroalkyl-" refers to alkyl group, defined above, having two or more fluorine atoms. 5 Examples of a C 1
-C
6 perfluoroalkyl- group include CF 3 , CH 2
CF
3 , CF 2
CF
3 and CH(CF 3
)
2 . A "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or gorilla. The term "optionally substituted" as used herein means that at least one hydrogen atom of the optionally substituted group has been substituted with halogen, -NH 2 , -NH(C 1
-C
6 alkyl), 10 N(C 1
-C
6 alkyl)(C 1
-C
6 alkyl), -N(C 1
-C
3 alkyl)C(O)(C 1
-C
6 alkyl), -NHC(O)(C 1
-C
6 alkyl), -NHC(O)H, C(O)NH 2 , -C(O)NH(C 1
-C
6 alkyl), -C(O)N(C 1
-C
6 alkyl)(C 1
-C
6 alkyl), -CN, hydroxyl, C 1
-C
6 alkoxy, Cl
C
6 alkyl, -C(O)OH, -C(O)O(C 1 -Cealkyl), -C(O)(C 1
-C
6 alkyl), C 6 -Cl 4 aryl, C 1 -Coheteroaryl, or C3
C
8 cycloalkyl. Representative "pharmaceutically acceptable salts" include but are not limited to, e.g., 15 water-soluble and water-insoluble salts, such as the acetate, aluminum, amsonate (4,4 diaminostilbene-2,2-disulfonate), benzathine (N,N'-dibenzylethylenediamine), benzenesulfonate, benzoate, bicarbonate, bismuth, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate (camphorsulfonate), carbonate, chloride, choline, citrate, clavulariate, diethanolamine, dihydrochloride, diphosphate, edetate, edisylate (camphorsulfonate), esylate 20 (ethanesulfonate), ethylenediamine, fumarate, gluceptate (glucoheptonate), gluconate, glucuronate, glutamate, hexafluorophosphate, hexylresorcinate, hydrabamine (N,N' bis(dehydroabietyl)ethylenediamine), hydrobromide, hydrochloride, hydroxynaphthoate, 1 hydroxy-2-naphthoate, 3-hydroxy-2-naphthoate, iodide, isothionate (2-hydroxyethanesulfonate), lactate, lactobionate, laurate, lauryl sulfate, lithium, magnesium, malate, maleate, mandelate, 25 meglumine (1-deoxy-1-(methylamino)-D-glucitol), mesylate, methyl bromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, palmitate, pamoate (4,4'-methylenebis-3-hydroxy-2-naphthoate, or embonate), pantothenate, phosphate, picrate, polygalacturonate, potassium, propionate, p-toluenesulfonate, salicylate, sodium, stearate, subacetate, succinate, sulfate, sulfosaliculate, suramate, tannate, tartrate, 30 teoclate (8-chloro-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione), triethiodide, tromethamine (2 amino-2-(hydroxymethyl)-1,3-propanediol), valerate, and zinc salts. An "effective amount" when used in connection with a compound of this invention is an amount effective for inhibiting mTOR or P13K in a subject. Some compounds within the present invention possess one or more chiral centers, and 35 the present invention includes each separate enantiomer of such compounds as well as mixtures of the enantiomers. Where multiple chiral centers exist in compounds of the present invention, the invention includes each combination as well as mixtures thereof. All chiral, 74 WO 2009/143313 PCT/US2009/044774 diastereomeric, and racemic forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. 5 The compounds of the present invention exhibit an mTOR inhibitory activity and therefore, can be utilized in order to inhibit abnormal cell growth in which mTOR plays a role. Thus, the compounds of the present invention are effective in the treatment of disorders with which abnormal cell growth actions of mTOR are associated, such as restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic 10 hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, cancer, etc. In particular, the compounds of the present invention possess excellent cancer cell growth inhibiting effects and are effective in treating cancers, preferably all types of solid cancers and malignant lymphomas, and especially, leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, 15 pancreas cancer, renal cancer, gastric cancer, brain tumor, advanced renal cell carcinoma, acute lymphoblastic leukemia, malignant melanoma, soft-tissue or bone sarcoma, etc. The compounds of the present invention exhibit a P13 kinase inhibitory activity and, therefore, can be utilized in order to inhibit abnormal cell growth in which P13 kinases play a role. Thus, the compounds of the present invention are effective in the treatment of disorders 20 with which abnormal cell growth actions of P13 kinases are associated, such as restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, cancer, etc. In particular, the compounds of the present invention possess excellent cancer cell growth inhibiting effects and are effective in treating cancers, preferably all 25 types of solid cancers and malignant lymphomas, and especially, leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain tumor, advanced renal cell carcinoma, acute lymphoblastic leukemia, malignant melanoma, soft-tissue or bone sarcoma, etc. For therapeutic use, the pharmacologically active compounds of Formula I will normally 30 be administered as a pharmaceutical composition comprising as the (or an) essential active ingredient at least one such compound in association with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjutants and excipients employing standard and conventional techniques. The pharmaceutical compositions of this invention include suitable dosage forms for 35 oral, parenteral (including subcutaneous, intramuscular, intradermal and intravenous) bronchial or nasal administration. Thus, if a solid carrier is used, the preparation may be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche or lozenge. The 75 WO 2009/143313 PCT/US2009/044774 solid carrier may contain conventional excipients such as binding agents, fillers, tableting lubricants, disintegrants, wetting agents and the like. The tablet may, if desired, be film coated by conventional techniques. If a liquid carrier is employed, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule, sterile vehicle for injection, an aqueous or non-aqueous 5 liquid suspension, or may be a dry product for reconstitution with water or other suitable vehicle before use. Liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, wetting agents, non-aqueous vehicle (including edible oils), preservatives, as well as flavoring and/or coloring agents. For parenteral administration, a vehicle normally will comprise sterile water, at least in large part, although saline solutions, glucose solutions and like 10 may be utilized. Injectable suspensions also may be used, in which case conventional suspending agents may be employed. Conventional preservatives, buffering agents and the like also may be added to the parenteral dosage forms. Particularly useful is the administration of a compound of Formula I directly in parenteral formulations. The pharmaceutical compositions are prepared by conventional techniques appropriate to the desired preparation containing 15 appropriate amounts of the active ingredient, that is, the compound of Formula I according to the invention. See, for example, Remington: The Science and Practice of Pharmacy, 20th Edition. Baltimore, MD: Lippincott Williams & Wilkins, 2000. The dosage of the compounds of Formula I to achieve a therapeutic effect will depend not only on such factors as the age, weight and sex of the patient and mode of administration, 20 but also on the degree of potassium channel activating activity desired and the potency of the particular compound being utilized for the particular disorder of disease concerned. It is also contemplated that the treatment and dosage of the particular compound may be administered in unit dosage form and that one skilled in the art would adjust the unit dosage form accordingly to reflect the relative level of activity. The decision as to the particular dosage to be employed (and 25 the number of times to be administered per day is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. A suitable dose of a compound of Formula I or pharmaceutical composition thereof for a mammal, including man, suffering from, or likely to suffer from any condition as described herein 30 is an amount of active ingredient from about 0.01 mg/kg to 10 mg/kg body weight. For parenteral administration, the dose may be in the range of 0.1 mg/kg to 1 mg/kg body weight for intravenous administration. For oral administration, the dose may be in the range about 0.1 mg/kg to 5 mg/kg body weight. The active ingredient will preferably be administered in equal doses from one to four times a day. However, usually a small dosage is administered, and the 35 dosage is gradually increased until the optimal dosage for the host under treatment is determined. 76 WO 2009/143313 PCT/US2009/044774 However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound of be administered, the chosen route of administration, the age, weight, and response of the individual patient, and the severity of the 5 patient's symptoms. The amount of the compound of the present invention or a pharmaceutically acceptable salt thereof that is effective for inhibiting mTOR or P13K in a subject. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed can also depend on the route of administration, the condition, the 10 seriousness of the condition being treated, as well as various physical factors related to the individual being treated, and can be decided according to the judgment of a health-care practitioner. Equivalent dosages may be administered over various time periods including, but not limited to, about every 2 hours, about every 6 hours, about every 8 hours, about every 12 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 15 hours, about every week, about every two weeks, about every three weeks, about every month, and about every two months. The number and frequency of dosages corresponding to a completed course of therapy will be determined according to the judgment of a health-care practitioner. The effective dosage amounts described herein refer to total amounts administered; that is, if more than one compound of the present invention or a pharmaceutically 20 acceptable salt thereof is administered, the effective dosage amounts correspond to the total amount administered. In one embodiment, the compound of the present invention or a pharmaceutically acceptable salt thereof is administered concurrently with another therapeutic agent. In one embodiment, a composition comprising an effective amount of a compound of the 25 present invention or a pharmaceutically acceptable salt thereof and an effective amount of another therapeutic agent within the same composition can be administered. Effective amounts of the other therapeutic agents are well known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective amount range. The compound of the present invention or a 30 pharmaceutically acceptable salt thereof and the other therapeutic agent can act additively or, in one embodiment, synergistically. In one embodiment, of the invention, where another therapeutic agent is administered to an animal, the effective amount of the compound of the present invention or a pharmaceutically acceptable salt thereof is less than its effective amount would be where the other therapeutic agent is not administered. In this case, without being 35 bound by theory, it is believed that the compound of the present invention or a pharmaceutically acceptable salt thereof and the other therapeutic agent act synergistically. 77 WO 2009/143313 PCT/US2009/044774 Methods useful for making the compounds of Formula I are set forth in the Examples below and generalized in Schemes 1-3: Scheme 1: One of skill in the art will recognize that Schemes 1-3 can be adapted to produce the 5 other compounds of Formula I and pharmaceutically acceptable salts of compounds of Formula I according to the present invention. The following abbreviations are used herein and have the indicated definitions: ACN is acetonitrile, AcOH is acetic acid, ATP is adenosine triphosphate, CHAPS is 3[(3 cholamidopropyl)dimethylammonio]-propanesulfonic acid, DEAD is diethyl azodicarboxylate, 10 DIAD is diisopropyl azodicarboxylate, DMAP is dimethyl aminopyridine, DMF is N,N dimethylformamide, DMF-DMA is dimethylformamide dimethyl acetal, DMSO is dimethylsulfoxide. Dowtherm T M is a eutectic mixture of biphenyl (C 1 2
H
10 ) and diphenyl oxide
(C
1 2
H
1 0 0). DowthermTM is a registered trademark of Dow Corning Corporation. DPBS is Dulbecco's Phosphate Buffered Saline Formulation, EDTA is ethylenediaminetetraacetic acid, 15 ESI stands for Electrospray Ionization, EtOAc is ethyl acetate, EtOH is ethanol, HEPES is 4-(2 hydroxyethyl)-1-piperazineethanesulfonic acid, GMF is Glass, Hunig's Base is diisopropylethylamine, HPLC is high pressure liquid chromatography, LPS is lipopolysaccharide, MeCN is acetonitrile, MeOH is methanol, MS is mass spectrometry, NEt 3 is triethylamine, NMR is nuclear magnetic resonance, PBS is phosphate-buffered saline (pH 7.4), RPMI 1640 is a 20 buffer (Sigma-Aldrich Corp., St. Louis, MO, USA), SDS is dodecyl sulfate (sodium salt), SRB is Sulforhodamine B, TBSCI is tert-butyldimethylsilyl chloride, TCA is tricholoroacetic acid, TFA is trifluoroacetic acid, THF is tetrahydrofuran, TLC is thin-layer chromatography, and TRIS is tris(hydroxymethyl)aminomethane. METHODS 25 The following methods outline the synthesis of the compounds of Formula 1. The following examples are presented to illustrate certain embodiments of the present invention, but should not be construed as limiting the scope of this invention. Example 1: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea Step 1: Preparation of 2-chloro-4,6-di-morpholin-4-yl-[1,3,5]triazine: 30 To a stirred solution of cyanuric chloride (18.4 g, 10 mmol) in acetone (100 ml) and crushed ice (500 g), a mixture of triethylamine (30.0 g, excess) and morpholine ( 17.4 g, 20 mmol) was added at -10 0 C. After the addition, reaction mixture was stirred at room temperature and for 1 hour and diluted with 50 ml water. Separated white solid was filtered and washed with water. The white solid was dried and filtered. The crude product was found to be pure and taken to 35 next step without purification. Yield: 25 g, 87%; (M+H) 286.7 78 WO 2009/143313 PCT/US2009/044774 Step 2: Preparation of 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline A mixture of 2-chloro-4,6-di-morpholin-4-yl-[1,3,5]triazine (1.4 g , 4.9 mmoles), a catalytic amount of tetrakis(triphenylphosphine)palladium(0) (70 mg , 0.061 mmoles), sodium carbonate solution 2 M (3 mL), 4-aminophenylboronic acid pinacol ester (1.6 g, 7.3 mmoles) and DME ( 5 100 mL) was refluxed for 24 hours. The solvent was evaporated, and the residue was dissolved in methylene chloride and filtered through Celite
TM
.The filtrate was washed with water (200 mL) and the organic layer was dried with magnesium sulfate. This was filtered and the solvent was evaporated. The residue was purified by Silica gel column chromatography and eluted with Ethyl acetate/hexanes (1:1) to give 1.40 g, (83% yield) of 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 10 yl)aniline as an amorphous solid. (M+H) 343. Step 3: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea To a mixture of 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.20 g 0.40 mmoles) in methylene chloride (80mL) at 0 0C was added triphosgene (0.25 mg, 0.84 mmoles) and triethylamine (3 mL). The mixture was stirred for 20 minutes at 0 0C and 4-amino pyridine ( 0.10 15 g 0.83 mmoles) was added to the reaction mixture and stirred for another 2 hours at room temperature. The solvent was evaporated and the residue was submitted to the HPLC using acetonitrile/TFA as mobile phase to give 98.2 mg (36 % yield) of 1-[4-(4,6-dimophorlin-4-yl 1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea. (M+H) = 463.3. Procedure A for preparation of ureas using aryl isocyanates: 20 To a stirred mixture of 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (140 mg, 0.40 mmoles) and a catalytic amount of dimethylaminopyridine (DMAP) in methylene chloride 100 (mL), was added a small excess of aryl isocyanate (0.61 mmoles). The mixture was stirred at room temperature for 48 hours. The reaction mixture was concentrated to half of its original volume and the separated precipitate was collected by filtration and washed with methanol (15 ml) and 25 then with diethyl ether. In some cases the crude product obtained was purified by Silica gel column chromatography by eluting it with appropriate solvents, depending upon the polarity of the products. The following compounds were prepared according to Procedure A: Example 2: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-3-ylurea 79 WO 2009/143313 PCT/US2009/044774 Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.08 g 0.23 mmoles) and 3-pyridyl isocyanate (30 mg, 0.25 mmoles) the title compound was isolated as a white solid. The product was purified by Silica gel column chromatography by eluting it with 10% MeOH: ethyl acetate. Yield; 60 mg (56 % ); (M+H)= 463.5. 5 Example 3: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-phenylurea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (140 mg, 0.40 mmoles) and phenyl isocyanate (72 mg, 0.61 mmoles), the title compound was isolated as a white solid. The product was purified by Silica gel column chromatography by eluting it with ethyl acetate. Yield: 0.128 g (68%) (M+H) = 462.3 10 Example 4: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-thiophen-2 ylurea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (60 mg, 0.17 mmoles) and 2 thienyl isocyanate (18 mg, 0.14 mmoles), the title compound was isolated as a grey solid after Silica gel column chromatography by eluting with 5% ethyl acetate: methanol. Yield: 12 mg 15 (14%); (M+H) = 470. Example 5: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4 methylphenyl)urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140 g 0.40 mmoles) and 4 methylphenyl isocyanate (74 mg, 0.56 mmoles), the title compound was isolated as a white 20 solid. Yield; 65 mg (33 %) (M+H)= 476.4 Example 6: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4 fluorophenyl)urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140 g 0.40 mmoles) and 4 fluorophenyl isocyanate (83 mg, 0.61 mmole), 65 mg (33% yield) of the title product was 25 isolated as white solid. (M+H) = 480.3 Example 7: Preparation of 1-(2,4-dimethoxyphenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 yl)phenyl]-urea 80 WO 2009/143313 PCT/US2009/044774 Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140 g 0.40 mmoles) and 2,4 dimethoxyphenyl isocyanate (131 mg, 0.73 mmoles), the title compound was isolated as a white solid. Yield; 76 mg (36 % ); (M+H)= 522.4 Example 8: Preparation of 1-(4-chlorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 5 yl)phenyl]-urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140 g 0.40 mmoles) and 4 chlorophenyl isocyanate (94 mg, 0.61 mmoles), the title compound was isolated as a white solid. Yield; 60 mg (30 % ); (M+H)= 496.3 Example 9: Preparation 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4 10 methoxyphenyl)urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140 g 0.40 mmoles) and 4 methoxyphenyl isocyanate (91 mg, 0.63 mmoles) the title compound was isolated as a white solid. Yield; 48 mg (24 % ); (M+H)= 492.3 Example 10: Preparation of (4-chlorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 15 yl)phenyl]urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140 g 0.40 mmoles) and 4 chlorophenyl isocyanate (94 mg, 0.61 mmoles) the title compound was isolated as a white solid. Yield; 60 mg (30 % ); (M+H)= 496.3 Example 11: Preparation of (2,4-difluorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 20 yl)phenyl]urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.105 g 0.30 mmoles) and 2,4 difluorophenyl isocyanate (71 mg, 0.45 mmoles) the title compound was isolated as a white solid. Yield; 40 mg (27 % ); (M+H)= 498.6 Example 12: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-ethylurea 25 Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.130 g 0.38 mmoles) and ethyl isocyanate (260 mg, 10 fold excess) the title compound was isolated as a white solid. Yield; 38 mg (25 % ); (M+H)= 414.4 81 WO 2009/143313 PCT/US2009/044774 Example 13: Preparation of tert-butyl 3-{[4-(4-{[(4-fluorophenyl)carbamoyl]-amino}phenyl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]amino}azetidine-1 -carboxylate Step 1: Preparation of 2,4-dichloro-6-morpholin-4-yl-[1,3,5]triazine: 5 To a stirred solution of cyanuric chloride (18.4 g, 10 mmol) in acetone (100 ml) and crushed ice (500 g), a mixture of triethylamine (30.0 g, excess) and morpholine ( 8.7 g, 10 mmol) was added at -10 0C. After the addition, reaction mixture was stirred at room temperature and for 1 hour and diluted with 50 ml water. Separated white solid was filtered and washed with water. The white solid was dried and filtered. The crude product was found to be pure and taken to next 10 step with out purification. Yield: 18 g, 76%; (M+H) 236.4 Step 2: Preparation of tert-butyl 3-(4-chloro-6-morpholine-1,3,5-triazin-2-2-ylamino)azetidine-1 carboxylate To a stirred solution of 2,4-dichloro-6-morpholin-4-yl-[1,3,5]triazine (2.35 g, 10 mmol) in acetone (50 ml) and crushed ice, a mixture of triethylamine and 1-boc-3-(amino)azetidine (1.72 g) was 15 added slowly. The reaction mixture was stirred at room temperature for 6 hours and the separated solid was filtered. The product was dried and taken to next step with out purification. Yield: 3.0 g (81%); (M+H) 373 Step 3: Preparation of tert-butyl-3-4-(4-(4-aminophenyl)-6-morpholine-1,3,5-triazin-2 ylamino)azetidine-1 -carboxylate. 20 A mixture of tert-butyl 3-(4-chloro-6-morpholine-1,3,5-triazin-2-2-ylamino)azetidine-1 carboxylate (1.1 g , 3.0 mmoles), tetrakis(triphenylphosphine)palladium (0) in catalytic amount (70 mg , 0061 mmoles), sodium carbonate solution 2 M (3 mL), 4-aminophenylboronic acid pinacol ester (0.97 g, 4.5 mmoles), DME ( 100 mL) was refluxed for 24 hours. The solvent was evaporated and the residue was dissolved in methylene chloride and filtered though Celite
TM
. 25 The organic layer was washed with water (200 mL) and dried over magnesium sulfate. It was filtered and the solvent was evaporated. The residue was chromatographed on silica gel column using Ethyl acetate/hexanes (1:1) as an eluent, to give 0.86 g, (68% yield) of tert-butyl-3-4-(4-(4 aminophenyl)-6-morpholine-1,3,5-triazin-2-ylamino)azetidine-1-carboxylate. (M+H) 428 Step 4: Preparation of tert-butyl 3-{[4-(4-{[(4-fluorophenyl)carbamoyl]amino}phenyl)-6 30 morpholin-4-yl- 1,3,5-triazin-2-yl]amino}azetidine-1-carboxylate 82 WO 2009/143313 PCT/US2009/044774 A mixture of tert-butyl 3-{[4-(4-aminophenyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]amino}azetidine 1-carboxylate (100 mg, 0.23 mmol), 4-fluorophenylisocyanate (63 mg, 0.46 mmol) and DMAP (5 mg) was stirred at room temperature for a period of 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. White solid; Yield 40 mg 5 (30%); (M+H) 565.6 Example 14: Preparation of tert-butyl 3-[(4-morpholin-4-yl-6-{4 [(phenylcarbamoyl)amino]phenyl}-1,3,5- triazin-2-yl)amino]azetidine-1-carboxylate The titled compound was prepared by starting from tert-butyl 3-{[4-(4-aminophenyl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]amino}azetidine-1-carboxylate (140 mg, 0.32 mmol) 10 phenylisocyanate (58 mg, 0.49 mmol) and DMAP (5 mg) was stirred at room temperature for a period of 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. White solid; Yield 40 mg (31%); (M+H) 547.6 Example 15: Preparation of tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridine-3 ylcarbamoyl)amino]phenyl}-1,3,5- triazin-2-yl)amino]azetidine-1-carboxylate 15 The titled compound was prepared by starting from tert-butyl 3-{[4-(4-aminophenyl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]amino}azetidine-1-carboxylate (140 mg, 0.32 mmol) 3 pyridylisocyanate (70 mg, 0.58 mmol) and DMAP (5 mg) was stirred at room temperature for a period of 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. White solid; Yield 40 mg (23%); (M+H) 548.7. 20 Example 16: Preparation of tert-butyl 3-{[4-(4-{[(4-methylphenyl)carbamoyl]amino}phenyl)-6 morpholin-4-yl- 1,3,5-triazin-2-yl]amino}azetidine-1-carboxylate The titled compound was prepared by starting from tert-butyl 3-{[4-(4-aminophenyl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]amino}azetidine-1 -carboxylate (130 mg, 0.27 mmol) 4-tolyl isocyanate (40 mg, 0.30 mmol) and DMAP (5 mg) was stirred at room temperature for a period 25 of 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. White solid; Yield 85 mg (47%); (M+H) 561.6. Example 17: Preparation of 1-{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}-3- phenylurea To a stirred solution of tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(phenylcarbamoyl)amino]phenyl} 30 1,3,5- triazin-2-yl)amino]azetidine-1-carboxylate 83 WO 2009/143313 PCT/US2009/044774 30 mg (0.055 mmoles) in DCM, (20 ml) TFA (1.5 ml) was added at room temperature and stirred for 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. Yield: 20 (83%); (M+H) 447. Example 18: Preparation of 1-{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2 5 yl]phenyl}-3-pyridin-3-ylurea To a stirred solution of tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridin-3 ylcarbamoyl)amino]phenyl}- 1,3,5-triazin-2-yl)amino]azetidine-1-carboxylate 30 mg (0.055 mmoles) in DCM, (20 ml) TFA (1.5 ml) was added at room temperature and stirred for 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, 10 using ACN/water and TFA. Yield: 21 (83%); (M+H) 448.5. Example 19: Preparation of 1-{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}-3-(4-fluorophenyl)urea To a stirred solution of tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(4-fluoro phenylcarbamoyl)amino]phenyl}-1,3,5- triazin-2-yl)amino]azetidine-1-carboxylate 15 30 mg (0.053 mmoles) in DCM, (20 ml) TFA (1.5 ml) was added at room temperature and stirred for 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. Yield: 20 (83%); (M+H) 465.5. Example 20: Preparation of 1-{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}-3-(4-methylphenyl)urea 20 To a stirred solution of tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(4-methyl phenylcarbamoyl)amino]phenyl}-1,3,5- triazin-2-yl)amino]azetidine-1-carboxylate 130 mg (0.23 mmoles) in DCM, (20 ml) TFA (1.5 ml) was added at room temperature and stirred for 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. Yield: 40 (37%); (M+H) 461.5. 25 Example 21: Preparation of tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridine-4 ylcarbamoyl)amino]phenyl}-1,3,5- triazin-2-yl)amino]azetidine-1-carboxylate 84 WO 2009/143313 PCT/US2009/044774 To a stirred solution of tert-butyl 3-{[4-(4-aminophenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]amino}azetidine-1-carboxylate (200 mg, 0.47 mmol) in DCM (100 ml) at 0 oC, triphosgene (300 mg) and triethylamine (3 ml) was added slowly. The reaction mixture was stirred for 15 minutes and 4-aminopyridine (200 mg. 2.1 mmol) was added. The reaction mixture was stirred 5 at room temperature for 24 hours and concentrated. It was quenched with cold water and the separated solid was filtered and washed with water. It was dried and purified by Gilson HPLC. Yield 100 mg (40%); (M+H) 548.6 Example 22: Preparation of 1-{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}-3-pyridin-4-ylurea 10 To a stirred solution of tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridine-4 ylcarbamoyl)amino]phenyl}-1,3,5- triazin-2-yl)amino]azetidine-1-carboxylate 40 mg (0.073 mmoles) in DCM, (20 ml) TFA (1.5 ml) was added at room temperature and stirred for 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. Yield: 26 (81%); (M+H) 448.5. 15 Example 23: Preparation of 1-{4-[4-morpholin-4-yl-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5 triazin-2-yl]phenyl}-3-phenylurea Step 1: Preparation of 3-(4-chloro-6-morpholin-4-yl-1,3,5-triazin-2-yl)-8-oxa-3 azabicyclo[3.2. 1 ]octane To a stirred acetone/crushed ice suspension of 2,4-dichloro-6-morpholin-4-yl-[1,3,5]triazine (1.5 20 g, 6.5 mmol), 8-oxa-3-azabicyclo[3.2.1]octane (980 mg, 6.5 mmol) and triethylamine (3 ml) was added and stirred at room temperature for 6 hours. At the end, the separated solid was filtered and washed with water. The crude product was found to be pure enough for further transformations. Yield: 2.0 g (99%); mp. 118; (M+H) 313.1 Step 2: Preparation of 4-[4-morpholin-4-yl-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2 25 yl]aniline A mixture of 3-(4-chloro-6-morpholin-4-yl-1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2. 1 ]octane (2.0 g, 6.4 mmol), tetrakis(triphenylphosphine)palladium (0) in catalytic amount (100 mg ), sodium carbonate solution 2 M (5 mL), 4-aminophenylboronic acid pinacol ester (1.5 g, 6.43 mmoles), DME ( 200 mL) was refluxed for 24 hours. The solvent was evaporated and the residue was 30 dissolved in methylene chloride and filtered though Celite
TM
.The organic layer was washed with 85 WO 2009/143313 PCT/US2009/044774 water (200 mL) and dried over magnesium sulfate. It was filtered and the solvent was evaporated. The residue was chromatographed on silica gel column using Ethyl acetate/hexanes (1:1) as an eluent, to give 1.4 g, (59% yield) of the titled product. mp. 154; (M+H) 369.4. 5 Step 3: Preparation of 1-{4-[4-morpholin-4-yl-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin 2-yl]phenyl}-3-phenylurea The titled compound was prepared by starting from 4-[4-morpholin-4-yl-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]aniline (120 mg, 0.32 mmol) phenylisocyanate (80 mg, 0.67 mmol) and DMAP (5 mg) was stirred at room temperature for a period of 24 hours. At 10 the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. White solid; mp: 242; Yield 35 mg (28%); (M+H) 488.56 Example 24: Preparation of 1-(4-fluorophenyl)-3-{4-[4-morpholin-4-yl-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}urea The titled compound was prepared by starting from 4-[4-morpholin-4-yl-6-(8-oxa-3 15 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]aniline (100 mg, 0.27 mmol)4-fluoro phenylisocyanate (50 mg, 0.36 mmol) and DMAP (5 mg) was stirred at room temperature for a period of 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and TFA. White solid; mp: 248; Yield 86 mg (86%); (M+H) 506.4 Example 25: Preparation of 1 -(4-methylphenyl)-3-{4-[4-morpholin-4-yl-6-(8-oxa-3 20 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}urea The titled compound was prepared by starting from 4-[4-morpholin-4-yl-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]aniline (100 mg, 0.27 mmol)4-tolylisocyanate (60 mg, 0.45 mmol) and DMAP (5 mg) was stirred at room temperature for a period of 24 hours. At the end, reaction mixture was concentrated and purified by Gilson HPLC, using ACN/water and 25 TFA. White solid; mp: 228; Yield 80 mg (80%); (M+H) 502.4 Following the procedure as outlined in example 25, compounds described in examples 26 to 32 were prepared. Example 26: 1-[4-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl-1,3,5-triazin-2-yl)phenyl]-3 methylurea (M+H) 452.53 86 WO 2009/143313 PCT/US2009/044774 Example 27: 2-hydroxyethyl [4-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl-1,3,5-triazin-2 yl)phenyl]carbamate (M+H) 483.54 Example 28: 1-[4-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(4 methylpiperazin-1-yl)phenyl]urea (M+H) 612.8 5 Example 29: 1-[4-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl-1,3,5-triazin-2-yl)phenyl]-3-ethylurea (M+H) 466.56 Example 30: 1-cyclopropyl-3-[4-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl-1,3,5-triazin-2 yl)phenyl]urea (M+H) 478.55 Example 31: 1-[4-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4 10 ylurea (M+H) 515 Example 32: 1-[4-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl-1,3,5-triazin-2-yl)phenyl]-3-[4 (hydroxymethyl)phenyl]urea (M+H) 544.6 Example 33: Preparation of 4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5 triazin-2-yl]aniline 15 Step 1: Synthesis of 4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine To a solution of cyanuric chloride (2.5 g, 13.5 mmol) in CH 2
CI
2 (150 mL) was added dropwise morpholine (1.14 g, 13.5 mmol) at -78 oC, followed by addition of Et3N (3.0 mL, 21.5 mmol). The resulting reaction mixture was stirred at -78 oC for 20 min, and then diluted with CH 2
CI
2 . The organic phase was washed with water and brine, and dried over MgSO 4 .The solvent was 20 removed in vacuum to give the title compound as white crystalline solid (3.027 g, 95% yield). MS(ESI) m/z 235.1. Step 2: Synthesis of 8-(4-chloro-6-morpholino-1,3,5-triazin-2-yl)-3-oxa-8-azabicyclo[3,2, 1 ]octane To a solution of 4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine (2.34 g, 10 mmol) in CH 2
CI
2 (100 mL) were added 3-oxa-8-azabicyclo[3,2,1]octane hydrochloride (1.645 g, 11 mmol) and Et3N 25 (4.2 mL, 30 mmol). The mixture was stirred at room temperature over night. The reaction mixture was washed with water and brine, and dried over MgSO 4 . The solvent was removed in vacuum to give the title compound as white solid (3.0 g, 96% yield). MS(ESI) m/z 312.1. 87 WO 2009/143313 PCT/US2009/044774 Step 3: Synthesis of 4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2 yl]aniline To a 10 mL vial were added 8-(4-chloro-6-morpholino-1,3,5-triazin-2-yl)-3-oxa-8 azabicyclo[3,2,1]octane (311 mg, 1.0 mmol), 4-aminophenylboronic acid pinacol ester (328 mg, 5 1.5 mmol), Pd(PPh3)4 (58 mg, 5 mol%), 1,2-dimethoxyethane (DME, 2.5 mL) and 2M Na2CO3 aqueous solution (1.5 mL). The resulting mixture was heated at 130 oC for 30 min in microwave oven. The reaction mixture was cooled to room temperature. The aqueous phase was extracted with EtOAc, and the combined organic phases were dried over (MgSO 4 ). The solvent was removed under reduced pressure and the residue was subjected to HPLC separation to give the 10 title compound as off-white solid (280 mg, 76% yield). MS(ESI) m/z 369.2. Example 34: Preparation of 1-{4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5 triazin-2-yl]phenyl}-3-pyridin-4-ylurea To a solution of 4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) in CHC13 (1 mL) were added Et3N (25 mL, 0.18 mmol) and triphosgene (18 15 mg, 0.06 mmol). The mixture was stirred at room temperature for 15 min and 4-aminopyridine (17 mg, 0.18 mmol) was added. The mixture was stirred at room temperature overnight. The solvent was removed, and the residue was subjected to HPLC separation to give the title compound as off-white solid (1TFA salt, 8.8 mg, 24% yield). MS(ESI) m/z 489.2. Example 35: Preparation of 4-[({4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5 20 triazin-2-yl]phenyl}carbamoyl)amino]benzamide Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, triphosgene (18 mg, 0.06 mmol) and 4-aminobenzamide (25 mg, 0.18 mmol) gave the title compound as off-white solid (10.6 mg, 33% yield). MS(ESI) m/z 531.2. 25 Example 36: Preparation of 1-{4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5 triazin-2-yl]phenyl}-3-pyridin-3-ylurea Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, triphosgene (18 mg, 0.06 mmol) and 3-aminopyridine (17 mg, 0.18 mmol) gave the title 30 compound as off-white solid (1TFA salt, 14.8 mg, 41% yield). MS(ESI) m/z 489.5. 88 WO 2009/143313 PCT/US2009/044774 Example 37: Preparation of 1-(4-fluorophenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, 5 triphosgene (18 mg, 0.06 mmol) and 4-fluoroaniline (20 mg, 0.18 mmol) gave the title compound as off-white solid (14.8 mg, 49% yield). MS(ESI) m/z 506.5. Example 38: Preparation of 1 -[4-(hydroxymethyl)phenyl]-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 10 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, triphosgene (18 mg, 0.06 mmol) and 4-aminobenzyl alcohol (22 mg, 0.18 mmol) gave the title compound as off-white solid (9.6 mg, 31% yield). MS(ESI) m/z 518.5. Example 39: Preparation of 1-[4-(2-hydroxyethyl)phenyl]-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea 15 Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, triphosgene (18 mg, 0.06 mmol) and 4-aminophenethyl alcohol (24 mg, 0.18 mmol) gave the title compound as off-white solid (10.6 mg, 33% yield). MS(ESI) m/z 532.5. Example 40: Preparation of 2-(diethylamino)ethyl 4-[({4-[4-morpholin-4-yl-6-(3-oxa-8 20 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoate Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, triphosgene (18 mg, 0.06 mmol) and procaine hydrochloride (50 mg, 0.18 mmol) gave the title compound as off-white solid (1TFA salt, 14.6 mg, 33% yield). MS(ESI) m/z 613.6. 25 Example 41: Preparation of 1 -(4-methylphenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, 89 WO 2009/143313 PCT/US2009/044774 triphosgene (18 mg, 0.06 mmol) and p-toluidine (20 mg, 0.18 mmol) gave the title compound as off-white solid (9.2 mg, 31% yield). MS(ESI) m/z 502.5. Example 42: Preparation of 1-(4-cyanophenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea 5 Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, triphosgene (18 mg, 0.06 mmol) and 4-aminobezonitrile (21 mg, 0.18 mmol) gave the title compound as off-white solid (14.3 mg, 46% yield). MS(ESI) m/z 513.5. Example 43: Preparation of 1-[4-(4-methylpiperazin-1-yl)phenyl]-3-{4-[4-morpholin-4-yl-6-(3 10 oxa-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, triphosgene (18 mg, 0.06 mmol) and 4-(4-methylpiperazin-1-yl)aniline (54 mg, 0.18 mmol) gave the title compound as off-white solid (2TFA salt, 3.2 mg, 7% yield). MS(ESI) m/z 586.6. 15 Example 44: Preparation of 1-isopropyl-3-{4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]oct 8-yl)-1,3,5-triazin-2-yl]phenyl}urea Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, triphosgene (18 mg, 0.06 mmol) and isopropylamine (11 mg, 0.18 mmol) gave the title 20 compound as off-white solid (13.6 mg, 50% yield). MS(ESI) m/z 454.5. Example 45: Preparation of 1-(2-hydroxyethyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea Following the procedure described in example 34, reaction of 4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]aniline (22 mg, 0.06 mmol) (22 mg, 0.06 mmol, 25 triphosgene (18 mg, 0.06 mmol) and ethanolamine (11 mg, 0.18 mmol) gave the title compound as off-white solid (14.4 mg, 53% yield). MS(ESI) m/z 456.5. Example 46: Preparation of 1 -[2-(dimethylamino)ethyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8 yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea, MS (ES+) 513.62 (M+H)+ 90 WO 2009/143313 PCT/US2009/044774 Example 47: Preparation of 1-{4-[4-morpholin-4-yl-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5 triazin-2-yl]phenyl}-3-pyridin-3-ylurea, MS (ESI) m/z 489.3. Example 48: Preparation of 1-{4-[4-morpholin-4-yl-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5 triazin-2-yl]phenyl}-3-pyridin-4-ylurea, mp 258 0C; MS (ESI) m/z 489.3. 5 Following the procedure as outlined in example 1, step 3 the following compounds were prepared. Example 49: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(2-methylpyridin-4-yl)urea MS (ESI) m/z 477.3. Example 50: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(2 10 hydroxyethyl)phenyl]urea MS (ESI) m/z 506.4. Example 51: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4 (hydroxymethyl)phenyl]urea. Example 52: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(1 hydroxyethyl)phenyl]urea MS (ESI) m/z 506.4. 15 Example 53: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4 (trifluoromethyl)phenyl]urea MS (ESI) m/z 530.2. Example 54: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-hydroxyphenyl)urea MS (ESI) m/z 478.2. Example 55: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[5-(trifluoromethyl)pyridin-2 20 yl]urea MS (ESI) m/z 530.5. Example 56: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[2,2,2-trifluoro-1-hydroxy 1-(trifluoromethyl)ethyl]phenyl}urea MS (ESI) m/z 621.54. Example 57: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[3-(1 hydroxyethyl)phenyl]urea MS (ESI) m/z 506.3. 25 Example 58: methyl 4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzoate MS (ESI) m/z 520.3. 91 WO 2009/143313 PCT/US2009/044774 Example 59: Preparation of 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)- 1, 3,5-triazin 2-yl]phenyl}-3-pyridin-4-ylurea Step 1: To a stirred solution of NaH (50% 460 mg) in dry THF tetrahydro-2H-pyran-4-ol (1.02 g, 10 mmol) was slowly added at room temperature. The reaction mixture was stirred at room 5 temperature for 30 min and 2,4-dichloro-6-morpholin-4-yl-[1,3,5]triazine (2.35 g, 10 mmol) in THF (50 ml) was slowly added. The reaction mixture was stirred at room temperature for 48 hours and slowly quenched with ice-cold water. It was extracted with CHCl 3 ; washed well with water and dried over anhydrous MgSO 4 . It was filtered and concentrated and 2-chloro-4 morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazine was purified by silica gel column 10 chromatography by eluting it with 40% ethyl acetate:hexane. Yield: 1.5 g, 50%; White solid; mp 91 C; MS (ESI) m/z 301.52 Step 2: 4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2-yl]aniline was prepared by the procedure as described in example 1, step 2. Starting from 2-chloro-4 morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazine (1.5 g, 4.9 mmol) 980 mg (56% 15 yield) of the product was isolated after purification using Silica gel column chromatography by eluting it with ethyl acetate. Mp. 188 oC; MS (ESI) m/z 358.2. Step 3: 1-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2-yl]phenyl}-3 pyridin-4-ylurea was prepared by the procedure as described in example 1, step 3. Starting from 4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2-yl]aniline (212 mg. 0.59 20 mmol) 190 mg (Yield, 67%) of the final product was isolated as a white solid. mp 238 0C; MS (ESI) m/z 478.3. Example 60: Preparation of 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)- 1, 3,5-triazin 2-yl]phenyl}-3-phenylurea 1-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2-yl]phenyl}-3-phenylurea 25 was prepared by reacting the 4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin 2-yl]aniline and the corresponding phenylisocyanate. Product was purified by Gilson, HPLC. MS (ESI) m/z 476.5. Example 61: Preparation of 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)- 1, 3,5-triazin 2-yl]phenyl}-3-pyridin-3-ylurea 30 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3 ylurea was prepared by reacting the 4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5 92 WO 2009/143313 PCT/US2009/044774 triazin-2-yl]aniline and the corresponding 3-pyridylisocyanate. Product was purified by Gilson, HPLC. MS (ESI) m/z 477.53. Example 62: Preparation of 1 -[4-(hydroxymethyl)phenyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro 2H-pyran-4-yloxy)-1,3,5-triazin-2-yl]phenyl}urea 5 1 -[4-(hydroxymethyl)phenyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1, 3,5 triazin-2-yl]phenyl}urea was prepared by the triphosgene procedure as described in example 1, step 3. Product was purified by Gilson, HPLC. MS (ESI) m/z 506.6. Example 63: Preparation of 1 -(2-methylpyridin-4-yl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H pyran-4-yloxy)-1,3,5-triazin-2-yl]phenyl}urea 10 1 -(2-methylpyridin-4-yl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)- 1,3,5-triazin-2 yl]phenyl}urea was prepared by the triphosgene procedure as described in example 1, step 3. Product was purified by Gilson, HPLC. MS (ESI) m/z 491.5. Example 64: Preparation of 1-[2-(methylamino)ethyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H pyran-4-yloxy)-1,3,5-triazin-2-yl]phenyl}urea 15 1-[2-(methylamino)ethyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2 yl]phenyl}urea was prepared by the triphosgene procedure as described in example 1, step 3. Product was purified by Gilson, HPLC. MS (ESI) m/z 457.54. Example 65: Preparation of 1 -(3-acetylphenyl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4 yloxy)-1,3,5-triazin-2-yl]phenyl}urea 20 1-(3-acetylphenyl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5-triazin-2 yl]phenyl}urea was prepared by reacting the 4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4 yloxy)-1,3,5-triazin-2-yl]aniline and the corresponding 3-acetylisocyanate. Product was purified by Gilson, HPLC. MS (ESI) m/z 518.58. Example 66: Preparation of 1-[4-(dimethylamino)phenyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro 25 2H-pyran-4-yloxy)-1,3,5-triazin-2-yl]phenyl}urea 1-[4-(dimethylamino)phenyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5 triazin-2-yl]phenyl}urea was prepared by reacting the 4-[4-morpholin-4-yl-6-(tetrahydro-2H 93 WO 2009/143313 PCT/US2009/044774 pyran-4-yloxy)-1,3,5-triazin-2-yl]aniline and the corresponding 4-(N,N-dimethyl amino)phenylisocyanate. Product was purified by Gilson, HPLC. MS (ESI) m/z 519.61. Example 67: Preparation of 4-[3-{4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl}ureido]benzoic acid 5 To a stirred mixture of methyl 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2 yl)phenyl)ureido)benzoate (1.4 g, 2.69 mmol), THF (10 mL), MeOH (5 mL) and H20 ( 2.5 mL) was added LiOH.H20 (339 mg, 8.07 mmol) then heated under reflux for 8 hrs. Concentrated and added H20 (5 mL) then acidified with 2N HCI. The solid was filtered washed with H20 and dried to give the product as a tan solid (1.3 g, 96% yield); MS (ESI) m/z = 506.3 10 Example 68: Preparation of N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1, 3,5-triazin 2-yl)phenyl)ureido)benzamide To a stirred solution of 4-[3-{4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl}ureido]benzoic acid (150 mg; 0.297 mmol), Hunig's base (303 pL, 1.782 mmol), HBTU ( 563 mg, 1.485 mmol) in 2 mL of NMP was stirred for 1 hr. at room temperature and added N',N'-dimethylethane-1,2 15 diamine (130 pL, 1.188 mmol) then stirred overnight. Added CH 2
CI
2 (40 mL) and washed with sat. NaHCO3 and H20. Concentrated and purified by silica gel chromatography
CH
2
CI
2 :MeOH:7N NH3 in MeOH (10:1:0.22) to give the product as a white solid (98 mg, 57% yield); MS (ESI) m/z = 576.4. Example 68: Preparation N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2 20 yl)phenyl)ureido)benzamide as an HCI salt To the N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2 yl)phenyl)ureido)benzamide (72 mg, 0.125 mmol) and MeOH (1 mL) was added 4N HCI in dioxane (1 mL) and stirred for 3 hrs. The solid was filtered and washed with ether to give the product as a white solid (73 mg, yield= 95%); MS (ESI) m/z = 576.4. 25 Example 69: Preparation of 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1-carbonyl)phenyl)urea hydrochloride To a stirred solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid (150 mg; 0.297 mmol), Hunig's base (303 pL, 1.782 mmol), HBTU ( 563 mg, 1.485 mmol) in 2 mL of NMP was reacted according to example 68 with 1-methylpiperazine (132 pL, 1.188 94 WO 2009/143313 PCT/US2009/044774 mmol) to give 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazine-1 carbonyl)phenyl)urea as a white solid (95 mg, 54% yield); MS (ESI) m/z = 588.4. To a 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazine-1 carbonyl)phenyl)urea (70 mg, 0.119 mmol) and MeOH (1 mL) was added 4N HCI in Dioxane (1 5 mL), stirred for 3 hrs. The solid was filtered and washed with ether to give the product as a white solid (74 mg, yield= 100%). Example 70: Preparation of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N methylbenzamide To the stirred solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid 10 (150 mg; 0.297 mmol), Hunig's base (303 pL, 1.782 mmol), HBTU ( 563 mg, 1.485 mmol) in 2 mL of NMP was reacted according to example 68 with methylamine (594 PL, 2M solution. in THF) to give the product as a white solid (118 mg, 77% yield); MS (ESI) m/z = 519.3. Example 71: Preparation of N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1, 3,5-triazin 2-yl)phenyl)ureido)-N-methylbenzamide hydrochloride 15 To the stirred solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid (150 mg; 0.297 mmol), Hunig's base (303 pL, 1.782 mmol), HBTU ( 563 mg, 1.485 mmol) in 2 mL of NMP was reacted according to example 68 with N1,N1,N2-trimethylethane-1,2-diamine (154 pL, 1.188 mmol) to give N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1,3,5-triazin 2-yl)phenyl)ureido)-N-methylbenzamide as a white solid (88mg, 50% yield); MS (ESI) m/z = 20 590.2. To the N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N methylbenzamide (55 mg, 0.127 mmol) and MeOH (1 mL) was added 4N HCI in Dioxane (1 mL) and stirred for 3 hrs. The solid was filtered and washed with ether to give the product as a white solid (70 mg, yield= 88%). 25 Example 72: Preparation of 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 morpholinopiperidine-1 -carbonyl)phenyl)urea To the stirred solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid (50 mg; 0.099 mmol), Hunig's base (103 pL, 0.594 mmol), HBTU ( 188 mg, 0.495 mmol) in 1 mL of NMP was reacted according to example 68 with 4-(piperidin-4-yl)morpholine (67 mg, 0.396 95 WO 2009/143313 PCT/US2009/044774 mmol). Evaporated the solvent and purified by HPLC to give the product (40.1 mg, 62% yield); MS (ESI) m/z = 658.7 Example 73: Preparation of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N (quinuclidin-3-yl)benzamide 5 To the solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid (50 mg; 0.099 mmol), Hunig's base (103 pL, 0.594 mmol), HBTU ( 188 mg, 0.495 mmol) in 2 mL of NMP was reacted according to according to example 68 with quinuclidin-3-amine (79 mg, 0.396 mmol). Evaporated the solvent and purified by HPLC to give the product (24.3 mg, 40% yield); MS (ESI) m/z = 614.7 10 Example 74: Preparation of 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-(pyrrolidin 1-yl)piperidine-1-carbonyl)phenyl)urea To the solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid (50 mg; 0.099 mmol), Hunig's base (103 pL, 0.594 mmol), HBTU ( 188 mg, 0.495 mmol) in 2 mL of NMP was reacted according to example 68 with 4-[1-pyrrolidinyl]piperidine (61 mg, 0.396 mmol). 15 Evaporated the solvent and purified by HPLC to give the product as a white solid (37 mg, 58% yield); MS (ESI) m/z = 642.7 Example 75: Preparation of 1-(4-(1,4'-bipiperidine-1'-carbonyl)phenyl)-3-(4-(4,6-dimorpholino 1,3,5-triazin-2-yl)phenyl)urea To the solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid (50 mg; 20 0.099 mmol), Hunig's base (103 pL, 0.594 mmol), HBTU ( 188 mg, 0.495 mmol) in 2 mL of NMP was reacted according to example 68 with 1,4'-bipiperidine (67 mg, 0.396 mmol). Evaporated the solvent and purified by HPLC to give the product as a white solid (39 mg, 60% yield); MS (ESI) m/z = 656.8. Example 76: Preparation of 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6 25 dimorpholino-1,3,5-triazin-2-yl)phenyl)urea To the solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid (50 mg; 0.099 mmol), Hunig's base (103 pL, 0.594 mmol), HBTU ( 188 mg, 0.495 mmol) in 2 mL of NMP was reacted according to example 68 with N,N-dimethylpiperidin-4-amine (51 mg, 0.396 mmol). Evaporated the solvent and purified by HPLC to give the product (30.6 mg, 52% yield); MS 30 (ESI) m/z = 616.7 96 WO 2009/143313 PCT/US2009/044774 Example 77: Preparation of 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea To the solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid (50 mg; 0.099 mmol), Hunig's base (103 pL, 0.594 mmol), HBTU ( 188 mg, 0.495 mmol) in 2 mL of NMP 5 was reacted according to example 68 with piperazine (34 mg, 0.396 mmol). Evaporated the solvent and purified by HPLC to give the product (17.2 mg, 30% yield); MS (ESI) m/z = 573.6 Example 78: Preparation of 1-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(2-(pyridin-2 yl)acetyl)phenyl)urea To the solution of 4-(3-(4-(4,6-dimorpholino-1,3,5-triazin-2yl)phenyl)ureido)benzoic acid (50 mg; 10 0.099 mmol), Hunig's base (103 pL, 0.594 mmol), HBTU ( 188 mg, 0.495 mmol) in 2 mL of NMP was reacted according to example 68 with pyridin-2-ylmethanamine (43 mg, 0.396 mmol). Evaporated the solvent and purified by HPLC to give the product (9 mg, 15% yield); MS (ESI) m/z = 596.6. Preparation of 3-(4,6-dichloro-1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2. 1 ]octane 15 To a solution of cyanuric chloride (2.00 g, 10.85 mmoles) in acetone (20 mL) and water (10 mL) at 0 0C was added a solution of 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (1.46 g, 9.76 mmoles) in saturated aqueous NaHCO3 (25 mL) and acetone (25 mL) via addition funnel over 15 minutes. The reaction was stirred at 0 0C for 2 hours, then filtered to collect a white precipitate. The precipitate was washed with water (25 mL) and dried. The crude product was 20 purified by column chromatography (30:70 ethyl acetate in hexanes) to provide 3-(4,6-dichloro 1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1.55 g) as a white solid. Procedure to prepare 3-(4-chloro-6-(substituted amino)-1,3,5-triazin-2-yl)-8-oxa-3 azabicyclo[3.2. 1 ]octane: To a solution of 3-(4,6-dichloro-1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2.1 ]octane (0.085 g, 0.33 25 mmoles) and Na2CO3 (0.041 g, 0.39 mmoles) in acetone (1 mL) and water (1 mL) was added the desired amine (0.36 mmoles). The solution was heated to 55 0C and stirred for 2 hours then concentrated to provide crude amino-triazine, which was used directly without purification. Following this procedure, the following compounds were prepared. 3-(4-chloro-6-(piperidin-1 -yl)-1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2. 1 ]octane: 97 WO 2009/143313 PCT/US2009/044774 (310.3, M+H) 3-(4-chloro-6-(pyrrolidin-1 -yl)-1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2. 1 ]octane (296.3, M+H) t-butyl 2-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-chloro-1,3,5-triazin-2 5 ylamino)ethylcarbamate (385.3, M+H) 2-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-chloro-1,3,5-triazin-2-ylamino)ethanol (286.3, M+H) 4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-chloro-N-phenyl-1,3,5-triazin-2-amine 10 (318.3, M+H) 4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-chloro-N-cyclohexyl-1,3,5-triazin-2-amine (324.3, M+H) t-butyl 3-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-chloro-1,3,5-triazin-2-ylamino)azetidine-1 carboxylate 15 (397.3, M+H) Method to prepare 4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(substituted amino)-1,3,5-triazin 2-yl)aniline A suspension of bis-amino triazine chloride (0.33 mmoles) in toluene (2 mL), ethanol (2 mL), and 2M aqueous Na2CO3 (0.700 mL) in a microwave vial was sparged with N2 for 5 minutes. 20 Pd(PPh3)4 (0.021 mgs, 0.018 mmoles) and 4-aminophenylboronic acid pinacol ester (0.094 mgs, 0.43 mmoles) were added and the vial was sealed and heated to 110 0C for 1 hour. The mixture was cooled and filtered through Celite T M . The filter cake was washed with ethyl acetate and the filtrate was washed with brine, dried, and concentrated. The crude material was purified by HPLC (Waters system, 5-70 % CH3CN in H20 w/ 0.05% NH40H) to provide the aryl 98 WO 2009/143313 PCT/US2009/044774 substituted triazine compounds. Following this procedure, the following compounds were prepared. 4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(piperidin-1 -yl)- 1, 3,5-triazin-2-yl)aniline (367.4, M+H) 5 4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(pyrrolidin-1 -yl)-1,3,5-triazin-2-yl)aniline (353.3, M+H) 2-(4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-1,3,5-triazin-2-ylamino)ethanol; (343.3, M+H) 4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-N-phenyl-1,3,5-triazin-2-amine; 10 (375.3, M+H) 4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-N-cyclohexyl-1,3,5-triazin-2-amine; (381.4, M+H) t-butyl 3-(4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1,3,5-triazin-2 ylamino)azetidine-1-carboxylate; (454.4, M+H). 15 Procedure to prepare 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(substituted amino)-1,3,5 triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea: A solution of triphosgene (0.034 mgs, 0.114 mmoles) in CH 2
CI
2 (1 mL) was prepared. A solution of the desired triazine aniline derivative (0.23 mmoles) in CH 2
CI
2 (1 mL) and triethylamine (0.095 mL, 0.68 mmoles) was added and the reaction was allowed to stir at room temperature 20 for 15 minutes. A solution of 4-aminopyridine (0.043 mgs, 0.46 mmoles) in THF (1 mL) was then added and the solution was stirred at room temperature for 3 hours, then concentrated and purified by HPLC (Waters system, 5-70 % CH3CN in H20 w/ 0.05% NH40H) to provide the 1 (4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(substituted amino)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea derivatives. The following compounds were prepared by this procedure: 25 Example 79: Preparation of 1 -(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(piperidin-1 -yl) 1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 487.2, M+H. 99 WO 2009/143313 PCT/US2009/044774 Example 80: Preparation of1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(pyrrolidin-1-yl) 1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 474.2, M+H. Example 81: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(1 hydroxyethyl)phenyl]urea 5 To a stirred mixture of 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140, 0.40 mmoles) in methylene chloride at 0 oC was added triphosgene (0.25, 0.84 mmoles) and Et3N ( 3 mL). The reaction mixture was stirred for 20 minutes at 0 oC. Then 1-(4-aminophenyl)ethanol (0.10 g, 0.73 mmoles) was added to the mixture. The reaction mixture was stirred for about 16 hours at room temperature. The solvent was removed. The residue was dissolved in DMSO and place at 10 HPLC using acetonitrile buffer TFA to give 48 mg (24 % ) of [4-(4,6-dimorpholin-4-yl-1,3,5 triazin-2-yl)phenyl]-3-[4-(1-hydroxyethyl)phenyl]urea. M+H 506.4. Example 82: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(2 methylpyrid in-4-yl)urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140, 0.40 mmoles) and 2 15 methyl-4-aminopyridine (80 mg, 0.73 mmol) and following the procedure as outlined in Example 81, 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(2-methylpyridin-4-yl)urea was isolated by HPLC purification. Yield: 60 mg, 27%; MS (ESI) m/z = 477.3. Example 83: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4 (hydroxymethyl)phenyl]urea 20 Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140, 0.40 mmoles) and 4 aminophenylmethanol (100 mg, 0.81 mmol) and following the procedure described in example 81, 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4- (hydroxymethyl) phenyl]urea was isolated by HPLC purification. Yield: 58 mg, 26%; MS (ESI) m/z = 492.3. Example 84: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4 25 hydroxyphenyl]urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140, 0.40 mmoles) and 4 aminophenol (89 mg, 0.81 mmol) and following the procedure as outlined in 100 WO 2009/143313 PCT/US2009/044774 example 81, 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4- hydroxyphenyl]urea was isolated by HPLC purification. Yield: 62 mg, 16%; MS (ESI) m/z = 478.2. Example 85: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4 (trifluoromethyl)phenyl]urea 5 Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140, 0.40 mmoles) and 4 trifluoromethylaniline (100 mg, 0.62 mmol) and following the procedure as outlined in example 81, 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4- (trifluoromethyl)phenyl]urea was isolated by HPLC purification. Yield: 25 mg, 13%; MS (ESI) m/z = 430.2. Example 86: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[2,2,2 10 trifluoro-1- hydroxy-1-(trifluoromethyl)ethyl]phenyl}urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.140, 0.40 mmoles) and 4 trifluoromethylaniline (140 mg, 0.40 mmol) and following the procedure as outlined in example 81, 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[2,2,2-trifluoro-1- hydroxy-1 (trifluoromethyl)ethyl]phenyl}urea was isolated by HPLC purification. Yield: 40 mg, 16%; MS 15 (ESI) m/z = 628.3. Example 87: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[5 (trifluoromethyl)pyridin-2-yl]urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.160, 0.47 mmoles) and 2 amino-5-trifluorophenylpyridine (100 mg, 0.61 mmol) and following the procedure as outlined in 20 example 81, 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[5- (trifluoromethyl)pyridin-2 yl]urea was isolated by HPLC purification. Yield: 10 mg, 4.1%; MS (ESI) m/z = 531.3. Example 88: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[3-(1 hydroxyethyl)phenyl]urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (0.160, 0.47 mmoles) and 1-(3 25 aminophenyl)ethanol (100 mg, 0.73 mmoles)and following the procedure as outlined in example 81, 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[3-(1 hydroxyethyl)phenyl]urea was isolated by HPLC purification. Yield: 10 mg, 4.1%; MS (ESI) m/z = 531.3. 101 WO 2009/143313 PCT/US2009/044774 Example 89: Preparation of 1-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin 2-yl}phenyl)-3-pyridin-4-ylurea Step 1: Preparation of 2-chloro-4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazine: To a stirred solution of dichoromonomorpholino derivative of 1,3,5-triazine (2.0 g , 8.5 mmoles) 5 in methylene chloride 200 mL, was added 3S-3-methylmorpholine (0.85 g , 8.5 mmoles) combined with two equivalents of triethylamine 1.7 mL dropwise manner. After the addition reaction mixture was stirred at room temperature for 3 hours and quenched with water. The aqueous layer was washed well with water; dried over anhydrous MgSO 4 and filtered. The solvent was evaporated and the residue obtained was triturated with diethyl ether/ hexane (1:1) 10 and filtered. The solid was used without further purification. (1.0 g, 40% yield). M+H 357.3. Step2 : Preparation of 4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}aniline: A mixture of 2-chloro-4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazine (1.26, 4.2 mmol), sodium carbonate solution ( 2M, 2 mL), tetrakis palladium triphenylphosphine 15 70 mg (catalytic amount) and 4-aminophenyl boronic pinacol ester (1.37 g, 6.3 mmoles) in DME (100 mL) was heated to reflux for 24 hours. The solvent was evaporated, the residue was re dissolved in methylene chloride and filtered through Celite T M . The solvent was evaporated and the residue was chromatographed on silica gel eluting with first 26/4 hexanes/ethyl acetate then increased to 1/1 hexanes ethyl acetate to give 1.0 of 4-{4-[(3S)-3-methylmorpholin-4-y]-6 20 morpholin-4-yl-1,3,5-triazin-2-yl}aniline (71% yield); M+H 357.2. Step 3: Preparation of 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1,3,5-triazin-2 yl}phenyl)-3-pyridin-4-ylurea: Starting from 4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}aniline (0.160, 0.44 mmoles) and 4-aminopyridine (100 mg, 1.06 mmoles)and following the procedure 25 as outlined in example 81, 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1, 3,5-triazin 2-yl}phenyl)-3-pyridin-4-ylurea was isolated by HPLC purification. Yield: 125 mg, 60%; MS (ESI) m/z 477.3. Example 90: Preparation of 1 -[4-(2-hydroxyethyl)phenyl]-3-(4-{4-[(3S)-3-methylmorpholin-4-yl] 6-morpholin- 4-yl-1,3,5-triazin-2-yl}phenyl)urea 102 WO 2009/143313 PCT/US2009/044774 Starting from 4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}aniline (0.160, 0.44 mmoles) and 4-(1-hydroxyethyl)aniline (137 mg, 1 mmole)and following the procedure described in example 81, 1-[4-(2-hydroxyethyl)phenyl]-3-(4-{4-[(3S)-3 methylmorpholin-4-yl]-6-morpholin- 4-yl-1,3,5-triazin-2-yl}phenyl)urea was isolated by HPLC 5 purification. Yield: 125 mg, 60%; MS (ESI) m/z 519.6 Example 91: Preparation of 1 -[4-(2-hydroxymethyll)phenyl]-3-(4-{4-[(3S)-3-methylmorpholin-4 yl]-6-morpholin- 4-yl-1,3,5-triazin-2-yl}phenyl)urea Starting from 4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}aniline (0.160, 0.44 mmoles) and 4-aminophenylmethanol (0.10 g , 0.81 mmoles) and following the 10 procedure as outlined in example 81, 1 -[4-(2-hydroxymethyll)phenyl]-3-(4-{4-[(3S)-3 methylmorpholin-4-yl]-6-morpholin- 4-yl-1,3,5-triazin-2-yl}phenyl)urea was isolated by HPLC purification. Yield: 55 mg, 16%; MS (ESI) m/z 506.3. Example 92: Preparation of 1-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin 2-yl}phenyl)-3-(2-methylpyridin-4-yl)urea 15 Starting from 4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}aniline (0.160, 0.44 mmoles) and 2-methyl-4-aminopyridine (0.10 g , 0.92 mmoles) and following the procedure as outlined in example 81, 1-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl 1,3,5-triazin-2-yl}phenyl)-3-(2-methylpyridin-4-yl)urea was isolated by HPLC purification. Yield: 75 mg, 36%; MS (ESI) m/z 491.3. 20 Example 93: Preparation of 1-[4-(1-hydroxyethyl)phenyl]-3-(4-{4-[(3S)-3-methylmorpholin-4-yl] 6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)urea Starting from 4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}aniline (0.160, 0.44 mmoles) and 1-(4-aminophenyl)ethanol (126 mg , 0.92 mmoles) and following the procedure as outlined in example 81, 1-[4-(1-hydroxyethyl)phenyl]-3-(4-{4-[(3S)-3 25 methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)urea was isolated by HPLC purification. MS (ESI) m/z 519.6. Example 94: Preparation of 1-[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3 pyridin-4-ylurea Step 1: To a stirred solution of isopropanol (250 mg, 4.1 mmol) in dry THF (50 ml) at -78 oC, n 30 butyllithium (2.6 ml, 1.6 mol solution) was slowly added. The reaction mixture was stirred for 30 103 WO 2009/143313 PCT/US2009/044774 minutes and a solution of 2,4-dichloro-6-morpholin-4-yl-[1,3,5]triazine (1.00 g, 4.25 mmol) in THF was added to the solution. The reaction mixture was stirred at room temperature for 24 hours and quenched with water and extracted with DCM. The crude product obtained was taken to next step without purification. 5 Step 2: A mixture of (crude) 4-(chloro-6-isopropoxyl-1,2,3-triazin-2yl)morpholine of (2.91 g, 11.27 mmol) 4-amino-phenylboronic acid pinacol ester (3.59 g, 16.4 mmoles) , tetrakis palladium triphenylphosphine (120 mg catalytic amount) and sodium carbonate solution ( 2M, 2 mL) was refluxed in DME (100 mL) for 24 hours. The solvent was removed and the residue was re-dissolved in methylene chloride and filtered through Celite
TM
.The solvent was evaporated 10 and the residue was chromatographed on silica gel eluting with first 26:4 hexane:ethyl acetate then increased to 1/1 hexanes ethyl acetate to give 0.65 g (yield 18%) of 4-(4-isopropoxy-6 morpholino-1,3,5-triazin-2-yl)aniline. M+H 316.3. Step 3: Starting from 4-(4-isopropoxy-6-morpholino-1,3,5-triazin-2-yl)aniline (0.140, 0.44 mmoles) and 4-aminopyridine (100 mg , 1.06 mmoles) and following the procedure as outlined 15 in example 81, 1-[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea was isolated by HPLC purification. Yield: 15 mg, 7.8%; MS (ESI) m/z = 436.3. Example 95: Preparation of methyl 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzoate A mixture of 4-(4-isopropoxy-6-morpholino-1,3,5-triazin-2-yl)aniline (1.3 g, 4.1 mmol), 20 triethylamine (2 ml) and 4-carbomethoxy-phenylisocyanate (1451 mg, 8.2 mmol) was stirred for 48 hours and quenched with water and washed well. The organic layer was dried and filtered. It was concentrated and purified by column chromatography by eluting it initially with 10% ethyl acetate: hexane and latter with 40% ethyl acetate:hexane. White solid; 600 mg, 30%; MS (ESI) m/z 492.5. 25 Example 96: Preparation of 1-[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4 [(4-methylpiperazin-1 -yl)carbonyl]phenyl}urea Starting from methyl 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl] carbamoyl}amino)benzoic acid (160 mg, 0.33 mmol) and 4-methylpiperazine following the procedure as outlined in Experimental 71, 80 mg (44% Yield) of the titled compound was 30 isolated as white solid. MS (ESI) m/z 281.2. 104 WO 2009/143313 PCT/US2009/044774 Example 97: Preparation of 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-(1 -methylpiperidin-4-yl)benzamide Starting from methyl 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl] carbamoyl}amino)benzoic acid (200 mg, 0.42 mmol) and 4-amino-1-methylpiperidine following 5 the procedure as outlined in Experimental 71, 65 mg (27% Yield) of the titled compound was isolated as white solid. MS (ESI) m/z 574.68. Example 98: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(1 methylpiperidin-4-yl)urea Starting from 4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)aniline (140 mg 0.40 mmoles) and 4 10 amino-1-methylpiperidine (70 mg, 0.62 mmol) and following the procedure as outlined in example 1, step 3, 20 mg (10 % Yield) of the final compound was isolated as a solid. MS (ESI) m/z = 483.4 Example 99: Preparation of 1-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin 2-yl}phenyl)-3-(1-methylpiperidin-4-yl)urea 15 Starting from 4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}aniline (0.140, 0.39 mmoles) and 4-amino-1-methylpiperidine (70 mg, 0.62 mmol) and following the procedure as outlined in example 81, the titled product was prepared and purified by HPLC. Yield: 120 mg, 40%; 497.4. Example 100: Preparation of 1-{4-[4-(3,6-Dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-[1,3,5]triazin 20 2-yl]-phenyl}-3-pyridin-4-yl-urea Step 1: Preparation of 2-Chloro-4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-[1,3,5]triazine: In a three necked flask under nitrogen equipped was dissolved 2,4-dichloro-6-morpholin-4-yl [1,3,5]triazine (610 mg, 2.6 mmol), tributyldihydropyranylstanane (1.45 g, 3.89 mmol, 1.5 eq), and (Ph 3
P)
2 PdC 2 (150 mg, 0.21 mmol, 0.1eq) in anhydrous dioxan (5 ml). The reaction mixture 25 was heated under stirring to 90 oC for 16 hrs. For purification silica gel (10 g ) was added to the mixture and the solvent was removed to let the product adsorbed on the silica gel. The silica gel plug was placed on a column and the mixture was flash chromatographed with hexane:ethyl acetate (10:1) to give after removal solvent the product as off white solid (345 mg = 47% yield); MS (ESI) m/z 281. 105 WO 2009/143313 PCT/US2009/044774 Step 2: Preparation of 4-[4-(3,6-Dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-[1,3,5]triazin-2-yl] phenylamine: To a microwave processing tube was added dimethoxyethane (4 mL), aqueous Na 2
CO
3 (2 molar)(1 mL, 2 mmol, 2 eq), (Ph 3
P)
4 Pd (101 mg, 0.088 mmol), 4-anilinoboronic acid or ester 5 (581 mg, 2.65 mmol, 1.5 eq) and the 2-chloro-4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl [1,3,5]triazine (500 mg, 1.76 mmol) and the vessel was sealed. The mixture was heated to 140 0C for 60 minutes. The solvents were distilled and the crude compound was purified by silica gel chromatography using CH 2
CI
2 /ethyl acetate (10:1) and later CH 2
CI
2 /MeOH/NH3 (20:1:0.1) to give the product as a off-white solid (520 mg, 87 % yield); MS (ESI) m/z 340.2 10 Step 3: Preparation of 1-{4-[4-(3,6-Dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-[1,3,5]triazin-2-yl] phenyl}-3-pyridin-4-yl-urea: To a stirred solution of triphosgene (140 mg, 0.47 mmol) in CH 2
CI
2 (6 mL) was added 4-[4-(3,6 dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-[1,3,5]triazin-2-yl]-phenylamine (200 mg, 0.59 mmol) at 25 oC. The reaction mixture was stirred for 15 min and 4-aminopyridine (166 mg, 1.77 mmol) 15 and NEt 3 (814 pL, 5.89 mmol) were added and the reaction mixture was stirred for additional 1 hr. The solvents were distilled and the crude mixture was purified by semi-prep-HPLC (TFA method) to give 1-{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-[1,3,5]triazin-2-yl]-phenyl} 3-pyridin-4-yl-urea (75 mg, 22 % yield); MS (ESI) m/z 460 Example 101: Preparation of 1-{4-[4-Morpholin-4-yl-6-(tetrahydro-pyran-4-yl)-[1,3,5]triazin-2-yl] 20 phenyl}-3-pyridin-4-yl-urea 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-[1,3,5]triazin-2-yl]-phenyl}-3-pyridin-4-yl urea (130 mg, 0.28 mmol) and Pd-C (10%, wet) (113 mg) were suspended in methanol/THF/CH 2
C
2 (4:1:1) (30mL) and hydrogenated (at 1 atm pressure) for 3h. After completion, the catalyst was removed by filtration over CeliteTM and the solvents were removed 25 in vacuo to obtain the crude product, which was purified by semi-prep-HPLC (TFA-method), to give (32mg=20%yield) of 1-{4-[4-Morpholin-4-yl-6-(tetrahydro-pyran-4-yl)-[1,3,5]triazin-2-yl] phenyl}-3-pyridin-4-yl-urea; MS (ESI) m/z 462. Example 102: Preparation of 1-{4-[4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-6-morpholin-4 yl-[1,3,5]triazin-2-yl]-phenyl}-3-pyridin-4-yl-urea 30 Step 1: Preparation of 3-(4-Chloro-6-morpholin-4-yl-[1,3,5]triazin-2-yloxy)-8-methyl-8-aza bicyclo[3.2. 1 ]octane: 106 WO 2009/143313 PCT/US2009/044774 In a three neck flask equipped with stirring bar under N 2 atmosphere tropine (1g, 4.24 mmol) was suspended in (anhydrous) THF (15 mL). The mixture was cooled to -78 0C and BuLi (2M in THF) (5.53 ml, 1.2 eq) was added dropwise and the mixture was allowed to warm to 25 0C over 30 minutes. To the reaction mixture 2,4,-dichloro-6-morpholin-4-yl-[1,3,5]triazine (996 mg, 4,24, 5 mmole) was added and allowed to stir overnight. For work up, ether(1 00 mL) was added. The organic layer was washed with water (20 mL ) and brine (20 mL) and dried over MgSO 4 . filtered and the solvents were removed to obtain a colorless oil. Further purification by flash chromatography using CH 2
CI
2 /MeOH/NH3 (15:1:0.1) gave the product as white solid (600mg, 42% yield); MS (ESI) m/z 340 10 Step 2: Preparation of 4-[4-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-6-morpholin-4-yl [1,3,5]triazin-2-yl]-phenylamine: To a microwave processing tube was added dimethoxyethane (4 mL), aqueous Na2CO3 (2 molar)(1 mL, 2 mmol, 2 eq), (Ph3P)4Pd (85 mg, 0.074 mmol), 4-(4,4,5,5-tetramethyl [1,3,2]dioxaborolan-2-yl)-phenylamine (482 mg, 2.21 mmol, 1.5 eq) and the 3-(4-chloro-6 15 morpholin-4-yl-[1,3,5]triazin-2-yloxy)-8-methyl-8-aza-bicyclo[3.2. 1 ]octane (500 mg, 1.47 mmol) and the vessel was sealed. The mixture was heated to 140 oC for 60 minutes. The solvents were distilled and the crude compound was purified by silica gel chromatography using
CH
2 Cl 2 /ethyl acetate (10:1) and later with CH 2 Cl 2 /MeOH/NH3 (10:1:0.1) to give the product as an off-white solid (300mg, 51 % yield); MS (ESI) m/z 369. 20 Step 3: Preparation of 1-{4-[4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-6-morpholin-4-yl [1,3,5]triazin-2-yl]-phenyl}-3-pyridin-4-yl-urea: To a stirred solution of triphosgene (60 mg, 0.20 mmol) in CH 2 Cl 2 (3 mL) was added 4-[4-(8 Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-6-morpholin-4-yl-[1,3,5]triazin-2-yl]-phenylamine (100 mg, 0.25 mmol) at 25 oC. The reaction mixture was stirred for 15 min and 4-aminopyridine (70 25 mg, 0.75 mmol) and NEt 3 (346 pL, 2.5 mmol) were added and the reaction mixture was stirred for additional 1 hr. The solvents were removed and the crude mixture was purified by semi-prep HPLC (NH3-method) to give 1-{4-[4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-6-morpholin-4-yl [1,3,5]triazin-2-yl]-phenyl}-3-pyridin-4-yl-urea (28 mg, 22 % yield); MS (ESI)m/z 517. Example 103: Preparation of 4-(3-{4-[4-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-6-morpholin 30 4-yl-[1,3,5]triazin-2-yl]-phenyl}-ureido)-benzamide To a stirred solution of triphosgene (120 mg, 0.40 mmol) in CH 2 Cl 2 (3 mL) was added 4-[4-(8 Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-6-morpholin-4-yl-[1,3,5]triazin-2-yl]-phenylamine (200 107 WO 2009/143313 PCT/US2009/044774 mg, 0.5 mmol) at 25 oC. The reaction mixture was stirred for 15 min and 4-aminobenzamide (204 mg, 1.5 mmol) and NEt 3 (692 pL, 5 mmol) were added and the reaction mixture was stirred for additional 1 hr. The solvents were removed and the crude mixture was purified by semi-prep HPLC (NIH3-method) to give 4-(3-{4-[4-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-6-morpholin-4 5 yl-[1,3,5]triazin-2-yl]-phenyl}-ureido)-benzamide (42 mg, 15 % yield)MS (ESI) m/z 559. Example 104: Preparation of 3-({4-Morpholin-4-yl-6-[4-(3-pyridin-4-yl-ureido)-phenyl] [1,3,5]triazin-2-ylamino}-methyl)-azetidine-1-carboxylic acid tert-butyl ester Step1: Preparation of 3-[(4-Chloro-6-morpholin-4-yl-[1,3,5]triazin-2-ylamino)-methyl]-azetidine-1 carboxylic acid tert-butyl ester: 10 To a solution of the 3-aminomethyl-azetidine-1-carboxylic acid tert-butyl ester HCI salt (945mg, 4.24 mmol) and NEt 3 (856 mg, 8.48 mmol) in THF (10 mL) at 0 oC was added a suspension of 2,4-dichloro-6-morpholin-4-yl-[1,3,5]triazine (996 mg, 4.24 mmol) at 0 oC. The reaction mixture was stirred for another 1 hr at 0 oC and allowed to warm to 20 oC and stirred for 1-4 hrs to drive the reaction to completion. Silica gel (20 g) was added to the reaction mixture and the solvent 15 was removed so that product was adsorbed on the silica gel. The silica gel plug was placed on top of a column to purify by flash chromatography using CH 2
CI
2 /MeOH/NH3 (20:1:01) eluent. After unifying the product fraction, and evaporation of solvent, (750 mg, 46%yield) product was obtained as yellow solid; MS (ESI) m/z 385 Step 2: Preparation of 3-{[4-(4-Amino-phenyl)-6-morpholin-4-yl-[1,3,5]triazin-2-ylamino]-methyl} 20 azetidine-1-carboxylic acid tert-butyl ester: To a microwave processing tube was added dimethoxyethane (15 mL), aqueous Na2CO3 (2 molar)(4 mL, 8 mmol, 2 eq), (Ph3P)4Pd (317 mg, 0.55 mmol), 4-(4,4,5,5-tetramethyl [1,3,2]dioxaborolan-2-yl)-phenylamine (1.81 g, 8.30 mmol, 1.5 eq) and 3-[(4-Chloro-6 morpholin-4-yl-[1,3,5]triazin-2-ylamino)-methyl]-azetidine-1-carboxylic acid tert-butyl ester (1.3 25 g, 5.53 mmol) and the vessel was sealed. The mixture was heated to 140 oC for 60 minutes. The solvents were removed and the crude compound was purified by silica gel chromatography using CH 2
CI
2 /Ethyl acetate (10:1) and later CH 2
CI
2 /MeOH/NH3 (15:1:0.1) to give the product as a off-white solid (1.3 g, 53 % yield). MS (ESI) m/z = 442 30 Step 3: Preparation of 3-({4-Morpholin-4-yl-6-[4-(3-pyridin-4-yl-ureido)-phenyl]-[1,3,5]triazin-2 ylamino}-methyl)-azetidine-1-carboxylic acid tert-butyl ester 108 WO 2009/143313 PCT/US2009/044774 To a stirred solution of triphosgene (269 mg, 0.90 mmol) in CH 2
CI
2 (5 mL) was added 3-{[4-(4 Amino-phenyl)-6-morpholin-4-yl-[1,3,5]triazin-2-ylamino]-methyl}-azetidine-1-carboxylic acid tert butyl ester (500 mg, 1.13 mmol) at 25 oC. The reaction mixture was stirred for 15 min and 4 aminopyridine (319 mg, 3.39 mmol) and NEt 3 (1.56 mL, 11.3 mmol) were added and the 5 reaction mixture was stirred for additional 1 hr. The solvents were removed on a rotary evaporator and the crude mixture was purified by semi-prep-HPLC (TFA-method) to give 3-({4 Morpholin-4-yl-6-[4-(3-pyridin-4-yl-ureido)-phenyl]-[1,3,5]triazin-2-ylamino}-methyl)-azetidine-1 carboxylic acid tert-butyl ester (150 mg, 16 % yield); MS (ESI) m/z 562. Example 105: Preparation of 1-(4-{4-[(azetidin-3-ylmethyl)-amino]-6-morpholin-4-yl 10 [1,3,5]triazin-2-yl}-phenyl)-3-pyridin-4-yl-urea 3-({4-Morpholin-4-yl-6-[4-(3-pyridin-4-yl-ureido)-phenyl]-[1,3,5]triazin-2-ylamino}-methyl) azetidine-1-carboxylic acid tert-butyl ester (100mg, 0.18 mmol) was dissolved CH 2
CI
2 (1 mL) and TFA (1 mL) was added. It was stirred for 16 hrs at 25 oC and then the solvents were removed under reduced pressure and the residue was treated with acetonitrile/MeOH (1:1) (2 15 mL) to obtain a white solid, which was collected by filtration to obtain the product as bis-TFA salt (59 mg, 46% yield). MS(ESI) m/z 462. Example 106: Preparation of Tert-butyl 4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(3 pyridin-4-ylureido)phenyl)-1,3,5-triazin-2-yl)piperazine-1 -carboxylate Tert-butyl 4-(4,6-dichloro-1,3,5-triazin-2-yl)piperazine-1-carboxylate was prepared according to 20 L6wik, D.W.P.M. and Lowe, C.R. Eur. J. Org. Chem. 2001, 2825-2839. Step1: Preparation of tert-butyl 4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-chloro-1,3,5-triazin 2-yl)piperazine-1 -carboxylate: To a solution of 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (0.49 g, 3.3 mmol) in water (18 mL) was added a suspension of tert-butyl 4-(4,6-dichloro-1,3,5-triazin-2-yl)piperazine-1 25 carboxylate (1.0 g, 3.0 mmol) in acetone (about 10 mL). The suspension was stirred magnetically while solid sodium carbonate (0.70 g, 6.6 mmol) was added in a single portion. The mixture was stirred for two hours while heating in a 70 - 75 IC in an oil bath. After allowing the mixture to cool to room temperature, the title compound was removed by filtration, washed with water, and dried under vacuum. 30 MS (ES+) 411.0, 412.3 (M+H) + 109 WO 2009/143313 PCT/US2009/044774 Step 2: Preparation of tert-butyl 4-(4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl) 1,3,5-triazin-2-yl)piperazine-1 -carboxylate: A suspension of tert-butyl 4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-chloro-1,3,5-triazin-2 yl)piperazine-1-carboxylate (1.0 g, 2.4 mmol), 4-aminophenylboronic acid, pinacol ester (0.69 g, 5 3.2 mmol), and tetrakis(triphenylphosphine) palladium (0.28 g, 0.24 mmol) in aqueous 2 M sodium carbonate solution (3 mL) and 1:1 ethanol/toluene (12 mL) was irradiated in the microwave at 120 0C for 1 hour. After cooling, the biphasic mixture was extracted thrice with ethyl acetate. The extracts were washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and concentrated to dryness under reduced 10 pressure to give the title compound. MS (ES+) 468.1 (M+H) + Step 3: Preparation of tert-butyl 4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-(3-pyridin-4 ylureido)phenyl)-1,3,5-triazin-2-yl)piperazine-1-carboxylate: Crude tert-butyl 4-(4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1,3,5-triazin-2 15 yl)piperazine-1-carboxylate (approx. 1.4 mmol) was dissolved in tetrahydrofuran (20 mL) and then treated sequentially with triphosgene (0.30 g, 1.0 mmol) and triethylamine (2 mL). After 5 minutes, the mixture was treated with a solution of 4-aminopyridine (0.53 g, 5.6 mmol) in tetrahydrofuran. The mixture was concentrated under reduced pressure to give crude tert-butyl 4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(3-pyridin-4-ylureido)phenyl)-1,3,5-triazin-2 20 yl)piperazine-1-carboxylate, a sample of which was purified by reversed phase HPLC to give a pure title compound. MS (ES+) 588.2 (M+H) + Example 107: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(piperazin-1-yl) 1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea 25 Crude tert-butyl 4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(3-pyridin-4-ylureido)phenyl) 1,3,5-triazin-2-yl)piperazine-1-carboxylate (approx 1.4 mmol) was taken up in dichloromethane (20 mL) and treated with trifluoroacetic acid (5 mL). The mixture was concentrated under reduced the pressure. To the residue was added diethyl ether to give the title compound as a solid di-TFA salt, which was collected by filtration and dried under house vacuum; MS (ES+) 30 488.1 (M+H) + 110 WO 2009/143313 PCT/US2009/044774 Example 108: Preparation of 1 -{4-[4-(4-methylpiperazin-1 -yl)-6-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3 yl)-1,3,5- triazin-2-yl]phenyl}-3-pyridin-4-ylurea 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(piperazin-1-yl)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea-2TFA (115 mg) in 1:1 98 % formic acid and 37 % formalin (4 mL) was heated 5 at 75 0C for 90 minutes, then concentrated to dryness and purified on HPLC to give the title compound as its di-TFA salt; MS (ES+) 502.3 (M+H) + Example 109: Preparation of 1-{4-[4-(4-benzylpiperazin-1-yl)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 yl)-1,3,5- triazin-2-yl]phenyl}-3-pyridin-4-ylurea 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(piperazin-1-yl)-1,3,5-triazin-2-yl)phenyl)-3 10 (pyridin-4-yl)urea-2TFA (130 mg) in dichloromethane (4 mL) and triethylamine (0.10 mL) was treated with benzaldehyde (0.10 mL), followed by sodium triacetoxyborohydride (80 mg). The mixture was concentrated to dryness and purified on HPLC to give the title compound as its di TFA salt; MS (ES+) 578.3 (M+H) +. Example 110: Preparation of 1-(4-{4-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6-[4-(pyridin-3 15 ylmethyl)piperazin- 1-yl]-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(piperazin-1-yl)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea-2TFA (150 mg) in dichloromethane (4 mL) and triethylamine (0.12 mL) was treated with 3-pyridinecarboxaldehyde (0.1 mL), followed by sodium triacetoxyborohydride (80 mg). The mixture was concentrated to dryness and purified on HPLC to give the title compound 20 as its tri-TFA salt; MS (ES+) 579.3 (M+H) + Example 111: Preparation of 1-{4-[4-(4-acetylpiperazin-1-yl)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 yl)-1,3,5- triazin-2-yl]phenyl}-3-pyridin-4-ylurea 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(piperazin-1-yl)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea-2TFA (230 mg) in dichloromethane (4 mL) and triethylamine (1 mL) was 25 treated with acetyl chloride. The mixture was concentrated to dryness and purified on HPLC to give the title compound as its TFA salt; MS (ES+) 530.3 (M+H) +. Example 112: Preparation of 1-(4-{4-[4-(N,N-dimethylglycyl)piperazin-1-yl]-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 111 WO 2009/143313 PCT/US2009/044774 1-(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(piperazin-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea-2TFA (64 mg) in dichloromethane (4 mL) and triethylamine (1 mL) was treated with dimethylaminoacetyl chloride hydrochloride (100 mg). The mixture was heated with a heat gun, then concentrated to dryness and purified on HPLC to give the title compound as its di-TFA 5 salt; MS (ES+) 573.3 (M+H) +. Example 113: Preparation of 1-{4-[4-(4-isonicotinoylpiperazin-1-yl)-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)- 1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(piperazin-1-yl)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea-2TFA (100 mg) in dichloromethane (4 mL) and triethylamine (1 mL) was 10 treated with isonicotinoyl chloride (100 mg). The mixture was concentrated to dryness and purified on HPLC to give the title compound as its di-TFA salt; MS (ES+) 593.1 (M+H) + Example 114: Preparation of Methyl 4-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6-{4-[(pyridin-4 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2-yl]piperazine-1-carboxylate 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(piperazin-1-yl)-1,3,5-triazin-2-yl)phenyl)-3 15 (pyridin-4-yl)urea-2TFA (75 mg) in dichloromethane (2 mL), tetrahydrofuran (2 mL), and triethylamine (1 mL) was treated with methyl chloroformate (0.10 mL). The mixture was concentrated to dryness and purified on RP-HPLC to give the title compound as its TFA salt. MS (ES+) 546.3 (M+H) + 20 Example 115: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea Step 1: Preparation of 1-(4,6-dichloro-1,3,5-triazin-2-yl)piperidin-4-one: To magnetically stirred ice-water (72 mL) was added a solution of cyanuric chloride (2.2 g, 12 mmol) in acetone (48 mL), followed by piperidone monohydrate hydrochloride (1.8 g, 12 mmol) 25 as a suspension in acetone (20 mL) and water (10 mL). To the mixture was added a suspension of sodium hydrogen carbonate (2.2 g, 24 mmol) in water (25 mL). The mixture was stirred at 0 0C for two hours. The title compound was collected by filtration, washed with water, and dried under vacuum. MS (ES+) 248.8 (M+H)+ 112 WO 2009/143313 PCT/US2009/044774 Step 2: Preparation of 1-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-chloro-1,3,5-triazin-2 yl)piperidin-4-one: To an aqueous solution of 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (66 mL) was added 1 (4,6-dichloro-1,3,5-triazin-2-yl)piperidin-4-one (2.7 g, 11 mmol) as a suspension in acetone (40 5 mL). To the mixture was added solid sodium carbonate (2.5 g, 24 mmol). The suspension was stirred at 80 0C for two hours and then allowed to cool to room temperature. The title compound was collected by filtration, washed with water, and dried under vacuum; MS (ES+) 324.4 (M+H)+ Step 3: Preparation of 1-(4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1,3,5 10 triazin-2-yl)piperidin-4-one: A suspension of 1 -(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-chloro- 1,3,5-triazin-2-yl)piperidin-4 one (1.0 g, 3.1 mmol), 4-aminophenylboronic acid, pinacol ester (1.0 g, 4.7 mmol), and tetrakis(triphenylphosphine) palladium (0.20 g, 0.17 mmol) in aqueous 2 M sodium carbonate solution (3 mL) and 1:1 ethanol/toluene (12 mL) was irradiated in the microwave at 120 0C for 1 15 hour. After cooling, the biphasic mixture was extracted thrice with ethyl acetate. The extracts were washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and concentrated to dryness under reduced pressure to give the title compound as a golden yellow foam. MS (ES+) = 381.6 (M+H)+ 20 Step 4: Preparation of 1 -(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin- 1 -yl) 1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea: A mixture of crude 1-(4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1,3,5-triazin-2 yl)piperidin-4-one (approx. 3.1 mmol) and triethylamine (4 mL) in dichloromethane (30 mL) was treated with triphosgene (0.71 g, 2.4 mmol). The mixture was then treated with a solution of 4 25 aminopyridine (1.8 g, 19 mmol) in tetrahydrofuran (20 mL). The mixture was concentrated to dryness under reduced pressure and the residue purified by HPLC to give the title compound as its TFA salt. MS (ES+) 501.2 (M+H)+ Example 116: Preparation of 1 -{4-[4-(4-hydroxypiperidin-1 -yl)-6-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3 yl)-1,3,5- triazin-2-yl]phenyl}-3-pyridin-4-ylurea 113 WO 2009/143313 PCT/US2009/044774 1-(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea-TFA (56 mg) was taken up in methanol/tetrahydrofuran (1:1, 6 mL), and the mixture at 0 C was treated with sodium borohydride (10 mg). After warming to room temperature, the mixture was concentrated to a residue which then was purified by HPLC to 5 give the title compound as its TFA salt.; MS (ES+) 503.0 (M+H)+ Example 117: Preparation of 1-(4-{4-[4-(benzylamino)piperidin-1-yl]-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)- 1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 1-(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea-TFA (85 mg) in dichloromethane (3 mL) and tetrahydrofuran (3 mL) was 10 treated with benzylamine (0.030 mL), followed by glacial acetic acid (0.016 mL) and sodium triacetoxyborohydride (89 mg). After completion of the reaction, methanol was added and mixture was concentrated to dryness. The residue was purified by HPLC to give the title compound as its di-TFA salt. MS (ES+) 592.3 (M+H)+ 15 Example 118: Preparation of 1-(4-{4-[4-(methylamino)piperidin-1-yl]-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)- 1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 1-(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea-TFA (50 mg) in tetrahydrofuran (5 mL) was treated with methylamine (2.0 M solution in tetrahydrofuran, 0.16 mL), followed by glacial acetic acid (0.009 mL) and sodium 20 triacetoxyborohydride (51 mg). After completion of the reaction, methanol was added and mixture was concentrated to dryness. The residue was purified by HPLC to give the title compound as its di-TFA salt; MS (ES+) 516.3 (M+H)+ Example 119: Preparation of 1-(4-{4-[4-(ethylamino)piperidin-1 -yl]-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)- 1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 25 1-(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea-TFA (50 mg) in tetrahydrofuran (5 mL) was treated with ethylamine (2.0 M solution in tetrahydrofuran, 0.16 mL), followed by glacial acetic acid (0.009 mL) and sodium triacetoxyborohydride (51 mg). After completion of the reaction, methanol was added and mixture was concentrated to dryness. The residue was purified by HPLC to give the title 30 compound as its di-TFA salt; MS (ES+) 530.3 (M+H)+ 114 WO 2009/143313 PCT/US2009/044774 Example 120: Preparation of 1-{4-[4-(4-{[2-(dimethylamino)ethyl]amino}piperidin-1-yl)-6-(8-oxa 3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea The titled compound was prepared by the procedure as outlined in example 118, by reacting 1 (4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3 5 (pyridin-4-yl)urea-TFA (50 mg) with N,N-dimethylethylenediamine (0.026 mL) and purified by HPLC and isolated as its tri-TFA salt; MS (ES+) 573.7 (M+H)+. Example 121: Preparation of 1-{4-[4-(4-morpholin-4-ylpiperidin-1-yl)-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)- 1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea By reacting 1 -(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin- 1 -yl)-1,3,5-triazin-2 10 yl)phenyl)-3-(pyridin-4-yl)urea-TFA (50 mg) with 1-(2-aminoethyl)pyrrolidine (0.030 mL) and following the procedure as mentioned in Experimental 118, the title product was isolated as its tri-TFA salt; MS (ES+) 599.8 (M+H)+. Example 122: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(4 methylpiperazin-1-yl)piperidin-1-yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea 15 By reacting 1 -(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2 yl)phenyl)-3-(pyridin-4-yl)urea-TFA (40 mg) and 1-methylpiperazine (0.050 mL) and following the procedure as outlined in example 118, the titled compound was isolated after HPLC purification as its tri-TFA salt; MS (ES+) 585.9 (M+H)+ Example 123: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(2 20 hydroxyethylamino)piperidin-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea Starting from 1 -(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2 yl)phenyl)-3-(pyridin-4-yl)urea-TFA (50 mg) and ethanolamine (0.020 mL) and following the procedure as outlined in example 118, the title compound was isolated as its di-TFA salt after HPLC purification. MS (ES+) 546.7 (M+H)+ 25 Example 124: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(2 morpholinoethylamino)piperidin-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea Starting from 1 -(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2 yl)phenyl)-3-(pyridin-4-yl)urea-TFA (50 mg)and 1-(2-aminoethyl)morpholine (0.031 mL) and 115 WO 2009/143313 PCT/US2009/044774 following the procedure as outlined in example 118, the titled compound was isolated as its tri TFA salt after HPLC purification; MS (ES+) 615.9 (M+H)+ Example 125: Preparation of Methyl 2-(1-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(3 pyridin-4-ylureido)phenyl)-1,3,5-triazin-2-yl)piperidin-4-ylamino)acetate 5 Starting from 1 -(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)- 1,3,5-triazin-2 yl)phenyl)-3-(pyridin-4-yl)urea-TFA (50 mg) and glycine methyl ester hydrochloride (20 mg) and triethylamine (10 drops) and following the procedure as outlined in example 118 the title compound was isolated as its di-TFA salt after HPLC purification; MS (ES+) 574.8 (M+H)+. Example 126: Preparation of 2-(1-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(3-pyridin-4 10 ylureido)phenyl)-1,3,5-triazin-2-yl)piperidin-4-ylamino)acetamide Starting from 1 -(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2 yl)phenyl)-3-(pyridin-4-yl)urea-TFA (50 mg) and glycinamide hydrochloride (18 mg) and triethylamine (10 drops) and following the procedure as outlined in example 118 the title compound was isolated as its di-TFA salt after HPLC purification; MS (ES+) 559.8 (M+H)+ 15 Example 127: Preparation of Tert-butyl 2-(1-(4-(8-oxa-3-azabicyclo[3.2.1 ]octan-3-yl)-6-(4-(3 pyridin-4-ylureido)phenyl)-1,3,5-triazin-2-yl)piperidin-4-ylamino)acetate Starting from 1 -(4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-(4-oxopiperidin-1 -yl)-1,3,5-triazin-2 yl)phenyl)-3-(pyridin-4-yl)urea-TFA (60 mg) and glycine tert-butyl ester hydrochloride (33 mg) and triethylamine (10 drops) and following the procedure as outlined in example 118, the title 20 compound was isolated as its di-TFA salt after HPLC purification; MS (ES+) 616.9 (M+H)+. Example 128: Preparation of 2-(1-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(3-pyridin-4 ylureido)phenyl)-1,3,5-triazin-2-yl)piperidin-4-ylamino)acetic acid Tert-butyl 2-(1-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(3-pyridin-4-ylureido)phenyl)-1,3,5 triazin-2-yl)piperidin-4-ylamino)acetate (28 mg) in dichloromethane (3 mL) was treated with 25 trifluoroacetic acid (1 mL) and then concentrated to dryness to give the title compound as its TFA salt. MS (ES+) 560.2 (M+H)+. 116 WO 2009/143313 PCT/US2009/044774 Example 129: Preparation of 4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]aniline; MS (ES+) 399.47 (M+H)+. Example 130: Preparation of 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}-3-pyridin-4-ylurea; MS (ES+) 519.58 (M+H)+. 5 Example 131: Preparation of 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ES+) 519.58 (M+H)+. Example 132: Preparation of 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}-3-phenylurea; MS (ES+) 518.59 (M+H)+. Example 133: Preparation of 1-[4-(dimethylamino)phenyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec 10 8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea; MS (ES+) 561.66 (M+H)+. Example 134: Preparation of 1-(4-cyanophenyl)-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea; MS (ES+) 543.60 (M+H)+. Example 135: Preparation of 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}-3-(2-methylpyridin-4-yl)urea; MS (ES+) 533.61 (M+H)+ 15 Example 136: Preparation of 1-[2-(dimethylamino)ethyl]-3-{4-[4- (1,4-dioxa-8-azaspiro[4.5]dec 8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea; MS (ES+) 513.62 (M+H)+ Example 137: Preparation of 1-[4-(4-morpholin-4-yl-6-quinolin-3-yl-1,3,5-triazin-2-yl)phenyl]-3 pyridin-4-ylurea HRMS: calcd for C28H24N802 + H+, 505.20950; found (ESI, [M+H]+ Obs'd), 505.2098; 20 HRMS: calcd for C28H24N802 + H+, 505.20950; found (ESI, [M+H]+ Calc'd), 505.2095; Example 138: Preparation of 2-(difluoromethyl)-1-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl 1,3,5-triazin-2-yl)-1 H-benzimidazole A solution of cyanuric chloride (922 mg, 5 mmol) in acetone (5 mL) was added to ice. A solution of 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (750 mg, 5 mmol) and triethylamine (2.1 mL, 25 15 mmol) in aqueous acetone was then added. After 20 min the precipitate was collected to give 1.0 g of a white powder which was a 7:3 mixture of 3-(4,6-dichloro-1,3,5-triazine-2,4-diyl)-8-oxa 117 WO 2009/143313 PCT/US2009/044774 3-azabicyclo[3.2.1 ]octane and 3,3'-(6-chloro-1,3,5-triazine-2,4-diyl)bis(8-oxa-3 azabicyclo[3.2.1]octane). Treatment of the mixture (400 mg) with 2-(difluoromethyl)-1 H benzo[d]imidazole (146 mg, 0.87 mmol) and K2CO3 (967 mg, 7 mmol) in DMF (2.5 mL) for 18 hours, followed by addition of 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (150 mg) gave, 5 after 1 h, 3,3'-(6-(2-(difluoromethyl)-1 H-benzo[d]imidazol-1 -yl)-1,3,5-triazine-2,4-diyl)bis(8-oxa-3 azabicyclo[3.2.1]octane) after purification by HPLC. (M+H) 475. Example 139: Preparation of 2-(difluoromethyl)-1-[4-morpholin-4-yl-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]-1 H-benzimidazole To a stirred solution of 3-(4,6-dichloro-1,3,5-triazine-2,4-diyl)(8-oxa-3-azabicyclo[3.2. 1 ]octane) 10 (2.61 g, 10 mmol) in acetone/ice, morpholine (900 mg, 12 mmol) and triethylamine (5 ml) was added. The reaction mixture was stirred at room temperature for 3 hours. Separated white solid was filtered and washed with water. The crude product obtained was pure enough and taken to next step without purification. Treatment of the mixture (270 mg. 0.87 mmol) with 2 (difluoromethyl)-1H-benzo[d]imidazole (146 mg, 0.87 mmol) and K2CO3 (967 mg, 7 mmol) in 15 DMF (2.5 mL) for 18 hours gave 2-(difluoromethyl)-1-[4-morpholin-4-yl-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]-1 H-benzimidazole after purification by HPLC. (M+H) 445. Example 140: Preparation of 1-[4-(4-azetidin-1-yl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3 pyridin-4-ylurea; mp 212 0C; MS (ESI) m/z 433.3. 20 Example 141: Preparation of methyl 4-({[4-(4-azetidin-1-yl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzoate; mp 212 0C; MS (ESI) m/z 490.2. Example 142: Preparation of 1-[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4 [(4-methylpiperazin-1-yl)carbonyl]phenyl}urea; MS (ESI) m/z 561.6. Example 143: Preparation of 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2 25 yl)phenyl]carbamoyl}amino)-N-(1-methylpiperidin-4-yl)benzamide MS (ESI) m/z 575.6 Example 144: Preparation of 1 -{4-[4-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6-(2-piperidin-1 ylethoxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 531.5 118 WO 2009/143313 PCT/US2009/044774 Example 145: Preparation of methyl(4-{4-[4-({[4-(4-methylpiperazin-1 yl)phenyl]carbamoyl}amino)phenyl]-6-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2 yl}phenyl)carbamate; MS (ESI) m/z 650.7 Example 146: Preparation of 1-cyclopropyl-3-(4-{4-[4-({[4-(4-methylpiperazin-1 5 yl)phenyl]carbamoyl}amino)phenyl]-6-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2 yl}phenyl)urea; MS (ESI) m/z 675.8 Example 147: Preparation of N',N"'-{[6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazine-2,4 diyl]di-4, 1 -phenylene}bis{1 -[4-(4-methylpiperazin-1 -yl)phenyl]urea}; MS (ESI) m/z 809.9 Example 148: Preparation of 1-[4-(4-methylpiperazin-1 -yl)phenyl]-3-{4-[4-(8-oxa-3 10 azabicyclo[3.2.1]oct-3-yl)-6-{4-[(pyridin-4ylcarbamoyl)amino] phenyl}-1,3,5-triazin-2 yl]phenyl}urea; MS (ESI) m/z 712.8 Example 149: Preparation of 1-(4-{4-[(2-aminoethyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea HRMS: calcd for C23H27N902 + H+, 462.23605; found (ESI, [M+H]+ Obs'd), 462.2358. 15 Example 150: Preparation of 1-{4-[4-anilino-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2 yl]phenyl}-3-pyridin-3-ylurea HRMS: calcd for C27H26N802 + H+, 495.22515; found (ESI, [M+H]+ Obs'd), 495.2249. Example 151: Preparation of 4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-(2-piperidin-1 -ylethyl)benzamide 20 MS (ESI) m/2 308.6; HRMS: calcd for C32H41N904 + H+, 616.33543; found (ESI, [M+H]+ Obs'd), 616.3347; HRMS: calcd for C32H41N904 + H+, 616.33543; found (ESI, [M+H]+ Calc'd), 616.3354; Example 152: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4 (morpholin-4-ylcarbonyl)phenyl]urea 25 MS (ESI) m/z 575.3; HRMS: calcd for C29H34N805 + H+, 575.27249; found (ESI, [M+H]+ Obs'd), 575.2722; HRMS: calcd for C29H34N805 + H+, 575.27249; found (ESI, [M+H]+ Calc'd), 575.2725. 119 WO 2009/143313 PCT/US2009/044774 Example 153: Preparation of 1-(4-{4-[(2-hydroxyethyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 463.5. Example 154: Preparation of 1-{4-[4-(azetidin-3-ylamino)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl) 1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 474.5 5 Example 155: Preparation of 1-(4-{4-[(2-morpholin-4-ylethyl)amino]-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 532.6. Example 156: Preparation of 1-(4-{4-[(3-aminopropyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 476.5. Example 157: Preparation of 1-(4-{4-[(4-cyclopentylpiperazin-1-yl)amino]-6-(8-oxa-3 10 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 571.7 Example 158: 1-{4-[4-isopropoxy-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl} 3-pyridin-4-ylurea; MS (ESI) m/z 462.53 Example 159: Preparation of 1-{4-[4-isopropoxy-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5 triazin-2-yl]phenyl}-3-[4-(4-methylpiperazin-1-yl)phenyl]urea 15 Example 160: Preparation of 1-{4-[4-chloro-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2 yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 438.8 Example 161: Preparation of 1-[4-(4-methyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin 4-ylurea; MS (ESI) m/z 391.5 Example 162: Preparation of methyl 4-({[4-(4-methyl-6-morpholin-4-yl-1,3,5-triazin-2 20 yl)phenyl]carbamoyl}amino)benzoate; MS (ESI) m/z 449.2. Example 163: Preparation of 1-{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin 2-yl]phenyl}-3-{4-[(4-methylpiperazin-1-yl)carbonyl] phenyl}urea; MS (ESI) m/z 584.7 Example 164: Preparation of 4-({[4-(4-methyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-(1-methylpiperidin-4-yl)benzamide; MS (ESI) m/z 530.63. 25 Example 165: Preparation of N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4-methyl-6-morpholin 4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzamide; MS (ESI) m/z 518.6 120 WO 2009/143313 PCT/US2009/044774 Example 166: Preparation of 1-[4-(4-methyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4 methylpiperazin-1-yl)carbonyl]phenyl}urea; MS (ESI) m/z 516.6. Example 167: Preparation of 1-(4-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-3-[4-(4,6 dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea 5 HRMS: calcd for C31H39N904 + H+, 602.31978; found (ESI, [M+H]+ Obs'd), 602.3192; Example 168: Preparation of 1-[4-({4-[2-(dimethylamino) ethyl]piperazin- 1 -yl}carbonyl)phenyl] 3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; HRMS: calcd for C33H44N1004 + H+, 645.36198; found (ESI, [M+H]+ Obs'd), 645.3615; Example 169: Preparation of 1-(4-{4-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6-[(piperid in-4 10 ylmethyl)amino]-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 515.6 Example 170: Preparation of 1-(4-{4-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6-[(2-piperidin-4 ylethyl)amino]-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 529.65. Example 171: Preparation of 1-{4-[4-(3-methylimidazolidin-1-yl)-6-(8-oxa-3-azabicyclo[3.2.1]oct 3-yl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 487.5 15 Example 172: Preparation of 1-{4-[4-(3-methyltetrahydropyrimidin-1(2H)-yl)-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 501.6 Example 173: Preparation of 1 -{4-[4-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6-(2-piperidin-1 ylethoxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 530.6 Example 174: Preparation of 1-(4-{4-[2-methoxy-1-(methoxymethyl)ethoxy]-6-(8-oxa-3 20 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea; MS (ESI) m/z 521.58 Example 175: Preparation of 1-(4-{4-[2-methoxy-1-(methoxymethyl)ethoxy]-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-[4-(4-methylpiperazin-1-yl)phenyl]urea; MS (ESI) m/z 618.7. Example 176: Preparation of 2-hydroxyethyl (4-{4-[2-methoxy-1-(methoxymethyl)ethoxy]-6-(8 25 oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)- 1,3,5-triazin-2-yl}phenyl)carbamate; MS (ESI) m/z 489.53. 121 WO 2009/143313 PCT/US2009/044774 Example 177: Preparation of 1-(4-{4-[2-methoxy-1-(methoxymethyl)ethoxy]-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-methylurea; MS (ESI) m/z 458.52. Example 178: Preparation of 1-cyclopropyl-3-(4-{4-[2-methoxy-1-(methoxymethyl)ethoxy]-6-(8 oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 484.56. 5 Example 179: Preparation of 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4 pyrrolidin-1-ylpiperidin-1-yl)carbonyl]phenyl}urea MS (ESI) m/z 642.4; HRMS: calcd for C34H43N904 + H+, 642.35108; found (ESI-FTMS, [M+H]1+), 642.3491; Example 180: Preparation of 1 -{4-[4-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6-(piperidin-3 10 ylmethoxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 516.61 Examples 181: Preparation of 1-{4-[4-(4-aminobutoxy)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl) 1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 490.57 Examples 182: Preparation of 1 -{4-[4-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6-(2-piperidin-4 ylethoxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 530.63 15 Example 183: Preparation of 1 -{4-[4-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6-(piperidin-4 ylmethoxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 516.61 Example 184: Preparation 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzoic acid; MS (ESI) m/z 476.53 Example 185: Preparation of N-[2-(dimethylamino)ethyl]-4-({[4-(4-isopropoxy-6-morpholin-4-yl 20 1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-methylbenzamide; MS (ESI) m/z 562.6 Example 186: Preparation of 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin 4-ylurea; MS (ESI) m/z 433.5 Example 187: Preparation of N-[2-(dimethylamino)ethyl]-4-({[4-(4-isopropoxy-6-morpholin-4-yl 1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzamide; MS (ESI) m/z 548.67 25 Example 188: Preparation of methyl 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzoate; MS (ESI) m/z 490.56. 122 WO 2009/143313 PCT/US2009/044774 Example 189: Preparation of 1-(4-{4-morpholin-4-yl-6-[(1 S,4S)-2-oxa-5-azabicyclo[2.2.1 ]hept-5 yl]-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea HRMS: calcd for C24H26N803 + H+, 475.22006; found (ESI, [M+H]+ Obs'd), 475.2201. Example 190: Preparation of 1-{4-[4-(methylamino)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5 5 triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 432.49. Example 191: Preparation of 1-{4-[4-(ethylamino)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5 triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 446.52 Example 192: Preparation of 1 -{4-[4-(dimethylamino)-6-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl) 1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 446.52. 10 Example 193: Preparation of 1-{4-[4-(isopropylamino)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl) 1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 460.54 Example 194: Preparation of 1 -{4-[4-(diethylamino)-6-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-1, 3,5 triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 474.57. Example 195: Preparation of 4-({[4-(4-azetidin-1-yl-6-morpholin-4-yl-1,3,5-triazin-2yl)phenyl] 15 carbamoyl} amino) benzoic acid; mp 204 0C; MS (ESI) m/z 476.2; Example 196: Preparation of 1-[4-(4-azetidin-1-yl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3 {4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}urea; mp 170 0C; MS (ESI) m/z 558.2. Example 197: Preparation of 4-({[4-(4-azetidin-1-yl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-[2-(dimethylamino)ethyl]-N-methylbenzamide 20 MS (ESI) m/z 280.7; Example 198: Preparation of 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-[2-(dimethylamino)ethyl]-N-methylbenzamide Example 199: Preparation of 1-{4-[4-(1-ethoxyvinyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl} 3-pyridin-4-ylurea; MS (ESI) m/z 447.499. 123 WO 2009/143313 PCT/US2009/044774 Example 200: Preparation of 1-{4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}-3-pyridin-4-ylurea HRMS: calcd for C22H25N704 + H+, 452.20408; found (ESI, [M+H]+ Obs'd), 452.2047; Example 201: Preparation of 1 -(diethylcarbamoyl)-4-[({4-[4-morpholin-4-yl-6-(3-oxa-8 5 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]pyridinium HRMS: calcd for C30H38N904 + H+, 589.31195; found (ESI, [M+H]+), 589.3035; Example 202: Preparation of 1-(4-{4-[ethyl(methyl)amino]-6-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl) 1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 460.54. Example 203: Preparation of 1-{4-[4-(sec-butylamino)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl) 10 1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 474.57. Example 204: Preparation of 1-{4-[4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 492.54. Example 205: Preparation of 1-(4-{4-[bis(2-hydroxyethyl)amino]-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 506.57 15 Example 206: Preparation of 1-(4-{4-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 499.58. Example 207: Preparation of 1-{4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 592.71. Example 208: Preparation of 1-(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6-[(4-piperazin-1 20 ylphenyl)amino]-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 578.68. Example 209: Preparation of 1-[4-(4-acetyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin 4-ylurea; MS (ESI) m/z 419.406 Example 210: Preparation of 1-(4-{4-morpholin-4-yl-6-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5 yl]-1,3,5-triazin-2-yl}phenyl)-3-{4-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]phenyl}urea; MS (ESI) 25 m/z 654.3; HRMS: calcd for C35H43N904 + H+, 654.35108; found (ESI-FTMS, [M+H]1+), 654.35129; 124 WO 2009/143313 PCT/US2009/044774 Example 211: Preparation of methyl 4-[({4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5-triazin 2-yl]phenyl}carbamoyl)amino]benzoate HRMS: calcd for C25H28N606 + H+, 509.21431; found (ESI, [M+H]+ Obs'd), 509.214. Example 212: Preparation of 1-methyl-3-(4-{4-[(1-methylethyl)amino]-6-(8-oxa-3 5 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 397.48. Example 213: Preparation of 1-cyclopropyl-3-(4-{4-[(1-methylethyl)amino]-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 423.52. Example 214: Preparation of 1-(2-hydroxyethyl)-3-(4-{4-[(1 -methylethyl)amino]-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 427.51. 10 Example 215: Preparation of 1-(4-{4-[(1-methylethyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea; MS (ESI) m/z 460.54. Example 216: Preparation of 1-(4-{4-[(1-methylethyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 yl)-1,3,5-triazin-2-yl}phenyl)-3-[6-(4-methylpiperazin-1 -yl)pyridin-3-yl]urea; MS (ESI) m/z 460.54. Example 217: Preparation of 1-(4-{4-[(1-methylethyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 15 yl)-1,3,5-triazin-2-yl}phenyl)-3-[4-(4-methylpiperazin-1-yl)phenyl]urea; MS (ESI) m/z 557.70. Example 218: Preparation of 1-{4-[(2,2-dimethylhydrazino)carbonyl]phenyl}-3-(4-{4-[(1 methylethyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 545.65. Example 219: Preparation of 4-{[(4-{4-[(1-methylethyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 20 yl)-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}-N-pyrrolidin-1-ylbenzamide; MS (ESI) m/z 571.69. Example 220: Preparation of 1-{4-[2-(dimethylamino)ethoxy]phenyl}-3-(4-{4-[(1 methylethyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 546.68. Example 221: Preparation of 1-[4-(hydroxymethyl)phenyl]-3-(4-{4-[(1-methylethyl)amino]-6-(8 25 oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 489.58 125 WO 2009/143313 PCT/US2009/044774 Example 222: Preparation of 1-[4-(2-hydroxyethyl)phenyl]-3-(4-{4-[(1-methylethyl)amino]-6-(8 oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 503.61. Example 223: Preparation of 1-{4-[4-(1-hydroxyethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 421.46. 5 Example 224: Preparation of 1-[4-(4,6-di-3-oxa-8-azabicyclo[3.2.1]oct-8-yl-1,3,5-triazin-2 yl)phenyl]-3-pyridin-4-ylurea; MS (ESI) m/z 514.59. Example 225: Preparation of methyl 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzoate; MS (ESI) m/z 462.51 Example 226: Preparation of methyl 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl 10 1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoate; MS (ESI) m/z 516.55. Example 227: Preparation of 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}carbamoyl)amino]benzoic acid; MS (ESI) m/z 502.53 Example 228: Preparation of 1-(4-{4-morpholin-4-yl-6-[2-(pyridin-4-ylamino)ethyl]-1,3,5-triazin 2-yl}phenyl)-3-pyridin-4-ylurea 15 HRMS: calcd for C26H27N902 + H+, 498.23605; found (ESI, [M+H]+ Obs'd), 498.2383; Example 229: Preparation of 1-[4-(4-methylpiperazin-1-yl)phenyl]-3-{4-[4-morpholin-4-yl-6-(3 oxa-8-azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea HRMS: calcd for C31 H39N903 + H+, 586.32486; found (ESI, [M+H]+ Obs'd), 586.3245; Example 230: Preparation of 1-(4-acetylphenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 20 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea HRMS: calcd for C28H31N704 + H+, 530.25103; found (ESI, [M+H]+ Obs'd), 530.2508; Example 231: Preparation of 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-[2-(dimethylamino)ethyl]benzamide; MS (ESI) m/z 546.676. Example 232: Preparation of 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4 25 methylpiperazin-1 -yI)carbonyl]phenyl}urea 126 WO 2009/143313 PCT/US2009/044774 MS (ESI) m/z 559.4. Example 233: Preparation of 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzoic acid; MS (ESI) m/z 448.483 Example 234: Preparation of 1 -methyl-3-{4-[4-(8-oxa-3-azabicyclo[3.2.1 ]oct-3-yI)-6-(9-oxa-3,7 5 diazabicyclo[3.3. 1 ]non-3-yl)-1,3,5-triazin-2-yl]phenyl}urea HRMS: calcd for C23H30N803 + H+, 467.25136; found (ESI, [M+H]+ Obs'd), 467.2525. Example 235: Preparation of 1-{4-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6-(9-oxa-3,7 diazabicyclo[3.3. 1 ]non-3-yl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea HRMS: calcd for C27H31 N903 + H+, 530.26226; found (ESI, [M+H]+ Obs'd), 530.2638; 10 Example 236: Preparation of 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4 methylpiperazin-1-yl)carbonyl]phenyl}urea; MS (ESI) m/z 531.1. Example 237: Preparation of N-[2-(dimethylamino)ethyl]-4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5 triazin-2-yl)phenyl]carbamoyl}amino)benzamide Example 238: Preparation of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4 15 ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; MS (ESI) m/z 558.711 Example 239: Preparation of 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4 (hydroxymethyl)phenyl]urea; MS (ESI) m/z 462.554. Example 240: Preparation of 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}carbamoyl)amino]-N-[2-(dimethylamino)ethyl]-N-methylbenzamide; MS (ESI) 20 m/z 586.721. Example 241: Preparation of 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-{[4 (dimethylamino)piperidin-1-yl]carbonyl}phenyl)urea; MS (ESI) m/z 586.741. Example 242: Preparation of N-[2-(dimethylamino)ethyl]-4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5 triazin-2-yl)phenyl]carbamoyl}amino)-N-methylbenzamide; MS (ESI) m/z 532.649. 127 WO 2009/143313 PCT/US2009/044774 Example 243: Preparation of N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-yl 1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-methylbenzamide; MS (ESI) m/z 534.62. Example 244: Preparation of N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-yl 1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzamide; MS (ESI) m/z 520.60. 5 Example 245: Preparation of 4-({[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-methyl-N-[2-(methylamino)ethyl]benzamide; MS (ESI) m/z 520.60. Example 246: Preparation of 1-[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4 [(4-methylpiperazin-1-yl)carbonyl]phenyl}urea; MS (ESI) m/z 532.61. 10 Example 247: Preparation of 1-{4-[(3,3-dimethylpiperazin-1-yl)carbonyl]phenyl}-3-[4-(4 methoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; MS (ESI) m/z 546.63. Example 248: Preparation of 4-({[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-(2-piperidin-1-ylethyl)benzamide; MS (ESI) m/z 560.66. Example 249: Preparation of 1-(4-ethenylphenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 15 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 514.3; HRMS: calcd for C28H31N703 + H+, 514.25611; found (ESI, [M+H]+ Obs'd), 514.2561. Example 250: Preparation of 1-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-3-{4-[4-morpholin-4 yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea; HRMS: calcd for C32H41 N903 + H+, 600.34051; found (ESI, [M+H]+ Obs'd), 600.3405. 20 Example 251: Preparation of 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-[4-(4-methylpiperazin-1-yl)phenyl]benzamide; MS (ESI) m/z 621.77. Example 252: Preparation of 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-({[2 (dimethylamino)ethyl]amino}methyl)phenyl]urea; MS (ESI) m/z 532.71. 128 WO 2009/143313 PCT/US2009/044774 Example 253: Preparation of 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-[4-(4-methylpiperazin-1-yl)phenyl]benzamide; MS (ESI) m/z 649.82. Example 254: Preparation of 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4 5 methylpiperazin-1-yl)methyl]phenyl}urea; MS (ESI) m/z 544.728. Example 255: Preparation of 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4 formylphenyl)urea; MS (ESI) m/z 461.2. Example 256: Preparation of tert-butyl(1 R,4R)-5-(4-morpholin-4-yl-6-{4-[(pyridin-4 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate; mp 10 192 0C; MS (ESI) m/z 574.3. Example 257: Preparation of tert-butyl (1 R,4R)-5-[4-(4-{[(4 acetylphenyl)carbamoyl]amino}phenyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2,5 diazabicyclo[2.2.1]heptane-2-carboxylate; mp 202 0C; MS (ESI) m/z 615.3; Example 258: Preparation of 1-(4-{4-[(2-methoxyethyl)amino]-6-(8-oxa-3-azabicyclo[3.2.1]oct-3 15 yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 476.54 Example 259: Preparation of 1-{4-[4-{[(1S)-2-hydroxy-1-methylethyl]amino}-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 476.54. Example 260: Preparation of 1 -{4-[4-{[(1 R)-2-hydroxy-1 -methylethyl]amino}-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 476.54. 20 Example 261: Preparation of 1-(4-{4-[(2-hydroxy-1,1-dimethylethyl)amino]-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea; MS (ESI) m/z 490.57. Example 262: Preparation of 1-{4-[4-(tert-butylamino)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl) 1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; MS (ESI) m/z 474.57. Example 263: Preparation of 4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 25 yl)phenyl]carbamoyl}amino)-N-(pyridin-2-ylmethyl)benzamide; mp 296-298 0C; MS (ESI) m/z 298.6; 129 WO 2009/143313 PCT/US2009/044774 HRMS: calcd for C31 H33N904 + H+, 596.27283; found (ESI, [M+H]+ Obs'd), 596.2724; HRMS: calcd for C31 H33N904 + H+, 596.27283; found (ESI, [M+H]+ Calc'd), 596.2728. Example 264: Preparation of 1-[4-(4,6-di-3-oxa-8-azabicyclo[3.2.1]oct-8-yl-1,3,5-triazin-2 yl)phenyl]-3-(4-piperazin-1 -ylphenyl)urea; 5 HRMS: calcd for C32H39N903 + H+, 598.32486; found (ESI, [M+H]+ Obs'd), 598.3247; HRMS: calcd for C32H39N903 + H+, 598.32486; found (ESI, [M+H]+ Calc'd), 598.3249; Example 265: Preparation of 1-[4-(4,6-di-3-oxa-8-azabicyclo[3.2.1]oct-8-yl-1,3,5-triazin-2 yl)phenyl]-3-[4-(4-methylpiperazin-1 -yl)phenyl]urea; HRMS: calcd for C33H41N903 + H+, 612.34051; found (ESI, [M+H]+ Obs'd), 612.3402; 10 Example 266: Preparation of 1-{4-[2-(dimethylamino)ethoxy]phenyl}-3-{4-[4-morpholin-4-yl-6-(3 oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea HRMS: calcd for C30H38N804 + H+, 575.30888; found (ESI, [M+H]+ Obs'd), 575.3088; HRMS: calcd for C30H38N804 + H+, 575.30888; found (ESI, [M+H]+ Calc'd), 575.3089. Example 267: Preparation of 1-(4-{4-[2-(1,3-dioxan-2-yl)ethyl]-6-morpholin-4-yl-1,3,5-triazin-2 15 yl}phenyl)-3-pyridin-4-ylurea HRMS: calcd for C25H29N704 + H+, 492.23538; found (ESI, [M+H]+ Obs'd), 492.2364. Example 268: Preparation of 1-(4-{4-[2,5-bis(hydroxymethyl)pyrrolidin-1-yl]-6-morpholin-4-yl 1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea HRMS: calcd for C25H30N804 + H+, 507.24628; found (ESI, [M+H]+ Obs'd), 507.2471. 20 Example 269: Preparation of 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-{4-[2-(dimethylamino)ethoxy]phenyl}benzamide; MS (ESI) m/z 638.773. 130 WO 2009/143313 PCT/US2009/044774 Example 270: Preparation of 1-{4-[(4-benzylpiperidin-1-yl)carbonyl]phenyl}-3-[4-(4-butyl-6 morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; MS (ESI) m/z 633.821. Example 271: Preparation of 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-(1-methylpiperidin-4-yl)benzamide; MS (ESI) m/z 545.3. 5 Example 272: Preparation of 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-(1-methylpiperidin-4-yl)benzamide; MS (ESI) m/z 573.4. Example 273: Preparation of 1-{4-[4-(6-hydroxy-3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-6-morpholin 4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 504.551. Example 274: Preparation of 1-(4-{4-[3-(dimethylamino)propyl]-6-morpholin-4-yl-1,3,5-triazin-2 10 yl}phenyl)-3-pyridin-4-ylurea; MS (ESI) m/z 462.56. Example 275: Preparation of 1-[4-(4-{3-[(1-methylethyl)amino]propyl}-6-morpholin-4-yl-1,3,5 triazin-2-yl)phenyl]-3-pyridin-4-ylurea; MS (ESI) m/z 476.59. Example 276: Preparation of 1-{4-[4-morpholin-4-yl-6-(3-pyrrolidin-1-ylpropyl)-1,3,5-triazin-2 yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 488.60. 15 Example 277: Preparation of 1-(4-{4-[3-(4-methylpiperazin-1-yl)propyl]-6-morpholin-4-yl-1,3,5 triazin-2-yl}phenyl)-3-pyridin-4-ylurea; MS (ESI) m/z 517.64. Example 278: Preparation of 1-{4-[4-(3-{[2-(dimethylamino)ethyl]amino}propyl)-6-morpholin-4 yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 505.63. Example 279: Preparation of 1-{4-[4-(3-hydroxypropyl)-6-morpholin-4-yl-1,3,5-triazin-2 20 yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 435.49. Example 280: Preparation of 1-{4-[4-morpholin-4-yl-6-(3-oxopropyl)-1,3,5-triazin-2-yl]phenyl}-3 pyridin-4-ylurea; MS (ESI) m/z 433.47. Example 281: Preparation of tert-butyl-7-(4-morpholin-4-yl-6-{4-[(pyridin-4 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2-yl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane-3 25 carboxylate HRMS: calcd for C30H37N905 + H+, 604.29904; found (ESI, [M+H]+ Obs'd), 604.2993. 131 WO 2009/143313 PCT/US2009/044774 Example 282: Preparation of 1-{4-[4-(6,8-dioxa-3-azabicyclo[3.2.1]oct-3-yl)-6-morpholin-4-yl 1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea HRMS: calcd for C24H26N804 + H+, 491.21498; found (ESI, [M+H]+ Obs'd), 491.2155. Example 283: Preparation of 1-{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin 5 2-yl]phenyl}-3-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)urea; MS (ESI) m/z 612.759. Example 284: Preparation of 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}carbamoyl)amino]-N-[2-(dimethylamino)ethyl]benzamide; MS (ESI) m/z 572.694. Example 285: Preparation of 1-[4-(4,6-di-3-oxa-8-azabicyclo[3.2.1]oct-8-yl-1,3,5-triazin-2 10 yl)phenyl]-3-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}urea; MS (ESI) m/z 625.78 Example 286: Preparation of N-[4-(4,6-di-3-oxa-8-azabicyclo[3.2.1]oct-8-yl-1,3,5-triazin-2 yl)phenyl]piperazine-1-carboxamide; MS (ESI) m/z 506.61 Example 287: Preparation of 1-[4-(4,6-di-3-oxa-8-azabicyclo[3.2.1]oct-8-yl-1,3,5-triazin-2 yl)phenyl]-3-[4-(hydroxymethyl)phenyl]urea; MS (ESI) m/z 543.63. 15 Example 288: Preparation of 1-[4-(4,6-di-3-oxa-8-azabicyclo[3.2.1]oct-8-yl-1,3,5-triazin-2 yl)phenyl]-3-{4-[(methylamino)methyl]phenyl}urea; MS (ESI) m/z 556.67. Example 289: Preparation of 1-{4-[2-(dimethylamino)ethoxy]phenyl}-3-[4-(4,6-di-3-oxa-8 azabicyclo[3.2.1]oct-8-yl-1,3,5-triazin-2-yl)phenyl]urea; MS (ESI) m/z 600.73. Example 290: Preparation of 1-{4-[4-morpholin-4-yl-6-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl) 20 1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 503.57. Example 291: Preparation of 1-{4-[4-(7-methyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 517.60. Example 292: Preparation of 1-{4-[4-(7-acetyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; MS (ESI) m/z 545.61. 25 Example 293: Preparation of 1-(4-{4-[7-(methylsulfonyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl] 6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea; MS (ESI) m/z 581.66. 132 WO 2009/143313 PCT/US2009/044774 Example 294: Preparation of 1-[4-(4-methylpiperazin-1-yl)phenyl]-3-[4-(4-morpholin-4-yl-6 propyl-1,3,5-triazin-2-yl)phenyl]urea; MS (ESI) m/z 517.4. Example 295: Preparation of 1-{4-[2-(dimethylamino)ethoxy]phenyl}-3-[4-(4-ethyl-6-morpholin 4-yl-1,3,5-triazin-2-yl)phenyl]urea; MS (ESI) m/z 492.2. 5 Example 296: Preparation of 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(4 methylpiperazin-1-yl)phenyl]urea; MS (ESI) m/z 503. Example 297: Preparation of 1-[4-(4-methylpiperazin-1-yl)phenyl]-3-{4-[4-(2-methylpropyl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 530.701. Example 298: Preparation of 1 -{4-[(3,3-dimethylpiperazin-1 -yl)carbonyl]phenyl}-3-[4-(4-ethyl-6 10 morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; MS (ESI) m/z 544.684. Example 299: Preparation of 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-(1 -methylazetidin-3-yl)benzamide MS (ESI) m/z 517.3; MS (ESI) m/z 259.2; 15 Example 300: Preparation of methyl 4-[({4-[4-(1-methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate mp 218 0C; MS (ESI) m/z 477.3. Example 301: Preparation of 4-[({4-[4-( 1 -methylethyl)-6-morpholin-4-yl- 1,3,5-triazin-2 20 yl]phenyl}carbamoyl)amino]benzoic acid MS (ESI) m/z 463.3. Example 302: Preparation of tert-butyl-(1 R,4R)-5-{4-[4-({[4-( 1 hydroxyethyl)phenyl]carbamoyl}amino)phenyl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}-2,5 diazabicyclo[2.2. 1 ]heptane-2-carboxylate 133 WO 2009/143313 PCT/US2009/044774 MS (ESI) m/z 617.4. Example 303: Preparation of 1-[4-(4-methylpiperazin-1 -yl)phenyl]-3-{4-[4-(3-oxa-8 azabicyclo[3.2. 1 ]oct-8-yl)-6-(8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}urea HRMS: calcd for C33H41N903 + H+, 612.34051; found (ESI, [M+H]+ Obs'd), 612.3402; 5 HRMS: calcd for C33H41N903 + H+, 612.34051; found (ESI, [M+H]+ Calc'd), 612.3405. Example 304: Preparation of 1-{4-[4-(1-methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl} 3-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}urea; MS (ESI) m/z 544.66. Example 305: Preparation of N-[2-(dimethylamino)ethyl]-4-[({4-[4-(1-methylethyl)-6-morpholin 4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide; MS (ESI) m/z 532.65. 10 Example 306: Preparation of N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-(1-methylethyl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide; MS (ESI) m/z 546.68. Example 307: Preparation of N-(1-methylazetidin-3-yl)-4-[({4-[4-(1-methylethyl)-6-morpholin-4 yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide; MS (ESI) m/z 530.63. Example 308: Preparation of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-{4-[4-(1 15 methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 572.72. Example 309: Preparation of 4-[({4-[4-( 1 -methylethyl)-6-morpholin-4-yl- 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]-N-pyridin-4-ylbenzamide; MS (ESI) m/z 538.61. Example 310: Preparation of 4-[({4-[4-( 1 -methylethyl)-6-morpholin-4-yl- 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]-N-pyridin-3-ylbenzamide; MS (ESI) m/z 538.61. 20 Example 311: Preparation of N-cyclobutyl-4-[({4-[4-(1-methylethyl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}carbamoyl)amino]benzamide; MS (ESI) m/z 515.62. Example 312: Preparation of 1-{4-[4,6-di-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1,3,5 triazin-2-yl]phenyl}-3-[4-(4-methylpiperazin-1-yl)phenyl]urea; MS (ESI) m/z 583.70. Example 313: Preparation of 1-{4-[4,6-di-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1,3,5 25 triazin-2-yl]phenyl}-3-(4-piperazin-1-ylphenyl)urea; MS (ESI) m/z 569.67. 134 WO 2009/143313 PCT/US2009/044774 Example 314: Preparation of 1-{4-[4,6-di-(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1,3,5 triazin-2-yl]phenyl}-3-[4-(4-methylpiperazin-1-yl)phenyl]urea; MS (ESI) m/z 583.70. Example 315: Preparation of 1-(2-fluoroethyl)-3-{4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino} 6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 561.6. 5 Example 316: Preparation of 1-cyclopropyl-3-{4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6 (8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 555.71. Example 317: Preparation of 1-methyl-3-{4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(8 oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 529.67. Example 318: Preparation of 4-[({4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(8-oxa-3 10 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide; MS (ESI) m/z 634.745. Example 319: 1-{4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}-3-phenylurea; MS (ESI) m/z 591.72. Example 320: Preparation of 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4 15 phenylpiperidin-1-yl)carbonyl]phenyl}urea MS m/z 08-301429LMS. Example 321: Preparation of 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-(pyridin-4-ylmethyl)benzamide MS (ESI) m/z 539.4; 20 MS (ESI) m/z 270.2. Example 322: Preparation of 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-{4-[4-(2 methylpropyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 558.711. Example 323: Preparation of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-{4-[4-(2 methylpropyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 586.765. 135 WO 2009/143313 PCT/US2009/044774 Example 324: Preparation of N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-(2-methylpropyl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide; MS (ESI) m/z 560.727. Example 325: Preparation of 1-methyl-3-(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6-[(4 piperazin-1-ylphenyl)amino]-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 515.62. 5 Example 326: Preparation of 1-cyclopropyl-3-(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6-[(4 piperazin-1-ylphenyl)amino]-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 541.66. Example 327: Preparation of 1-(2-fluoroethyl)-3-(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6-[(4 piperazin-1-ylphenyl)amino]-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 547.64. Example 328: Preparation of 1-(2-hydroxyethyl)-3-(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6 10 [(4-piperazin-1-ylphenyl)amino]-1,3,5-triazin-2-yl}phenyl)urea; MS (ESI) m/z 545.65. Example 329: Preparation of 4-{[(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6-[(4-piperazin-1 ylphenyl)amino]-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; MS (ESI) m/z 620.72. Example 330: Preparation of 1-(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-6-[(4-piperazin-1 ylphenyl)amino]-1,3,5-triazin-2-yl}phenyl)-3-phenylurea; MS (ESI) m/z 577.69. 15 Example 331: Preparation of 1-methyl-3-{4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(8 oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 529.67. Example 332: Preparation of 1-cyclopropyl-3-{4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6 (8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 555.71. Example 333:Preparation of 1-(2-fluoroethyl)-3-{4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino} 20 6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 561.69. Example 334:Preparation of 4-[({4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-yl]phenyl}carbamoyl) amino] benzamide; MS (ESI) m/z 634.745. Example 335:Preparation of 1-{4-[4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(8-oxa-3 25 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}-3-phenylurea; MS (ESI) m/z 591.72; 136 WO 2009/143313 PCT/US2009/044774 Example 336:Preparation of 1-(2,3'-bipyridin-4-yl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea MS (ESI) m/z 566.4; HRMS: calcd for C30H31 N903 + H+, 566.26226; found (ESI, [M+H]+ Calc'd), 566.2623. 5 Example 337:Preparation of 1-{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}-3-{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}urea MS (ESI) m/z 593.5. Example 338:Preparation of N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-(4-methylphenyl)-6 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide; MS (ESI) m/z 595.5. 10 Example 339:Preparation of 1-{4-[4-(dimethylamino)piperidin-1-yl]phenyl}-3-{4-[4-(4 methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea MS (ESI) m/z 593.4. Example 340:Preparation of 1-{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}-3-pyridin-4-ylurea. MS (ESI) m/z 468.3. 15 Example 341:Preparation of 1-{4-[4-(dimethylamino)piperidin-1-yl]phenyl}-3-[4-(4-ethyl-6 morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; MS (ESI) m/z 531.4. Example 342:Preparation of 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoic acid, MS (ESI) m/z 511.4. Example 343:Preparation of 1-{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2 20 yl]phenyl}-3-[4-(4-methylpiperazin-1-yl)phenyl]urea; MS (ESI) m/z 565.4. Example 344:Preparation of methyl 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate; MS (ESI) m/z 525.4. Example 345:Preparation of 1-{4-[4-(dimethylamino)piperidin-1-yl]phenyl}-3-[4-(4-morpholin-4 yl-6-phenyl-1,3,5-triazin-2-yl)phenyl]urea; MS (ESI) m/z 578.745 137 WO 2009/143313 PCT/US2009/044774 Example 346:Preparation of 1-[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2-yl)phenyl]-3-pyridin 4-ylurea; MS (ESI) m/z 454.1. Preparation of (2S,5R)-pyrrolidine-2,5-diyldimethanol hydrochloride ((2S,5R)-1-benzylpyrrolidine-2,5-diyl)dimethanol (2.2 g, 10 mmol) was dissolved in 5 ethanol/tetrahydrofuran (200 mL, 1:1), and the mixture was treated with 10 % palladium on carbon (250 mg). The suspension was shaken under 50 psi of hydrogen until the consumption of hydrogen had ceased. The mixture was filtered through a pad of Celite TM diatomaceous earth, eluting with ethanol. The filtrate was concentrated to dryness to provide the title compound as a golden oil that solidified upon prolonged storage. MS (ES*) = 132.2 (M+H)* 10 Preparation of ((2S,5R)-1-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)pyrrolidine-2,5 diyl)dimethanol A suspension of 2,4-dichloro-6-(4-nitrophenyl)-1,3,5-triazine (2.2 g, 8.0 mmol) in acetone (40 mL) was added to magnetically stirred ice water (60 mL). The mixture was treated with a solution of (2S,5R)-pyrrolidine-2,5-diyldimethanol hydrochloride (1.0 g, 6.0 mmol) in 15 acetone/water (20 mL, 3:1), followed by a suspension of sodium hydrogen carbonate (1.0 g, 12 mmol) in water (12 mL). After 30 minutes of stirring at 0 0C, the mixture was treated with an additional quantity of (2S,5R)-pyrrolidine-2,5-diyldimethanol hydrochloride (0.26 g, 1.6 mmol) in water (3 mL), followed by sodium hydrogen carbonate (0.35 g) in water (5 mL). The suspension was allowed to stir overnight while regaining room temperature. The title compound was 20 isolated by BOchner filtration, washed with water, and dried under house vacuum. Compound identification by mass spectrometry was achieved via the analysis of the product reaction product of ((2S,5R)-1-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)pyrrolidine-2,5 diyl)dimethanol with excess morpholine in ethanol. MS (ES*) = 417.2 (M + morpholine - Cl)* Preparation of ((2S,5R)-1-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(4-nitrophenyl)-1,3,5 25 triazin-2-yl)pyrrolidine-2,5-diyl)dimethanol A suspension of ((2S,5R)-1-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)pyrrolidine-2,5 diyl)dimethanol (0.91 g, 2.5 mmol), 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride (0.37 g, 2.5 mmol) in ethanol (13 mL) was treated with triethylamine (1 mL) and heated in a microwave reactor for 20 minutes at 130 C. The reaction mixture was purified by automated flash 30 chromatography (methanol/chloroform) to provide the title compound as a hard peach colored foam. MS (ES*) = 443.2 (M+H)* 138 WO 2009/143313 PCT/US2009/044774 Preparation of 8-(4-((2S,5R)-2,5-bis((tert-butyldimethylsilyloxy)methyl)pyrrolidin-1-yl)-6-(4 nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8-azabicyclo[3.2. 1 ]octane A solution of ((2S,5R)-1-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(4-nitrophenyl)-1,3,5-triazin 2-yl)pyrrolidine-2,5-diyl)dimethanol (approximately 2.7 mmol) in dichloromethane (15 mL) was 5 treated successively with tert-butyl dimethyl chlorosilane (1.0 g, 6.8 mmol) and imidazole (0.55 g, 8.1 mmol). The resulting suspension was stirred overnight at room temperature and then quenched with water. The aqueous phase was extracted three times with dichloromethane. The combined extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude residue was purified by automated flash 10 chromatography (hexanes/ethyl acetate) to provide the title material. MS (ES*) = 671.4 (M+H)* Preparation of 4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((2S,5R)-2,5-bis((tert butyldimethylsilyloxy)methyl)pyrrolidin- 1 -yl)-1,3,5-triazin-2-yl)aniline A suspension of palladium on charcoal (10 %, 50 mg) and 8-(4-((2S,5R)-2,5-bis((tert butyldimethylsilyloxy)methyl)pyrrolidin-1-yl)-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8 15 azabicyclo[3.2.1]octane (0.55 g, 1.2 mmol) in tetrahydrofuran (20 mL) was stirred under a balloon of hydrogen overnight. The mixture was filtered through a pad of Celite T M diatomaceous earth and concentrated under reduced pressure to provide the title compound as a tan foam (0.42 g, 80 %). MS (ES*) = 642.4 (M+H)* Example 347: Preparation of 1-(4-{4-[(2R,5S)-2,5-bis(hydroxymethyl)pyrrolidin-1-yl]-6-(3-oxa-8 20 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea A solution of 4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-((2S, 5R)-2,5-bis((tert butyldimethylsilyloxy)methyl)pyrrolidin-1 -yl)-1,3,5-triazin-2-yl)aniline (0.16 mmol) in dichloromethane (4 mL) was treated successively with triethylamine (1.6 mmol, 210 pL) and a triphosgene (24 mg, 0.08 mmol) solution in dichloromethane (500 pL). After 5 minutes, the 25 mixture was treated with a solution of 4-aminopyridine (45 mg, 0.48 mmol) in warm tetrahydrofuran. After 1 hour, the reaction mixture was quenched with methanol and concentrated to dryness. The crude residue was treated with a saturated solution of hydrogen chloride in methanol. Upon complete desilylation, the mixture was concentrated to dryness and the residue purified by reverse-phase high performance liquid chromatography using a 30 Phenomenex Prodigy column running a gradient elution of 5 % acetonitrile/95 % of 0.1 % aqueous trifluoroacetic acid to 50 % acetonitrile over 25 minutes. After concentration, the title compound was obtained as it trifluoroacetic acid salt (132 mg). MS (ES*) = 533.3 (M+H)* 139 WO 2009/143313 PCT/US2009/044774 Example 348: Preparation of 1-(4-{4-[(2R,5S)-2,5-bis(hydroxymethyl)pyrrolidin-1-yl]-6-(3-oxa-8 azabicyclo[3.2. 1 ]oct-8-yl)- 1,3,5-triazin-2-yl}phenyl)-3-[4-(4-methylpiperazin-1 -yl)phenyl]urea A solution of 4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-((2S, 5R)-2,5-bis((tert butyldimethylsilyloxy)methyl)pyrrolidin-1 -yl)- 1,3,5-triazin-2-yl)aniline (0.16 mmol) in 5 dichloromethane (4 mL) was treated successively with triethylamine (1.6 mmol, 210 pL) and a triphosgene (24 mg, 0.08 mmol) solution in dichloromethane (500 pL). After 5 minutes, the mixture was treated with 4-(4-methylpiperazin-1-yl)aniline (61 mg, 0.32 mmol). After 1 hour, the reaction mixture was quenched with methanol and concentrated to dryness. The crude residue was treated with a saturated solution of hydrogen chloride in methanol. Upon complete 10 desilylation, the mixture was concentrated to dryness and the residue purified by reverse-phase high performance liquid chromatography using a Phenomenex Prodigy column running a gradient elution of 5 % acetonitrile/95 % of 0.1 % aqueous trifluoroacetic acid to 50 % acetonitrile over 25 minutes. After concentration, the title compound was obtained as it trifluoroacetic acid salt (100 mg). MS (ES*) = 630.4 (M+H)* 15 Example 349: Preparation of 1-(6-chloropyridin-3-yl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}urea. HRMS: calcd for C25H27CIN803 + H+, 523.19674; found (ESI, [M+H]+ Obs'd), 523.1975. Example 350: Preparation of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-{4-[4 morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)- 1,3,5-triazin-2-yl]phenyl}urea; MS (ESI) m/z 614.8 20 Example 351: Preparation of 1-(4-aminophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; MS (ESI) m/z 477.1. Example 352: Preparation of N-[4-({[4-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)phenyl]-N2,N2-dimethylglycinamide The 4-(4,6-di-8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl-1,3,5-triazin-2-yl)aniline (50 mg, 0.127 mmol) 25 was dissolved in dichloromethane (1.5 mL) and triethylamine (0.120 mL) and added to a solution of triphosgene (17 mg) in dichloromethane (0.5 mL). Stir for 5 minutes then added N-(4 aminophenyl)-N2,N2-dimethylglycinamide (27 mg, 0.14 mmol). Purified by Gilson HPLC to provide the title compound as the TFA salt: 31.8 mg (35%) (M+H) m/z 614.3. Example 353: Preparation of N-[4-({[4-(4,6-di-8-oxa-3-azabicyclo[3.2.1]oct-3-yl-1,3,5-triazin-2 30 yl)phenyl]carbamoyl}amino)phenyl]-2-pyrrolidin-1-ylacetamide 140 WO 2009/143313 PCT/US2009/044774 The 4-(4,6-di-8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl-1,3,5-triazin-2-yl)aniline (50 mg, 0.127 mmol) was dissolved in dichloromethane (1.5 mL) and triethylamine (0.120 mL) and added to a solution of triphosgene (17 mg) in dichloromethane (0.5 mL). Stir for 5 minutes then added N-(4 aminophenyl)-2-pyrrolidin-1-ylacetamide (30 mg, 0.14 mmol) Purified by Gilson HPLC to provide 5 the title compound as the TFA salt: 63.1 mg (66%) (M+H) m/z 640.3. Example 354: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(piperazin-1 yl)phenylamino)-1,3,5-triazin-2-yl)phenyl)-3-methylurea Prepared as shown in Scheme 1, using commercially available tert-butyl 4-(4 aminophenyl)piperazine-1-carboxylate in the second nucleophilic aromatic substitution step. 10 Following urea formation using methylamine, the Boc-piperazine intermediate was treated with TFA to provide the title compound. (M+H) 516.3. Example 355: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(piperazin-1 yl)phenylamino)-1,3,5-triazin-2-yl)phenyl)-3-cyclopropylurea Prepared as shown in Scheme 1, using commercially available tert-butyl 4-(4 15 aminophenyl)piperazine-1-carboxylate in the second nucleophilic aromatic substitution step. Following urea formation using cyclopropylamine, the Boc-piperazine intermediate was treated with TFA to provide the title compound. (M+H) 542.3. Example 356: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(piperazin-1 yl)phenylamino)-1,3,5-triazin-2-yl)phenyl)-3-(2-fluoroethyl)urea 20 Prepared as shown in Scheme 1, using commercially available tert-butyl 4-(4 aminophenyl)piperazine-1-carboxylate in the second nucleophilic aromatic substitution step. Following urea formation using 2-fluoroethylamine, the Boc-piperazine intermediate was treated with TFA to provide the title compound. (M+H) 548.3. Example 357: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(piperazin-1 25 yl)phenylamino)-1,3,5-triazin-2-yl)phenyl)-3-(2-hydroxyethyl)urea Prepared as shown in Scheme 1, using commercially available tert-butyl 4-(4 aminophenyl)piperazine-1-carboxylate in the second nucleophilic aromatic substitution step. Following urea formation using 2-aminoethanol, the Boc-piperazine intermediate was treated with TFA to provide the title compound. (M+H) 546.3. 141 WO 2009/143313 PCT/US2009/044774 Example 358: Preparation of 4-(3-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(piperazin-1 yl)phenylamino)-1,3,5-triazin-2-yl)phenyl)ureido)benzamide Prepared as shown in Scheme 1, using commercially available tert-butyl 4-(4 aminophenyl)piperazine-1-carboxylate in the second nucleophilic aromatic substitution step. 5 Following urea formation using 4-aminobenzamide, the Boc-piperazine intermediate was treated with TFA to provide the title compound. (M+H) 621.3. Example 359: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-(piperazin-1 yl)phenylamino)-1,3,5-triazin-2-yl)phenyl)-3-phenylurea Prepared as shown in Scheme 1, using commercially available tert-butyl 4-(4 10 aminophenyl)piperazine-1-carboxylate in the second nucleophilic aromatic substitution step. Following urea formation using aniline, the Boc-piperazine intermediate was treated with TFA to provide the title compound. (M+H) 578.3. Example 360: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-(piperid in-4 ylamino)-1,3,5-triazin-2-yl)phenyl)-3-ethylurea 15 Prepared as shown in Scheme 1, using commercially available tert-butyl 4-aminopiperidine-1 carboxylate in the second nucleophilic aromatic substitution step. Following urea formation using ethylamine, the Boc-piperidine intermediate was treated with TFA to provide the title compound. (M+H) 453.6. Example 361: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-(piperid in-4 20 ylamino)-1,3,5-triazin-2-yl)phenyl)-3-ethylurea Prepared as shown in Scheme 1, using N1-(2-(dimethylamino)ethyl)-N1-methylbenzene-1,4 diamine in the urea formation step. (M+H) 614.3. The required benzene-1,4-diamine intermediates for the following compounds were prepared as outlined in Scheme 4. 25 Example 362: Preparation of 1 -(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-(piperidin-4 ylamino)-1,3,5-triazin-2-yl)phenyl)-3-ethylurea Prepared as shown in Scheme 1, using 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine in the urea formation step. (M+H) 640.4. 142 WO 2009/143313 PCT/US2009/044774 Preparation of 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine: Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. Example 363: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-(piperid in-4 ylamino)-1,3,5-triazin-2-yl)phenyl)-3-ethylurea 5 Prepared as shown in Scheme 1, using N1-(2-methoxyethyl)benzene-1,4-diamine in the urea formation step. (M+H) 587.3. Preparation of N1-(2-methoxyethyl)benzene-1,4-diamine: Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. Example 364: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-(piperid in-4 10 ylamino)-1,3,5-triazin-2-yl)phenyl)-3-ethylurea Prepared as shown in Scheme 1, using 2-(4-aminophenylamino)ethanol in the urea formation step. (M+H) 573.3. Preparation of 2-(4-aminophenylamino)ethanol: Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. 15 Example 365: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-(piperid in-4 ylamino)-1,3,5-triazin-2-yl)phenyl)-3-ethylurea Prepared as shown in Scheme 1, using N1-(1-methylpiperidin-4-yl)benzene-1,4-diamine in the urea formation step. (M+H) 626.3. Preparation of N1-(1-methylpiperidin-4-yl)benzene-1,4-diamine: 20 Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. Example 366: Preparation of 1-(4-(4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2 yl)phenyl)-3-(4-(piperazin-1 -ylmethyl)phenyl)urea 143 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 1, using commercially available tert-butyl 4-(4 aminobenzyl)piperazine-1-carboxylate in the urea formation step. Following urea formation, the Boc-piperidine intermediate was treated with TFA to provide the title compound. (M+H) 612.3. Example 367: Preparation of 1-(4-(4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2 5 yl)phenyl)-3-(4-((dimethylamino)methyl)phenyl)urea Prepared as shown in Scheme 1, using commercially available 4-((dimethylamino)methyl)aniline in the urea formation step. (M+H) 571.3. Example 368: Preparation of 1-(4-(aminomethyl)phenyl)-3-(4-(4,6-di(3-oxa-8 azabicyclo[3.2. 1 ]octan-8-yl)-1,3,5-triazin-2-yl)phenyl)urea 10 Prepared as shown in Scheme 1, using commercially available tert-butyl 4 aminobenzylcarbamate in the urea formation step. Following urea formation, the Boc-amine intermediate was treated with TFA to provide the title compound. (M+H) 543.3. Example 369: Preparation of 1-(4-(4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2 yl)phenyl)-3-(4-(pyrrolidin-1 -ylmethyl)phenyl)urea 15 Prepared as shown in Scheme 1, using commercially available 4-(pyrrolidin-1-ylmethyl)aniline in the urea formation step. (M+H) 597.3. Example 370: Preparation of 1-(4-(4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2 yl)phenyl)-3-(4-(2-(4-methylpiperazin-1 -yl)ethoxy)phenyl)urea Prepared as shown in Scheme 1, using 4-(2-(4-methylpiperazin-1-yl)ethoxy)aniline in the urea 20 formation step. (M+H) 656.4. The required 4-(alkoxy)aniline intermediates for the following compounds were prepared as outlined in Scheme 5. Example 371: Preparation of 1-(4-(4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2 yl)phenyl)-3-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)urea 25 Prepared as shown in Scheme 1, using 4-(2-(pyrrolidin-1-yl)ethoxy)aniline in the urea formation step. (M+H) 627.3. Preparation of 4-(2-(pyrrolidin-1-yl)ethoxy)aniline: 144 WO 2009/143313 PCT/US2009/044774 Prepared from 4-fluoronitrobenzene and the appropriate alcohol as shown in Scheme 5. Example 372: Preparation of 1-(4-(4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2 yl)phenyl)-3-(4-(2-hydroxyethoxy)phenyl)urea Prepared as shown in Scheme 1, using 2-(4-aminophenoxy)ethanol in the urea formation step. 5 (M+H) 574.3. Preparation of 2-(4-aminophenoxy)ethanol: Prepared from 4-fluoronitrobenzene and the appropriate alcohol as shown in Scheme 5. Example 373: Preparation of N-(4-(3-(4-(4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5 triazin-2-yl)phenyl)ureido)phenyl)-2-(dimethylamino)acetamide 10 Prepared as shown in Scheme 1, using commercially available N-(4-aminophenyl)-2 (dimethylamino)acetamide in the urea formation step. (M+H) 614.3. Example 374: Preparation of N-(4-(3-(4-(4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5 triazin-2-yl)phenyl)ureido)phenyl)-2-(4-methylpiperazin-1 -yl)acetamide Prepared as shown in Scheme 1, using commercially available N-(4-aminophenyl)-2-(4 15 methylpiperazin-1-yl)acetamide in the urea formation step. (M+H) 669.4. Example 375: Preparation of N-(4-(3-(4-(4,6-di(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5 triazin-2-yl)phenyl)ureido)phenyl)-2-(pyrrolidin-1 -yl)acetamide Prepared as shown in Scheme 1, using commercially available N-(4-aminophenyl)-2-(pyrrolidin 1-yl)acetamide in the urea formation step. (M+H) 640.3. 20 Example 376: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea Prepared as shown in Scheme 1, using commercially available pyridin-3-amine in the urea formation step. (M+H) 461.2. Example 377: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 25 1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea 145 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 1, using commercially available pyridin-4-amine in the urea formation step. (M+H) 461.2. Example 378: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1 -yl)phenyl)urea 5 Prepared as shown in Scheme 1, using commercially available 4-(4-methylpiperazin-1-yl)aniline in the urea formation step. (M+H) 558.3. Example 379: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-((4-methylpiperazin-1 -yl)methyl)phenyl)urea Prepared as shown in Scheme 1, using commercially available 4-((4-methylpiperazin-1 10 yl)methyl)aniline in the urea formation step. (M+H) 572.3. Example 380: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazin-1-ylmethyl)phenyl)urea Prepared as shown in Scheme 1, using commercially available tert-butyl 4-(4 aminobenzyl)piperazine-1-carboxylate in the urea formation step. Following urea formation, the 15 Boc-piperazine intermediate was treated with TFA to provide the title compound. (M+H) 558.3. Example 381: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-((dimethylamino)methyl)phenyl)urea Prepared as shown in Scheme 1, using commercially available 4-((dimethylamino)methyl)aniline in the urea formation step. (M+H) 517.3. 20 Example 382: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-(aminomethyl)phenyl)urea Prepared as shown in Scheme 1, using commercially available tert-butyl 4 aminobenzylcarbamate in the urea formation step. Following urea formation, the Boc-amine intermediate was treated with TFA to provide the title compound. (M+H) 489.3. 25 Example 383: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-(pyrrolidin-1 -ylmethyl)phenyl)urea 146 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 1, using commercially available 4-(pyrrolidin-1-ylmethyl)aniline in the urea formation step. (M+H) 543.3. Example 384: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-(2-(pyrrolidin-1 -yl)ethoxy)phenyl)urea 5 Prepared as shown in Scheme 1, using 4-(2-(pyrrolidin-1-yl)ethoxy)aniline in the urea formation step. (M+H) 573.3. Example 385: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-(2-(dimethylamino)ethoxy)phenyl)urea Prepared as shown in Scheme 1, using 4-(2-(dimethylamino)ethoxy)aniline in the urea formation 10 step. (M+H) 547.3. Preparation of 4-(2-(dimethylamino)ethoxy)aniline: Prepared from 4-fluoronitrobenzene and the appropriate alcohol as shown in Scheme 5. Example 386: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)urea 15 Prepared as shown in Scheme 1, using commercially available 5-(4-methylpiperazin-1 yl)pyridin-2-amine in the urea formation step. (M+H) 559.3. Example 387: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazin-1 -yl)phenyl)urea Prepared as shown in Scheme 1, using commercially available tert-butyl 4-(4 20 aminophenyl)piperazine-1-carboxylate in the urea formation step. Following urea formation, the Boc-amine intermediate was treated with TFA to provide the title compound. (M+H) 544.3. Example 388: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(isopropylamino) 1,3,5-triazin-2-yl)phenyl)-3-(4-(4-(dimethylamino)piperidin-1-yl)phenyl)urea Prepared as shown in Scheme 1, using 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine in the 25 urea formation step. (M+H) 586.4. 147 WO 2009/143313 PCT/US2009/044774 Example 389: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6 (isopropyl(methyl)amino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1 -yl)phenyl)urea Prepared as shown in Scheme 1, using commercially available 4-(4-methylpiperazin-1-yl)aniline in the urea formation step. (M+H) 572.3. 5 Example 390: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6 (isopropyl(methyl)amino)-1,3,5-triazin-2-yl)phenyl)-3-(4-((dimethylamino)methyl)phenyl)urea Prepared as shown in Scheme 1, using commercially available 4-((dimethylamino)methyl)aniline in the urea formation step. (M+H) 531.3. Example 391: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6 10 (isopropyl(methyl)amino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(2-(dimethylamino)ethoxy)phenyl)urea Prepared as shown in Scheme 1, using 4-(2-(dimethylamino)ethoxy)aniline in the urea formation step. (M+H) 561.3. Example 392: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-thiomorpholino 1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea (Scheme 6). 15 Step 1: Preparation of 8-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8 azabicyclo[3.2. 1 ]octane: A solution of 2,4-dichloro-6-(4-nitrophenyl)-1,3,5-triazine (1.25 g, 4.61 mmol) in acetone (20 mL) and ice water (20 mL) was prepared. To this was added dropwise over 10 minutes a suspension of 3-oxa-8-azabicyclo[3.2.1]octane-hydrochloride (0.655 g, 4.38 mmol) and sodium bicarbonate 20 (0.775 g, 9.22 mmol) in acetone (15 mL) and water (15 mL). The resulting tan solution was allowed to stir at 0 0C for 2 hours, then gradually allowed to warm to room temperature over 18 hours. The light brown suspension was filtered and washed with water. The crude product was purified by silica gel column chromatography, eluting with 0-1.5% methanol in methylene chloride to provide 8-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8 25 azabicyclo[3.2.1]octane (0.89 g, 56%) as an off-white solid. (M+H) 348.1. Step 2: Preparation of 8-(4-(4-nitrophenyl)-6-thiomorpholino-1,3,5-triazin-2-yl)-3-oxa-8 azabicyclo[3.2. 1 ]octane: 148 WO 2009/143313 PCT/US2009/044774 A solution of 8-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8-azabicyclo[3.2.1 ]octane (0.450 g, 1.29 mmol) in acetone (5 mL) and water (10 mL) was prepared. To this was added sodium carbonate (0.274 g, 2.59 mmoles), followed by thiomorpholine (0.134 ml, 1.42 mmol). The resulting light tan suspension was allowed to stir at 60 0C for 2.5 hours. The suspension 5 was filtered and the solid was washed with water and dried in vacuo to provide 8-(4-(4 nitrophenyl)-6-thiomorpholino-1,3,5-triazin-2-yl)-3-oxa-8-azabicyclo[3.2.1 ]octane (0.455 g, 85%) as a white solid. HRMS 415.1546 (M+H, calc.), 415.1526 (M+H, obs.). Step 3: Preparation of 4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-thiomorpholino-1,3,5-triazin 2-yl)aniline: 10 A suspension of 8-(4-(4-nitrophenyl)-6-thiomorpholino-1,3,5-triazin-2-yl)-3-oxa-8 azabicyclo[3.2.1]octane (0.418 g, 1.01 mmol) in pyridine (3 ml) and DMF (6 ml) was prepared. Tin(II) chloride dihydrate (0.569 g, 2.52 mmol) was then added and the off-white suspension was allowed to stir at room temperature for 16 hours, at which time the suspension was light yellow. The suspension was filtered, washing with methanol, and concentrated. LCMS indicated 15 reaction had not gone to completion. The crude product was dissolved in DMF (6 ml) and pyridine (3 ml) and additional tin(II) chloride dihydrate (0.569 g, 2.52 mmol) was added. The solution was allowed to stir at room temperature for 18 hours, then filtered. The precipitate was washed with methanol and the filtrate was concentrated to provide 4-(4-(3-oxa-8 azabicyclo[3.2.1]octan-8-yl)-6-thiomorpholino-1,3,5-triazin-2-yl)aniline (0.195 g, 50%) as a 20 yellow solid. (M+H) 385.1. Step 4: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-thiomorpholino-1,3,5 triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea: The method of urea formation using triphosgene and triethylamine in methylene chloride, described in Scheme 1, was utilized using commercially available pyridin-3-amine as the amine 25 component. Purification by HPLC (5-95% acetonitrile in water over 20 minutes, 0.05% TFA buffer, Waters Atlantis column) provided 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6 thiomorpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea (0.032 g, 63%) as an off-white solid. (M+H) 505.2. Example 393: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-thiomorpholino 30 1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea Prepared as shown in Scheme 6, using commercially available pyridin-4-amine in the urea formation step. Yield; 28 mg (54%); (M+H) 505.2. 149 WO 2009/143313 PCT/US2009/044774 Example 394: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-thiomorpholino 1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1 -yl)phenyl)urea Prepared as shown in Scheme 6, using commercially available 4-(4-methylpiperazin-1-yl)aniline in the urea formation step. Yield; 44 mg (73%); (M+H) 602.3. 5 Example 395: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-thiomorpholino 1,3,5-triazin-2-yl)phenyl)-3-(4-((dimethylamino)methyl)phenyl)urea Prepared as shown in Scheme 6, using commercially available 4-((dimethylamino)methyl)aniline in the urea formation step. Yield; 19 mg (34%); (M+H) 561.3. Example 365: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-thiomorpholino 10 1,3,5-triazin-2-yl)phenyl)-3-(4-(2-(dimethylamino)ethoxy)phenyl)urea Prepared as shown in Scheme 6, using 4-(2-(dimethylamino)ethoxy)aniline in the urea formation step. Yield; 35 mg (59%); (M+H) 591.3. Example 397: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-4-yl)urea 15 Prepared as shown in Scheme 1, using commercially available pyridin-4-amine in the urea formation step. Yield; 44 mg (75%); (M+H) 491.2. Example 398: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (pyridin-3-yl)urea Prepared as shown in Scheme 1, using commercially available pyridin-3-amine in the urea 20 formation step. Yield; 46 mg (79%); (M+H) 491.2. Example 399: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (4-(4-methylpiperazin-1 -yl)phenyl)urea Prepared as shown in Scheme 1, using commercially available 4-((dimethylamino)methyl)aniline in the urea formation step. Yield; 57 mg (81%); (M+H) 588.3. 25 Example 400: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (6-(4-methylpiperazin-1 -yl)pyridin-3-yl)urea 150 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 1, using commercially available 5-(4-methylpiperazin-1 yl)pyridin-2-amine in the urea formation step. Yield; 56 mg (79%); (M+H) 589.3. Example 401: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (4-((dimethylamino)methyl)phenyl)urea 5 Prepared as shown in Scheme 1, using commercially available 4-((dimethylamino)methyl)aniline in the urea formation step. Yield; 28 mg (43%); (M+H) 547.3. Example 402: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (4-(2-(dimethylamino)ethoxy)phenyl)urea Prepared as shown in Scheme 1, using 4-(2-(dimethylamino)ethoxy)aniline in the urea formation 10 step. Yield; 50 mg (72%); (M+H) 577.3. Example 403: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (4-(2-(pyrrolidin-1 -yl)ethoxy)phenyl)urea Prepared as shown in Scheme 1, using 4-(2-(pyrrolidin-1-yl)ethoxy)aniline in the urea formation step. Yield; 41 mg (57%); (M+H) 603.3. 15 Example 404: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(3,6-dihydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea (Scheme 7) Step 1: Preparation of 8-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8 azabicyclo[3.2.1]octane: Prepared as shown in Scheme 6, described in Example 392, Step 1. Step 2: Preparation of 8-(4-(3,6-dihydro-2H-pyran-4-yl)-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3 20 oxa-8-azabicyclo[3.2.1]octane: A microwave vial was charged with 8-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8 azabicyclo[3.2.1]octane (0.440 g,1.27 mmoles). Toluene (6 mL) was then added and the solution was sparged with nitrogen for 10 minutes. Tetrakis(triphenylphosphine)palladium(O) (0.088 g, 0.076 mmol) and tributyl(3,6-dihydro-2H-pyran-4-yl)stannane (0.567 g, 1.52 mmol) 25 were added. The vial was sealed and heated to 100 0C for 40 minutes via microwave. Additional tributyl(3,6-dihydro-2H-pyran-4-yl)stannane (0.283 g, 0.76 mmoles) and tetrakis(triphenylphosphine)palladium(0) (0.022 g, 0.019 mmol) were added and the suspension was heated to 110 0C by microwave for additional 90 minutes. The suspension was then cooled 151 WO 2009/143313 PCT/US2009/044774 to room temperature and filtered through Celite T M . The filter cake was washed with ethyl acetate and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel chromatography, eluting with 0-2% methanol in methylene chloride, to provide 8-(4 (3,6-dihydro-2H-pyran-4-yl)-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8-azabicyclo[3.2. 1 ]octane 5 (0.430 g, 86 %) as a light yellow solid. HRMS 396.1666 (M+H, calc.), 396.1668 (M+H, obs.). Step 3: Preparation of 4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(3,6-dihydro-2H-pyran-4-yl) 1,3,5-triazin-2-yl)aniline: A mixture of iron powder (0.071 g, 1.27 mmoles) in acetic acid (2 ml) was heated to 55 0C for 15 minutes. Water (2 ml) was then added and oil bath was turned off. A solution of 8-(4-(3,6 10 dihydro-2H-pyran-4-yl)-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8-azabicyclo[3.2. 1 ]octane (0.100 g, 0.253 mmol) in ethyl acetate (2 ml) was then added to this warm solution over 5 minutes. The mixture was cooled to RT and allowed to stir for 16 hours. The mixture was extracted with ethyl acetate by decantation (4X) into a sep. funnel containing saturated aqueous sodium carbonate. The combined organic extracts were washed with water, brine, dried, and 15 concentrated to provide 4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(3,6-dihydro-2H-pyran-4 yl)-1,3,5-triazin-2-yl)aniline (0.068 g, 74%), which was used in the next step without purification. (M+H) 366.4. Step 4: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(3,6-dihydro-2H-pyran-4 yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea : 20 The method of urea formation using triphosgene and triethylamine in methylene chloride, described in Scheme 1, was utilized using commercially available pyridin-4-amine as the amine component. Purification by HPLC (5-95% acetonitrile in water over 20 minutes, 0.05% TFA buffer, Waters Atlantis column) provided 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(3,6 dihydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea (0.034 g, 75%) as a light 25 yellow solid. (M+H) 486.2. Example 405: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(3,6-dihydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 7, using commercially available 4-(4-methylpiperazin-1-yl)aniline in the urea formation step.. Yield; 44 mg (82%); (M+H) 583.3. 30 Example 406: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea: 152 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 7; representative synthesis described below. Preparation of 4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5 triazin-2-yl)aniline: A solution of 8-(4-(3,6-dihydro-2H-pyran-4-yl)-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8 5 azabicyclo[3.2.1]octane (prepared as described in Example DJR-51, Step 2) (0.260 g, 0.658 mmol) in ethyl acetate (5 ml), methanol (5 ml), and methylene chloride (2 ml - added due to poor solubility of SM in EA/methanol) was prepared and 10% palladium on carbon (0.078 g, 30% by weight) was added. The flask was purged with hydrogen gas (balloon) and allowed to stir under positive pressure of hydrogen for 16 hours. Additional palladium on carbon (0.039 g) was added 10 and the suspension was purged with hydrogen gas (balloon) and stirred for an additional 3 hours. The flask was purged with hydrogen gas and stirred for an additional 1 hour. The suspension was filtered through Celite
TM
, the filter cake was washed with ethyl acetate, and the filtrate was concentrated to provide 4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)aniline (0.220 g, 91%) as an off-white solid. HRMS 368.2080 (M+H, 15 calc.), 368.2085 (M+H, obs.). Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5 triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea : The method of urea formation using triphosgene and triethylamine in methylene chloride, described in Scheme 1, was utilized using commercially available pyridin-4-amine as the amine 20 component. Purification by HPLC (5-95% acetonitrile in water over 20 minutes, 0.05% TFA buffer, Waters Atlantis column) provided 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyrid in-4-yl)urea (0.0461 g, 82%) as an off-white solid. (M+H) 488.2. Example 407: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H 25 pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 7, using commercially available 4-(4-methylpiperazin-1-yl)aniline in the urea formation step. Yield; 54 mg (79%); (M+H) 585.3. Example 408: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(2-(dimethylamino)ethoxy)phenyl)urea: 153 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 7, using 4-(2-(dimethylamino)ethoxy)aniline in the urea formation step. Yield; 49 mg (73%); (M+H) 572.3. Example 409: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-((dimethylamino)methyl)phenyl)urea : 5 Prepared as shown in Scheme 7, using commercially available 4-((dimethylamino)methyl)aniline in the urea formation step. Yield; 21 mg (33%); (M+H) 544.3. Example 410: Preparation of 1-(4-(4-((1 S,4S)-2-oxa-5-azabicyclo[2.2. 1 ]heptan-5-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea : Prepared as shown in Scheme 1, using commercially available pyridin-4-amine in the urea 10 formation step. Yield; 45 mg (70%); (M+H) 489.2. Example 411: Preparation of 1-(4-(4-((1 S,4S)-2-oxa-5-azabicyclo[2.2. 1 ]heptan-5-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea : Prepared as shown in Scheme 1, using commercially available pyridin-3-amine in the urea formation step. Yield; 60 mg (95%); (M+H) 489.2. 15 Example 412: Preparation of 1-(4-(4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 1, using commercially available 4-(4-methylpiperazin-1-yl)aniline in the urea formation step. Yield; 69 mg (90%); (M+H) 586.3. Example 413: Preparation of 1-(4-(4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-6-((R)-3 20 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-((4-methylpiperazin-1-yl)methyl)phenyl)urea: Prepared as shown in Scheme 1, using commercially available 4-((4-methylpiperazin-1 yl)methyl)aniline in the urea formation step. Yield; 73 mg (94%); (M+H) 600.3. Example 414: Preparation of 1-(4-(4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(pyrrolidin-1-ylmethyl)phenyl)urea : 25 Prepared as shown in Scheme 1, using commercially available 4-(pyrrolidin-1-ylmethyl)aniline in the urea formation step. Yield; 56 mg (75%); (M+H) 571.3. 154 WO 2009/143313 PCT/US2009/044774 Example 415: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea : Prepared as shown in Scheme 1, using commercially available pyridin-3-amine in the urea formation step. Yield; 44 mg (66%); (M+H) 503.2. 5 Example 416: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea : Prepared as shown in Scheme 1, using commercially available pyridin-4-amine in the urea formation step. Yield; 35 mg (53%); (M+H) 503.2. Example 417: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 10 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea Prepared as shown in Scheme 1, using commercially available 4-(4-methylpiperazin-1-yl)aniline in the urea formation step. Yield; 58 mg (62%); (M+H) 600.3. Example 418: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(pyrrolidin-1-ylmethyl)phenyl)urea 15 Prepared as shown in Scheme 1, using commercially available 4-(pyrrolidin-1-ylmethyl)aniline in the urea formation step. Yield; 41 mg (45%); (M+H) 585.5. Example 419: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(2-(dimethylamino)ethoxy)phenyl)urea: Prepared as shown in Scheme 1, using 4-(2-(dimethylamino)ethoxy)aniline in the urea formation 20 step. Yield; 43 mg (47%); (M+H) 589.3. Example 420: Preparation of (R)- 1 -(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl) 1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea : Prepared as shown in Scheme 7, using commercially available pyridin-3-amine in the urea formation step. Yield; 45 mg (77%); (M+H) 476.2. 25 Example 421: Preparation of (R)-1-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl) 1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea: 155 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 7, using commercially available 4-(4-methylpiperazin-1-yl)aniline in the urea formation step. Yield; 53 mg (75%); (M+H) 573.3. Example 422: Preparation of (R)-1-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl) 1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazin-1-yl)phenyl)urea : 5 Prepared as shown in Scheme 7, using commercially available tert-butyl 4-(4 aminophenyl)piperazine-1-carboxylate in the urea formation step. Following urea formation, the Boc-piperazine intermediate was treated with TFA to provide the title compound. Yield; 63 mg (90%); (M+H) 559.3. Example 423: Preparation of 1 -(4-(4-((R)-3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl) 10 1,3,5-triazin-2-yl)phenyl)-3-(4-((S)-3-methylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 7, using (S)-tert-butyl 4-(4-aminophenyl)-3-methylpiperazine-1 carboxylate in the urea formation step. Following urea formation, the Boc-piperazine intermediate was treated with TFA to provide the title compound. Yield; 60 mg (71%); (M+H) 573.3. 15 Preparation of (S)-tert-butyl 4-(4-aminophenyl)-3-methylpiperazine-1-carboxylate: Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. Example 424: Preparation of 1 -(4-(4-((R)-3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl) 1,3,5-triazin-2-yl)phenyl)-3-(4-((R)-3-methylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 7, using (R)-tert-butyl 4-(4-aminophenyl)-3-methylpiperazine-1 20 carboxylate in the urea formation step. Following urea formation, the Boc-piperazine intermediate was treated with TFA to provide the title compound. Yield; 68 mg (90%); (M+H) 573.3. Preparation of (R)-tert-butyl 4-(4-aminophenyl)-3-methylpiperazine-1-carboxylate: Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. 25 Example 425: Preparation of 1-(4-((3R,5S)-3,5-dimethylpiperazin-1-yl)phenyl)-3-(4-(4-((R)-3 methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea: 156 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 7, using (3,5-cis)-tert-butyl 4-(4-aminophenyl)-3,5 dimethylpiperazine-1-carboxylate in the urea formation step. Following urea formation, the Boc piperazine intermediate was treated with TFA to provide the title compound. Yield; 67 mg (77%); (M+H) 587.3. 5 Preparation of (3,5-cis)-tert-butyl 4-(4-aminophenyl)-3,5-dimethylpiperazine-1-carboxylate: Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. Example 426: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-sulfoxymorpholino 1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 6. A solution of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6 10 thiomorpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea (0.020 g, 0.033 mmol) in acetonitrile (1.5 ml) and water (0.5 ml) was prepared and oxone (0.020 g, 0.033 mmol) was added. The solution was stirred at room temperature for 16 hours. The suspension was diluted with ethyl acetate and washed with saturated sodium bicarbonate. The organic phase was washed with brine, dried, and concentrated, then purified by HPLC (5-95% 15 acetonitrile in water over 20 minutes, 0.05% TFA buffer, Waters Atlantis column) to provide the TFA salt of the sulfoxide of 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-sulfoxymorpholino 1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea (0.0029 g, 14%) as a white solid. (M+H) 618.4. Example 427: Preparation of (R)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-3-(4-(4-(3 20 methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea : Prepared as shown in Scheme 7, using 4-(2-(dimethylamino)ethoxy)aniline in the urea formation step. Yield; 34 mg (51%); (M+H) 562.3. Example 428: Preparation of (R)-1-(4-(4-ethylpiperazin-1-yl)phenyl)-3-(4-(4-(3 methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea : 25 Prepared as shown in Scheme 7, using commercially available 4-(4-ethylpiperazin-1-yl)aniline in the urea formation step. Yield; 66 mg (93%); (M+H) 587.3. Example 429: Preparation of (R)-1 -(4-(4-isopropylpiperazin-1 -yl)phenyl)-3-(4-(4-(3 methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea: 157 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 7, using 4-(4-isopropylpiperazin-1-yl)aniline in the urea formation step. Yield; 66 mg (91%); (M+H) 601.4. Preparation of 4-(4-isopropylpiperazin-1-yl)aniline: Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. 5 Example 430: Preparation of (R)-1-(4-(4-(dimethylamino)piperidin-1-yl)phenyl)-3-(4-(4-(3 methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea : Prepared as shown in Scheme 7, using 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine in the urea formation step. Yield; 69 mg (95%); (M+H) 601.4. Example 431: Preparation of (R)-1-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl) 10 1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazine-1-carbonyl)phenyl)urea : Prepared as shown in Scheme 7, using (4-aminophenyl)(4-methylpiperazin-1-yl)methanone in the urea formation step. Yield; 38 mg (52%); (M+H) 601.3. The (4-aminophenyl)(piperazin-1-yl)methanone intermediates prepared as shown in Scheme 8 were used to make the following compounds. 15 Example 432: Preparation of (R)-1-(4-(4-isopropylpiperazine-1-carbonyl)phenyl)-3-(4-(4-(3 methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)urea : Prepared as shown in Scheme 7, using (4-aminophenyl)(4-isopropylpiperazin-1-yl)methanone in the urea formation step. Yield; 68 mg (89%); (M+H) 629.3. Preparation of (4-aminophenyl)(4-isopropylpiperazin-1-yl)methanone: 20 Prepared from 4-nitrobenzoyl chloride and the appropriate amine as shown in Scheme 8. Example 433: Preparation of (R)-1-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-yl) 1,3,5-triazin-2-yl)phenyl)-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)urea : Prepared as shown in Scheme 7, using commercially available 6-(4-methylpiperazin-1 yl)pyridin-3-amine in the urea formation step. Yield; 69 mg (99%); (M+H) 574.3. 158 WO 2009/143313 PCT/US2009/044774 Example 434: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-ethylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 7, using commercially available 4-(4-ethylpiperazin-1-yl)aniline in the urea formation step. Yield; 32 mg (43%); (M+H) 599.3. 5 Example 435: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-isopropylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 7, using 4-(4-isopropylpiperazin-1-yl)aniline in the urea formation step. Yield; 51 mg (66%); (M+H) 613.4. Example 436: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H 10 pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-cyclopropylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 7, using 4-(4-cyclopropylpiperazin-1-yl)aniline in the urea formation step. Yield; 11 mg (14%); (M+H) 611.3. Preparation of 4-(4-cyclopropylpiperazin-1-yl)aniline: Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. 15 Example 437: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-(dimethylamino)piperidin-1-yl)phenyl)urea : Prepared as shown in Scheme 7, using 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine in the urea formation step. Yield; 28 mg (36%); (M+H) 613.4. Example 438: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H 20 pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazine-1-carbonyl)phenyl)urea : Prepared as shown in Scheme 7, using (4-aminophenyl)(4-methylpiperazin-1-yl)methanone in the urea formation step. Yield; 36 mg (46%); (M+H) 613.3. Example 439: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-isopropylpiperazine-1-carbonyl)phenyl)urea: 159 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 7, using (4-aminophenyl)(4-isopropylpiperazin-1-yl)methanone in the urea formation step. Yield; 41 mg (50%); (M+H) 641.3. The following 1-(4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-((R)-3-methylmorpholino) 1,3,5-triazin-2-yl)phenyl)-3-urea compounds were prepared as shown in Scheme 9. 5 Example 440: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-ethylpiperazin-1-yl)phenyl)urea: Step 1: Preparation of (R)-4-(4-ch loro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-methylmorpholine: A solution of 2,4-dichloro-6-(4-nitrophenyl)-1,3,5-triazine (1.25 g, 4.61 mmol) and sodium bicarbonate (0.775 g, 9.22 mmol) in acetone (20 mL) and ice water (20 mL) was prepared. To 10 this was added dropwise over 5 minutes (R)-3-methylmorpholine (0.466 g, 4.61 mmol). The resulting tan solution was allowed to stir at 0 0C for 2 hours, then gradually allowed to warm to room temperature over 18 hours. The light brown suspension was filtered and washed with water to provide (R)-4-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-methylmorpholine (1.40 g, 90%) as a light brown solid. HRMS 336.0857 (M+H, calc.), 336.0845 (M+H, obs.). 15 Step 2: Preparation of 8-(4-((R)-3-methylmorpholino)-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa 8-azabicyclo[3.2. 1 ]octane: A solution of (R)-4-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-methylmorpholine (0.94 g, 2.80 mmol) in acetone (10 mL) and ice water (10 mL) was prepared. To this was added dropwise over 10 minutes a suspension of 3-oxa-8-azabicyclo[3.2.1]octane-hydrochloride 20 (0.419 g, 2.80 mmol) and sodium bicarbonate (0.470 g, 5.60 mmol) in acetone (10 mL) and water (10 mL). The resulting tan solution was allowed to stir at 0 0C for 2 hours, then gradually allowed to warm to room temperature over 3 hours. The light brown suspension was filtered and washed with water to provide 8-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8 azabicyclo[3.2.1]octane (0.964 g, 83%) as a brown solid. HRMS 413.1931 (M+H, calc.), 25 413.1936 (M+H, obs.). Step 3: Preparation of 4-(4-(3-oxa-8-azabicyclo[3.2. 1 ]octan-8-yl)-6-((R)-3-methylmorpholino) 1,3,5-triazin-2-yl)aniline: A solution of 8-(4-((R)-3-methylmorpholino)-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-oxa-8 azabicyclo[3.2.1]octane (0.915 g, 2.22 mmol) in ethyl acetate (10 ml), methanol (10 ml), and 30 methylene chloride (5 ml - added due to poor solubility of SM in EA/methanol) was prepared 160 WO 2009/143313 PCT/US2009/044774 and 10% palladium on carbon (0.270 g, 30% by weight) was added. The flask was purged with hydrogen gas (balloon) and allowed to stir under positive pressure of hydrogen for 16 hours. The suspension was filtered through Celite
TM
, the filter cake was washed with ethyl acetate, and the filtrate was concentrated to provide 4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 5 methylmorpholino)-1,3,5-triazin-2-yl)aniline (0.587 g, 69%) as an off-white solid. (M+H) 383.3. Step 4: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3-methylmorpholino) 1,3,5-triazin-2-yl)phenyl)-3-(4-(4-ethylpiperazin-1-yl)phenyl)urea : The method of urea formation using triphosgene and triethylamine in methylene chloride, described in Scheme 1, was utilized using commercially available 4-(4-ethylpiperazin-1 10 yl)aniline as the amine component. Purification by HPLC (5-95% acetonitrile in water over 20 minutes, 0.05% TFA buffer, Waters Atlantis column) provided 1-(4-(4-(3-oxa-8 azabicyclo[3.2. 1 ]octan-8-yl)-6-((R)-3-methylmorpholino)- 1,3,5-triazin-2-yl)phenyl)-3-(4-(4 ethylpiperazin-1-yl)phenyl)urea (0.0761 g, 95%) as a light yellow solid. (M+H) 614.3. Example 441 : Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 15 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-isopropylpiperazin-1-yl)phenyl)urea: Prepared as shown in Scheme 9, using 4-(4-isopropylpiperazin-1-yl)aniline in the urea formation step. Yield; 82 mg (100%); (M+H) 628.4. Example 442: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-cyclopropylpiperazin-1-yl)phenyl)urea: 20 Prepared as shown in Scheme 9, using 4-(4-cyclopropylpiperazin-1-yl)aniline in the urea formation step. Yield; 32 mg (39%); (M+H) 626.3. Example 443: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-(dimethylamino)piperidin-1-yl)phenyl)urea: Prepared as shown in Scheme 9, using 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine in the 25 urea formation step. Yield; 77 mg (93%); (M+H) 628.4. Example 444: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-methylpiperazine-1-carbonyl)phenyl)urea: 161 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 9, using (4-aminophenyl)(4-methylpiperazin-1-yl)methanone in the urea formation step. Yield; 43 mg (52%); (M+H)628.3. Example 445: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)urea 5. Prepared as shown in Scheme 9, using (4-aminophenyl)(4-isopropylpiperazin-1-yl)methanone in the urea formation step. Yield; 72 mg (84%); (M+H) 656.4. Example 446: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((R)-3 methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)urea: 10 Prepared as shown in Scheme 9, using commercially available 6-(4-methylpiperazin-1 yl)pyridin-3-amine in the urea formation step. Yield; 74 mg (94%); (M+H) 601.3. Example 447: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (4-(4-ethylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 1, using commercially available 4-(4-ethylpiperazin-1-yl)aniline in 15 the urea formation step. Yield; 80 mg (99%); (M+H) 602.3. Example 448: Preparation of 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (4-(4-isopropylpiperazin-1-yl)phenyl)urea : Prepared as shown in Scheme 1, using 4-(4-isopropylpiperazin-1-yl)aniline in the urea formation step. Yield; 74 mg (88%); (M+H) 616.4. 20 Example 449: Preparation of 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (4-(4-(dimethylamino)piperidin-1-yl)phenyl)urea : Prepared as shown in Scheme 1, using 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine in the urea formation step. Yield; 80 mg (96%); (M+H) 616.4. Example 450: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 25 (4-(4-methylpiperazine-1-carbonyl)phenyl)urea : 162 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 1, using (4-aminophenyl)(4-methylpiperazin-1-yl)methanone in the urea formation step. Yield; 79 mg (95%); (M+H) 616.3. Example 451: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (4-(4-isopropylpiperazine-1-carbonyl)phenyl)urea : 5 Prepared as shown in Scheme 1, using (4-aminophenyl)(4-isopropylpiperazin-1-yl)methanone in the urea formation step. Yield; 18 mg (20%); (M+H) 644.4. Example 452: Preparation of 4-(3-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2 yl)phenyl)ureido)-N,N-dimethylbenzamide : Prepared as shown in Scheme 1, using commercially available 4-amino-N,N 10 dimethylbenzamide in the urea formation step. Yield; 43 mg (57%); (M+H) 561.3. Example 453: Preparation of 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3 (4-(pyrrolidin-1-ylmethyl)phenyl)urea : Prepared as shown in Scheme 1, using commercially available 4-(pyrrolidin-1-ylmethyl)aniline in the urea formation step. Yield; 61 mg (79%); (M+H) 573.3. 15 Example 454: Preparation of 4-(3-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)ureido)benzamide : Prepared as shown in Scheme 7, using commercially available 4-aminobenzamide in the urea formation step. Yield; 22 mg (21%); (M+H) 530.2. Example 455: Preparation of 4-(3-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H 20 pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)ureido)-N,N-dimethylbenzamide : Prepared as shown in Scheme 7, using commercially available 4-amino-N,N dimethylbenzamide in the urea formation step. Yield; 22 mg (21%); (M+H) 558.3. Example 456: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(pyrrolidine-1-carbonyl)phenyl)urea : 25 Prepared as shown in Scheme 7, using (4-aminophenyl)(pyrrolidin-1-yl)methanone in the urea formation step. Yield; 41 mg (36%); (M+H) 584.3. 163 WO 2009/143313 PCT/US2009/044774 Preparation of (4-aminophenyl)(pyrrolidin-1-yl)methanone: Prepared from 4-nitrobenzoyl chloride and the appropriate amine as shown in Scheme 8. Example 457: Preparation of 4-(3-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)ureido)-N-(2-(dimethylamino)ethyl)benzamide : 5 Prepared as shown in Scheme 7, using 4-amino-N-(2-(dimethylamino)ethyl)benzamide in the urea formation step. Yield; 36 mg (32%); (M+H) 601.3. Preparation of 4-amino-N-(2-(dimethylamino)ethyl)benzamide: Prepared from 4-nitrobenzoyl chloride and the appropriate amine as shown in Scheme 8. Example 458: Preparation of 4-(3-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H 10 pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)ureido)-N-(2-(methylamino)ethyl)benzamide : Prepared as shown in Scheme 7, using tert-butyl 2-(4-aminobenzamido)ethyl(methyl)carbamate in the urea formation step. Following urea formation, the Boc-amine intermediate was treated with TFA to provide the title compound. Yield; 25 mg (22%); (M+H) 587.3. Preparation of tert-butyl 2-(4-aminobenzamido)ethyl(methyl)carbamate: 15 Prepared from 4-nitrobenzoyl chloride and the appropriate amine as shown in Scheme 8. Example 459: Preparation of 4-(3-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)ureido)-N-(2-(dimethylamino)ethyl)-N-methylbenzamide: Prepared as shown in Scheme 7, using 4-amino-N-(2-(dimethylamino)ethyl)-N methylbenzamide in the urea formation step. Yield; 10 mg (9%); (M+H) 615.3. 20 Preparation of 4-amino-N-(2-(dimethylamino)ethyl)-N-methylbenzamide: Prepared from 4-nitrobenzoyl chloride and the appropriate amine as shown in Scheme 8. Example 460: Preparation of 1-(4-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(morpholine-4-carbonyl)phenyl)urea: 164 WO 2009/143313 PCT/US2009/044774 Prepared as shown in Scheme 7, using (4-aminophenyl)(morpholino)methanone in the urea formation step. Yield; 25 mg (21%); (M+H) 600.3. Preparation of (4-aminophenyl)(morpholino)methanone: Prepared from 4-nitrobenzoyl chloride and the appropriate amine as shown in Scheme 8. 5 Example 461: Preparation of 1-(4-(2-aminoethylamino)phenyl)-3-(4-(4,6-di(3-oxa-8 azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2-yl)phenyl)urea : Prepared as shown in Scheme 1, using di-Boc protected N1-(2-aminoethyl)benzene-1,4 diamine in the urea formation step. Following urea formation, the di-Boc-amine intermediate was treated with TFA to provide the title compound. Yield; x mg (x%); HRMS 572.3092 (M+H, 10 calc.), 572.3098 (M+H, obs.). Preparation of di-Boc protected N1-(2-aminoethyl)benzene-1,4-diamine: Prepared from 4-fluoronitrobenzene and the appropriate amine as shown in Scheme 4. Example 462: Preparation of 4-({[4-(4-{4-[(methylcarbamoyl) amino] phenyl}-6-morpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl] carbamoyl} amino) benzamide 15 Step 1: Preparation of phenyl 4-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2 yl)phenylcarbamate To a solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (25.0g, 114 mmol) and pyridine (4mL, 57 mmol)in dry dichloromethane (250 mL) phenyl chloroformate (12mL, 114 mmol) was added drop wise at -10 0C. The reaction mixture was stirred at -10 0C for 30 min and 20 then at room temperature for 30 minutes. The reaction mixture was diluted with dichloromethane (100 mL) and washed with water (2 x 70 mL). The organic layer was dried over anhydrous Na 2
SO
4 and concentrated to get the crude product. Then the crude product was dissolved in diethyl ether (15 mL) and sonicated for 10 min and then pentane (30 mL) was added. the resulting solid was filtered and washed with pentane to give phenyl 4-(4, 4, 5, 5 25 tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenylcarbamate (26g, 88% yield). 'HNMR (300 MHz, CDC13): 6 7.8 (d, 2H) 7.5 (d, 2H), 7.4(m, 2H), 7.2(m, 3H), 7.0(s, 1 H), 1.3(s, 12H). 165 WO 2009/143313 PCT/US2009/044774 Step 2: Preparation of 1-methyl-3-(4-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl) urea A mixture of phenyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate (26g, 76.6mmol)), 2.0M Methylamine/THF (265 mL, 530 mmol) in 150 mL of THF was stirred at room 5 temperature for 6 hours, then excess solvent was distilled off from the reaction mixture; residue was dissolved into water, extracted with ethyl acetate. The organic layer was dried over anhydrous Na 2
SO
4 , concentrated under reduced pressure. The crude product was purified by silica gel column chromatography by using 5-60% ethyl acetate in pet-ether as an eluent. to give 1-methyl-3- [4-(4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-phenyl]-urea.(20g, 88%yield) as 10 white solid. 'HNMR (300 MHz, CDC13): 6 7.7(d, 2H), 7.2 (d, 2H), 6.7(s, 1H), 5.0(s, 1H), 2.8(s, 3H), 1.2(s, 12H). Step 3: Preparation of 4-(4, 6-dichloro-1, 3, 5-triazin-2-yl) morpholine Morpholine (9.5mL, 108 mmol)) was added to a solution of cyanuric chloride (20g, 108 mmol) in 15 chloroform (10 mL) and stirred at -5 C for 1 hour. Reaction mixture was diluted with water, extracted with dichloromethane. The organic layer was dried over anhydrous Na 2
SO
4 , filtered and concentrated under reduced pressure. Crude product was purified by silica gel (100-200 mesh) column chromatography using 5% ethyl acetate in pet-ether as an eluent to give 4-(4,6 dichloro-1,3,5-triazin-2-yl)morpholine (10g, 39% yield). 20 Step 4: Preparation of 1-(4-(4-chloro-6-morpholino-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea A mixture of compound 4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine (10g, 42.7 mmol), Pd (PPh 3
)
4 (2.46g, 2.1 mmol), 1 -methyl-3- [4-(4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-phenyl] urea.(11.7g, 42.4 mmol) and 1N Na 2 CO3 ( 168mL, 168 mmol)in degassed 1,2-dimethoxyethane (400mL) was heated to 65 0C for 8 hours under N 2 atmosphere. The reaction mixture filtered, 25 diluted with water, extracted with ethyl acetate and washed with water, brine, dried over anhydrous Na 2
SO
4 , filtered and concentrated under reduced pressure. Crude product was purified by silica gel (100-200 mesh) column chromatography using 20-60% ethyl acetate in pet ether as an eluent. To give 1-(4-(4-chloro-6-morpholino-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea (5.0g, 34% yield). 166 WO 2009/143313 PCT/US2009/044774 'HNMR (300 MHz, DMSO-d6): 6 9.4 (br, 1 H), 8.2(d, 2H), 7.6(d, 2H), 6.6 (br, 1 H), 4.0 (m, 2H), 3.8(m, 6H), 2.8 (s, 3H). Step 5: Preparation of 1-(4-(4-(4-aminophenyl)-6-morpholino-1, 3, 5-triazin-2-yl) phenyl)-3 methylurea 5 The title compound was prepared by following the procedure of Example 462 step 4 using 1-(4 (4-chloro-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-methylurea and 4-(4,4,5,5-tetramethyl- 1,3,2 dioxaborolan-2-yl)aniline. Yield 2g, 45% yield. Step 6: Preparation of phenyl 4-carbamoylphenylcarbamate To a solution of 4-aminobenzamide (5.0g, 36.7 mmol) and pyridine (2.9g, 36.7mmol)) in dry 10 CH 2
CI
2 (100 mL) at -10 C, phenyl chloroformate (6.9g, 44.1 mmol) was added dropwise, stirred at -10 0C for 30 min and then at room temperature for 30 minutes The reaction mixture was diluted with CH 2
CI
2 (100 mL) and washed with water (2 x 70 mL). The organic layer was dried over anhydrous Na 2
SO
4 and concentrated to get the crude product. The crude product was dissolved in diethyl ether (15 mL) and sonicated for 10 minutes and then pentane (30 mL) was 15 added, the resulting solid was filtered and washed with pentane to give phenyl 4 carbamoylphenylcarbamate (7.2g, 77% yield). Step 7: Preparation of 4-({[4-(4-{4-[(methylcarbamoyl) amino] phenyl}-6-morpholin-4-yl-1, 3, 5 triazin-2-yl) phenyl] carbamoyl} amino) benzamide To a solution of 1-(4-(4-(4-aminophenyl)-6-morpholino-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea 20 (0.6g, 1.5 mmol) and triethylamine (4-5 mL) in dry DMF (10 mL), phenyl 4 carbamoylphenylcarbamate (1.15g, 4.5mmol).) was added at room temperature and mixture was heated to 90 0C for 10 hours under nitrogen atmosphere. After cooling to room temperature reaction mixture was quenched with ice water and resulting solid was filtered to get crude product. Crude product was purified by Preparative HPLC to give 4-({[4-(4-{4 25 [(methylcarbamoyl)amino]phenyl}-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzamide (45mg, 5.3% yield). Example 463: Preparation of 1-{4-[4-(3, 5-dimethylmorpholin-4-yl)-6-{4-[(methylcarbamoyl) amino] phenyl}-1, 3, 5-triazin-2-yl] phenyl}-3-pyridin-3-ylurea Step 1: Preparation of 4-(4, 6-dichloro-1, 3, 5-triazin-2-yl)-3, 5-dimethylmorpholine 167 WO 2009/143313 PCT/US2009/044774 The title compound was prepared by following the procedure of Example 462 step 3 using cyanuric chloride and 3, 5-dimethylmorpholine. Yield 5g, 35% yield. 'HNMR (300 MHz, CDC13): 6 4.6 (i, 2H), 3.6 (m, 2H), 2.8(m, 2H), 1.2(d, 6H). Step 2: Preparation of 1-(4-(4-chloro-6-(3, 5-dimethylmorpholino)-1, 3, 5-triazin-2-yl) phenyl)-3 5 methylurea The title compound was prepared by following the procedure of example 462 step 4 using 4 (4,6-dichloro-1,3,5-triazin-2-yl)-3,5-dimethylmorpholine and 1 -methyl-3- [4-(4,4,5,5-tetramethyl [1,3,2] dioxaborolan-2-yl)-phenyl]-urea.. Yield 1.15g, 16% yield. Step 3: Preparation of 1-(4-(4-(4-aminophenyl)-6-(3, 5-dimethyl morpholino)-1, 3, 5-triazin-2-yl) 10 phenyl)-3-methylurea The title compound was prepared by following the procedure of example 462 step 4 using 1-(4 (4-chloro-6-(3,5-dimethylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-methylurea and 4-(4,4,5,5 tetramethyl-1,3,2-dioxaborolan-2-yl)aniline. Yield 2g, 86% yield. Step 4: Preparation of phenyl pyridin-3-ylcarbamate 15 The title compound was prepared by following the procedure of example 462 step 6 using 3 aminopyridine and phenyl chloroformate. Yield 7g, 62% yield. Step 5: Preparation of 1-{4-[4-(3, 5-dimethylmorpholin-4-yl)-6-{4-[(methylcarbamoyl) amino] phenyl}-1, 3, 5-triazin-2-yl] phenyl}-3-pyridin-3-ylurea The title compound was prepared by following the procedure of example 462 step 7 using 1-(4 20 (4-(4-aminophenyl)-6-(3, 5-dimethylmorpholino)-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea and phenyl pyridin-3-ylcarbamate. Yield 77mg, 6% yield. EXAMPLE 464: Preparation of 4-[({4-[4-{4-[(methylcarbamoyl)amino]phenyl}-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide Step 1: Preparation of 3-(4, 6-dichloro-1, 3, 5-triazin-2-yl)-8-oxa-3-azabicyclo [3.2.1]octane 25 The title compound was prepared by following the procedure of example 462 step 3 using cyanuric chloride and 8-oxa-3-azabicyclo [3.2.1] octane. Yield 10g, 47% yield. 168 WO 2009/143313 PCT/US2009/044774 Step 2: Preparation of 1-(4-(4-(8-oxa-3-azabicyclo [3.2.1]octan-3-yl)-6-chloro-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea The title compound was prepared by following the procedure of example 462 step 4 using 3 (4,6-dichloro-1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2. 1 ]octane and 1-methyl-3- [4-(4,4,5,5 5 tetramethyl- [1,3,2] dioxaborolan-2-yl)-phenyl]-urea.. Yield 5g, 29% yield. Step 3: Preparation of 1-(4-(4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo [3.2.1]octan-3-yl)-1, 3, 5 triazin-2-yl) phenyl)-3-methylurea The title compound was prepared by following the procedure of example 462 step 4 using 1-(4 (4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-chloro-1,3,5-triazin-2-yl)phenyl)-3-methylurea and 4 10 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline. Yield 2.8g, 49% yield. Step 4: Preparation of 4-[({4-[4-{4-[(methylcarbamoyl) amino] phenyl}-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide The title compound was prepared by following the procedure of example 462 step 7 using 1-(4 (4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo [3.2.1] octan-3-yl)-1, 3, 5-triazin-2-yl) phenyl)-3 15 methylurea and phenyl 4-carbamoylphenylcarbamate. Yield 90mg, 13% yield. EXAMPLE 465 Preparation of 3-[({4-[4-{4-[(methylcarbamoyl)amino]phenyl}-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide Step 1: Preparation of phenyl 3-carbacarbamoylphenylcarbamate The title compound was prepared by following the procedure of example 462 step 6 using 3 20 aminobenzamide and phenyl chloroformate. Yield 7g, 74% yield. Step 2: Preparation of 3-[({4-[4-{4-[(methylcarbamoyl) amino] phenyl}-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide The title compound was prepared by following the procedure of example 462 step 7 using 1-(4 (4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo [3.2.1] octan-3-yl)-1, 3, 5-triazin-2-yl) phenyl)-3 25 methylurea and phenyl 3-carbamoylphenylcarbamate. Yield 90mg, 13% yield. EXAMPLE: 466: Preparation of 3-({[4-(4-{4-[(methylcarbamoyl) amino] phenyl}-6-morpholin-4 yl-1, 3, 5-triazin-2-yl) phenyl] carbamoyl} amino) benzamide 169 WO 2009/143313 PCT/US2009/044774 The title compound was prepared by following the procedure of example 462 step 7 using 1-(4 (4-(4-aminophenyl)-6-morpholino-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea and phenyl 3 carbamoylphenylcarbamate. Yield 51mg, 4% yield. EXAMPLE 467: Preparation of 1-methyl-3-[4-(4-morpholin-4-yl-6-{4-[(pyridin-3-ylcarbamoyl) 5 amino] phenyl}-1, 3, 5-triazin-2-yl) phenyl] urea The title compound was prepared by following the procedure of example 462 step 7 using 1-(4 (4-(4-aminophenyl)-6-morpholino-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea and phenyl pyridin-3 ylcarbamate. Yield 77mg, 6% yield. Example 468: Preparation of 1-methyl-3-[4-(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl) 10 amino] phenyl}-1, 3, 5-triazin-2-yl) phenyl] urea Step 1: Preparation of phenyl pyridin-4-ylcarbamate The title compound was prepared by following the procedure of example 462 step 6 using 4 aminopyridine and phenyl chloroformate. Yield 6g, 534% yield. Step 2: Preparation of 1-methyl-3-[4-(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl) amino] 15 phenyl}-1, 3, 5-triazin-2-yl) phenyl] urea The title compound was prepared by following the procedure of example 462 step7 using 1-(4 (4-(4-aminophenyl)-6-morpholino-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea and phenyl pyridin-4 ylcarbamate. Yield 75mg, 3.9% yield. Example 469: Preparation of 3-[({4-[4-(3,5-dimethylmorpholin-4-yl)-6-{4 20 [(methylcarbamoyl)amino]phenyl}-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide The title compound was prepared by following the procedure of example 462 step 7 using 1-(4 (4-(4-aminophenyl)-6-(3, 5-dimethylmorpholino)-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea and phenyl 3-carbamoylphenylcarbamate. Yield 56mg, 4.1% yield. Example 470: Preparation of 4-[({4-[4-(3,5-dimethylmorpholin-4-yl)-6-{4 25 [(methylcarbamoyl)amino]phenyl}-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzamide 170 WO 2009/143313 PCT/US2009/044774 The title compound was prepared by following the procedure of example 462 step 7 using 1-(4 (4-(4-aminophenyl)-6-(3, 5-dimethylmorpholino)-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea and phenyl 4-carbamoylphenylcarbamate. Yield 70mg, 12.8% yield. Example 471: Preparation of 1-methyl-3-{4-[4-(8-oxa-3-azabicyclo [3.2.1]oct-3-yl)-6-{4-[(pyridin 5 4-ylcarbamoyl) amino] phenyl}-1, 3, 5-triazin-2-yl] phenyl} urea The title compound was prepared by following the procedure of example 462 step 7 using 1-(4 (4-(4-aminophenyl)-6-(8-oxa-3-azabicyclo [3.2.1] octan-3-yl)-1, 3, 5-triazin-2-yl) phenyl)-3 methylurea and phenyl pyridin-4-ylcarbamate. Yield 51 mg, 4% yield. Example 472: Preparation of 1-{4-[4-(3, 5-dimethylmorpholin-4-yl)-6-{4-[(methylcarbamoyl) 10 amino] phenyl}-1, 3, 5-triazin-2-yl] phenyl}-3-pyridin-4-ylurea The title compound was prepared by following the procedure of example 462 step 7 using 1-(4 (4-(4-aminophenyl)-6-(3, 5-dimethylmorpholino)-1, 3, 5-triazin-2-yl) phenyl)-3-methylurea and phenyl pyridin-4-ylcarbamate. Yield 15mg, 0.8% yield. Example 473: Preparation of N-[4-(4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl]-2, 2 15 difluoroacetamide Step 1: Preparation of 4, 4'-(6-chloro-1, 3, 5-triazine-2, 4-diyl)dimorpholine A solution of morpholine (8.71g, 100mmol) in 100 mL of methylene was added dropwise to a mixture of cyanuric chloride (9.22 g, 50.0 mmol) and triethylamine (10.1g, 100mmol) in 200 mL of methylene chloride at 0 0C. Then the reaction mixture was stirred at 0 0C for 1 hr and slowly 20 warmed up to room temperature. After stirring at room temperature for 1 hr, the reaction mixture was filtered to remove the triethylamine hydrochloride salt. The filtrate was concentrated to give 4, 4'-(6-chloro-1, 3, 5-triazine-2, 4-diyl) dimorpholine (14.2g, 100 yield) as a white solid. HPLC: Rt = 2.43min; MS 286, 288 [M+H]. Step 2:Preparation of 4-(4, 6-dimorpholino-1, 3, 5-triazin-2-yl)aniline 25 A mixture of 4,4'-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (1.40g, 4.90 mmol), 4-(4,4,5,5 tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.62g, 11.9mmol) and tetrakis (triphenylphosphine) palladium (0) (282 mg, 0.240 mmol) in 2M sodium carbonate aqueous solution (10 mL, 20 mmol) and 40 mL of DME was stirred at 80 0C for 2hr. The reaction mixture was diluted with 300 mL of ethyl acetate and washed with water. The organic layer was concentrated and purified by 171 WO 2009/143313 PCT/US2009/044774 flash chromatography (ISCO, 120g silica gel column, eluting with 0-100% EtOAc/Hexane) to give 4-(4,6-dimorpholino-1,3,5-triazin-2-yl)aniline (0.68g, 40%yield). HPLC: Rt = 2.09min; MS 343 [M+H]. Step 3: Preparation of N-[4-(4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl]-2, 2 5 difluoroacetamide To a mixture of 2, 2-difluoroacetic acid (20 mg, 0.21 mmol), HBTU (76mg, 0.2 mmol), and DIEA (52 mg, 0.40 mmol) in 2 mL of DMF was added 4-(4, 6-dimorpholino-1, 3, 5-triazin-2-yl) aniline (40 mg, 0.12 mmol). The reaction was stirred at 60 0C 16hr. Then the reaction mixture was cooled to room temperature and purified by reverse phase chromatography to give N-[4-(4, 6 10 dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl]-2, 2-difluoroacetamide (23mg, 46% yield). HPLC: Rt = 2.19min; MS 421 [M+H]. Example 474: Preparation of N-[4-(4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl]-4, 5 dihydro-1 H-imidazol-2- amine A mixture of 4-(4,6-dimorpholino-1,3,5-triazin-2-yl)aniline (40 mg, 0.12 mmol), imidazolidine-2 15 thione (15mg, 0.15 mmol0 and mercury(lI) chloride (40mg, 0.15 mmol) in 2 mL of DMF was stirred at 140 0C 16hr. Then the reaction mixture was cooled to room temperature and filtered through Celite TM. The filtration was concentrated and purified by reverse phase chromatography to give N-[4-(4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl]-4, 5-dihydro-1 H-imidazol-2- amine (9.0mg, 22% yield). HPLC: Rt = 1.74min; MS 411 [M+H]. 20 Example 475: Preparation of 2, 4-dimorpholin-4-yl-6-[4-(2H-tetrazol-5-yl) phenyl]-1, 3, 5-triazine Step 1:Preparation of 4-(4, 6-dimorpholino-1, 3, 5-triazin-2-yl)benzonitrile The title compound was prepared by following the procedure of example 473 step 2 using 4, 4' (6-chloro-1, 3, 5-triazine-2, 4-diyl) dimorpholine and 4-cyanophenyl-boronic acid. Yield 86 mg, 50% yield; HPLC: Rt = 2.60min; MS 353 [M+H]. 25 Step 2:Preparation of 2, 4-dimorpholin-4-yl-6-[4-(2H-tetrazol-5-yl) phenyl]-1, 3, 5-triazine A mixture of 4-(4,6-dimorpholino-1,3,5-triazin-2-yl)benzonitrile (11mg, 0.031 mmol), sodium azide (5.5mg, 0.085 mmol) and triethylamine hydrochloride (6.0mg, 0.043mmol) in 2 mL of DMF was stirred at 120 0C for 6hr. Then the reaction mixture was cooled to room temperature and 172 WO 2009/143313 PCT/US2009/044774 purified by reverse phase chromatography to give 2,4-dimorpholin-4-yl-6-[4-(2H-tetrazol-5 yl)phenyl]-1,3,5-triazine. Yield 12mg, 97% yield; HPLC: Rt = 2.09min; MS 394 [M-H]. Example 476: Preparation of 1-[4-(4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl]-3 methylurea 5 Step 1:Preparation of 1-Methyl-3- [4-(4, 4, 5, 5-tetramethyl- [1, 3, 2] dioxaborolan-2-yl)-phenyl] urea A mixture of 2-(4-isocyanatophenyl)-4,4,5,5-tetramethyl-1, 3,2-dioxaborolane (750mg, 3.06 mmol), 2.OM Methylamine/THF (2.3 mL, 4.60 mmol) in 50 mL of THF was stirred at room temperature for 6 hr. Then the traction mixture was concentrated to give 1-methyl-3- [4-(4, 4, 5, 10 5-tetramethyl- [1, 3, 2] dioxaborolan-2-yl)-phenyl]-urea. (760 mg, 90%yield). Rt = 2.21 min; 277 [M+H]. Step 2:Preparation of 1-[4-(4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl]-3-methylurea The title compound was prepared by following the procedure of example 473 step 2 using 4,4' (6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine and 1-Methyl-3- [4-(4,4,5,5-tetramethyl- [1,3,2] 15 dioxaborolan-2-yl)-phenyl]-urea. Yield 13mg, 11% yield; HPLC: Rt = 1.98min; MS 400 [M+H]. Example 477: Preparation of 2-[4-(4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl]-N-pyridin-3 ylacetamide Step 1: Preparation of 2-(4-(4, 6-dimorpholino-1, 3, 5-triazin-2-yl) phenyl)acetic acid A mixture of 4,4'-(6-chloro-1,3,5-triazine-2,4-diyl)dimorpholine (285mg, 1.0mmol), 2-(4-(4,4,5,5 20 tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetic acid. (315mg, 1.2mmol) and tetrakis (triphenylphosphine) palladium (0) (58 mg, 0.05 mmol) in 2M sodium carbonate aqueous solution (3 mL, 8 mmol) and 20 mL of DME was stirred at 80 0C for 2hr. Then the reaction mixture was diluted with 50 mL of ethyl acetate and extracted with 1 N NaOH (50mL, three times)). The combined aqueous layers were neutralized to pH=6. Then the aqueous solution 25 was extracted with ethyl acetate (50 mL, three times). The combined organic layers were washed with saturated sodium carbonate and brine. Then the organic layer was dried over anhydrous sodium sulfate and concentrated to give 2-(4-(4, 6-dimorpholino-1, 3, 5-triazin-2-yl) phenyl) acetic acid (68mg, 18%yield). HPLC: Rt = 2.04min; MS 386 [M+H]. 173 WO 2009/143313 PCT/US2009/044774 Step 2: Preparation of 2-[4-(4, 6-dimorpholin-4-yl-1, 3, 5-triazin-2-yl) phenyl]-N-pyridin-3 ylacetamide The title compound was prepared by following the procedure of example 473 step 3 using 2-(4 (4, 6-dimorpholino-1, 3, 5-triazin-2-yl) phenyl) acetic acid and 3-aminopyridine. Yield 21 mg, 5 44% yield; HPLC: Rt = 1.91 min; MS 462 [M+H]. Preparation of ((2S,5R)-1-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-nitrophenyl)-1,3,5 triazin-2-yl)pyrrolidine-2,5-diyl)dimethanol A suspension of ((2S,5R)-1-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)pyrrolidine-2,5 diyl)dimethanol (1.3 g, 2.7 mmol), 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (0.51 g, 3.4 10 mmol) in ethanol (15 mL) was treated with triethylamine (1.35 mL, 10 mmol) and heated with a heat gun briefly to reflux. The reaction mixture was purified by automated flash chromatography (methanol/chloroform) to provide the title compound as a hard peach colored foam. MS (ES*) = 443.2 (M+H)* Preparation of 3-(4-((2S,5R)-2,5-bis((tert-butyldimethylsilyloxy)methyl)pyrrolidin-1-yl)-6-(4 15 nitrophenyl)-1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2. 1 ]octane A solution of ((2S,5R)-1-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(4-nitrophenyl)-1,3,5-triazin 2-yl)pyrrolidine-2,5-diyl)dimethanol (1.5 g, 3.4 mmol) in dichloromethane (15 mL) was treated successively with tert-butyl dimethyl chlorosilane (1.3 g, 8.5 mmol) and imidazole (0.69 g, 10 mmol). The resulting suspension was stirred overnight at room temperature and then quenched 20 with water. The aqueous phase was extracted three times with dichloromethane. The combined extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated to dryness under reduced pressure. The crude residue (a peach-colored solid) was carried on to the following step without further purification. MS (ES*) = 671.4 (M+H)* Preparation of 4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-((2S,5R)-2,5-bis((tert 25 butyldimethylsilyloxy)methyl)pyrrolidin- 1 -yl)-1,3,5-triazin-2-yl)aniline A suspension of palladium on charcoal (10 %, 100 mg) and crude 3-(4-((2S,5R)-2,5-bis((tert butyldimethylsilyloxy)methyl)pyrrolidin-1-yl)-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-8-oxa-3 azabicyclo[3.2.1]octane (3.4 mmol maximum) in tetrahydrofuran (30 mL) was shaken for 8 hours under 50 psi of hydrogen. The mixture was filtered through a pad of Celite TM 30 diatomaceous earth and concentrated under reduced pressure to provide the title compound as an orange foam. MS (ES*) = 642.4 (M+H)* 174 WO 2009/143313 PCT/US2009/044774 Example 667: Preparation of 1-(4-{4-[(2R,5S)-2,5-bis(hydroxymethyl)pyrrolidin-1-yl]-6-(8-oxa-3 azabicyclo[3.2. 1 ]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea A solution of 4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-((2S, 5R)-2,5-bis((tert butyldimethylsilyloxy)methyl)pyrrolidin-1 -yl)- 1,3,5-triazin-2-yl)aniline (0.24 g, 0.37 mmol) in 5 dichloromethane (5 mL) was treated successively with triethylamine (500 pL) and a triphosgene (56 mg) solution in dichloromethane (1 mL). After 5 minutes, the mixture was treated with a solution of 4-aminopyridine (70 mg) in warm tetrahydrofuran. After 1 hour, the reaction mixture was quenched with methanol and concentrated to dryness. Half of the crude residue was treated with a saturated solution of hydrogen chloride in methanol. Upon complete desilylation, 10 the mixture was concentrated to dryness and the residue purified by reverse-phase high performance liquid chromatography using a Phenomenex Prodigy column running a gradient elution of 5 % acetonitrile/95 % of 0.1 % aqueous trifluoroacetic acid to 50 % acetonitrile over 25 minutes. After concentration, the title compound was obtained as it trifluoroacetic acid salt (75 mg). MS (ES*) = 533.3 (M+H)* 15 Example 668: Preparation of 1-(4-{4-[(2R,5S)-2,5-bis(hydroxymethyl)pyrrolidin-1-yl]-6-(8-oxa-3 azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin-2-yl}phenyl)-3-[4-(4-methylpiperazin-1-yl)phenyl]urea A solution of 4-(4-(8-oxa-3-azabicyclo[3.2. 1 ]octan-3-yl)-6-((2S, 5R)-2,5-bis((tert butyldimethylsilyloxy)methyl)pyrrolidin-1 -yl)-1,3,5-triazin-2-yl)aniline (0.25 g, 0.39 mmol) in dichloromethane (5 mL) was treated successively with triethylamine (500 pL) and a triphosgene 20 (59 mg, 0.08 mmol) solution in dichloromethane (1 mL). After 5 minutes, the mixture was treated with 4-(4-methylpiperazin-1-yl)aniline (150 mg). After 1 hour, the reaction mixture was quenched with methanol and concentrated to dryness. The crude residue was treated with a saturated solution of hydrogen chloride in methanol. Upon complete desilylation, the mixture was concentrated to dryness and the residue purified by reverse-phase high performance liquid 25 chromatography using a Phenomenex Gemini column running a gradient elution of 5 % acetonitrile/55 % of 0.1 % aqueous trifluoroacetic acid to 50 % acetonitrile over 15 minutes. After concentration, the title compound was obtained as it trifluoroacetic acid salt (130 mg). MS (ES*) = 630.4 (M+H)* Example 823 Preparation of 1-[4-(4,6-di-3,7-dioxa-9-azabicyclo[3.3.1]non-9-yl-1,3,5-triazin-2 30 yl)phenyl]-3-[4-(4-methylpiperazin-1 -yl)phenyl]urea To a solution of cyanuric chloride (0.368 g, 2 mmol) in CH 2
CI
2 (20 mL) was added 3,7-dioxa-9 azabicyclo[3.3.1]nonane. HCO 2 H (0.718 g, 4.1 mmol), followed by addition of Et 3 N (0.98 mL, 7 mmol). The resulting reaction mixture was stirred for 24h, and then diluted with CH 2
CI
2 . The 175 WO 2009/143313 PCT/US2009/044774 organic phase was washed with aqueous 1 N HCI (3X) and dried over MgSO 4 . The solvent was removed in vacuum to give 9,9'-(6-chloro-1,3,5-triazine-2,4-diyl)bis(3,7-dioxa-9 azabicyclo[3.3.1]nonane) as white solid (0.15 g, 95% yield). To a 10 mL vial were added 9,9'-(6-chloro-1,3,5-triazine-2,4-diyl)bis(3,7-dioxa-9 5 azabicyclo[3.3.1]nonane) (150 mg, 0.406 mmol), 4-aminophenylboronic acid pinacol ester (133 mg, 0.61 mmol), Pd(PPh 3
)
4 (10 mg), toluene (1 mL), EtOH (1 mL) and 2M Na 2
CO
3 aqueous solution (0.305 mL). The resulting mixture was heated at 120 0C for 20 minutes in microwave oven. The reaction mixture was cooled to room temperature. The aqueous phase was extracted with EtOAc, and the combined organic phases were dried over (MgSO 4 ). The solvent was 10 removed under reduced pressure and the residue was subjected to HPLC separation to give 4 (4,6-di(3,7-dioxa-9-azabicyclo[3.3. 1 ]nonan-9-yl)-1,3,5-triazin-2-yl)aniline as a white solid (120 mg). To a solution of 4-(4,6-di(3,7-dioxa-9-azabicyclo[3.3.1] nonan-9-yl)-1,3,5-triazin-2-yl)aniline (120 mg, 0.281 mmol) in CH 2
CI
2 was added Et 3 N (0.237 mL, 1.69 mmol) and triphosgene (42 mg, 15 0.14 mmol). The mixture was stirred at room temperature for 15 minutes and 4-(4 methylpiperazin-1-yl)aniline (107 mg, 0.56 mmol) was added. The mixture was stirred at room temperature overnight. The solvent was removed, and the residue was subjected to HPLC separation to give the title compound (1TFA salt) MS(ESI) m/z 644.3306. Preparation of (6S)-tert-butyl 6-hydroxy-3-oxa-8-azabicyclo[3.2. 1 ]octane-8-carboxylate (Scheme 20 10) Step 1: (2R',5S')-1 -tert-butyl 2,5-dimethyl 1 H-pyrrole-1,2,5(2H,5H)-tricarboxylate (cis-diester) was synthesized by following the procedure described in literature: Organic Letters 2004, 6(18), 3055-8. Step 2: Reduction of cis-diester to (2R',5S')-tert-butyl 2,5-bis(hydroxymethyl)-2,5-dihydro-1 H 25 pyrrole-1-carboxylate (cis-diol) To a solution of (2R',5S')-1-tert-butyl 2,5-dimethyl 1 H-pyrrole-1,2,5(2H,5H)-tricarboxylate (6.6 g, 23.1 mmol) in THF (100 mL) was added slowly of LiBH 4 solution (2M in THF, 34.7 mL, 69.4 mmol) at 0 0C. The resulting mixture was stirred at room temperature for 3 hours, then cooled to 0 C again. HCI solution (1M, 30 mL) was added to the reaction mixture, and stirred for 10 30 minutes before diluted with EtOAc. The organic layer was separated, and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with water and brine, and dried (MgSO 4 ). The organic solvent was removed in vacuo to give the crude product, which 176 WO 2009/143313 PCT/US2009/044774 was purified by flash chromatography in silica gel with EtOAc:Hex:MeOH(50:50:10) to give the cis-diol (3.8 g, 72%). Step 3: Preparation of (2R',5S')-tert-butyl 2,5-bis((tert-butyldimethylsilyloxy)methyl)-2,5-dihydro 1 H-pyrrole-1 -carboxylate 5 To a solution of the cis-diol (3.57 g, 15.6 mmol) in DMF (15 mL) were added TBSCI (5.16 g, 34.3 mmol) and imidazole (3.18 g, 46.7 mmol). The mixture was heated at 80 0C for 30 minutes in microwave oven (150 watt). Cooled to room temperature, the mixture was taken up in water (50 mL) and EtOAc (50 mL). The organic layer was separated, and the aqueous phase was extracted with EtOAc. Combined organic phases were washed with water and brine, and dried 10 (MgSO 4 ). The organic solvent was removed in vacuo to give the crude product, which was purified by flash chromatography in silica gel with EtOAc:Hex (10:90) to give the title compound (7.12 g, 98%). Step 4: Synthesis of (2R',3S',5R')-tert-butyl 2,5-bis((tert-butyldimethylsilyloxy)methyl)-3 hydroxypyrrolidine-1-carboxylate (trans-alcohol) 15 To a solution of (2R',5S')-tert-butyl 2,5-bis((tert-butyldimethylsilyloxy)methyl)-2,5-dihydro-1 H pyrrole-1-carboxylate (4.8 g, 10.5 mmol) in THF (50 mL) was added slowly of BH 3 DMS solution (2M in THF, 6.97 mL, 13.9 mmol) at 0 0 C. The resulting mixture was stirred at room temperature for 3 hours, then cooled to 0 0 C again. NaOH solution (5M, 12.6 mL, 63.2 mmol) was added to the reaction mixture, followed by addition of H 2 0 2 (30%, 6.33 mL, 62.0 mmol). The resulting 20 mixture was stirred for 5 hours before diluted with EtOAc. The organic layer was separated, and the aqueous phase was extracted with EtOAc. Combined organic phases were washed with water and brine, and dried (MgSO 4 ). The organic solvent was removed in vacuo to give the crude product, which was purified by flash chromatography in silica gel with EtOAc:Hex (30:70) to give the title compound (3.8 g, 77%). 25 Step 5: Benzyl protection of the trans alcohol To a solution of (2R',3S',5R')-tert-butyl 2,5-bis((tert-butyldimethylsilyloxy)methyl)-3 hydroxypyrrolidine-1-carboxylate (2.515 g, 5.3 mmol) in THF (50 mL) were added NaH (60%, 0.423 g, 10.6 mmol). The mixture was stirred at room temperature for 30 minutes, and benzyl bromide (1.085 g, 6.3 mmol) and TBAI (0.195 g, 0.5 mmol) were added. The mixture was stirred 30 at room temperature for 12 hours, and quenched by addition of sat.NH 4 CI solution (20 mL). Concentrated in vacuo, and the residue was taken up in water and EtOAc. The organic layer was separated, and the aqueous phase was extracted with EtOAc. Combined organic phases 177 WO 2009/143313 PCT/US2009/044774 were washed with water and brine, and dried (MgSO 4 ). The organic solvent was removed in vacuo to give the crude product, which was purified by flash chromatography in silica gel with EtOAc: Hex (10:90) to give (2R',3S',5R')-tert-butyl 3-(benzyloxy)-2,5-bis((tert butyldimethylsilyloxy)methyl)pyrrolidine-1-carboxylate (3.0 g, 100%) as colorless oil. 5 Step 6: Synthesis of (2R',3S',5R')-tert-butyl 3-(benzyloxy)-2,5-bis(hydroxymethyl)pyrroid ine-1 carboxylate (benzyloxy diol) To a solution of (2R',3S',5R')-tert-butyl 3-(benzyloxy)-2,5-bis((tert butyldimethylsilyloxy)methyl)pyrrolidine-1-carboxylate (3.0 g, 5.3 mmol) in THF (50 mL) was added slowly of TBAF solution (1 M in THF, 21.8 mL, 21.8 mmol) at 0 0C. The resulting mixture 10 was stirred at room temperature for 6, and quenched by addition of sat.NH 4 CI solution (10 mL). Concentrated in vacuo, and the residue was treated with water and EtOAc. The organic layer was separated, and the aqueous phase was extracted with EtOAc. Combined organic phases were washed with water and brine, and dried (MgSO 4 ). The organic solvent was removed in vacuo to give the crude product, which was purified by flash chromatography in silica gel with 15 EtOAc:Hex:MeOH (50:50:5) to give the title compound (1.15 g, 62.5%). Step 7: Synthesis of (6S')-tert-butyl 6-(benzyloxy)-3-oxa-8-azabicyclo[3.2. 1 ]octane-8 carboxylate by cyclization To a solution of (2R',3S',5R')-tert-butyl 3-(benzyloxy)-2,5-bis(hydroxymethyl)pyrrolidine-1 carboxylate (1.15 g, 3.4 mmol) in THF (50 mL) was added NaH (60%, 0.409 g, 10.2 mmol). The 20 mixture was stirred at room temperature for 30 minutes , and cooled down to 0 0 C. A solution of p-TsCI (0.65 g, 3.4 mmol) in THF (5 mL) was slowly added to the mixture. The reaction mixture was then stirred at room temperature for 12 hours, and quenched by addition of sat.NH 4 CI solution (20 mL). Concentrated in vacuo, and the residue was taken up in water and EtOAc. The organic layer was separated, and the aqueous phase was extracted with EtOAc. Combined 25 organic phases were washed with water and brine, and dried (MgSO 4 ). The organic solvent was removed in vacuo to give the crude product, which was purified by flash chromatography in silica gel with EtOAc:Hex (20:80) to give the title compound (716 mg, 66%) as off-white solid. The compounds in Table I were made by the proceeding methods. Table! Example Name MS (ESI) 178 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-(4-{[4-(dimethylamino)piperidin-1 478 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6- 615.5 (tetrahyd ro-2 H-pyran-4-yl)- 1,3,5-triazin-2 yl]phenyl}urea 1-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-(4 479 {4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3-yloxy]- 589.6 1,3,5-triazin-2-yl}phenyl)urea 1-{4-[4-(5-hydroxy-3-oxa-7-azabicyclo[4.1.1]oct-7-yl)- 505.3 253.2 480 6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin- 273.8 4-ylurea 481 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3- 464.2 253.1 pyridazin-4-ylurea 1-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-{4 482 [4-morpholin-4-yl-6-(oxetan-3-yloxy)-1,3,5-triazin-2- 575.5 yl]phenyl}urea 1 -{4-[4-morpholin-4-yl-6-(3-oxa-8 483 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}-3- 490.6 pyridazin-4-ylurea 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 484 yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5- 602.5 triazin-2-yl)phenyl]urea 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 485 yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5- 602.6 triazin-2-yl)phenyl]urea 1-[4-(4-isopropyl-6-morpholin-4-yl-1,3,5-triazin-2- 545.1 293.5 486 yl)phenyl]-3-{4-[(4-methylpiperazin-1
-
273 yl)carbonyl]phenyl}urea 487 1 -{4-[4-(1 -methylethyl)-6-morpholin-4-yl- 1, 3,5-triazin- 497.3 2-yl]phenyl}-3-(4-pyrimidin-5-ylphenyl)urea 488 1-(4-{4-[(2,2-dimethoxyethyl)amino]-6-morpholin-4- 481.2 241.1 yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3-ylurea 261.6 489 1 -{4-[4-(1 -methylethyl)-6-morpholin-4-yl- 1, 3,5-triazin- 496.3 248.6 2-yl]phenyl}-3-(4-pyridin-4-ylphenyl)urea 269.1 490 1-(4-iodophenyl)-3-{4-[4-(1 -methylethyl)-6-morpholin- 545.1 4-yl-1,3,5-triazin-2-yl]phenyl}urea 1 -{4-[4-(1 -methylethyl)-6-morpholin-4-yl- 1, 3,5-triazin 491 2-yl]phenyl}-3-(4-{[4-(1 -methylethyl)piperazin-1 - 573.4 287.2 yl]carbonyl}phenyl)urea 1-[4-(4-azetidin-1 -yl-6-morpholin-4-yl-1,3,5-triazin-2 492 yl)phenyl]-3-(4-{[4-(1-methylethyl)piperazin-1- 586.6 yl]carbonyl}phenyl)urea 1 -{4-[2-(dimethylamino)pyrimidin-5-yl]phenyl}-3-{4-[4 493 (1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2- 540.5 yl]phenyl}urea tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridin-4 494 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2- 549.6 yl)oxy]azetidine-1-carboxylate 179 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-(4-{[4-(dimethylamino)piperidin-1 495 yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5- 616.4 308.7 triazin-2-yl)phenyl]urea 496 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3- 507.1 (4-nitrophenyl)urea 497 1-(4-aminophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5- 477.1 259.6 triazin-2-yl)phenyl]urea N-[4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2- 603.2 302.1 498 yl)phenyl]carbamoyl}amino)phenyl]-4- 322.6 methylpiperazine-1-carboxamide 4-(dimethylamino)-N-[4-({[4-(4,6-dimorpholin-4-yl 499 1,3,5-triazin-2- 631.3 yl)phenyl]carbamoyl}amino)phenyl]piperidine-1 carboxamide 1-[2-(dimethylamino)ethyl]-3-[4-({[4-(4,6-dimorpholin 500 4-yl-1,3,5-triazin-2- 605.3 yl)phenyl]carbamoyl}amino)phenyl]-1-methylurea 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3 501 (4-{[(2-piperidin-1- 631.3 ylethyl)carbamoyl]amino}phenyl)urea N-[4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 502 yl)phenyl]carbamoyl}amino)phenyl]-4-methyl-1,4- 617.3 diazepane-1 -carboxamide N-[4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 503 yl)phenyl]carbamoyl}amino)phenyl]-4- 617.3 ethylpiperazine-1 -carboxamide 504 1 -{4-[(dimethylcarbamoyl)amino]phenyl}-3-[4-(4,6- 548.3 dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl 505 1,3,5-triazin-2-yl]phenyl}-3-(4-{[4- 613.4 (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)urea 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4 506 yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]-N-[2- 587.4 (dimethylamino)ethyl]-N-methylbenzamide 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl 507 1,3,5-triazin-2-yl]phenyl}-3-{4-[(4-methylpiperazin-1 - 585.3 yl)carbonyl]phenyl}urea 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4 508 yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]-N-[2- 573.3 (dimethylamino)ethyl]benzamide N-[4-({[4-(4,6-di-8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl 509 1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)phenyl]-2- 668.4 (4-methylpiperazin-1 -yl)acetamide 1-(4-{[4-(dimethylamino)piperidin-1 510 yl]carbonylrphenyl)-3-{4-[4-morpholin-4-yl-6- 615.5 (tetra hyd ro-2 H-pyra n-4-yl)- 1, 3,5-triazi n-2 yl]phenyl}urea 180 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-{4 511 [4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5- 587.3 triazin-2-yl]phenyl}urea N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-yl-6 512 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2- 575.3 yl]phenyl}carbamoyl)amino]benzamide 4-[({4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl) 513 1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]-N-(2- 601.3 pyrrolidin-1 -ylethyl)benzamide 4-[({4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl) 514 1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]-N-(2- 615.3 piperidin-1 -ylethyl)benzamide 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3- 616.3 308.6 515 (4-{[4-(1 -methylethyl)piperazin-1
-
329.2 yl]carbonyl}phenyl)urea 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 516 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa- 627.7 8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2 yl]phenyl}urea 517 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1- 449.4 yl]carbonyl}phenyl)-3-{4-[4-morpholin 518 4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5- 616.4 triazin-2-yl]phenyl}urea N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4 519 morpholin-4-yl-6-[(3S)-tetrahydrofuran-3-yloxy]-1,3,5- 616.4 triazin-2-yl}phenyl)carbamoyl]amino}benzamide 4-{[(4-{4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3 520 yloxy]-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}-N- 616.4 (2-piperidin-1 -ylethyl)benzamide 4-{[(4-{4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3 521 yloxy]-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}-N- 616.4 (2-pyrrolidin-1 -ylethyl)benzamide 1-(4-{[4-(1 -methylethyl)piperazin-1 522 yl]carbonyl}phenyl)-3-(4-{4-morpholin-4-yl-6-[(3S)- 616.4 tetrahyd rofu ran-3-yloxy]- 1,3,5-triazin-2 yl}phenyl)urea 1-(4-{[4-(1 -methylethyl)piperazin-1 523 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6- 616.4 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2 yl]phenyl}urea N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4 524 morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5- 616.4 triazin-2-yl]phenyl}carbamoyl)amino]benzamide 181 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 525 4-[({4-[4-(2-methylpropyl)-6-morpholin-4-yl-1,3,5- 477.3 triazin-2-yl]phenyl}carbamoyl)amino]benzoic acid 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5 526 triazin-2-yl]phenyl}-3-[4-(4-methylpiperazin-1- 565.4 yl)phenyl]urea 527 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5- 511.4 triazin-2-yl]phenyl}carbamoyl)amino]benzoic acid 528 methyl 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl- 525.4 1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoate 529 1-{4-[4-(dimethylamino)piperidin-1-yl]phenyl}-3-[4-(4- 531.4 ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea 530 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5- 468.3 triazin-2-yl]phenyl}-3-pyridin-4-ylurea 1 -{4-[4-(dimethylamino)piperidin-1 -yl]phenyl}-3-{4-[4 531 (4-methylphenyl)-6-morpholin-4-yl- 1,3,5-triazin-2- 593.4 yl]phenyl}urea N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-(4 532 methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2- 595.5 yl]phenyl}carbamoyl)amino]benzamide 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5 533 triazin-2-yl]phenyl}-3-{4-[(4-methylpiperazin-1- 593.5 yl)carbonyl]phenyl}urea 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 534 yl)phenyl]-3-{4-[(4-pyridin-2-ylpiperazin-1 - 594.5 yl)carbonyl]phenyl}urea 1 -{4-[4-(dimethylamino)piperidin-1 -yl]phenyl}-3-[4-(4 535 morpholin-4-yl-6-phenyl-1,3,5-triazin-2- 579.5 yl)phenyl]urea 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 536 yl)phenyl]-3-{4-[(4-methylpiperazin-1 - 531.1 yl)carbonyl]phenyl}urea 537 1-[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2- 454.1 yl)phenyl]-3-pyridin-4-ylurea 538 methyl 4-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5- 511 triazin-2-yl)phenyl]carbamoyl}amino)benzoate N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4 539 morpholin-4-yl-6-phenyl-1,3,5-triazin-2- 581.2 yl)phenyl]carbamoyl}amino)benzamide 540 methyl 4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 548 1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzoate 541 4-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2- 497 yl)phenyl]carbamoyl}amino)benzoic acid I 182 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz N-[2-(dimethylamino)ethyl]-4-[({4-[4-(4 542 methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2- 581.3 yl]phenyl}carbamoyl)amino]benzamide 1-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-[4 543 (4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2- 579.2 yl)phenyl]urea 1-(4-{[4-(dimethylamino)piperidin-1 544 yl]carbonyl}phenyl)-3-[4-(4-morpholin-4-yl-6-phenyl- 661.5 1,3,5-triazin-2-yl)phenyl]urea N-[2-(dimethylamino)ethyl]-4-({[4-(4-morpholin-4-yl 545 6-phenyl-1,3,5-triazin-2- 567.2 yl)phenyl]carbamoyl}amino)benzamide 4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 546 triazin-2-yl}phenyl)carbamoyl]amino}-N-[2- 604.4 (dimethylamino)ethyl]benzamide 1 -{4-[(4-isopropylpiperazin-1 -yl)carbonyl]phenyl}-3 547 {4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin- 621.5 2-yl]phenyl}urea 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1, 3,5 548 triazin-2-yl]phenyl}carbamoyl)amino]-N-(2-pyrrolidin- 607.5 1-ylethyl)benzamide 549 4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5- 534.5 triazin-2-yl}phenyl)carbamoyl]amino}benzoic acid N-(2-methoxyethyl)-4-[({4-[4-(4-methylphenyl)-6 550 morpholin-4-yl-1,3,5-triazin-2- 568.2 yl]phenyl}carbamoyl)amino]benzamide N-(2-methoxyethyl)-4-({[4-(4-morpholin-4-yl-6 551 phenyl-1,3,5-triazin-2- 554.2 yl)phenyl]carbamoyl}amino)benzamide 4-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2 552 yl)phenyl]carbamoyl}amino)-N-(2-pyrrolidin-1- 593.5 ylethyl)benzamide 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5 553 triazin-2-yl]phenyl}-3-[4-(pyrrolidin-1 - 567.6 ylcarbonyl)phenyl]urea N-[3-(dimethylamino)propyl]-4-[({4-[4-(4 554 methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2- 595.4 yl]phenyl}carbamoyl)amino]benzamide 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5 555 triazin-2-yl]phenyl}-3-[4-(piperidin-1 - 578.1 ylcarbonyl)phenyl]urea N-[3-(dimethylamino)propyl]-4-({[4-(4-morpholin-4-yl 556 6-phenyl-1,3,5-triazin-2- 581.4 291.2 yl)phenyl]carbamoyl}amino)benzamide 557 1 -{4-[4-morpholin-4-yl-6-(2-thienyl)-1,3,5-triazin-2- 460.2 230.6 yl]phenyl}-3-pyridin-4-ylurea 183 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 558 4-[({4-[4-morpholin-4-yl-6-(2-thienyl)-1,3,5-triazin-2- 503.4 yl]phenyl}carbamoyl)amino]benzoic acid 1-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-{4 559 [4-morpholin-4-yl-6-(2-thienyl)-1,3,5-triazin-2- 585.5 yl]phenyl}urea 560 methyl 4-[({4-[4-morpholin-4-yl-6-(2-thienyl)-1 3,5- 517.2 triazin-2-yl]phenyl}carbamoyl)amino]benzoate N-(2-methoxyethyl)-4-[({4-[4-morpholin-4-yl-6-(2 561 thienyl)-1,3,5-triazin-2- 560.3 yl]phenyl}carbamoyl)amino]benzamide N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4 562 morpholin-4-yl-6-(2-thienyl)-1,3,5-triazin-2- 587.3 294.1 yl]phenyl}carbamoyl)amino]benzamide N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-yl-6 563 (2-thienyl)-1,3,5-triazin-2- 573.1 yl]phenyl}carbamoyl)amino]benzamide 4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 564 triazin-2-yl}phenyl)carbamoyl]amino}-N-[2- 618.4 309.7 (dimethylamino)ethyl]-N-methylbenzamide 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1,3,5- 616.4329.2 565 triazin-2-yl}phenyl)-3-{4-[(4-methylpiperazin-1 - 308.7 yl)carbonyl]phenyl}urea 566 1 -{4-[4-morpholin-4-yl-6-(1,4-oxazepan-4-yl)-1,3,5- 477.2 triazin-2-yl]phenyl}-3-pyridin-4-ylurea methyl 4-[({4-[4-morpholin-4-yl-6-(1,4-oxazepan-4 567 yl)-1,3,5-triazin-2- 534.4 yl]phenyl}carbamoyl)amino]benzoate 1-(4-{[4-(dimethylamino)piperidin-1 568 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(2- 613.4 307.2 thienyl)-1,3,5-triazin-2-yl]phenyl}urea 569 4-[({4-[4-morpholin-4-yl-6-(1,4-oxazepan-4-yl)-1,3,5- 520.3 triazin-2-yl]phenyl}carbamoyl)amino]benzoic acid N-[3-(dimethylamino)propyl]-4-[({4-[4-morpholin-4-yl 570 6-(2-thienyl)-1,3,5-triazin-2- 587.3 294.2 yl]phenyl}carbamoyl)amino]benzamide 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 571 triazin-2-yl}phenyl)-3-[4-(pyrrolidin-1 - 587.5 ylcarbonyl)phenyl]urea N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-yl-6 572 (1,4-oxazepan-4-yl)-1,3,5-triazin-2- 590.3 295.6 yl]phenyl}carbamoyl)amino]benzamide 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-{4- 602.3 322.2 573 [4-morpholin-4-yl-6-(1,4-oxazepan-4-yl)-1,3,5-triazin- 301.7 2-yl]phenyl}urea N-(2-methoxyethyl)-4-[({4-[4-morpholin-4-yl-6-(1,4 574 oxazepan-4-yl)-1,3,5-triazin-2- 577.2 yl]phenyl}carbamoyl)amino]benzamide 184 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-{4-[4- 599.3 300.2 575 morpholin-4-yl-6-(2-thienyl)-1,3,5-triazin-2- 320.7 yl]phenyl}urea 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl-1 ,35- 593.3 317.7 576 triazin-2-yl]phenyl}-3-{3-[(4-methylpiperazin-1- 521 .3 yl)carbonyl]phenyl}urea 577 3-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1, 3,5- 511.2 triazin-2-yl]phenyl}carbamoyl)amino]benzoic acid 578 methyl 3-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl- 525.2 1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoate 1-(3-{[4-(dimethylamino)piperidin-1 579 yl]carbonyl}phenyl)-3-{4-[4-(4-methylphenyl)-6- 521.3 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}urea N-[2-(dimethylamino)ethyl]-N-methyl-3-[({4-[4-(4 580 methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2- 595.3 298.2 yl]phenyl}carbamoyl)amino]benzamide 581 methyl 3-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin- 463.5 2-yl)phenyl]carbamoyl}amino)benzoate 582 methyl 3-({[4-(4-morpholin-4-yl-6-thiophen-2-yl-1,3,5- 517.2 triazin-2-yl)phenyl]carbamoyl}amino)benzoate N-[2-(dimethylamino)ethyl]-3-[({4-[4-(4 583 methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2- 581.3 291.1 yl]phenyl}carbamoyl)amino]benzamide N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4 584 morpholin-4-yl-6-(1,4-oxazepan-4-yl)-1,3,5-triazin-2- 604.4 302.7 yl]phenyl}carbamoyl)amino]benzamide 585 3-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2- 449.4 yl)phenyl]carbamoyl}amino)benzoic acid 586 methyl 3-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5- 511.4 triazin-2-yl)phenyl]carbamoyl}amino)benzoate 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 587 yl)phenyl]-3-{3-[(4-pyridin-2-ylpiperazin-1 - 594.6 yl)carbonyl]phenyl}urea N-[2-(dimethylamino)ethyl]-3-({[4-(4-ethyl-6 588 morpholin-4-yl-1,3,5-triazin-2- 533.3 267.1 yl)phenyl]carbamoyl}amino)-N-methylbenzamide 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2- 531.3 266.1 589 yl)phenyl]-3-{3-[(4-methylpiperazin-1
-
286.7 yl)carbonyl]phenyl}urea 590 3-({[4-(4-morpholin-4-yl-6-phenyl-1,3,5-triazin-2- 497.3 yl)phenyl]carbamoyllamino)benzoic acid 591 methyl 4-({[4-(4-morpholin-4-yl-6-piperidin-1-yl-1,3,5- 518.3 triazin-2-yl)phenyl]carbamoylamino)benzoate 185 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 592 1-[4-(4-morpholin-4-yl-6-piperidin-1 -yl-1,3,5-triazin-2- 461.3 yl)phenyl]-3-pyridin-4-ylurea 593 4-({[4-(4-morpholin-4-yl-6-piperidin-1 -yl-1,3,5-triazin- 504..3 2-yl)phenyl]carbamoyl}amino)benzoic acid 594 methyl 4-({[4-(4-morpholin-4-yl-6-pyrrolidin-1-yl- 504.5 1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate 1-(4-{[4-(1 -methylethyl)piperazin-1 595 yl]carbonyl}phenyl)-3-[4-(4-morpholin-4-yl-6- 604.5 piperidin-1 -yl-1,3,5-triazin-2-yl)phenyl]urea 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-[4-(4 596 morpholin-4-yl-6-piperidin-1 -yl-1,3,5-triazin-2- 600.5 yl)phenyl]urea 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-[4 597 (4-morpholin-4-yl-6-piperidin-1 -yl-1,3,5-triazin-2- 586.5 yl)phenyl]urea 1-(4-{[4-(dimethylamino)piperidin-1 598 yl]carbonyl}phenyl)-3-[4-(4-morpholin-4-yl-6- 614.5 piperidin-1 -yl-1,3,5-triazin-2-yl)phenyl]urea 599 4-({[4-(4-morpholin-4-yl-6-pyrrolidin-1 -yl-1,3,5-triazin- 490.5 2-yl)phenyl]carbamoyl}amino)benzoic acid 600 1-[4-(4-morpholin-4-yl-6-pyrrolidin-1-yl-1,3,5-triazin- 447.5 2-yl)phenyl]-3-pyridin-4-ylurea N-[2-(dimethylamino)ethyl]-4-({[4-(4-morpholin-4-yl 601 6-piperidin-1-yl-1,3,5-triazin-2- 474.6 yl)phenyl]carbamoyl}amino)benzamide 1-(4-{[4-(dimethylamino)piperidin-1 602 yl]carbonyl}phenyl)-3-[4-(4-morpholin-4-yl-6- 600.4 300.7 pyrrolidin-1 -yl-1,3,5-triazin-2-yl)phenyl]urea 1-(4-{[4-(1 -methylethyl)piperazin-1 603 yl]carbonyl}phenyl)-3-[4-(4-morpholin-4-yl-6- 600.4 300.7 pyrrolidin-1 -yl-1,3,5-triazin-2-yl)phenyl]urea N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4 604 morpholin-4-yl-6-pyrrolidin-1 -yl-1,3,5-triazin-2- 574.6 yl)phenyl]carbamoyl}amino)benzamide N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4 605 morpholin-4-yl-6-piperidin-1 -yl-1,3,5-triazin-2- 588.3 294.6 yl)phenyl]carbamoyl}amino)benzamide 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-[4-(4- 586.3 293.7 606 morpholin-4-yl-6-pyrrolidin-1 -yl-1,3,5-triazin-2- 286.7 yl)phenyl]urea 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-[4 607 (4-morpholin-4-yl-6-pyrrolidin-1 -yl-1,3,5-triazin-2- 572.3 yl)phenyl]urea 186 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz N-[2-(dimethylamino)ethyl]-4-({[4-(4-morpholin-4-yl 608 6-pyrrolidin-1-yl-1,3,5-triazin-2- 560.1 280.6 yl)phenyl]carbamoyl}amino)benzamide 609 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5- 491.2 266.6 triazin-2-yl}phenyl)-3-pyridin-4-ylurea 246.1 N-[3-(dimethylamino)propyl]-4-({[4-(4-morpholin-4-yl 610 6-piperidin-1-yl-1,3,5-triazin-2- 588.3 294.6 yl)phenyl]carbamoyl}amino)benzamide N-(2-methoxyethyl)-4-({[4-(4-morpholin-4-yl-6 611 piperidin-1-yl-1,3,5-triazin-2- 561.4 281.2 yl)phenyl]carbamoyl}amino)benzamide 612 1-[4-(4-morpholin-4-yl-6-pyrrolidin-1-yl-1,3,5-triazin- 543.3 2-yl)phenyl]-3-[4-(pyrrolidin-1-ylcarbonyl)phenyl]urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 613 triazin-2-yl}phenyl)-3-{4-[(4-ethylpiperazin-1- 630.6 yl)carbonyl]phenyl}urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 614 triazin-2-yl}phenyl)-3-(4-{[4-(1 -methylethyl)piperazin- 644.7 1 -yl]carbonyl}phenyl)urea methyl 4-{[(4-{4-[(3S)-3-methylmorpholin-4-yl]-6 615 morpholin-4-yl-1,3,5-triazin-2- 534.3 yl}phenyl)carbamoyl]amino}benzoate 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 616 triazin-2-yl}phenyl)-3-(4-{[4-(dimethylamino)piperidin- 644.6 1 -yl]carbonyl}phenyl)urea 1-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4- 602.3322.2 617 yl-1,3,5-triazin-2-yl}phenyl)-3-{4-[(4-methylpiperazin- 301. 7 1 -yl)carbonyl]phenyl}urea 1-(4-{[4-(1 -methylethyl)piperazin-1 618 yl]carbonyl}phenyl)-3-(4-{4-[(3S)-3-methylmorpholin- 630.4315.7 4-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)urea 4-{[(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin 619 4-yl-1,3,5-triazin-2- 520.2 yl}phenyl)carbamoyl]amino}benzoic acid 1-{4-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}-3-(4-{4- 616.4 308.7 620 [(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5- 329.2 triazin-2-yl}phenyl)urea N-[3-(dimethylamino)propyl]-4-{[(4-{4-[(3S)-3 621 methylmorpholin-4-yl]-6-morpholin-4-yl-1,3,5-triazin- 604.6 2-yl}phenyl)carbamoyl]amino}benzamide 4-{[(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin 622 4-yl-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}-N-(2- 616.5 pyrrolidin-1 -ylethyl)benzamide 187 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-(4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[(3S)-3- 616.4 308.7 623 methylmorpholin-4-yl]-1,3,5-triazin-2-yl}phenyl)-3-{4- 329.2 [(4-methylpiperazin-1 -yl)carbonyl]phenyl}urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 624 triazin-2-yl}phenyl)-3-(4-{[4-(dipropylamino)piperidin- 700.6 350.8 1 -yl]carbonyl}phenyl)urea 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-(4-{4 625 [(3R)-3-methylmorpholin-4-yl]-6-[(3S)-3- 630.5 315.7 methylmorpholin-4-yl]-1,3,5-triazin-2-yl}phenyl)urea 4-{[(4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[(3S)-3 626 methylmorpholin-4-yl]-1,3,5-triazin-2- 534.3 yl}phenyl)carbamoyl]amino}benzoic acid 1-{4-[(4-butylpiperazin-1-yl)carbonyl]phenyl}-3-(4-{4 627 [(3R)-3-methylmorpholin-4-yl]-6-[(3S)-3- 658.6 methylmorpholin-4-yl]-1,3,5-triazin-2-yl}phenyl)urea methyl 4-{[(4-{4-[(3R)-3-methylmorpholin-4-yl]-6 628 [(3S)-3-methylmorpholin-4-yl]-1,3,5-triazin-2- 548.2 yl}phenyl)carbamoyl]amino}benzoate 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 629 triazin-2-yl}phenyl)-3-{4-[(4-butylpiperazin-1 - 658.5 329.7 yl)carbonyl]phenyl}urea 1-(4-{[4-(1 -methylethyl)piperazin-1 630 yl]carbonyl}phenyl)-3-(4-{4-[(3R)-3-methylmorpholin- 644.5 4-yl]-6-[(3S)-3-methylmorpholin-4-yl]-1,3,5-triazin-2 yl}phenyl)urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 631 triazin-2-yl}phenyl)-3-(4-{[4-(2- 658.5 methylpropyl)piperazin-1 -yl]carbonyl}phenyl)urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 632 triazin-2-yl}phenyl)-3-(4-{[4-(1- 658.6 methylpropyl)piperazin-1 -yl]carbonyl}phenyl)urea 4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 633 triazin-2-yl}phenyl)carbamoyl]amino}-N-[2-(4- 659.6 methylpiperazin-1 -yl)ethyl]benzamide N-[2-(dimethylamino)ethyl]-4-{[(4-{4-[(3R)-3 634 methylmorpholin-4-yl]-6-[(3S)-3-methylmorpholin-4- 604.5 yl]-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzamide 4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 635 triazin-2-yl}phenyl)carbamoyl]amino}-N-(2-pyrrolidin- 626.5 1-ylethyl)benzamide 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 636 triazin-2-yl}phenyl)-3-{4-[(4-propylpiperidin-1- 643.4 322.2 yl)carbonyl]phenyl}urea 188 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 637 triazin-2-yl}phenyl)-3-[4-(piperidin-1 - 601.5 ylcarbonyl)phenyl]urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 638 triazin-2-yl}phenyl)-3-{4-[(4-propylpiperazin-1 - 643.5 yl)carbonyl]phenyl}urea 4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 639 triazin-2-yl}phenyl)carbamoyl]amino}-N-(2- 591.6 methoxyethyl)benzamide 1 -{4-[4-morpholin-4-yl-6-(4-tricyclo[3.3.1.13,7]dec- 1 640 ylpiperazin-1 -yl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4- 596.7 ylurea methyl 4-{[(4-{4-[4-(dimethylcarbamoyl)piperazin-1 641 yl]-6-morpholin-4-yl-1,3,5-triazin-2- 590.5 yl}phenyl)carbamoyl]amino}benzoate N,N-dimethyl-4-(4-morpholin-4-yl-6-{4-[(pyridin-4 642 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2- 533.6 yl)piperazine-1 -carboxamide N,N-dimethyl-4-(4-{4-[({4-[(4-methylpiperazin-1 643 yl)carbonyl]phenyl}carbamoyl)amino]phenyl}-6- 658.3 329.7 morpholin-4-yl-1,3,5-triazin-2-yl)piperazine-1 carboxamide N,N-dimethyl-4-{4-morpholin-4-yl-6-[4-({[4-(pyridazin 644 4-ylcarbamoyl)phenyl]carbamoyl}amino)phenyl]- 653.3 1,3,5-triazin-2-yl}piperazine-1 -carboxamide N,N-dimethyl-4-(4-morpholin-4-yl-6-{4-[({4-[(4 645 propylpiperidin-1- 685.6 yl)carbonyl]phenyl}carbamoyl)amino]phenyl}-1,3,5 triazin-2-yl)piperazine-1 -carboxamide 4-{[(4-{4-[4-(dimethylcarbamoyl)piperazin-1 -yl]-6 646 morpholin-4-yl-1,3,5-triazin-2- 576.2 yl}phenyl)carbamoyl]amino}benzoic acid 4-(4-{4-[({4-[(2 647 methoxyethyl)carbamoyl]phenyl}carbamoyl)amino]ph 633.3 317.1 enyl}-6-morpholin-4-yl-1,3,5-triazin-2-yl)-NN dimethylpiperazine-1 -carboxamide 4-[4-(4-{[(4-{[2 648 (dimethylamino)ethyl](methyl)carbamoyl}phenyl)carb 660.3 330.7 amoyl]amino}phenyl)-6-morpholin-4-yl-1,3,5-triazin 2-yl]-N,N-dimethylpiperazine-1 -carboxamide 4-(4-{4-[({4-[(4-ethylpiperazin- 1 649 yl)carbonyl]phenyl}carbamoyl)amino]phenyl}-6- 672.6 morpholin-4-yl-1,3,5-triazin-2-yl)-N,N dimethylpiperazine-1 -carboxamide 650 1-(4-{4-[4-(ethylsulfonyl)piperazin-1 -yl]-6-morpholin- 554.2 4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 189 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz methyl 4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1-yl]-6 651 morpholin-4-yl-1,3,5-triazin-2- 611.2 yl}phenyl)carbamoyl]amino}benzoate 4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1 -yl]-6-morpholin 652 4-yl-1,3,5-triazin-2- 597.7 yl}phenyl)carbamoyl]amino}benzoic acid N-[3-(dimethylamino)propyl]-4-{[(4-{4-[4 653 (ethylsulfonyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5- 681.2 341.1 triazin-2-yl}phenyl)carbamoyl]amino}benzamide N-[2-(dimethylamino)ethyl]-4-{[(4-{4-[4 654 (ethylsulfonyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5- 667.3 334.2 triazin-2-yl}phenyl)carbamoyl]amino}benzamide 4-{[(4-{4-[4-(1-methylethyl)-1,4-diazepan-1-yl]-6 655 morpholin-4-yl-1,3,5-triazin-2- 561.5 yl}phenyl)carbamoyl]amino}benzoic acid methyl 4-{[(4-{4-[4-(acetylamino)piperidin-1-yl]-6 656 morpholin-4-yl-1,3,5-triazin-2- 575.4 yl}phenyl)carbamoyl]amino}benzoate 1-(4-{4-[4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6 657 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-{4-[(4- 643.6 methylpiperazin-1 -yl)carbonyl]phenyl}urea N-[1 -(4-morpholin-4-yl-6-{4-[(pyridin-4 658 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2- 518.5 yl)piperidin-4-yl]acetamide 4-{[(4-{4-[4-(acetylamino)piperidin-1 -yl]-6-morpholin 659 4-yl-1,3,5-triazin-2- 561.5 yl}phenyl)carbamoyl]amino}benzoic acid N-[2-(dimethylamino)ethyl]-4-{[(4-{4-[4-(1 660 methylethyl)-1,4-diazepan-1 -yl]-6-morpholin-4-yl- 631.5 1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzamide N-{1 -[(4-{[(4-{4-[4-(1 -methylethyl)-1,4-diazepan-1 -yl] 661 6-morpholin-4-yl-1,3,5-triazin-2- 685.6 yl}phenyl)carbamoyl]amino}phenyl)carbonyl]piperidin -4-yl}acetamide 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-(4-{4- 657.4 329.2 662 [4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6-morpholin-4- 219.8 yl-1,3,5-triazin-2-yl}phenyl)urea 1-(4-{4-[4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6- 671.4 336.2 663 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-(4-{[4-(1- 224.5 methylethyl)piperazin-1 -yl]carbonyl}phenyl)urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 664 triazin-2-yl}phenyl)-3-(4-{[(3S)-3-methylmorpholin-4- 617.5 yl]carbonyl}phenyl)urea 190 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-{4-[(4-butylpiperazin-1-yl)carbonyl]phenyl}-3-(4-{4 665 [4-(1-methylethyl)-1,4-diazepan-1-yl]-6-morpholin-4- 685.6 yl-1,3,5-triazin-2-yl}phenyl)urea N-[4-({[4-(4,6-di-8-oxa-3-azabicyclo[3.2. 1 ]oct-3-yl 666 1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)phenyl]-2 (4-methylpiperazin-1 -yl)acetamide 1-(4-{4-[(2R,5S)-2,5-bis(hydroxymethyl)pyrrolidin-1 667 yl]-6-(8-oxa-3- azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin- 533.3 2-yl}phenyl)-3-pyridin-4-ylurea 1-(4-{4-[(2R,5S)-2,5-bis(hydroxymethyl)pyrrolidin-1 668 yl]-6-(8-oxa-3- azabicyclo[3.2.1]oct-3-yl)-1,3,5-triazin- 630.4 2-yl}phenyl)-3-[4-(4-methylpiperazin-1 -yl)phenyl]urea 1 -{4-[4-morpholin-4-yl-6-(3-oxa-8 669 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}-3- 489.3 pyridin-4-ylurea 4-[({4-[4-morpholin-4-yl-6-(3-oxa-8 670 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2- 531.2 yl]phenyl}carbamoyl)amino]benzamide 1 -{4-[4-morpholin-4-yl-6-(3-oxa-8 671 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}-3- 489.5 pyridin-3-ylurea 1-(4-fluorophenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 672 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2- 506.5 yl]phenyl}urea 1-[4-(hydroxymethyl)phenyl]-3-{4-[4-morpholin-4-yl 673 6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 518.5 yl]phenyl}urea 1-[4-(2-hydroxyethyl)phenyl]-3-{4-[4-morpholin-4-yl 674 6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 532.5 yl]phenyl}urea 2-(diethylamino)ethyl 4-[({4-[4-morpholin-4-yl-6-(3 675 oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 631.6 yl]phenyl}carbamoyl)amino]benzoate 1 -(4-methylphenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa 676 8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 502.5 yl]phenyl}urea 1-(4-cyanophenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 677 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 513.5 yl]phenyl}urea 1-[4-(4-methylpiperazin-1 -yl)phenyl]-3-{4-[4 678 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 586.6 1,3,5-triazin-2-yl]phenyl}urea 1 -isopropyl-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 679 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2- 454.5 yl]phenyl}urea 1-(2-hydroxyethyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 680 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2- 456.5 yl]phenyl}urea 191 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 681 4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct- 369.2 8-yl)-1,3,5-triazin-2-yl]aniline 682 {3-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct- 384.4 8-yl)-1,3,5-triazin-2-yl]phenyl}methanol 683 3-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct- 370.4 8-yl)- 1,3,5-triazin-2-yl]phenol 684 5-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct- 409.4 8-yl)-1,3,5-triazin-2-yl]-1 H-benzimidazol-2-amine 1 -{4-[4-(3-hydroxy-8-azabicyclo[3.2.1 ]oct-8-yl)-6 685 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3- 502.5 phenylurea 686 1-(4-{4-[(4-methylpiperazin-1 -yl)amino]-6-morpholin- 490.5 4-yl-1,3,5-triazin-2-yl}phenyl)-3-phenylurea 687 1-(4-{4-[(1 -methylpiperidin-4-yl)oxy]-6-morpholin-4- 491.5 yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 688 1 -{4-[4-morpholin-4-yl-6-(piperidin-4-yloxy)- 1,3,5- 477.5 triazin-2-yl]phenyl}-3-pyridin-4-ylurea ethyl 4-[(4-morpholin-4-yl-6-{4-[(pyridin-4 689 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2- 549.5 yl)oxy]piperidine-1 -carboxylate N-ethyl-4-[(4-morpholin-4-yl-6-{4-[(pyridin-4 690 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2- 548.5 yl)oxy]piperidine-1 -carboxamide tert-butyl 4-[(4-morpholin-4-yl-6-{4-[(pyridin-4 691 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2- 577.3 yl)oxy]piperidine-1 -carboxylate 4-[(4-morpholin-4-yl-6-{4-[(pyridin-4 692 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2- 556.5 yl)oxy]piperidine-1 -sulfonamide methyl 4-[({4-[4-morpholin-4-yl-6-(3-oxa-8 693 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2- 546.3 yl]phenyl}carbamoyl)amino]benzoate N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-yl-6 694 (3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 602.4 yl]phenyl}carbamoyl)amino]benzamide N,N-dimethyl-4-[({4-[4-morpholin-4-yl-6-(3-oxa-8 695 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2- 559.2 yl]phenyl}carbamoyl)amino]benzamide N-methyl-4-[({4-[4-morpholin-4-yl-6-(3-oxa-8 696 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2- 545.2 yl]phenyl}carbamoyl)amino]benzamide 192 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-3-{4 697 [4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8- 614.3 yl)-1,3,5-triazin-2-yl]phenyl}urea N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4 698 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 616.4 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide N-(2-hydroxyethyl)-4-[({4-[4-morpholin-4-yl-6-(3-oxa 699 8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 575.4 yl]phenyl}carbamoyl)amino]benzamide N-[3-(dimethylamino)propyl]-4-[({4-[4-morpholin-4-yl 700 6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 616.4 yl]phenyl}carbamoyl)amino]benzamide N-methyl-N-[2-(methylamino)ethyl]-4-[({4-[4 701 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 602.4 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide N-(2-morpholin-4-ylethyl)-4-[({4-[4-morpholin-4-yl-6 702 (3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 644.4 yl]phenyl}carbamoyl)amino]benzamide 1 -{4-[(3,5-dimethylpiperazin-1 -yl)carbonyl]phenyl}-3 703 {4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct- 628.4 8-yl)-1,3,5-triazin-2-yl]phenyl}urea 704 4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin- 399.3 4-yl-1,3,5-triazin-2-yl]aniline 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6 705 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4- 519.7 ylurea 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6 706 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3- 519.2 ylurea 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6 707 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3- 518.2 phenylurea 1-[4-(dimethylamino)phenyl]-3-{4-[4-(1,4-dioxa-8 708 azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin- 561.3 2-yl]phenyl}urea 1-(4-cyanophenyl)-3-{4-[4-(1,4-dioxa-8 709 azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin- 543.2 2-yl]phenyl}urea 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6 710 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(2- 533.7 methyl pyrid in-4-yl)urea 1-[2-(dimethylamino)ethyl]-3-{4-[4-(1,4-dioxa-8 711 azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin- 513.7 2-yl]phenyl}urea 193 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 712 1-[4-(4-morpholin-4-yl-6-quinolin-3-yl-1,3,5-triazin-2- 505.7 yl)phenyl]-3-pyridin-4-ylurea 1 -(diethylcarbamoyl)-4-[({4-[4-morpholin-4-yl-6-(3 713 oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 588.3 yl]phenyl}carbamoyl)amino]pyridinium 714 1 -{4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5- 452.6 triazin-2-yl]phenyl}-3-pyridin-4-ylurea 715 methyl 4-[({4-[4-(2-methoxyethoxy)-6-morpholin-4-yl- 509.4 1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoate 716 4-(4,6-di-3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl-1,3,5- 395.3 triazin-2-yl)aniline 717 1-[4-(4,6-di-3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl-1,3,5- 515.8 triazin-2-yl)phenyl]-3-pyridin-4-ylurea 718 1-(4-{4-morpholin-4-yl-6-[2-(pyridin-4-ylamino)ethyl]- 498.6 1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 1-(4-acetylphenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa-8 719 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 530.4 yl]phenyl}urea N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6 720 morpholin-4-yl-1,3,5-triazin-2- 535.5 yl)phenyl]carbamoyl}amino)-N-methylbenzamide N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6 721 morpholin-4-yl-1,3,5-triazin-2- 521.5 yl)phenyl]carbamoyl}amino)benzamide 4-({[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2 722 yl)phenyl]carbamoyl}amino)-N-methyl-N-[2- 521.5 (methylamino)ethyl]benzamide 1-[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2 723 yl)phenyl]-3-{4-[(4-methylpiperazin-1 - 533.5 yl)carbonyl]phenyl}urea 1 -{4-[(3,3-dimethylpiperazin-1 -yl)carbonyl]phenyl}-3 724 [4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2- 547.5 yl)phenyl]urea 4-({[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2 725 yl)phenyl]carbamoyl}amino)-N-(2-piperidin-1- 561.5 ylethyl)benzamide 1-(4-ethenylphenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa 726 8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 514.3 yl]phenyl}urea 1 -{4-[(4-methylpiperazin-1 -yl)methyl]phenyl}-3-{4-[4 727 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 601.1 1,3,5-triazin-2-yl]phenyl}urea 194 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-(4-{4-[2,5-bis(hydroxymethyl)pyrrolidin-1 -yl]-6 728 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4- 508 ylurea 1 -{4-[2-(dimethylamino)ethoxy]phenyl}-3-{4-[4 729 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 575.5 1,3,5-triazin-2-yl]phenyl}urea 730 1-(4-{4-[2-(1,3-dioxan-2-yl)ethyl]-6-morpholin-4-yl- 492.9 1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 731 1-(4-{4-[3-(dimethylamino)propyl]-6-morpholin-4-yl- 463.4 1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea 732 1-[4-(4-{3-[(1 -methylethyl)amino]propyl}-6-morpholin- 4774 4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea 733 1 -{4-[4-morpholin-4-yl-6-(3-pyrrolidin-1 -ylpropyl)- 489.4 1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea 1-(4-{4-[3-(4-methylpiperazin-1 -yl)propyl]-6 734 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4- 518.4 ylurea 1 -{4-[4-(3-{[2-(dimethylamino)ethyl]amino}propyl)-6 735 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4- 506.5 ylurea 736 1 -{4-[4-(3-hydroxypropyl)-6-morpholin-4-yl-1,3,5- 436.3 triazin-2-yl]phenyl}-3-pyridin-4-ylurea 737 1-{4-[4-morpholin-4-yl-6-(3-oxopropyl)-1,3,5-triazin-2- 434.3 yl]phenyl}-3-pyridin-4-ylurea 738 4-[4-(6,8-dioxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6- 371.3 morpholin-4-yl-1,3,5-triazin-2-yl]aniline tert-butyl 7-[4-(4-aminophenyl)-6-morpholin-4-yl 739 1,3,5-triazin-2-yl]-9-oxa-3,7- 484.4 diazabicyclo[3.3. 1 ]nonane-3-carboxylate 1 -{4-[4-(6,8-dioxa-3-azabicyclo[3.2. 1 ]oct-3-yl)-6 740 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4- 491.3 ylurea tert-butyl 7-(4-morpholin-4-yl-6-{4-[(pyridin-4 741 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2-yl)-9-oxa- 604.4 3,7-diazabicyclo[3.3. 1 ]nonane-3-carboxylate 1 -{4-[4-morpholin-4-yl-6-(9-oxa-3,7 742 diazabicyclo[3.3. 1 ]non-3-yl)-1,3,5-triazin-2- 504.4 yl]phenyl}-3-pyridin-4-ylurea 1 -{4-[4-(7-methyl-9-oxa-3,7-diazabicyclo[3.3. 1 ]non-3 743 yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3- 518.4 pyridin-4-ylurea 195 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1 -{4-[4-(7-acetyl-9-oxa-3,7-diazabicyclo[3.3. 1 ]non-3 744 yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3- 546.4 pyridin-4-ylurea 1-(4-{4-[7-(methylsulfonyl)-9-oxa-3,7 745 diazabicyclo[3.3. 1 ]non-3-yl]-6-morpholin-4-yl-1,3,5- 582.5 triazin-2-yl}phenyl)-3-pyridin-4-ylurea 1-(2-chloropyridin-4-yl)-3-{4-[4-morpholin-4-yl-6-(3 746 oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 523.3 yl]phenyl}urea 1-(2,3'-bipyridin-4-yl)-3-{4-[4-morpholin-4-yl-6-(3-oxa 747 8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 566.4 yl]phenyl}urea 748 tert-butyl N-[4-morpholin-4-yl-6-(4-nitrophenyl)-1,3,5- 417.2 triazin-2-yl]glycinate 1-(6-chloropyridin-3-yl)-3-{4-[4-morpholin-4-yl-6-(3 749 oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 523.3 yl]phenyl}urea 750 N-[4-morpholin-4-yl-6-(4-nitrophenyl)-1,3,5-triazin-2- 361.3 yl]glycine 1,3-bis{4-[4-morpholin-4-yl-6-(3-oxa-8 751 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2- 763.5 yl]phenyl}urea 1-(4-{[4-(dimethylamino)piperidin-1 752 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa- 642.4 8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2 yl]phenyl}urea N-[2-(4-methylpiperazin-1 -yl)ethyl]-4-[({4-[4 753 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 657.4 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide 1 -{4-[(4-isopropylpiperazin-1 -yl)carbonyl]phenyl}-3 754 {4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct- 642.4 8-yl)-1,3,5-triazin-2-yl]phenyl}urea 1 -{4-[(4-cyclopentylpiperazin-1 -yl)carbonyl]phenyl}-3 755 {4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct- 668.4 8-yl)-1,3,5-triazin-2-yl]phenyl}urea 1 -{4-[4-morpholin-4-yl-6-(3-oxa-8 756 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}-3- 600.4 [4-(piperazin-1 -ylcarbonyl)phenyl]urea 1 -{4-[4-morpholin-4-yl-6-(3-oxa-8 757 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}-3- 684.4 {4-[(4-morpholin-4-ylpiperidin-1 yl)carbonyl]phenyl}urea 4-[({4-[4-morpholin-4-yl-6-(3-oxa-8 758 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2- 628.4 yI]phenyl}carbamoyl)amino]-N-(2-pyrrolidin-1 ylethyl)benzamide 196 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 4-[({4-[4-morpholin-4-yl-6-(3-oxa-8 759 azabicyclo[3.2.1]oct-8-yl)-1,3,5-triazin-2- 642.4 yI]phenyl}carbamoyl)amino]-N-(2-piperidin-1 ylethyl)benzamide 1-[4-(1,4'-bipiperidin-1'-ylcarbonyl)phenyl]-3-{4-[4 760 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 682.5 1,3,5-triazin-2-yl]phenyl}urea 1 -{4-[4-morpholin-4-yl-6-(3-oxa-8 761 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}-3- 668.5 {4-[(4-pyrrolidin-1 -ylpiperidin-1 yl)carbonyl]phenyl}urea 1 -{4-[4-morpholin-4-yl-6-(3-oxa-8 762 azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2-yl]phenyl}-3- 617.3 [4-(thiomorpholin-4-ylcarbonyl)phenyl]urea 1-[4-(morpholin-4-ylcarbonyl)phenyl]-3-{4-[4 763 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 601.4 1,3,5-triazin-2-yl]phenyl}urea 4-[({4-[4-morpholin-4-yl-6-(3-oxa-8 764 azabicyclo[3.2.1 ]oct-8-yl)-1,3,5-triazin-2- 532.3 yl]phenyl}carbamoyl)amino]benzoic acid 1 -{4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 765 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4- 505.3 ylurea 1-[6-(4-methylpiperazin-1 -yl)pyridin-3-yl]-3-{4-[4 766 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 587.4 1,3,5-triazin-2-yl]phenyl}urea 1-(4-{[4-(dimethylamino)piperidin-1 767 yl]carbonyl}phenyl)-3-{4-[4-(3,7-dioxa-9- 658.4 azabicyclo[3.3. 1 ]non-9-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yllphenyl}urea N-[2-(dimethylamino)ethyl]-4-[({4-[4-(3,7-dioxa-9 768 azabicyclo[3.3. 1 ]non-9-yl)-6-morpholin-4-yl-1,3,5- 632.4 triazin-2-yl]phenyl}carbamoyl)amino]-N methylbenzamide 1 -{4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 769 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-{4-[(4- 630.4 methylpiperazin-1 -yl)carbonyl]phenyl}urea methyl 4-[({4-[4-(3,7-dioxa-9-azabicyclo[3.3.1]non-9 770 yl)-6-morpholin-4-yl-1,3,5-triazin-2- 562.3 yl]phenyl}carbamoyl)amino]benzoate 4-[({4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 771 morpholin-4-yl-1,3,5-triazin-2- 548.3 yl]phenyl}carbamoyl)amino]benzoic acid 1 -{4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 772 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-[4- 616.3 (piperazin-1 -ylcarbonyl)phenyl]urea 1 -{4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 773 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-{4-[(4- 658.3 isopropylpiperazin-1 -yl)carbonyl]phenyl}urea 197 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 4-[({4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 774 morpholin-4-yl-1,3,5-triazin-2- 644.3 yI]phenyl}carbamoyl)amino]-N-(2-pyrrolidin-1 ylethyl)benzamide 4-[({4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 775 morpholin-4-yl-1,3,5-triazin-2- 658.4 yI]phenyl}carbamoyl)amino]-N-(2-piperidin-1 ylethyl)benzamide 1 -{4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 776 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-{4-[(4- 684.4 pyrrolidin-1 -ylpiperidin-1 -yl)carbonyl]phenyl}urea 1-[4-(1,4'-bipiperidin-1'-ylcarbonyl)phenyl]-3-{4-[4 777 (3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6-morpholin- 698.4 4-yl-1,3,5-triazin-2-yl]phenyl}urea 4-[({4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 778 morpholin-4-yl-1,3,5-triazin-2- 652.4 yl]phenyl}carbamoyl)amino]-N-(2-pyridin-2 ylethyl)benzamide 4-[({4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 779 morpholin-4-yl-1,3,5-triazin-2- 652.4 yl]phenyllcarbamoyl)amino]-N-(2-pyridin-4 ylethyl)benzamide 780 N-[4-(4-aminophenyl)-6-morpholin-4-yl-1,3,5-triazin- 413.2 2-yl]benzenesulfonamide N-(4-morpholin-4-yl-6-{4-[(pyridin-4 781 ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2- 533.4 yl)benzenesulfonamide N-{4-[4-({[4-(4-methylpiperazin-1 782 yl)phenyl]carbamoyl}amino)phenyl]-6-morpholin-4-yl- 630.3 1,3,5-triazin-2-yl}benzenesulfonamide N-(4-{4-[({4-[2 783 (dimethylamino)ethoxy]phenyl}carbamoyl)amino]phe 619.3 nyl}-6-morpholin-4-yl-1,3,5-triazin-2 yl)benzenesulfonamide N-(4-{4-[({4-[(4-methylpiperazin-1 784 yl)carbonyl]phenyl}carbamoyl)amino]phenyl}-6- 658.3 morpholin-4-yl-1,3,5-triazin-2-yl)benzenesulfonamide N-{4-morpholin-4-yl-6-[4-({[4-(piperazin- 1 785 ylcarbonyl)phenyl]carbamoyl}amino)phenyl]-1,3,5- 644.4 triazin-2-yl}benzenesulfonamide N-[4-(4-{[(4-{[4-(dimethylamino)piperidin-1 786 yl]carbonyl}phenyl)carbamoyl]amino}phenyl)-6- 686.4 morpholin-4-yl-1,3,5-triazin-2-yl]benzenesulfonamide N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4 787 morpholin-4-yl-6-[(phenylsulfonyl)amino]-1,3,5- 660.4 triazin-2-yl}phenyl)carbamoyl]amino}benzamide N-[2-(dimethylamino)ethyl]-4-{[(4-{4-morpholin-4-yl 788 6-[(phenylsulfonyl)amino]-1,3,5-triazin-2- 646.4 yl}phenyl)carbamoyl]amino}benzamide 198 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz methyl 4-{[(4-{4-morpholin-4-yl-6 789 [(phenylsulfonyl)amino]-1 ,3,5-triazin-2- 590.3 yllphenyl)carbamoyl]aminolbenzoate 4-{[(4-{4-morpholin-4-yl-6-[(phenylsulfonyl)amino] 790 1 ,3,5-triazin-2-yllphenyl)carbamoyl]aminolbenzoic 576.2 acid 1 -{4-[4-morpholin-4-yl-6-(3-oxa-9 791 azabicyclo[3.3. 1 ]non-9-yl)-1 ,3,5-triazin-2-yl]phenyl}- 503.2 3-pyridin-4-ylurea 1 -{4-[(4-methylpiperazin- 1 -yl)carbonyl]phenyl}-3-{4 792 [4-morpholin-4-yl-6-(3-oxa-9-azabicyclo[3.3. 1 ]non-9- 628.5 yl)-l ,3,5-triazin-2-yl]phenyllurea 1 -{4-[4-morpholin-4-yl-6-(3-oxa-9 793 azabicyclo[3.3. 1 ]non-9-yl)-1 ,3,5-triazin-2-yl]phenyl}- 614.5 3-[4-(piperazin-1 -ylcarbonyl)phenyl]urea 1 -(4-{[4-(dimethylamino)piperidin-1 794 yl]carbonyllphenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa- 656.5 9-azabicyclo[3.3. 1 ]non-9-yl)-1 ,3,5-triazin-2 yllphenyllurea N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4 795 morpholin-4-yl-6-(3-oxa-9-azabicyclo[3.3. 1 ]non-9-yl)- 630.4 1 ,3,5-triazin-2 yllphenyllcarbamoyl)aminolbenzamide N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-yl-6 796 (3-oxa-9-azabicyclo[3.3. 1 ]non-9-yl)-1 ,3,5-triazin-2- 616.4 yl]phenyllcarbamoyl)amino]benzamide N-(2-methoxyethyl)-4-[({4-[4-morpholin-4-y1-6-(3-oxa 797 9-azabicyclo[3.3. 1 ]non-9-yl)-1 ,3,5-triazin-2- 603.4 yl]phenyllcarbamoyl)amino]benzamide 4-[({4-[4-morpholin-4-yl-6-(3-oxa-9 798 azabicyclo[3.3. 1 ]non-9-yl)-1 ,3,5-triazin-2- 642.4 yl]phenyllcarbamoyl)amino]-N-(2-pyrrolidin-1 ylethyl)benzamide 4-[({4-[4-morpholin-4-yl-6-(3-oxa-9 799 azabicyclo[3.3. 1 ]non-9-yl)-1 ,3,5-triazin-2- 656.4 yI]phenyllcarbamoyl)amino]-N-(2-piperidin-1 ylethyl)benzamide 1 -{4-[4-morpholin-4-yl-6-(3-oxa-9 800 azabicyclo[3.3. 1 ]non-9-yl)-1 ,3,5-triazin-2-yl]phenyl}- 682.5 3-{4-[(4-pyrrolidin-1 -ylpiperidin-1 yl)carbonyll phenyllurea N-[2-( 1 -methylpyrrolidin-2-yl)ethyl]-4-[({4-[4 801 morpholin-4-yl-6-(3-oxa-9-azabicyclo[3.3. 1 ]non-9-yl)- 656.6 1 ,3,5-triazin-2 yllphenyllcarbamoyl)aminolbenzamide N-m ethyl- N-[2- (m ethyl am ino)ethyl]-4-[({4-[4 802 morpholin-4-yl-6-(3-oxa-9-azabicyclo[3.3. 1 ]non-9-yl)- 616.5 1 ,3,5-triazin-2 ____________ yllphenyllcarbamoyl)aminolbenzamide______ 199 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-{4-[4 803 morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2. 1 ]oct-8-yl)- 628.3 1,3,5-triazin-2-yl]phenyl}urea 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-{4-[4 804 morpholin-4-yl-6-(3-oxa-9-azabicyclo[3.3. 1 ]non-9-yl)- 642.5 1,3,5-triazin-2-yl]phenyl}urea 1-(4-{[4-(1 -methylethyl)piperazin-1 805 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa- 656.3 9-azabicyclo[3.3. 1 ]non-9-yl)-1,3,5-triazin-2 yl]phenyl}urea 1 -{4-[4-(3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl)-6 806 morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-{4-[(4- 644.5 ethylpiperazin-1 -yl)carbonyl]phenyl}urea 1 -{4-[4-morpholin-4-yl-6-(2-oxa-5 807 azabicyclo[2.2.2]oct-5-yl)-1,3,5-triazin-2-yl]phenyl}-3- 489.2 pyridin-4-ylurea 1-(1,3-dimethyl-1 H-pyrazol-5-yl)-3-{4-[4-morpholin-4 808 yl-6-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-1,3,5-triazin- 506.2 2-yl]phenyl}urea 1 -{4-[4-morpholin-4-yl-6-(2-oxa-5 809 azabicyclo[2.2.2]oct-5-yl)-1,3,5-triazin-2-yl]phenyl}-3- 478.2 (1 H-pyrazol-3-yl)urea 1-(4-{[4-(dimethylamino)piperidin-1 810 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(2-oxa- 642.2 5-azabicyclo[2.2.2]oct-5-yl)-1,3,5-triazin-2 yl]phenyl}urea 1-(4-{[4-(1 -methylethyl)piperazin-1 811 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(2-oxa- 642.5 5-azabicyclo[2.2.2]oct-5-yl)-1,3,5-triazin-2 yllphenyl}urea 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-{4-[4 812 morpholin-4-yl-6-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)- 628.2 1,3,5-triazin-2-yl]phenyl}urea 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-{4 813 [4-morpholin-4-yl-6-(2-oxa-5-azabicyclo[2.2.2]oct-5- 614.2 yl)-1,3,5-triazin-2-yl]phenyl}urea 1 -{4-[4-morpholin-4-yl-6-(2-oxa-5 814 azabicyclo[2.2.2]oct-5-yl)-1,3,5-triazin-2-yl]phenyl}-3- 600.3 [4-(piperazin-1 -ylcarbonyl)phenyl]urea N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-yl-6 815 (2-oxa-5-azabicyclo[2.2.2]oct-5-yl)-1,3,5-triazin-2- 602.5 yl]phenyl}carbamoyl)amino]benzamide N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4 816 morpholin-4-yl-6-(2-oxa-5-azabicyclo[2.2.2]oct-5-yl)- 616.3 1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide 817 2-tert-butoxy-4-morpholin-4-yl-6-(4-nitrophenyl)- 360.1 1,3,5-triazine 200 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-(4-{4-[(6S)-6-hydroxy-3-oxa-8-azabicyclo[3.2.1 ]oct 818 8-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3- 505.2 pyridin-4-ylurea 1-(4-{4-[6-(benzyloxy)-3-oxa-8-azabicyclo[3.2. 1 ]oct 819 8-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3- 595.2 pyridin-4-ylurea 1-(4-{4-[(6R)-6-hydroxy-3-oxa-8-azabicyclo[3.2. 1 ]oct 820 8-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3- 505.2 pyridin-4-ylurea 1-(4-{4-[(6R)-6-(benzyloxy)-3-oxa-8 821 azabicyclo[3.2. 1 ]oct-8-yl]-6-morpholin-4-yl-1,3,5- 595.2 triazin-2-yl}phenyl)-3-pyridin-4-ylurea 1 -{4-[(1,1 -dioxidothiomorpholin-4 822 yl)carbonyl]phenyl}-3-{4-[4-morpholin-4-yl-6-(3-oxa- 649.1 8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2 yl]phenyl}urea 1-[4-(4,6-di-3,7-dioxa-9-azabicyclo[3.3. 1 ]non-9-yl 823 1,3,5-triazin-2-yl)phenyl]-3-[4-(4-methylpiperazin-1 - 644.3306 yl)phenyl]urea 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 824 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa- 628.5, 8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 314.8, 356.8 yl]phenyl}urea 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin- 1 825 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(3-oxa- 628.5, 8-azabicyclo[3.2. 1 ]oct-8-yl)-1,3,5-triazin-2- 314.8, 356.8 yl]phenyl}urea 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-[4- 519.1, 826 (6-morpholin-4-yl-4-oxo-4,5-dihydro-1,3,5-triazin-2- 280.5, 260 yl)phenyl]urea 1 -{4-[(4-butylpiperazin-1 -yl)carbonyl]phenyl}-3-(4-{4 827 [4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6-morpholin-4 yl-1,3,5-triazin-2-yl}phenyl)urea 1-(4-{4-[4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6- 671.4;336.2 828 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-(4-{[4-(1- 2245; methylethyl)piperazin-1 -yl]carbonyl}phenyl)urea -4 ' 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-(4-{4- 657.4;329.2; 829 [4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6-morpholin-4- 219.8; yl-1,3,5-triazin-2-yl}phenyl)urea 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-{4- 587.6;314.8; 830 [4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5- 294.3; triazin-2-yl]phenyl}urea 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin- 1 831 yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 832 yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea 201 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1-(4-{[4-(1 -methylethyl)piperazin-1 833 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6- 615.5;308.3; (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2- 328.8; yl]phenyl}urea N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4 834 morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5- 589.5;295.3; triazin-2-yl]phenyl}carbamoyl)amino]benzamide 835 1 -{4-[4-(azetidin-3-yloxy)-6-morpholin-4-yl-1,3,5- 449.1;225.1 triazin-2-yl]phenyl}-3-pyridin-4-ylurea N-(1 -methylethyl)-3-[(4-morpholin-4-yl-6-{4-[(pyridin 836 4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2- 534.4;267.7; yl)oxy]azetidine-1 -carboxamide N-{1 -[(4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl] 837 1 ,3,S-triazin-2-68539; yl}phenyl)carbamoyl]amino phenyl)carbonyl]piperidin 658.5;329.8; -4-yl}acetamide 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 838 triazin-2-yl}phenyl)-3-(4-{[4-(1 -methylethyl)-1,4- 658.8;329.8; diazepan-1 -yl]carbonyl}phenyl)urea 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 839 triazin-2-yl}phenyl)-3-[4-(3-oxa-8- 629.7;315.3; azabicyclo[3.2.1 ]oct-8-ylcarbonyl)phenyl]urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 840 triazin-2-yl}phenyl)-3-{4-[(4-cyanopiperidin-1 yl)carbonyl]phenyl}urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 841 triazin-2-yl}phenyl)-3-(4-{[(3S)-3 (dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)urea 1-(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1, 3,5 842 triazin-2-yl}phenyl)-3-(4-{[(3R)-3 (dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)urea 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 843 yl]carbonyl}phenyl)-3-(4-{4-(morpholin-4-yl)-6-[4- 657.6;329.3; (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2- 233.6; yl}phenyl)urea 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin- 1 844 yl]carbonyl}phenyl)-3-(4-{4-(morpholin-4-yl)-6-[4- 657.5;329.3 (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2- ' yl}phenyl)urea 845 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl} 3-{4-[(2-methylpiperazin-1 -yl)carbonyl]phenyl}urea 1-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4 846 diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)-3-[4 (piperazin-1 -ylcarbonyl)phenyl]urea 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin- 1 847 yl]carbonyl}phenyl)-3-(4-{4-(morpholin-4-yl)-6-[4 (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2 yl}phenyl)urea 202 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}- 616.3;638.3; 848 3-{4-[(3,3,4-trimethylpiperazin- 1- 654.3; yl)carbonyl]phenyl}urea 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl} 849 3-(4-{[(3R)-3-methylpiperazin-1 yl]carbonyl}phenyl)urea 1-(4-{[(3R)-3,4-dimethylpiperazin-1 850 yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl)-1,3,5 triazin-2-yl]phenyl}urea 1-(4-{[(3R)-4-cyclobutyl-3-methylpiperazin- 1 851 yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl)-1,3,5 triazin-2-yl]phenyl}urea 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl} 852 3-(4-{[(3R)-3-methyl-4-(propan-2-yl)piperazin- 1 yl]carbonyl}phenyl)urea 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl} 853 3-(4-{[(3S)-3-methylpiperazin-1 yl]carbonyl}phenyl)urea N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4-[(3S) 854 3-methylmorpholin-4-yl]-6-[4-(propan-2-yl)-1, 4 diazepan-1 -yl]-1,3,5-triazin-2 yl}phenyl)carbamoyllamino}benzamide 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-[4-(propan-2 855 yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)-3-{4 [(4-methylpiperazin-1 -yl)carbonyl]phenyl}urea 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 856 yl]carbonyl}phenyl)-3-(4-{4-[(3S)-3-methylmorpholin 4-yl]-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5 triazin-2-yl}phenyl)urea N-[3-(dimethylamino)propyl]-4-{[(4-{4-(morpholin-4 857 yl)-6-[4-(propan-2-yl)-1,4-diazepan- 1-yl]-1,3,5-triazin 2-yl}phenyl)carbamoyl]amino}benzamide N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4 858 (morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 yl]-1,3,5-triazin-2 yl}phenyl)carbamoyllamino}benzamide 1-[4-(morpholin-4-ylcarbonyl)phenyl]-3-(4-{4 859 (morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 yl]-1,3,5-triazin-2-yl}phenyl)urea N-(2-methoxyethyl)-4-{[(4-{4-(morpholin-4-yl)-6-[4 860 (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzamide 1-[4-(1,4-diazepan-1 -ylcarbonyl)phenyl]-3-(4-{4 861 (morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 - 643.4; yl]-1,3,5-triazin-2-yl}phenyl)urea 1-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4 862 diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)-3-(4-{[4 (propan-2-yl)-1,4-diazepan-1-yl]carbonyl}phenyl)urea 203 WO 2009/143313 PCT/US2009/044774 Example Name MS (ESI) mlz 1 -(4-{[(3S)-4-cyclobutyl-3-methylpiperazin- 1 863 yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl)-1,3,5 triazin-2-yl]phenyl}urea 1-(4-{[(3S)-3,4-dimethylpiperazin-1 864 yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl)-1,3,5 triazin-2-yl]phenyl}urea 1 -{4-[4-(morpholin-4-yl)-6-(tetrahydro-2H-pyran-4-yl) 865 1,3,5-triazin-2-yl]phenyl}-3-{4-[(3,3,4 trimethylpiperazin-1 -yl)carbonyl]phenyl}urea 1-(4-{[(3S)-3,4-dimethylpiperazin-1 866 yl]carbonyl}phenyl)-3-{4-[4-(morpholin-4-yl)-6 (tetrahydro-2H-pyran-4-yl)- 1,3,5-triazin-2 yllphenyl}urea 1-(4-{[(3S)-3-methylpiperazin-1 -yl]carbonyl}phenyl) 867 3-{4-[4-(morpholin-4-yl)-6-(tetrahydro-2H-pyran-4-yl) 1,3,5-triazin-2-yl]phenyl}urea 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin- 1 868 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2 yl]phenyl}urea 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 869 yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2 yl]phenyl}urea BIOLOGICAL EVALUATION mTOR kinase assay methods Human mTOR assays (See Toral-Barza, et al. Biochem Biophys. Res. Commun. 2005 5 June 24;332(1):304-10) with purified enzyme are performed in 96-well plates by DELFIA format as follows. Enzymes are first diluted in kinase assay buffer (10 mM HEPES (pH 7.4), 50 mM NaCI, 50 mM p-glycerophosphate, 10 mM MnCl 2 , 0.5 mM DTT, 0.25 mM microcystin LR, and 100 mg/mL BSA). To each well, 12 pL of the diluted enzyme is mixed briefly with 0.5 pL test inhibitor or control vehicle dimethylsulfoxide (DMSO). The kinase reaction is initiated by adding 10 12.5 pL kinase assay buffer containing ATP and His6-S6K to give a final reaction volume of 25 pL containing 800 ng/mL FLAG-TOR, 100 mM ATP and 1.25 mM His6-S6K. The reaction plate is incubated for 2 hours (linear at 1-6 hours) at room temperature with gentle shaking and then terminated by adding 25 pL Stop buffer (20 mM HEPES (pH 7.4), 20 mM EDTA, 20 mM EGTA). The DELFIA detection of the phosphorylated (Thr-389) His6-S6K is performed at room 15 temperature using a monoclonal anti-P(T389)-p70S6K antibody (1A5, Cell Signaling) labeled with Europium-N1-ITC (Eu) (10.4 Eu per antibody, PerkinElmer). The DELFIA Assay buffer and Enhancement solution can be purchased from PerkinElmer. 45 pL of the terminated kinase reaction mixture is transferred to a MaxiSorp plate (Nunc) containing 55 pL PBS. The His6-S6K 204 WO 2009/143313 PCT/US2009/044774 is allowed to attach for 2 hours after which the wells are aspirated and washed once with PBS. 100 pL of DELFIA Assay buffer with 40 ng/mL Eu-P(T389)-S6K antibody is added. The antibody binding is continued for 1 hour with gentle agitation. The wells are then aspirated and washed 4 times with PBS containing 0.05% Tween-20 (PBST). 100 pL of DELFIA Enhancement solution 5 is added to each well and the plates are read in a PerkinElmer Victor model plate reader. Data obtained is used to calculate enzymatic activity and enzyme inhibition by potential inhibitors. PI3K-alpha and P13K-gamma Fluorescence Polarization Assay Protocols The reaction buffer was 20 mM HEPES, pH 7.5, 2 mM MgCl 2 , 0.05% CHAPS; and 0.01% PME (added fresh). The Stop/Detection Buffer was 100 mM HEPES, pH 7.5, 4 mM 10 EDTA, 0.05% CHAPS; ATP 20 mM in water; PIP2 (diC8, Echelon, Salt Lake City Utah cat # P 4508) 1 mM in water (MW=856.5). The GST-GRP was 1.75 mg/mL or 1.4 mg/mL in 10% glycerol. The Red detector (TAMRA) was 2.5 pM. Nunc 384-well black polypropylene fluorescent plates were used for P13K assays. The assay is run by placing 5 pL of diluted enzyme per well, then 5 pL of diluted 15 compound (or 9.5 pL enzyme then 0.5 pL compound in DMSO) is added and mixed. Then, 10 pL substrate is added to start the reaction. The samples are incubated 30-60 minutes, then the reaction is stopped by adding 20 pL stop/detector mix. P13K is diluted with reaction buffer (e.g., 5 pL or 7.5 pL P13K into 620 pL reaction buffer), and 5 pL of diluted enzyme is used per well. A 5 pL portion of reaction buffer or of drug diluted in buffer (e.g., 4 pL/100 so final DMSO is 1% in 20 reaction) is added to each. Pipetting up and down mixes the samples. Alternatively, the enzyme can be diluted to 1215 pL. In this case 9.8 pL is added per well and 0.2 pL compound is added in DMSO. To prepare 1 mL of substrate solution, 955 pL reaction buffer, 40 pL PIP2, and 2.5 pL ATP are mixed. 10 pL of substrate is added to each well to start the reaction. This results in 20 25 pM PIP2, and 25 pM ATP per reaction. The stop/detector mix is prepared by mixing 4 pL Red detector and 1.6 pL or 2.0 pL GST-GRP with 1 mL stop buffer, which results in 10 nM probe and 70 nM GST-GRP. 20 pL of the stop/detector mix is added to each well to stop the reaction. The plates are read after 30-90 minutes keeping the red probe solutions dark. For the zero time point, stop/detector mix is added to the enzyme just before adding substrate. For an extra 30 control, stop/detector mix is added to buffer (no enzyme) and substrate or to just buffer (no substrate). Pooled P13K preparations had a protein concentration of 0.25 mg/mL. The recommended reaction has 0.06 pL per 20 pL (0.015 pg/20 pL) or 0.01125 pg/15 pL or 0.75 pg/mL. Plates are read on machines with filters for TAMRA. The units are mP with no enzyme 35 controls reading app 190-220 mP units. Fully active enzyme reduces fluorescence polarization down to 70-100 mP after 30 minutes. An active compound raises the mP values halfway to control or to 120-150 mP units. 205 WO 2009/143313 PCT/US2009/044774 In vitro cell culture growth assay methods Cell Lines used are human breast MDA-MB-361, human prostate PC3-mm2, and human prostate LNCap tumor cell lines. Cells are plated in 96-well culture plates at approximately 3000 cells per well. One day following plating, various concentrations of P13K inhibitors in DMSO are 5 added to cells (final DMSO concentration in cell assays is 0.25%). Three days after drug treatment, viable cell densities are determined by cell mediated metabolic conversion of the dye MTS, a well-established indicator of cell proliferation in vitro. Cell growth assays are performed using kits purchased from Promega Corporation (Madison, WI), following the protocol provided by the vendor. Measuring absorbance at 490 nm generates MTS assay results. Compound 10 effect on cell proliferation is assessed relative to untreated control cell growth. The drug concentration that conferred 50% inhibition of growth is determined as IC 50 (pM). hSMG-1 kinase assay The human SMG-1 (hSMG-1) kinase assay employs the recombinant hSMG-1 protein prepared from transiently transfected HEK293 cells and a GST-p53 (aa 1-70) fusion substrate 15 protein derived from cellular tumor suppressor gene p53. The routine assay is performed in a 96-well plate format as follows. Enzymes were first diluted in kinase assay buffer (10 mM HEPES, pH 7.4, 50 mM NaCI, 0.2 mM DTT, 50 mM p-glycerophosphate, 0.5 PM microcystin LR, 10 mM MnCl 2 ). To each well, 12 pL of the diluted enzyme were mixed briefly with 0.5 PL test inhibitor or control vehicle dimethylsulfoxide (DMSO). The kinase reaction was initiated by 20 adding 12.5 pL kinase assay buffer containing ATP and GST-p53 to give a final reaction volume of 25 pL containing 400-800 ng/mL FLAG-hSMG-1, 0.5 pg GST-p53, 10 pM ATP. The reaction was carried out at room temperature for 1.0 hour before terminated by addition of 25 Pl stop solution. The assay mixture was then transferred to FluoroNunc Plates with MaxiSorp Surface (Nunc #439454). The plates were incubated at room temperature for 2 hr (4 0 C for overnight) to 25 achieve efficient binding of substrate protein to the plate. The plates were aspirated, washed with PBS. Phospho-substrate proteins were detected by incubating for 1 hour with 125 ng of europium-labeled anti-mouse secondary antibody (PerkinElmer AD2027) and the primary phospho(S15)-p53 monoclonal antibody (Cell Signal #9286) in 100 PL DELFIA assay buffer (PerkinElmer #1244-111). Plates were then washed and incubated for 0.5 hour with 100 Pl of 30 DELFIA enhancement solution (PerkinElmer #1244-105). DELFIA assay results are recorded in a Victor Plate Reader (PerkinElmer). Data obtained were used to calculate enzymatic activity and enzyme inhibition by potential inhibitors. Table 2 shows the results of the described P13K-a, PI3K-y, and mTOR kinase assays. 206 WO 2009/143313 PCT/US2009/044774 Table 2 Example IC50 PI3Ka nM IC50 PI3Ky nM IC50 mTOR M 1 3 29 0.0013 2 2 35 0.001 3 3 27 0.00385 4 2 23 0.0017 5 17 438 0.0063 6 6 53 0.006 7 >10000 >100000 >4,0000 8 20 220 0.008 9 10 65 0.004 10 75 289 0.068 11 61 528 0.00925 12 248 815 0.011 13 51 879 0.0115 14 25 154 0.00845 15 23 177 0.0025 16 >10,000 >100000 0.01205 17 8 90 0.01395 18 9 71 0.036 19 23 206 0.039 20 41 258 0.0305 21 22 92 0.00175 22 12 142 0.00475 23 18 51 0.00205 24 22 99 0.0027 25 58 105 0.00405 26 680 10,000 0.0025 27 1230 >10,000 0.00415 28 54 5550 0.00095 29 2690 >10,000 0.0028 30 2120 >10,000 0.00265 31 142 3520 0.00049 32 45 2540 0.00029 33 NA NA 0.091 34 9 95 0.00049 35 6 54 0.00021 36 17 150 0.00051 37 39 155 0.00195 38 7 91 0.00028 39 14 75 0.00032 40 21 136 0.00066 41 69 122 0.0013 42 86 290 0.00335 43 28 35 0.00165 44 NA NA 0.0135 207 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 45 NA NA 0.0036 46 208 4920 0.024 47 13 52 0.0016 48 6 40 0.0018 49 3 21 0.01 50 1 21 0.002 51 1 15 0.0019 52 2 38 0.001 53 45 403 0.024 54 10 88 0.00475 55 205 1580 0.05 56 122 444 0.015 57 8 74 0.0165 58 13 85 0.0025 59 3 30 0.00105 60 5 36 0.0018 61 9 32 0.00076 62 2 24 0.00068 63 5 36 0.00195 64 1457 1190 1.5 65 15 83 0.00505 66 7 30 0.00165 67 6 48 0.00145 68 0.3 7 0.00057 69 0.4 8 0.00085 70 2 20 0.0007 71 0.4 8 0.00067 72 2 19 0.00085 73 0.3 7 0.00077 74 0.4 8 0.00063 75 0.6 10 0.00075 76 0.4 8 0.00067 77 0.3 4 0.00068 78 3 23 0.00085 79 773 193 0.0051 80 851 2120 0.00715 81 2 38 0.001 82 3 21 0.0089 83 1 15 0.0019 84 10 88 0.00475 85 45 403 0.018 86 122 444 0.01 87 205 1580 0.05 88 8 74 0.0165 89 10 31 0.0016 90 8 42 0.00083 208 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 91 6 73 0.00071 92 11 92 0.00235 93 12 133 0.00855 94 5 56 0.001 95 48 101 0.00275 96 NA NA 0.0012 97 NA NA 0.0011 98 1350 9000 2.1 99 1520 7500 0.46 100 5 38 0.0035 101 6 33 0.00044 102 6 84 0.0061 103 3 73 0.0053 104 19 234 0.015 105 14 112 0.0305 106 393 1840 0.00755 107 115 1490 0.019 108 586 4150 0.019 109 1460 2960 0.0735 110 884 3510 0.029 111 116 1830 0.0023 112 488 777 0.012 113 NA NA 0.0037 114 106 1180 0.00315 115 109 2000 0.0032 116 1740 2310 0.0027 117 177 3000 0.083 118 379 297 0.195 119 1240 7530 0.14 120 262 1550 0.079 121 1850 4000 0.0435 122 1160 9500 0.0745 123 760 6350 0.115 124 1650 9650 0.155 125 840 8750 0.016 126 510 5510 0.0195 127 1390 4730 0.0515 128 1330 10,000 0.031 129 7217 10,000 2.35 130 14 132 0.008 131 25 336 0.0145 132 14 234 0.026 133 39 8890 0.043 134 20 183 0.0245 135 15 143 0.034 136 208 4920 0.024 209 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 137 9 117 0.00855 138 123.5 459 0.0435 139 24 43 0.074 140 27 100 0.027 141 241 3380 0.026 142 3 50 0.0011 143 2 22 0.0012 144 NA NA NA 145 574 1000 0.009 146 >10000 >100000 0.003 147 1930 6830 0.006 148 300 620 0.008 149 889 1400 0.08 150 832 >10,000 0.005 151 0.6 8117 0.007 152 2 5 0.002 153 868 10,000 0.015 154 275 3820 0.064 155 2300 4940 0.016 156 746 10,000 0.053 157 1451 7090 0.17 158 300 1290 0.007 159 133 3920 0.002 160 358 9070 0.007 161 39 155 0.03 162 10 495 0.023 163 2 9 0.0039 164 378 1380 4 165 9 101 0.028 166 4 33 0.06 167 0.8 7 0.00068 168 1 3 0.0036 169 408 7960 0.0083 170 384 9500 0.004 171 300 9500 0.0012 172 435 10,000 0.008 173 1210 10,000 0.084 174 861 727 0.0021 175 549 453 0.0048 176 1120 3730 0.022 177 5840 4120 0.0016 178 >10,000 >10,000 0.014 179 1 13 0.001 180 531 8000 0.0016 210 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 181 426 6730 0.011 182 308 5000 0.003 183 526 11000 0.014 184 30 143 0.004 185 1 18 0.0029 186 28 221 0.006 187 3 24 0.0035 188 7540 2380 0.011 189 19 203 0.028 190 780 1320 0.0063 191 435 4630 0.016 192 1120 453 0.043 193 401 3133 0.0008 194 NA NA 0.027 195 115 498 0.021 196 6 55 0.013 197 2 36 0.024 198 2 33 0.002 199 44 144 0.001 200 14 128 0.0065 201 28 606 0.0009 202 NA NA 0.0055 203 NA NA 0.001 204 NA NA 0.0035 205 NA NA 0.002 206 NA NA 0.056 207 NA NA 0.00084 208 Na NA 0.0005 209 24 99 0.009 210 6 31 NA 211 80 108 0.006 212 902 8770 0.0064 213 5280 10,000 0.0095 214 2670 10,000 0.0029 215 187 3160 0.0012 216 521 7030 0.003 217 253 3230 0.0032 218 279 2780 0.0026 219 561 8280 0.0059 220 275 2830 0.0035 221 214 4280 0.0027 222 152 572 0.0005 223 2 200 NA 211 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 224 444 5870 0.0004 225 109 388 0.047 226 75 294 0.062 227 23 81 0.0073 228 46 280 0.051 229 19 70 0.00077 230 22 119 0.0012 231 4 63 0.0025 232 6 37 0.083 233 55 121 0.0079 234 4534 9534 NA 235 3206 4110 NA 236 3 15 0.011 237 2 23 0.003 238 1 10 0.0036 239 11 38 0.0032 240 1 6 0.0016 241 6 23 0.009 242 2 24 0.007 243 1 9 0.0077 244 1 9 0.0051 245 1 13 0.01 246 1 12 0.015 247 2 5 0.019 248 2 18 0.0064 249 25 216 0.002 250 21 190 0.0009 251 2 21 0.006 252 22 184 0.018 253 8 267 0.009 254 63 253 0.017 255 48 85 0.016 256 68 182 0.032 257 90 323 0.085 258 403 6170 0.0023 259 408 5410 0.0024 260 417 4730 0.0009 261 158 2530 0.00031 262 105 954 0.00029 263 3 20 0.001 264 947 5440 NA 265 1079 10,000 0.0015 266 16 93 0.0017 212 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 267 17 58 0.0035 268 12 41 0.00039 269 6 140 0.08 270 68 318 0.16 271 2 23 0.013 272 5 54 0.03 273 4 33 0.0008 274 34 616 0.059 275 46 711 0.07 276 34 597 0.06 277 30 276 0.06 278 26 344 0.25 279 10 70 0.035 280 5 29 0.004 281 2188 4981 2.8 282 10 32 0.0047 283 1 11 0.0031 284 0.7 12 0.0009 285 1127 3433 0.001 286 4195 10,000 120 287 253 3304 0.00016 288 226 2784 0.00097 289 955 3880 0.0015 290 97 166 0.15 291 368 711 0.19 292 1501 3693 0.07 293 764 533 0.5 294 9 26 0.018 295 19 81 0.029 296 13 35 0.021 297 38 70 0.01 298 2 24 0.021 299 3 34 0.08 300 39 106 0.0053 301 21 58 0.0008 302 35 263 0.036 303 NA NA 0.017 304 2 18 0.0025 305 1 18 0.0006 306 1 19 0.0021 307 3 30 0.0028 308 3 14 0.0029 309 12 95 0.0035 213 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 310 14 82 0.0059 311 40 125 0.012 312 3440 10,000 0.037 313 1730 7490 0.037 314 1820 10,000 0.08 315 1100 7900 0.005 316 1410 2690 0.071 317 216 6830 0.084 318 15.5 679 0.855 319 80 1446 0.0044 320 3.3 25 0.0129 321 25 116 0.0165 322 2.4 30 0.006 323 2.9 32 0.007 324 1 22 0.0052 325 74 6244 0.0046 326 830 6189 0.0122 327 394 5899 0.0063 328 261 14,000 0.0046 329 9.5 385 0.00068 330 42 827 0.0033 331 NA NA 0.0035 332 NA NA 0.011 333 NA NA 0.0058 334 16 680 0.0009 335 81 144 0.004 336 40 44 0.0036 337 7 98 0.07 338 3 77 0.022 339 71 485 0.09 340 92 706 0.046 341 10 48 0.012 342 20 127 0.0066 343 97 6700 0.04 344 1610 4140 1.5 345 43 112 0.08 346 43 89 0.023 347 796 8440 NA 348 1030 10,000 NA 349 59 163 NA 350 1 7 NA 351 3 16 0.0042 352 13.5 732 0.00024 214 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 353 8.5 501 0.00022 354 69 6224 0.0046 355 830 6189 0.012 356 394 5899 0.0063 357 261 14000 0.0046 358 9 363 0.00068 359 42 827 0.0034 360 6672 >10000 0.082 361 6028 >10000 0.0013 362 3090 >10000 0.00074 363 1097 7142 0.00077 364 1465 8038 0.0035 365 6340 >10000 0.0012 366 585 2996 0.0011 367 499 4076 0.001 368 109 1936 0.00068 369 362 2560 0.0013 370 483 3502 0.00085 371 389 2256 0.00084 372 961 7245 0.00025 373 70 2962 0.00016 374 64 3915 0.00014 375 44 2589 0.00015 376 2602 >10000 0.0023 377 2614 4718 0.0039 378 2506 5375 0.0054 379 4749 5255 0.0073 380 3344 3559 0.0051 381 2955 5395 0.0059 382 522 4306 0.0045 383 2978 3609 0.0061 384 4220 5381 0.0064 385 3397 4692 0.0057 386 5122 4476 0.0042 387 3416 2858 0.0032 388 3450 4285 0.0048 389 4766 5663 0.0065 390 2467 2354 0.012 391 2398 4000 0.0096 392 1178 2781 0.0055 393 444 1539 0.0036 394 592 3226 0.0088 395 584 2221 0.014 215 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 396 586 2432 0.01 397 173 2073 0.00016 398 644 3909 0.00021 399 330 1691 0.0011 400 846 4099 0.0017 401 413 3247 0.002 402 543 3643 0.0018 403 314 2383 0.00075 404 63 433 0.00069 405 50 193 0.00064 406 478 1881 0.00038 407 766 2255 0.00052 408 876 3342 0.00072 409 856 4487 0.0015 410 826 5684 0.0023 411 1896 >10000 0.0036 412 1230 7483 0.0073 413 1518 >10000 0.0092 414 969 5453 0.0069 415 787 3263 0.00038 416 446 2505 0.00055 417 656 4299 0.0011 418 520 3476 0.0015 419 610 4272 0.0017 420 593 4363 0.00063 421 414 1571 0.00072 422 269 1221 0.00079 423 610 1854 0.0011 424 576 1871 0.0014 425 309 2383 0.0012 426 1224 8477 0.053 427 580 1419 0.0013 428 450 840 0.0014 429 483 1005 0.0019 430 402 484 0.0017 431 43 340 0.001 432 90 480 0.00069 433 220 1510 0.0023 434 571 4740 0.00056 435 643 4603 0.00075 436 749 3119 0.00062 437 381 1612 0.00056 438 77 663 0.00081 216 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 439 182 1283 0.00042 440 1006 >10000 0.0012 441 970 >10000 0.0012 442 1756 >10000 0.0015 443 427 1883 0.00089 444 60 1099 0.00057 445 100 1002 0.00041 446 835 4013 0.00082 447 390 2802 0.0019 448 519 >10000 0.0023 449 287 1640 0.0019 450 76 888 0.0017 451 85 702 0.0014 452 41 502 0.00055 453 659 4273 0.0033 454 278 1490 0.0002 455 113 1390 0.0003 456 150 1547 0.0007 457 63 839 0.0002 458 33 512 0.0002 459 26 483 0.0003 460 143 1083 0.0004 461 482 4415 0.0011 462 < 0.001 463 0.017 464 0.001 465 0.001 466 0.001 467 < 0.001 468 < 0.001 469 0.023 470 0.007 471 0.000 472 0.035 473 0.035 474 0.048 475 18.500 476 0.005 477 14.000 478 1.1 6.0 0.00089 479 <2.1 14.0 0.0017 480 13.0 53.0 0.0029 481 11.0 65.0 0.0023 217 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 482 0.6 10.0 0.00305 483 28.5 150.0 0.00155 484 1.0 8.0 0.00063 485 1.4 10.0 0.00125 486 1.1 7.0 0.0045 487 32.3 27.0 0.0018 488 42.0 180.0 0.0034 489 3671.7 9045.0 0.0022 490 586.0 1077.0 0.0116 491 3.5 17.0 0.0011 492 6.5 35.0 0.018 493 2924.0 1078.0 0.0325 494 16.5 104.0 0.0042 495 <1.00 6.0 0.00195 496 NA NA NA 497 3.0 19.0 0.0046 498 <1.70 2.5 0.00235 499 <1.90 4.5 0.0022 500 0.4 10.0 0.00109 501 <1.75 6.5 0.00069 502 0.5 6.0 0.001 503 0.5 1.8 504 1.8 10.0 0.00135 505 0.6 5.0 NA 506 0.3 7.0 NA 507 1.6 8.7 0.0032 508 <1.9 12.5 0.00097 509 11.5 662.5 0.00045 510 1.1 6.3 0.00089 511 2.3 10.3 0.00052 512 <1.9 10.0 0.00012 513 <2.4 12.0 0.00012 514 1.6 15.0 0.00017 515 0.4 7.6 0.00155 516 2.1 17.0 NA 517 3.4 18.5 0.00106 518 0.9 6.5 0.0011 519 <1.1 4.8 0.00071 520 1.4 8.0 0.00038 521 1.4 6.0 0.0003 522 1.4 7.5 0.00106 523 3.2 9.5 0.00043 524 0.8 10.0 0.00026 218 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 525 NA NA NA 526 96.5 6701.5 0.0475 527 20.5 127.0 0.0093 528 1612.0 4140.0 1.6 529 10.5 48.5 0.0155 530 92.0 705.5 0.0495 531 71.5 484.5 0.08 532 3.0 76.5 0.019 533 7.0 98.5 0.0705 534 2.1 11.1 0.0534 535 43.5 112.0 0.0815 536 1.5 13.0 0.0094 537 43.5 89.0 0.000022 538 333.0 197.0 0.000125 539 1.1 16.0 0.0000085 540 54.0 121.0 0.0000034 541 28.000 57.000 0.017 542 8.000 67.000 0.0215 543 3.500 15.500 0.042 544 3.500 20.500 0.017 545 4.000 17.000 0.0109 546 3.500 73.500 0.000225 547 11.000 70.000 0.00775 548 40.000 387.000 0.00975 549 724.000 4541 0.0265 550 47.000 374.000 0.0124 551 24.000 117.500 0.01 552 11.500 127.000 0.00355 553 12.500 72.000 0.0195 554 15.000 156.500 0.0119 555 87.500 378.500 0.405 556 8.500 54.000 0.0044 557 18.000 64.000 0.00855 558 17.000 41.000 0.0061 559 2.000 13.500 0.01005 560 269.000 504.500 0.1 561 11.5 59.0 0.006 562 1.0 10.5 0.004 563 2.5 33.5 0.003 564 0.6 16.5 0.001 565 4.1 38.0 0.001 566 2.6 18.0 0.002 567 14.5 90.0 0.002 219 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 568 3.5 18.0 0.010 569 74.5 375.0 0.008 570 5.5 48.0 0.013 571 21.0 108.0 0.000 572 0.9 15.0 0.000 573 6.5 64.0 0.004 574 1.0 12.5 0.006 575 3.0 19.0 0.015 576 761.0 2081.0 0.140 577 63.0 104.0 0.030 578 2406.0 2511.0 2.100 579 462.0 658.0 0.120 580 465.0 1315.0 0.100 581 113.5 461.0 0.037 582 513.0 1094.0 0.230 583 123.0 718.0 0.048 584 585 65.0 131.0 0.012 586 947.0 1246.0 0.365 587 350.0 675.0 0.100 588 524.5 2249.0 0.054 589 718.0 1615.0 0.057 590 343.0 403.5 0.049 591 250.0 726.0 0.033 592 25.5 122.0 0.009 593 40.0 143.0 0.012 594 349.5 744.0 0.022 595 6.5 58.5 0.010 596 5.0 40.5 0.013 597 5.0 58.0 0.011 598 5.5 40.0 0.010 599 64.5 190.0 0.013 600 45.5 161.5 0.008 601 3.5 57.5 0.003 602 7.0 46.5 0.011 603 8.5 50.5 0.017 604 3.5 55.5 0.010 605 2.2 46.0 0.003 606 12.0 87.0 0.026 607 12.0 94.0 0.019 608 9.0 107.0 0.005 609 11.5 93.5 0.003 610 3.5 50.5 0.005 220 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 611 18.5 151.5 0.013 612 5.5 67.0 0.061 613 3.8 53.5 0.001 614 2.7 32.5 0.001 615 26.5 115.5 0.001 616 4.0 58.5 0.001 617 2.5 27.0 0.001 618 2.0 18.5 0.001 619 33.0 137.0 0.001 620 4.0 32.5 0.003 621 3.5 43.5 0.001 622 3.0 50.5 0.000 623 12.5 104.0 0.001 624 17.5 58.5 0.001 625 16.5 102.5 0.003 626 59.0 207.5 0.001 627 18.5 101.5 0.002 628 629 26.0 95.0 0.004 630 13.5 84.5 0.001 631 28.0 133.0 0.004 632 15.0 74.5 0.001 633 11.5 175.0 0.001 634 6.0 121.5 0.000 635 22.0 377.5 0.000 636 231.0 468.5 0.027 637 21.5 190.5 0.004 638 16.0 113.5 0.002 639 14.5 123.0 0.001 640 345.0 795.0 2.800 641 88.5 275.5 0.007 642 69.0 254.5 0.001 643 6.2 42.5 0.007 644 7.8 59.5 0.001 645 105.0 230.5 0.120 646 23.0 85.5 0.006 647 24.3 107.0 0.003 648 2.0 27.0 0.003 649 6.4 38.0 0.006 650 23.5 103.5 0.022 651 71.0 247.5 0.014 652 36.0 84.5 0.004 653 4.1 34.0 0.007 221 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 654 6.0 70.0 0.008 655 91.5 745.5 0.625 656 73.0 651.0 0.019 657 11.5 127.5 0.385 658 41.5 265.0 0.020 659 3621.0 10000.0 0.720 660 7.5 168.5 0.305 661 56.5 461.5 0.580 662 34.3 197.0 0.770 663 47.3 296.0 0.590 664 NA NA NA 665 71.0 283.5 0.445 666 11.5 662.5 0.000 667 102 1081 0.000405 668 122 625.000 0.00056 669 8.0 89.0 0.00048 670 5.0 53.0 0.000212 671 17.5 150.5 0.000505 672 39.5 154.5 0.00195 673 7.0 98.7 0.00043 674 14.0 74.5 0.000325 675 21.0 135.5 0.00066 676 69.5 122.0 0.0013 677 86.5 290.0 0.00335 678 21.3 45.3 0.001168 679 1575.0 9500.0 0.0135 680 504.0 2083.0 0.0036 681 2547 >10,000 0.091 682 84.3 1282.5 0.0885 683 121.3 1329.0 0.025 684 154.3 2345.0 0.0235 685 7.0 26.5 0.000825 686 77.0 540.0 0.026 687 4.0 39.5 0.00485 688 3.0 35.5 0.008 689 217.4 2482 0.03902 690 5.0 83.5 0.000525 691 6.0 199.0 0.00135 692 3.2 29.0 0.00375 693 69.0 289.0 0.00135 694 2.0 40.0 0.000245 695 4.0 70.5 0.00028 696 4.5 73.5 0.000275 222 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 697 2.7 42.7 0.000459 698 2.7 44.7 0.000302 699 5.0 62.5 0.0003 700 2.5 41.5 0.00053 701 2.0 25.0 0.00036 702 6.5 125.5 0.000555 703 1.5 23.5 0.00051 704 7217 >10,000 2.35 705 13.5 132.0 0.0124 706 25.5 336.0 0.0145 707 14.0 234.5 0.034 708 39.5 8890.5 0.043 709 20.0 182.5 0.0245 710 15.5 143.5 0.034 711 207.5 4919.5 0.02 712 9.5 117.0 0.00855 713 36.0 444.0 0.0009 714 15.5 69.0 0.00645 715 59.5 146.5 0.006 716 NA NA NA 717 444.0 5874.0 0.000395 718 40.5 210.5 0.055 719 17.5 96.0 0.00015 720 0.4 7.0 0.0077 721 0.6 10.5 0.00565 722 0.8 9.5 0.0145 723 1.3 13.5 0.0225 724 1.5 4.0 0.0185 725 2.0 20.5 0.0082 726 25.0 216.5 0.0025 727 21.0 189.5 0.000805 728 10.5 47.0 0.00038 729 14.5 100.0 0.00185 730 15.5 64.5 0.0043 731 33.0 413.0 0.059 732 44.0 478.0 0.069 733 31.5 412.0 0.0755 734 25.5 210.0 0.0595 735 26.5 289.5 0.1225 736 9.5 53.5 0.0036 737 7.0 30.0 0.00445 738 NA NA NA 739 NA NA NA 223 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 740 11.5 34.5 0.00405 741 2188 4981 2.80 742 97.0 166.0 0.145 743 368.0 711.0 0.19 744 1501.0 3693.0 0.068 745 764.0 533.0 0.47 746 23.5 99.0 0.001265 747 40.0 44.0 0.00345 748 NA NA NA 749 59.0 163.5 0.002 750 NA NA NA 751 143.0 403.5 0.003 752 1.2 18.5 0.00029 753 2.0 31.0 0.000315 754 3.0 28.0 0.000327 755 2.0 26.5 0.00057 756 0.5 7.0 0.0002 757 5.5 37.5 0.00028 758 2.0 16.0 0.00017 759 2.0 38.0 0.00016 760 4.3 28.3 0.00021 761 2.0 19.0 0.00012 762 2.7 19.7 0.000428 763 3.0 24.0 0.000445 764 8.5 67.5 0.00021 765 8.5 78.5 0.000195 766 24.0 85.5 0.001315 767 2.1 17.0 0.0002 768 1.2 18.5 0.000115 769 2.1 17.5 0.00023 770 30.5 99.0 0.00027 771 19.5 66.0 0.000215 772 0.8 9.5 0.00029 773 3.0 36.5 0.000305 774 2.0 41.5 0.00023 775 2.5 46.5 0.00023 776 3.0 29.5 0.000345 777 4.0 39.0 0.000265 778 11.5 126.0 0.00028 779 4.2 49.7 0.00023 780 NA NA NA 781 136.0 374.5 0.0305 782 124.5 251.5 0.11 224 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 783 346.0 736.0 0.295 784 40.5 174.0 0.088 785 6.0 45.5 0.0555 786 30.5 129.0 0.089 787 10.5 145.5 0.0585 788 13.0 160.0 0.026 789 870.0 1163.0 0.059 790 244.0 593.0 0.065 791 12.5 64.5 0.00068 792 3.3 35.5 0.00081 793 1.0 15.0 0.00042 794 4.1 26.0 0.00063 795 2.7 26.5 0.000425 796 2.6 31.5 0.00039 797 11.5 76.0 0.0013 798 4.1 43.5 0.000445 799 5.0 71.5 0.0005 800 5.5 35.5 0.00072 801 5.0 38.0 0.000455 802 3.5 23.0 0.000675 803 3.0 29.0 0.00019 804 6.0 59.5 0.000425 805 6.5 64.0 0.000415 806 4.5 47.0 0.00024 807 Na NA NA 808 381.0 1261.0 0.26 809 395.0 2189.0 0.067 810 2.8 30.5 0.00205 811 3.2 33.5 0.0015 812 2.8 30.5 0.002 813 3.1 30.0 0.0019 814 0.8 10.0 0.00105 815 1.9 24.0 0.000765 816 2.4 26.0 0.001065 817 NA NA NA 818 37.7 185.0 0.002 819 44.0 357.5 0.017 820 6.1 67.0 0.000515 821 9.3 58.3 0.0034 822 3.0 31.5 0.000335 823 661.0 2788.0 0.0000015 824 2 17 NA 825 2 13 NA 225 WO 2009/143313 PCT/US2009/044774 Example IC50 P13Ka nM IC50 P13Ky nM IC50 mTOR M 826 15 96 1.200 827 71.000 283.500 445.000 828 47.333 296.000 590.000 829 34.333 197.000 770.000 830 2.125 10.800 0.393 831 0.950 7.500 0.635 832 1.350 10.500 1.250 833 2.575 8.250 0.430 834 0.750 10.000 0.255 835 4.150 18.500 8.550 836 5.000 17.500 4.050 837 11.900 75.000 1.450 838 4.950 24.500 0.965 839 6.650 29.000 2.500 840 5.150 15.000 1.700 841 6.500 107.500 0.990 842 3.550 54.500 0.325 843 28.500 291.000 1500.000 844 21.000 237.500 345.000 845 0.250 2.750 1.300 846 3.500 22.500 485.000 847 10.500 87.500 165.000 848 1.050 6.000 2.200 849 0.300 3.167 0.865 850 0.650 6.100 1.200 851 0.850 5.600 1.010 852 0.400 5.550 1.250 853 0.300 5.050 1.400 854 8.840 164.000 260.000 855 54.000 864.000 305.000 856 28.500 532.000 11.000 857 10.000 145.500 660.000 858 5.000 134.500 290.000 859 17.850 239.500 830.000 860 57.000 434.500 150.000 861 4.000 56.000 425.000 862 23.500 154.000 835.000 863 2.100 8.000 3.600 864 1.000 7.500 5.250 865 2.450 12.000 1.350 866 1.600 16.500 0.980 867 0.400 7.000 0.610 868 0.650 4.500 226 WO 2009/143313 PCT/US2009/044774 Example IC5 P13Ka nM IC50 P13Ky nM IC50 mTOR M 869 0.600 6.500 Table 3 shows the results of the described hSMG-1 kinase assay. Table 3 Example hSMG-1 IC5o (M) 462 0.001 463 0.510 464 0.003 465 0.005 466 0.000 467 0.000 468 <0.000 469 0.130 470 0.195 471 0.005 472 0.200 473 3.650 474 5.650 475 >20 476 0.019 477 9.250 5 Table 4 shows the results of the described MDA-MB-361, PC3-mm2, and LNCap assays. Table 4 IC50 MDA-MB- ICo PC3-mm2 ICo LNCap Example 361 nM) (nM) (nM) 1 45.0 43.0 2 45.0 43.0 3 45.0 43.0 4 45.0 43.0 5 45.0 43.0 6 45.0 43.0 7 ND ND 8 407.0 293.0 9 102.0 161.0 10 2709.0 1782.0 11 794.0 5630.5 12 ND ND 13 603.0 845.0 14 376.0 590.0 15 255.0 328.0 16 ND ND 17 501.0 994.0 18 2656.0 7102.0 227 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 19 1031.0 1596.0 20 >10000 >10000 21 129.0 246.0 22 1424.0 2445.0 23 104.0 147.0 24 122.0 142.0 25 264.0 258.0 26 ND ND 190.0 27 ND ND 350.0 28 ND ND 2.4 29 ND ND 180.0 30 ND ND 90.0 31 ND ND 45.0 32 ND ND 0.7 33 ND ND 34 28.0 41.0 35 22.5 27.5 36 73.0 98.0 37 98.0 176.0 38 15.0 28.0 39 22.0 30.0 40 < 30 62.0 41 167.0 301.0 42 345.0 3600.0 43 35.8 40.0 44 ND ND 45 ND ND 46 ND ND 47 116.0 95.0 48 38.0 48.0 49 84.0 79.0 50 36.0 39.0 51 <30 <30 52 < 30 49.0 53 662.0 987.0 54 133.0 214.0 55 ND ND 56 ND ND 57 119.0 187.0 58 115.0 45.0 59 14.0 16.0 60 83.0 92.0 61 48.0 23.0 1 62 27.0 34.0 228 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 63 69.0 62.0 64 ND ND 65 151.0 267.0 66 59.0 66.0 67 816.0 28.0 68 <3 11.0 69 10.0 13.0 70 19.0 24.0 71 < 9.8 18.3 72 1.0 13.0 73 30.0 107.0 74 < 3 8.3 75 < 3 7.0 76 4.0 13.1 77 <30 <30 78 68.0 31.0 79 ND 320.0 80 ND 320.0 81 ND ND 82 ND ND 83 ND ND 84 ND ND 85 ND ND 86 ND ND 87 ND ND 88 ND ND 89 30.0 47.0 90 19.0 19.0 91 25.0 1567.0 92 140.0 87.0 93 42.0 60.0 94 54.0 82.0 95 333.0 364.0 96 5.0 33.0 97 < 30 52.0 98 ND ND 99 ND ND 100 56.0 56.0 101 32.7 37.3 3.0 102 592.0 854.0 103 2917.0 4453.0 104 412.0 684.0 105 3710.0 > 10000 106 ND ND 370.0 229 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 107 ND ND 1000.0 108 ND ND 320.0 109 ND ND 1900.0 110 ND ND 220.0 111 ND ND 58.0 112 ND ND 300.0 113 ND ND 120.0 114 ND ND 38.0 115 ND ND 200.0 116 ND ND 70.0 117 ND ND 700.0 118 ND ND 3000.0 119 ND ND 2800.0 120 ND ND 1200.0 121 ND ND 1000.0 122 ND ND 900.0 123 ND ND 4100.0 124 ND ND 1950.0 125 ND ND 1000.0 126 ND ND 1300.0 127 ND ND 1350.0 128 ND ND 30000.0 129 ND ND 130 191.0 416.0 131 696.0 839.0 132 586.0 1012.0 133 795.0 1950.0 134 805.0 857.0 135 533.0 509.0 136 ND ND 137 582.0 551.0 138 ND ND 680.0 139 ND ND 180.0 140 225 279 141 ND ND 142 5 33 143 ND 52 144 ND ND 1500 145 ND ND 120 146 ND ND 5 147 ND ND 1000 148 ND ND 680 149 ND ND 32000 150 ND ND 290 230 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 151 ND 14 152 9 14 153 ND ND 4200 154 ND ND 22000 155 ND ND 400 156 ND ND 22000 157 ND ND 2700 158 ND ND 49 159 ND ND 1.2 160 ND ND 220 161 328 675 162 ND ND 163 10.7 28.3 164 ND ND 165 210 333 166 134 249 167 ND 10 168 ND ND 169 ND ND 5000 170 ND ND 4500 171 ND ND 5200 172 ND ND 9500 173 ND ND 2500 174 ND ND 4.25 175 ND ND 9.5 176 ND ND 1000 177 ND ND 600 178 ND ND 850 179 ND 8.333 180 ND ND 5800 181 ND ND 3400 182 ND ND 3500 183 ND ND 8500 184 1246 2094 185 5 13 186 473 703 187 11 41 188 ND ND 189 84 99 190 ND ND 950 191 ND ND 220 192 ND ND 620 193 ND ND 105 194 ND ND 600 231 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 195 ND ND 196 50 82 197 17 49 198 ND 43 199 96 93 200 162 248 201 29 44 202 ND ND 700 203 ND ND 78 204 ND ND 6000 205 ND ND 400 206 ND ND 5100 207 ND ND 33.333 208 ND ND 50 209 174 278 210 ND ND 211 254 389 212 ND ND 420 213 ND ND 420 214 ND ND 700 215 ND ND 30 216 0 ND 50 217 ND ND 13 218 ND ND 12 219 ND ND 40 220 ND ND 40 221 ND ND 120 222 ND ND 10 223 187 229 224 ND ND 225 ND ND 226 ND ND 227 1495 4026 228 3924 7174 229 35.75 40 230 ND ND 231 20 121 232 38 177 233 1214 3337 234 ND ND 10000 235 ND ND 7900 236 22.333 67 237 28 69 238 23 61 232 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 239 184 317 240 ND 12 241 24 135 242 11 49 243 15 34 244 ND 71 245 110 374 246 35 91 247 30 111 248 ND 69 249 92 142 250 14 31 251 ND 65 252 219 747 253 12 574 254 ND ND 255 174 328 256 ND ND 257 ND ND 258 ND ND 60 259 ND ND 580 260 ND ND 380 261 ND ND 30 262 ND ND 22 263 68 31 264 ND ND 265 ND ND 1.7 266 ND ND 267 94 200 268 59 107 38 269 ND 144 270 397 953 271 68 129 272 70 340 273 32 80 274 1000 1491 275 3100 4309 276 1347 1654 277 530 572 278 2297 3701 279 176 247 280 176 404 281 ND ND 282 83 84 233 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 283 12.333 33.333 284 12 36.333 285 ND ND 4 286 ND ND 32000 287 ND ND 288 ND ND 3 289 ND ND 3 290 ND ND 291 ND ND 292 ND ND 293 ND ND 294 69 154 295 133 189 296 83 133 297 115 290 298 38 165 299 73 219 300 297 340 301 430 759 302 299 539 303 ND ND 0.8 304 7 39.333 305 4 46 306 7 30 307 ND 362 308 4 53 309 64 109 310 44 117 311 126 366 312 ND ND 80 313 ND ND 100 314 ND ND 550 315 ND ND 300 316 ND ND 320 317 ND ND 120 318 ND ND 1000 319 ND ND 220 320 32.333 73.667 321 106 325 322 13 86 323 ND 77 324 4 35 325 ND ND 310 326 ND ND 580 234 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 327 ND ND 400 328 ND ND 1500 329 ND ND 5900 330 ND ND 260 331 0 0 0 332 0 0 0 333 0 0 0 334 0 0 0 335 0 0 0 336 56 45 0 337 142 373 338 122 266 339 ND ND 340 ND ND 341 150 237 342 1256 2429 343 ND ND 344 ND ND 345 554 395 346 ND ND 347 ND ND 9 348 ND ND 349 87 81 350 ND 8.5 351 50 66 352 ND ND < 0.8 353 ND ND < 0.8 354 ND ND 310 355 ND ND 580 356 ND ND 400 357 ND ND 1500 358 ND ND 5900 359 ND ND 260 360 ND ND 10000 361 ND ND 2.2 362 ND ND 1 363 ND ND 1.2 364 ND ND 70 365 ND ND 3 366 ND ND 2.8 367 ND ND 5 368 ND ND 0.7 369 ND ND 3 370 ND ND 0.8 235 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 371 ND ND 0.8 372 ND ND 0.8 373 ND ND 1 374 ND ND < 0.8 375 ND ND < 0.8 376 ND ND 50 377 ND ND 90 378 ND ND 50 379 ND ND 140 380 ND ND 300 381 ND ND 140 382 ND ND 48 383 ND ND 150 384 ND ND 50 385 ND ND 70 386 ND ND 140 387 ND ND 70 388 ND ND 110 389 ND ND 240 390 ND ND 650 391 ND ND 300 392 ND ND 480 393 ND ND 580 394 ND ND 800 395 ND ND 590 396 ND ND 280 397 ND ND 7 398 ND ND 12 399 ND ND 3 400 ND ND 12 401 ND ND 21 402 ND ND 7 403 ND ND 8 404 ND ND 60 405 ND ND 25 406 ND ND 2.4 407 ND ND 0.8 408 ND ND 9 409 ND ND 50 410 ND ND 110 411 ND ND 250 412 ND ND 25 413 ND ND 150 414 ND ND 120 236 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 415 ND ND 29 416 ND ND 12 417 ND ND 6 418 ND ND 40 419 ND ND 12 420 ND ND 2 421 ND ND 1 422 ND ND 2 423 ND ND 2.8 424 ND ND 1 425 ND ND 2.8 426 ND ND 700 427 ND ND 7 428 ND ND 1 429 ND ND 9 430 ND ND 16 431 ND ND < 0.8 432 ND ND < 0.8 433 ND ND 40 434 ND ND < 0.8 435 ND ND 4 436 ND ND 10 437 ND ND 1 438 ND ND < 0.8 439 ND ND 1 440 ND ND 1 441 ND ND 6 442 ND ND 13 443 ND ND 8 444 ND ND < 0.8 445 ND ND < 0.8 446 ND ND 15 447 ND ND 8 448 ND ND 18 449 ND ND 40 450 ND ND < 0.8 451 ND ND < 0.8 452 ND ND < 0.8 453 ND ND 30 454 ND ND < 0.8 455 ND ND < 0.8 456 ND ND < 0.8 457 ND ND < 0.8 458 ND ND 8 237 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 459 ND ND < 0.8 460 ND ND < 0.8 461 ND ND 68 462 ND ND ND 463 ND ND ND 464 ND ND ND 465 ND ND ND 466 ND ND 420 467 ND ND 170 468 ND ND 50 469 ND ND 2800 470 ND ND 1000 471 ND ND 130 472 ND ND 3800 473 ND ND ND 474 ND ND ND 475 ND ND ND 476 ND ND ND 477 ND ND ND 478 < 3.080 8.5 479 6 21 480 ND ND 481 ND ND 482 ND ND 483 ND ND 484 ND ND 485 ND ND 486 7.0 39.3 487 175.0 339.0 488 ND ND 489 ND ND 4300 490 ND ND 491 8.0 35.0 492 26.0 57.0 493 ND ND 494 115.0 276.0 495 4.0 13.1 496 ND ND 497 50.0 66.0 498 4.0 16.5 499 21.0 31.0 500 1.0 6.5 501 <31 41 502 4.0 11.0 238 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 503 7.5 12.5 504 22.5 25.5 505 12.3 33.3 506 <21.7 12 507 10.7 28.3 508 12.0 36.3 509 ND ND < 0.8 510 ND ND 511 2.0 10.0 512 1.0 8.0 513 2.0 13.0 514 < 3.2 12 515 3 12 516 ND ND 517 18.0 7.0 518 4.0 24.0 519 3.0 9.0 520 5.0 18.0 521 8.0 27.0 522 3.0 11.0 523 ND ND 524 ND ND 525 ND ND 526 ND ND 527 1256.0 2429.0 528 ND ND 529 150.0 237.0 530 ND ND 531 ND ND 532 122.0 266.0 533 142.0 373.0 534 32.3 73.7 535 554.0 395.0 536 22.3 67.0 537 <31 <31 538 ND ND 539 9.0 161.0 540 165.0 309.0 541 964.0 1764.0 542 281.0 569.0 543 < 31 262.0 544 58.0 253.0 545 30.0 219.0 546 7.0 25.0 239 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 547 68.0 197.0 548 524.0 869.0 549 ND ND 550 315.0 711.0 551 106.0 270.0 552 105.0 243.0 553 113.0 522.0 554 521.0 >1000 555 ND ND 556 128.0 379.0 557 34.0 31.0 558 751.0 939.0 559 8.0 149.0 560 ND ND 561 66.0 218.0 562 3.0 93.0 563 10.0 171.0 564 1.0 7.0 565 9.0 27.0 566 28.0 55.0 567 106.0 130.0 568 18.0 107.0 569 ND ND 570 28.0 344.0 571 90.0 168.0 572 13.0 56.0 573 99.0 206.0 574 6.0 25.0 575 15.0 242.0 576 ND ND 577 ND ND 578 ND ND 579 ND ND 580 ND ND 581 ND ND 582 ND ND 583 ND ND 584 ND ND 585 ND ND 586 ND ND 587 ND ND 588 ND ND 589 ND ND 590 ND ND 240 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 591 ND ND 592 239.0 718.0 593 >1000 >1000 594 ND ND 595 43.0 193.0 596 26.0 155.0 597 45.0 229.0 598 22.0 214.0 599 ND ND 600 ND ND 601 22.0 155.0 602 17.0 122.0 603 17.0 137.0 604 4.0 73.0 605 7.0 92.0 606 28.0 173.0 607 24.0 213.0 608 52.0 298.0 609 24.0 26.0 610 28.0 297.0 611 194.0 581.0 612 38.0 227.0 613 6.0 21.0 614 4.0 15.0 615 88.0 123.0 616 4.0 21.0 617 4.0 17.0 618 2.0 13.0 619 ND ND 620 4.0 16.0 621 8.0 35.0 622 5.0 25.0 623 6.0 32.0 624 4.0 19.0 625 12.0 43.0 626 ND ND 627 16.0 55.0 628 ND ND 629 28.0 133.0 630 5.0 23.0 631 28.0 120.0 632 9.0 38.0 633 15.0 64.0 634 5.0 16.0 241 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 635 26.0 106.0 636 ND ND 637 26.0 62.0 638 9.0 44.0 639 16.0 27.0 640 ND ND 641 ND ND 642 ND ND 643 19.0 59.0 644 51.0 185.0 645 ND ND 646 32.0 223.0 647 46.0 136.0 648 12.0 34.0 649 9.0 37.0 650 ND ND 651 ND ND 652 ND ND 653 ND ND 654 ND ND 655 ND ND 656 ND ND 657 ND ND 658 ND ND 659 ND ND 660 ND ND 661 ND ND 662 ND ND 663 ND ND 664 ND ND 665 ND ND 666 ND ND 667 ND ND 60.0 668 ND ND 0.8 669 28.0 41.0 670 22.5 27.5 671 73.0 98.0 672 98.0 176.0 673 15.0 28.0 674 22.0 30.0 675 <30 62.0 676 167.0 301.0 677 345.0 3600.0 678 35.8 40.0 242 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 679 ND ND 680 ND ND 681 ND ND 682 1044.0 766.0 683 673.0 584.0 684 806.0 1015.0 685 >10000 >10000 686 569.0 1105.0 687 355.0 389.0 688 1412.0 1950.0 689 53.0 85.0 690 112.0 405.0 691 52.0 131.0 692 97.0 326.0 693 ND ND 694 < 3 11.0 695 6.0 7.0 696 13.0 13.0 697 <30 <30 698 < 3 6.0 699 36.0 40.0 700 5.0 20.0 701 <30 <30 702 4.0 14.0 703 <3 13.0 704 ND ND 705 191.0 416.0 706 696.0 839.0 707 586.0 1012.0 708 795.0 1950.0 709 805.0 857.0 710 533.0 509.0 711 ND ND 712 582.0 551.0 713 29.0 44.0 714 162.0 248.0 715 254.0 389.0 716 ND ND 717 ND ND < 0.8 718 3924.0 7174.0 719 <31 <31 720 15.0 34.0 721 < 31 71.0 722 110.0 374.0 243 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 723 35.0 91.0 724 30.0 111.0 725 <31 69.0 726 92.0 142.0 727 14.0 31.0 728 59.0 107.0 38.000 729 <31 <31 730 94.0 200.0 731 1000.0 1491.0 732 3100.0 4309.0 733 1347.0 1654.0 734 530.0 572.0 735 2297.0 3701.0 736 176.0 247.0 737 176.0 404.0 738 ND ND 739 ND ND 740 83.0 84.0 741 ND ND 742 ND ND 743 ND ND 744 ND ND 745 ND ND 746 93.0 118.0 747 56.0 45.0 748 ND ND 749 87.0 81.0 750 ND ND 751 144.0 238.0 752 < 3 6.0 753 4.0 14.0 754 31.3 70.8 755 3.0 13.0 756 < 3 12.000 757 < 3 6.000 758 3.0 14.0 759 1.0 10.0 760 0.0 4.0 761 < 3 4.0 762 8.0 7.0 763 4.0 7.0 764 628.0 678.0 765 21.0 27.0 766 26.0 50.0 244 WO 2009/143313 PCT/US2009/044774 0IC, MDA-MB- IC50 PC3-mm2 IC50 LNCap Example 361 (nM) (nM) (nM) 767 5.0 13.0 768 7.0 8.0 769 6.0 14.0 770 40.0 25.0 771 >1000 >1000 772 5.0 15.0 773 4.0 6.0 774 14.0 19.0 775 5.0 7.0 776 < 3.2 6.0 777 2.0 4.0 778 17.0 29.0 779 13.0 23.0 780 ND ND 781 ND ND 782 ND ND 783 ND ND 784 >1000 >1000 785 >1000 >1000 786 >1000 >1000 787 >1000 >1000 788 >1000 >1000 789 ND ND 790 ND ND 791 11.0 42.0 792 2.0 16.0 793 2.0 26.0 794 2.0 20.0 795 < 3.2 10.0 796 2.0 18.0 797 11.0 29.0 798 3.0 24.0 799 < 3.2 24.0 800 1.0 11.0 801 3.0 32.0 802 3.0 50.0 803 1.0 6.0 804 3.0 11.0 805 3.0 13.0 806 < 3.2 9.0 807 35.000 37.000 808 ND ND 809 ND ND 810 2.0 26.0 245 WO 2009/143313 PCT/US2009/044774 Example ICo MDA-MB- IC50 PC3-mm2 IC50 LNCap _____36 1Y (nM) (nM) (nM) 811 2.0 19.0 812 3.0 23.0 813 < 3.2 24.0 814 4.0 37.0 815 3.0 24.0 816 2.0 11.0 817 ND ND 818 129.0 237.0 819 442.0 768.0 820 ND ND 821 ND ND 822 ND ND 823 ND ND 55.0 823 ND ND 825 ND ND 826 >1000 >1000 While particular aspects of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to 5 cover in the appended claims all such changes and modifications that are within the scope of this invention. Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date 10 of the invention described and claimed herein. 246

Claims (26)

1. A compound of the Formula 1: R1 N N R4 N4 R2 wherein: 5 R'is R7 0 R 8 R7 R8 R N R 9 R- R 9 or ; wherein: R 6 , R 7 , R , R 9 are each independently selected from the group consisting of a hydrogen atom, and a C 1 -C 6 alkyl optionally substituted with C
2 -C 6 alkenyl, C 4 -C 6 alkadienyl, C 2 -C 6 alkynyl or 10 C 4 -C 6 alkadiynyl; or one of R 6 and R 7 or R 8 and R 9 , together with the carbon atoms to which they are attached form an optionally substituted 5-8 membered saturated or unsaturated ring containing 0, 1 or 2 atoms independently selected from 0, NH and S; the dashed line ----- represents an optional second bond; 15 R 2 is optionally substituted C 6 -C 1 4 aryl-NH-COR 3 , optionally substituted C 1 -Coheteroaryl NH-COR 3 , -CH=CH-C 6 -C 1 0 aryl-NH-COR 3 or -CH=CH-C 1 -Coheteroaryl-NH-COR 3 ; R 3 is OR 5 , NR 5 R 5 or NHR 5 ; R 5 is independently selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C3 C 6 alkynyl, optionally substituted C 6 -C 1 0 aryl, C 1 -C 6 haloalkyl, optionally substituted Cj 20 Coheteroaryl, C 1 -C 6 hydroxylalkyl-, C 3 -Closaturated or unsaturated mono or bicyclic C3 Clacycloalkyl optionally substituted with OH, NR 11 R 1 1 or 3-7 membered C 1 -C 6 heterocyclyl, and
3-10 membered saturated or unsaturated mono or bicyclic C 1 -Coheterocyclyl, with the proviso that three-membered cycloalkyl and heterocyclyl rings are saturated; or two R 5 groups taken together with the nitrogen atom to which they are attached form a 25 3 to 8 membered ring system optionally substituted with C 1 -C 6 alkyl, which ring system is 247 WO 2009/143313 PCT/US2009/044774 saturated or unsaturated and has, in addition to said nitrogen atom, 0 to 2 heteroatom ring members selected from 0, S, S(O), S(O) 2 and NR 10 ; R 10 is selected from the group consisting of H, C 1 -C 6 alkyl, -SO 2 (C 1 -C 6 alkyl), -COO(Cl C 6 alkyl), -CONH(C 1 -C 6 alkyl), -CON(C 1 -C 6 alkyl) 2 , -CO(C 1 -C 6 alkyl), and -SO 2 NHR 11 ; 5 R" is selected from the group consisting of H, C 1 -C 6 alkyl optionally substituted with OH, NR 11 R 1 1 or a 3-7 membered C 1 -C 6 heterocyclyl, -CO(C 1 -C 6 alkyl), optionally substituted C6 Cloaryl, and optionally substituted C 1 -Coheteroaryl; R 4 is selected from the group consisting of: a) C 1 -C 6 alkyl'optionally substituted with: i) 3 10 membered C 1 -Coheterocyclyl optionally substituted with C 1 -C 6 alkyl-, ii) H 2 N-, iii) (Cl 10 C 6 alkyl)NH-, iv) (C 1 -C 6 alkyl) 2 N-, v) NH(CH 2 ) 2 N(C 1 -C 6 alkyl) 2 wherein a is 2, 3 or 4, and vi) CHO, b) C 3 -C 6 alkenyl, c) C 3 -C 6 alkynyl, d) -O-C 1 -C 8 alkyl optionally substituted with -O-C 1 -C 8 alkyl, e) O-C 3 -C 8 alkenyl, f) -O-C 3 -C 8 alkynyl, g) saturated or unsaturated mono or bicyclic C 3 -C 8 cycloalkyl, and h) saturated or unsaturated mono or bicyclic -O-C 3 -C 12 cycloalkyl, all the above optionally substituted with OH, NR 11 R 11 or a 3-7 membered C 1 -C 6 heterocyclyl optionally substituted with 15 C 1 -C 6 alkyl-, provided that an OH or NR 1 1 R 11 is not directly bonded to a carbon atom that is double- or triple-bonded to another carbon atom; i) -CH=CH-C 6 -C 10 aryl; j) -CH=CH-C 1 Coheteroaryl; k) optionally substituted C 6 -C 1 0 aryl; I) optionally substituted 5-10 membered Cj Coheteroaryl attached to the triazine moiety via a carbon atom; m) 3-10 membered saturated or unsaturated monocyclic C 1 -Coheterocyclyl attached to the triazine moiety through a carbon or 20 nitrogen atom and optionally substituted with from 1 to 3 substituents independently selected from: OH, NR 1 1 R 11 , C 1 -C 6 alkyl, (C 1 -C 6 alkyl)amido-, (C 1 -C 6 alkyl)C(O)-, (C 1 -C 6 alkoxy)carbonyl-, adamantyl, C 1 -C 6 hydroxylalkyl-, (C 1 -C 6 alkyl)amido-; or a 3-7 membered C 1 -C 6 heterocyclyl, with the proviso that 3 membered heterocyclyl is saturated and attached to the triazine moiety through a nitrogen atom, and 5 membered bicyclic heterocyclyl is saturated; n) optionally 25 substituted -O-C 6 -Cloaryl; o) optionally substituted -O-C 1 -Coheteroaryl; p) -O-(3-12 membered saturated or unsaturated mono or bicyclic)Ci-Cgheterocyclyl optionally substituted with (Cl C 6 alkoxy)carbonyl-, H 2 NS(O) 2 -, or C 1 -C 6 alkyl further optionally substituted with OH, NR 11 R 11 or a 3-7 membered C 1 -C 6 heterocyclyl, with the proviso that three membered heterocyclyl is saturated; q) -NHC 6 -Cloaryl, r) -NHC 1 -Coheteroaryl, s) -NHNH 2 , t) -NHNHC 1 -C 6 alkyl, u) 30 NHN(C 1 -C 6 alkyl) 2 , v) -NHOH, w) -COOH, x) -COO-C 1 -C 6 alkyl, y) -CONR R , z) -NR R, 248 WO 2009/143313 PCT/US2009/044774 R 6 R 7 R 6 R 7 aa) N-N bb) -N cc) _N-N Z dd) N Z R 9 R 8 R 9 R 8 wherein Z is CH 2 , 0, S(O), or NR 1 0 and n is 0, 1 or 2; ee) halogen, ff) C 6 -C 14 aryl-S(O) 2 -NH-, gg) R 1 NHC(O)NH-O-, and hh) optionally substituted 5 membered monocyclic C 1 -C 4 heteroaryl attached to the triazine moiety via a nitrogen atom; R 12 and R 1 3 are each independently selected from H, optionally mono or disubstituted 5 C 1 -C 8 alkyl, optionally substituted C 3 -C 8 alkenyl, and optionally substituted C 3 -C 8 alkynyl, the optional substituents being selected from C 1 -C 6 alkoxy, OH, NR 11 R 11 , and 3-7 membered Cj C 6 heterocyclyl, provided that an OH or NR 1 1 R 11 is not directly bonded to a carbon atom that is double- or triple-bonded to another carbon atom; or R 1 2 and R 1 3 taken together with the nitrogen atom to which they are attached form a 3 10 to 8 membered monocyclic ring system optionally substituted with C 1 -C 6 alkyl, which ring system is saturated or unsaturated and has, in addition to said nitrogen atom, 0 to 2 heteroatom ring members selected from 0, S(O), and NR 1 0 ; or R 1 2 and R 13 taken together with the nitrogen atom to which they are attached form (CH2)xNH R9a b R8 R ' FK-FhRO R8 N N NQN or N N R 6 N R 7 R 6 N R 7 R1 LiJR1 wherein a and b are each independently -CH 2 -, 0, S, or NR 1 0 , and x is 1-3; 15 C 1 -Coheteroaryl refers to a 5-10 membered aromatic ring system having one or more rings and 1, 2, 3 or 4 ring members independently selected from 0, NR 1 0 , and S(O),; C 1 -Coheterocyclyl refers to a 3-10 membered ring system having one or more rings and 1, 2, 3 or 4 ring members independently selected from 0, NR 1 0 , and S(O),; and optionally substituted aryl and heteroaryl groups are unsubstituted or are substituted with 20 1 or 2 moieties selected from the group consisting of: a) C 1 -C 6 alkyl optionally substituted with OH, NH 2 , NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , -NH(CH 2 )wN(C 1 -C 6 alkyl) 2 wherein w is 2, 3 or 4, or 3 10 membered C 1 -Coheterocyclyl optionally substituted with from 1 to 3 independently selected C 1 -C 6 alkyl- substituents; b) halogen; c) hydroxy; d) NH 2 ; e) NO 2 ; f) SO 2 NH 2 ; g) COOH; h) COO(C 1 -Cealkyl); i) NHCOO(C 1 -C 6 alkyl); j) NH(C 1 -Cealkyl); k) N(C 1 -C 6 alkyl) 2 ; I) C(O)NR"R , 25 wherein R" is H or C 1 -C 6 alkyl, and Rb is H, C 1 -C 6 alkyl, (C 6 -Cl 4 aryl)alkyl-, or (Cl Cgheteroaryl)alkyl-; m) -Y-Q, wherein Y is: i) 0, ii) NH, iii) N(C 1 -Cealkyl), iv) NHSO 2 , v) SO 2 NH, vi) NHCONH, vii) NHCON(C 1 -C 6 alkyl), viii) S(O)q, q is 0, 1 or 2, ix) -C(O)NH-, x) -NHC(O)- xi) C(O)N(CH 3 )-, xii) C(O), or xiii) absent, and Q is selected from: i) C 6 -C 1 0 aryl, optionally substituted with from 1 to 3 substituents independently selected from: A) C 1 -C 6 alkoxy- optionally 30 substituted with 1) H 2 N-, 2) (C 1 -C 6 alkyl)amino-, 3) di(C 1 -C 6 alkyl)amino-,
4) C 1 -Coheterocyclyl 249 WO 2009/143313 PCT/US2009/044774 optionally substituted by C 1 -C 6 alkyl-, or 5) hydroxyl, B) (C 1 -C 6 alkoxy)carbonyl-, C) (Cl C 6 alkoxy)C(O)NH-, D) C 1 -C 6 alkyl- optionally substituted with 1) H 2 N-, 2) (C 1 -C 6 alkyl)amino-, or 3) di(C 1 -C 6 alkyl)amino-, E) (C 1 -C 6 alkyl)amino-, F) di(C 1 -C 6 alkyl)amino-, G) (C 1 -C 6 alkyl)amido optionally substituted with 1) H 2 N-, 2) (C 1 -C 6 alkyl)amino-, or 3) di(C 1 -C 6 alkyl)amino-, H) (Cl 5 C 6 alkyl)carboxyamido-, I) C 1 -Coheterocyclyl- optionally substituted by C 1 -C 6 alkyl- or Cj C 6 hydroxylalkyl-, J) heterocyclyl(C 1 -C 6 alkyl)- optionally substituted by C 1 -C 6 alkyl-, K) halogen, L) hydroxyl, M) C 1 -C 6 hydroxylalkyl-, N) perfluoro(C 1 -C 6 )alkyl-, 0) H 2 N-, P) 0 2 N-, Q) H 2 NSO 2 -, R) HO 2 C-, and S) NC-, ii) 5-10 membered C 1 -Coheteroaryl, optionally substituted with from 1 to 3 substituents independently selected from: A) C 1 -C 6 alkoxy- optionally substituted with 1) H 2 N-, 2) 10 (C 1 -C 6 alkyl)amino-, 3) di(C 1 -C 6 alkyl)amino-, 4) C 1 -Cgheterocyclyl- optionally substituted by Cj C 6 alkyl-, or 5) hydroxyl, B) (C 1 -C 6 alkoxy)carbonyl-, C) (C 1 -C 6 alkoxy)C(O)NH-, D) C 1 -C 6 alkyl optionally substituted with 1) H 2 N-, 2) (C 1 -C 6 alkyl)amino-, or 3) di(C 1 -C 6 alkyl)amino-, E) (Cl C 6 alkyl)amino-, F) di(C 1 -C 6 alkyl)amino-, G) (C 1 -C 6 alkyl)amido- optionally substituted with 1) H 2 N-, 2) (C 1 -C 6 alkyl)amino-, or 3) di(C 1 -C 6 alkyl)amino-, H) (C 1 -C 6 alkyl)carboxyamido-, I) Cj 15 Coheterocyclyl- optionally substituted by C 1 -C 6 alkyl- or C 1 -C 6 hydroxylalkyl-, J) heterocyclyl(C 1 C 6 alkyl)- optionally substituted by C 1 -C 6 alkyl-, K) halogen, L) hydroxyl, M) C 1 -C 6 hydroxylalkyl-, N) perfluoro(C 1 -C 6 )alkyl-, 0) H 2 N-, P) 0 2 N-, Q) H 2 NSO 2 -, R) HO 2 C-, and S) NC-, iii) 3-10 membered C 1 -Coheterocyclyl, optionally substituted with from 1 to 3 substituents independently selected from: A) C 1 -C 6 alkyl-, B) heterocyclyl(C 1 -C 6 alkyl)-, C) (C 6 -C 1 4 aryl)alkyl-, D) C 1 -C 8 acyl-, 20 E) (C 1 -C 6 alkoxy)carbonyl-, F) (C 1 -C 6 alkyl)carboxyl- , G) halogen, H) C 1 -C 6 haloalkyl-, I) hydroxyl, J) C 1 -C 6 hydroxyalkyl-, K) H 2 N-, L) (C 1 -C 6 alkyl)amino-, M) di(C 1 -C 6 alkyl)amino-, N) HO 2 C-, 0) (C 1 -C 6 alkoxy)carbonyl-, P) (C 1 -C 6 alkyl)carboxyl-, Q) (C 1 -C 6 alkyl)amido-, R) H 2 NC(O)-, S) (Ci C 6 alkyl)carboxyamido-, T) 5-10 membered C 1 -Cgheteroaryl, U) C 6 -C 14 ary, V) C 3 -C 8 cycloalkyl W) 3-10 membered C 1 -Coheterocyclyl, X) NC-; and Y) -NO 2 ; iv) C 3 -C 10 cycloalkyl, v) C 1 -C 6 alkyl, vi) 25 C 2 -C 6 alkenyl, vii) C 2 -C 6 alkynyl, viii) C 1 -C 6 hydroxyalkyl-, ix) (CH 2 )vO(C 1 -Cealkyl), x) (CH 2 )vNH 2 , xi) (CH 2 )vNH(C 1 -C 6 alkyl), xii) (CH 2 )vN(C 1 -C 6 alkyl) 2 , xiii) O(CH 2 )vN(C 1 -C 6 alkyl) 2 , xiv) (CH 2 )vC 6 -C 1 oaryl, xv) -CN, xvi) (CH 2 )v 5-10 membered C 1 -Coheteroaryl, xvii) (CH 2 )v 3-10 membered Cj Coheterocyclyl, optionally substituted by C 1 -C 6 alkyl-, wherein v is 1, 2, 3 or 4, and xviii) Cj C 6 perfluoroalkyl- ; and n) C(O)R wherein R' is: i) H, ii) C 1 -C 6 alkyl, or iii) C 3 -C 6 cycloalkyl, 30 and pharmaceutically acceptable salts thereof. 250 WO 2009/143313 PCT/US2009/044774 2. The compound of claim 1 wherein R 1 is 0 N 3. The compound of claim 1 or claim 2 wherein R 2 is optionally substituted C6 C 1 4 aryl-NH-COR 3 5 4. The compound of claim 3 wherein R 2 is optionally substituted phenyl-NH-COR 3
5. The compound of claim 4 wherein R 3 is NHR 5 .
6. The compound of claim 5 wherein R 5 is optionally substituted phenyl or Cj Coheteroaryl.
7. The compound of claim 6 wherein R 5 is phenyl substituted with -Y-Q. 10
8. The compound of claim 7 wherein -Y- is C(O).
9. The compound of claim 8 wherein Q is 3-10 membered C 1 -Coheterocyclyl, substituted with di(C 1 -C 6 alkyl)amino-. 251 WO 2009/143313 PCT/US2009/044774
10. The compound of any of claims 1-9 wherein R 4 is 0or 0/ and pharmaceutically acceptable salts thereof.
11. The compound of claim 10 wherein R 4 is 0 N I I and pharmaceutically acceptable salts thereof. 5
12. The compound selected from the group consisting of: 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-3-ylurea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-phenylurea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-thiophen-2-ylurea; 10 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-methylphenyl)urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-fluorophenyl)urea; 1-(2,4-dimethoxyphenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-urea; 1-(4-chlorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-methoxyphenyl)urea; 15 (4-chlorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; (2,4-difluorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-ethylurea; tert-butyl 3-{[4-(4-{[(4-fluorophenyl)carbamoyl]amino}phenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]amino}azetidine-1 -carboxylate; 20 tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(phenylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)amino]azetidine-1 -carboxylate; 252 WO 2009/143313 PCT/US2009/044774 tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridine-3-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)amino]azetidine-1 -carboxylate; tert-butyl 3-{[4-(4-{[(4-methylphenyl)carbamoyl]amino}phenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]amino}azetidine-1 -carboxylate; 5 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-phenylurea; 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-3-ylurea; 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yI]phenyl}-3-(4-fluorophenyl)urea; 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(4-methylphenyl)urea; tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridine-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 10 yl)amino]azetidine-1-carboxylate; 1 -{4-[4-(azetidin-3-ylamino)-6-morpholin-4-yl-1,3,5-triazin-2-yI]phenyl}-3-pyridin-4-ylurea 1-[2-(dimethylamino)ethyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}urea; 1 -[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(2-methylpyridin-4-yl)urea; 15 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(2-hydroxyethyl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(hydroxymethyl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-hydroxyphenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(1 -hydroxyethyl)phenyl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(trifluoromethyl)phenyl]urea; 20 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-hydroxyphenyl)urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[5-(trifluoromethyl)pyridin-2-yl]urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[2,2,2-trifluoro-1 -hydroxy- 1 (trifluoromethyl)ethyl]phenyl}urea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[3-(1 -hydroxyethyl)phenyl]urea; 25 methyl 4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate; 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)- 1,3,5-triazin-2-yl]phenyl}-3-pyridin-4 ylurea; 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)- 1,3,5-triazin-2-yl]phenyl}-3-phenylurea; 1 -{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)- 1,3,5-triazin-2-yl]phenyl}-3-pyridin-3 30 ylurea; 1 -[4-(hydroxymethyl)phenyl]-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yloxy)-1, 3,5 triazin-2-yl]phenyl}urea; 253 WO 2009/143313 PCT/US2009/044774 1 -(2-m ethyl pyrid in-4-yI)-3-{4- [4-mo rpholIi n-4-yI-6-(tetra hyd ro-2 H-pyra n-4-yloxy)- 1, 3,5-tri azi n-2 yI] phenyllu rea; 1 -[2-(methylamino)ethyl]-3-{4-[4-morpholin-4-yI-6-(tetrahydro-2H-pyran-4-yloxy)- 1,3,5-triazin-2 yI] phenyllu rea; 5 1 -(3-acetylphenyl)-3-{4-[4-morpholin-4-yI-6-(tetrahydro-2H-pyran-4-yloxy)-1 ,3,5-triazin-2 yI] phenyllu rea; 1 -[4-(dimethylamino)phenyl]-3-{4-[4-morpholin-4-yI-6-(tetrahydro-2H-pyran-4-yloxy)-1,3,5 triazin-2-yI]phenyllurea; 4-[3-{4-(4,6-dimorpholino-1 ,3,5-triazin-2yl)phenyllureido]benzoic acid; 10 N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino- 1,3,5-triazin-2-yI)phenyl)ureido)benzamide HOI salt; 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-methylpiperazine-1 15 carbonyl)phenyl)urea; 4-(3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)ureido)-N-methylbenzamide; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)ureido)-N methylbenzamide; 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-morpholinopiperidine-1 20 carbonyl)phenyl)urea; 4-(3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)ureido)-N-(quinuclidin-3-yI)benzamide; 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-(pyrrolidin-1 -yI)piperidine-1 carbonyl)phenyl)urea; 1 -(4-(1 ,4'-bipiperidine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 25 1 -(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(piperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4,6-dimorpholino- 1,3,5-triazin-2-yI)phenyl)-3-(4-(2-(pyridin-2-yI)acetyl)phenyl)urea; 1 -[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-[4-( 1 -hydroxyethyl)phenyl]urea; 30 1 -[4- (4,6-d imo rphoIi n-4-y- 1, ,3,5-triazi n-2-yI)p he nyl]-3- (2-m ethyl pyrid in-4-yI)u rea; 1 -[4-(4,6-dimorpholin-4-y- 1,3,5-triazin-2-yI)phenyl]-3-[4-(hydroxymethyl)phenyl]urea; 1 -[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-[4-(trifluoromethyl)phenyl]urea; 1 -[4-(4,6-dimorpholin-4-y- 1,3,5-triazin-2-yI)phenyl]-3-{4-[2,2,2-trifluoro- 1 -hydroxy- 1 (trifluoromethyl)ethyl]phenyllurea; 35 1 -[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-[5-(trifluoromethyl)pyrid in-2-yI]urea; 254 WO 2009/143313 PCT/US2009/044774 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[3-(1 -hydroxyethyl)phenyl]urea; 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1,3,5-triazin-2-yl}phenyl)-3-pyridin-4 ylurea; 1 -[4-(2-hydroxyethyl)phenyl]-3-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1, 3,5-triazin 5 2-yl}phenyl)urea; 1 -[4-(2-hydroxymethyl)phenyl]-3-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1,3,5 triazin-2-yl}phenyl)urea; 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1,3,5-triazin-2-yl}phenyl)-3-(2 methylpyrid in-4-yl)urea; 10 1-[4-(1 -hydroxyethyl)phenyl]-3-(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1, 3,5-triazin 2-yl}phenyl)urea; 1-[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; methyl 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl} amino)benzoate; 15 1-[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; 4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-( 1 methylpiperidin-4-yl)benzamide; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(1 -methylpiperidin-4-yl)urea; 20 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-morpholin-4-yl- 1,3,5-triazin-2-yl}phenyl)-3-( 1 methylpiperidin-4-yl)urea; 1 -{4-[4-(3,6-Dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-[1,3,5]triazin-2-yl]-phenyl}-3-pyridin-4-yl urea; 1 -{4-[4-Morpholin-4-yl-6-(tetrahydro-pyran-4-yl)-[1,3,5]triazin-2-yl]-phenyl}-3-pyridin-4-yl-urea; 25 3-({4-Morpholin-4-yl-6-[4-(3-pyridin-4-yl-ureido)-phenyl]-[1,3,5]triazin-2-ylamino}-methyl) azetidine-1-carboxylic acid tert-butyl ester; 1-(4-{4-[(azetidin-3-ylmethyl)-amino]-6-morpholin-4-yl-[1,3,5]triazin-2-yl}-phenyl)-3-pyridin-4-yl urea; 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yI]phenyl}-3-pyridin 30 4-ylurea; 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yI]phenyl}-3-pyridin 3-ylurea; 1-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yI]phenyl}-3 phenylurea; 35 1-[4-(dimethylamino)phenyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}urea; 255 WO 2009/143313 PCT/US2009/044774 1 -(4-cyanophenyl)-3-{4-[4-( 1,4-dioxa-8-azaspiro[4.5]dec-8-y)-6-morpholin-4-y-1 ,3,5-triazin-2 yI] phenyllu rea; 1 -{4-[4-( 1,4-dioxa-8-azaspiro[4.5]dec-8-y)-6-morpholin-4-y- 1,3,5-triazin-2-yI]phenyl}-3-(2 m ethyl pyrid i n-4-yI)u rea; 5 1 -[2-(dimethylamino)ethyl]-3-{4-[4-( 1,4-dioxa-8-azaspiro[4.5]dec-8-y)-6-morpholin-4-y- 1,3,5 triazin-2-yI]phenyllurea; 1 -[4-(4-morpholin-4-yI-6-quinolin-3-y- 1,3,5-triazin-2-yI)phenyl]-3-pyridin-4-ylurea; 1 -[4-(4-azetidin-1 -yI-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-pyrid in-4-ylurea; methyl 4-({[4-(4-azetidin-1 -yI-6-morpholin-4-yI- 1,3,5-triazin-2 10 yI)phenyl]carbamoyllamino)benzoate; 1 -[4-(4-isopropoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-{4-[(4-methylpiperazin-1 yI)carbonyl]phenyllurea; 4-({[4-(4-isopropoxy-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-( 1 methylpiperidin-4-yI)benzamide; 15 4-({[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(2-piperidin- 1 ylethyl)benzamide; 1 -[4-(4,6-dimorpholin-4-y- 1,3,5-triazin-2-yI)phenyl]-3-[4-(morpholin-4-ylcarbonyl)phenyl]urea; 1 -[4-(4-methyl-6-morpholin-4-yI- 1,3,5-triazin-2-yI)phenyl]-3-pyridin-4-ylurea; 4-(Q[4- (4-m ethyl-6-mo rphoi n-4-y- 1, 3,5-triazi n-2-yI) ph enyl] ca rba moylla m ino)be nzo ate; 20 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yI)-6-morpholin-4-y- 1,3,5-triazin-2-y]phenyl}-3-{4-[(4 methylpiperazin-1-yI)carbonyl] phenyllurea; 4-({[4-(4-methyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-( 1 methylpiperidin-4-yI)benzamide; N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4-methyl-6-morpholin-4-y-1 ,3,5-triazin-2 25 yI)phenyl]carbamoyllamino)benzamide; 1 -[4-(4-methyl-6-morpholin-4-yI- 1,3,5-triazin-2-yI)phenyl]-3-{4-[(4-methylpiperazin-1 yI)carbonyl]phenyllurea; 1 -(4-{[3-(dimethylamino)pyrrolidin-1 -yI]carbonyllphenyl)-3-[4-(4,6-dimorpholin-4-y-1,3,5-triazin 2-yI)phenyl]urea; 30 1 -[4-({4-[2-(dimethylamino) ethylpi perazin- I -yIlcarbonyl)phenyl]-3-[4-(4,6-dimorpholin-4-y 1 ,3,5-triazin-2-yI)phenyl]urea; 1 -[4-(4,6-dimorpholin-4-y- 1,3,5-triazin-2-yI)phenyl]-3-{4-[(4-pyrrolidin-1 -ylpiperidin-1 yI)carbonyl]phenyllurea; 4-({[4-(4-butyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)benzoic acid;N-2 35 (dimethylamino)ethyl]-4-({[4-(4-isopropoxy-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)-N-methylbenzamide; 1 -[4-(4-butyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-pyridin-4-ylurea; 256 WO 2009/143313 PCT/US2009/044774 N-[2-(dimethylamino)ethyl]-4-({[4-(4-isopropoxy-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzamide; 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate; 4-({[4-(4-azetidin-1-yl-6-morpholin-4-yl-1,3,5-triazin-2yl)pheny] carbamoyl} amino) benzoic acid; 5 mp 204 C; 1-[4-(4-azetidin-1 -yl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; mp 170 0C; 4-({[4-(4-azetidin-1 -yl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-[2 (dimethylamino)ethyl]-N-methylbenzamide; 10 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-[2 (dimethylamino)ethyl]-N-methylbenzamide; 1 -{4-[4-(1 -ethoxyvinyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 1 -{4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 1-[4-(4-acetyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; 15 methyl 4-[({4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate; 1-{4-[4-(1-hydroxyethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; methyl 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate; 20 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoic acid; 1-(4-{4-morpholin-4-yl-6-[2-(pyridin-4-ylamino)ethyl]-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea; 4-({[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-[2 (dimethylamino)ethyl]benzamide; 25 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; 1 -[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin- 1 yl)carbonyl]phenyl}urea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 30 yl)phenyl]carbamoyl}amino)benzamide; 1-(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-[4-(4-ethyl-6-morpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea; 1-[4-(4-butyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(hydroxymethyl)phenyl]urea; 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2 35 yl]phenyl}carbamoyl)amino]-N-[2-(dimethylamino)ethyl]-N-methylbenzamide; 257 WO 2009/143313 PCT/US2009/044774 1 -[4-(4-butyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-(4-{[4-(dimethylamino)piperidin- 1 yI]carbonyllphenyl)urea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-ethyl-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)-N-methylbenzamide; 5 N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)-N-methylbenzamide; N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 4-({[4-(4-methoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-methyl-N-[2 10 (methylamino)ethyl]benzamide; 1 -[4-(4-methoxy-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]-3-{4-[(4-methylpiperazin- 1 yI)carbonyl]phenyllurea; 1 -{4-[(3,3-dimethylpiperazin- 1 -yI)carbonyl]phenyl}-3-[4-(4-methoxy-6-morpholin-4-y- 1,3,5 triazin-2-yI)phenyl]urea; 15 4-({[4-(4-methoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(2-piperidin- 1 ylethyl)benzamide; 4-({[4-(4-ethyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-[4-(4 methylpiperazin-1 -yI)phenyl]benzamide; 1 -[4-(4-butyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]-3-[4-({[2 20 (dimethylamino)ethyl]aminolmethyl)phenyl]urea; 4-({[4-(4-butyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-[4-(4 methylpiperazin-1 -yI)phenyl]benzamide; 1 -[4-(4- butyl-6-mo rphoi n-4-y- 1, ,3,5-triazi n-2-yI)p he nyl]-3-{4- [(4-m ethyl p ipe razi n- 1 yI)m ethyl] phenyllu rea; 25 1 -[4-(4-butyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-(4-formylphenyl)urea; 4-({[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(pyridin-2 ylmethyl)benzamide; 1 -(4-{4-[2-( 1,3-dioxan-2-yI)ethyl]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3-pyridin-4-ylurea; 1 -(4-{4-[2,5-bis(hydroxymethyl)pyrrolidin-1 -yI]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3 30 pyridin-4-ylurea; 4-({[4-(4-butyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-{4-[2 (dimethylamino)ethoxy]phenyllbenzamide; 1 -{4-[(4-benzylpiperidin-1 -yI)carbonyl]phenyl}-3-[4-(4-butyl-6-morpholin-4-y-1 ,3,5-triazin-2 yI)phenyl] urea; 35 4-({[4-(4-ethyl-6-morpholin-4-yI- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-( 1 -methylpiperidin 4-yI)benzamide; 4-({[4-(4-butyl-6-morpholin-4-yI- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-( 1 -methylpiperidin 4-yI)benzamide; 258 WO 2009/143313 PCT/US2009/044774 1-(4-{4-[3-(dimethylamino)propyl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea; 1-[4-(4-{3-[(1 -methylethyl)amino]propyl}-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4 ylurea; 1 -{4-[4-morpholin-4-yl-6-(3-pyrrolidin-1 -ylpropyl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 5 1-(4-{4-[3-(4-methylpiperazin-1 -yl)propyl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4 ylurea; 1 -{4-[4-(3-{[2-(dimethylamino)ethyl]amino}propyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3 pyridin-4-ylurea; 1 -{4-[4-(3-hydroxypropyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 10 1 -{4-[4-morpholin-4-yl-6-(3-oxopropyl)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2-y]phenyl}-3-(4-{[4 (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)urea; 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl} carbamoyl)amino]-N-[2-(dimethylamino)ethyl]benzamide; 15 1-[4-(4-methylpiperazin-1 -yl)phenyl]-3-[4-(4-morpholin-4-yl-6-propyl-1,3,5-triazin-2 yl)phenyl]urea; 1 -{4-[2-(dimethylamino)ethoxy]phenyl}-3-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 1-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(4-methylpiperazin-1 -yl)phenyl]urea; 20 1-[4-(4-methylpiperazin-1 -yl)phenyl]-3-{4-[4-(2-methylpropyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}urea; 1 -{4-[(3,3-dimethylpiperazin-1 -yl)carbonyl]phenyl}-3-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 4-({[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-(1 -methylazetidin 25 3-yl)benzamide; methyl 4-[({4-[4-(1-methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate N-[2-(dimethylamino)ethyl]-4-[({4-[4- (1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; 30 N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; N-(1 -methylazetidin-3-yl)-4-[({4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzamide; 1-(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-{4-[4-(1 -methylethyl)-6-morpholin-4-yl 35 1,3,5-triazin-2-yl]phenyl}urea; 4-[({4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoy)amino]-N-pyridin 4-ylbenzamide; 259 WO 2009/143313 PCT/US2009/044774 4-[({4-[4-(l1 -methylethyl)-6-morpholin-4-y-1 ,3,5-triazin-2-yI]phenyllcarbamoy)amino]-N-pyrid in 3-ylbenzamide; N-cyclobutyl-4-[({4-[4-( 1 -m ethyl ethyl)-6- mo rphoIi n-4-y- 1, ,3,5-triazi n-2 yI]phenyllcarbamoyl)amino]benzamide; 5 1 -[4-(4-ethyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-{4-[(4-phenylpiperidin-1 yI)carbonyl]phenyllurea; 4-({[4-(4-ethyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(pyrid in-4 ylmethyl)benzamide; 1 -{4-[(4-methylpiperazin-1 -yI)ca rbo nyl] ph enyl}-3-{4-[4-(2-m ethyl pro pyl)-6- mo rphol in-4-y- 1, 3,5 10 triazin-2-yI]phenyllurea; 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-{4-[4-(2-methylpropyl)-6-morpholin-4 yI-l ,3,5-triazin-2-yI]phenyllurea; N- [2-(d im ethyla m ino)ethyl]- N-m ethyl-4- [({4- [4-(2-m ethyl pro pyl)-6- mo rphoin -4-y- 1, 3,5-tri azi n-2 yI]phenyllcarbamoyl)amino]benzamide; 15 1 -{4-[4- (4-m ethyl ph enyl)-6-mo rphoIi n-4-y- 1, 3,5-triazi n-2-yI] ph enyl}-3-{4-[(4-m ethyl p ipe razi n- 1 yI)carbonyl]phenyllurea; N- [2-(d im ethyla m ino)ethyl]- N-m ethyl-4- [({4- [4-(4-m ethyl ph enyl)-6- mo rphoi n-4-y- 1, 3,5-tri azi n-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[4-(dimethylamino)piperid in-i -yI]phenyl}-3-{4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5 20 triazin-2-yI]phenyllurea; 1 -{4-[4- (4-m ethyl ph enyl)-6-mo rphoIi n-4-y- 1, 3,5-triazi n-2-yI] ph enyl}-3-pyrid in-4-yl urea; 1 -{4-[4-(dimethylamino)piperid in-i -yI]phenyl}-3-[4-(4-ethyl-6-morpholin-4-y-l1,3,5-triazin-2 yI)phenyl] urea; 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-y-1,3, 5-triazin-2-yI]phenyllcarbamoyl)amino]benzoic 25 acid; 1 -{4-[4- (4-m ethyl ph enyl)-6-mo rphoIi n-4-y- 1, 3,5-triazi n-2-yI] ph enyl}-3-[4-(4-m ethyl p ipe razi n- 1 yI)phenyl] urea; methyl 4- [({4-[4-(4-m ethyl ph enyl)-6- mo rphoi n-4-y- 1, ,3,5-tri azi n-2 yI]phenyllcarbamoyl)amino]benzoate; 30 1 -{4-[4-(dimethylamino)piperidin- 1-yI]phenyl}-3-[4-(4-morpholin-4-yI-6-phenyl- 1,3,5-triazin-2 yI)phenyl] urea; 1 -[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2-yI)phenyl]-3-pyridin-4-ylurea; 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-{4-[4-morpholin-4-yI-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI]phenyllurea; 35 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-3-yI)urea; 260 WO 2009/143313 PCT/US2009/044774 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-methylpiperazin-1 yI)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(6-(4-methylpiperazin-1 yI)pyrid in-3-yI)urea; 5 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4 ((d imethylam ino)methyl )phenyl )u rea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 (dimethylamino)ethoxy)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2-(pyrrolidin-1 10 yI)ethoxy)phenyl)urea; (R)-1 -(4-(4-(3- methyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3 (pyridin-3-yI)urea; (R)-1 -(4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)- 1, 3,5-triazi n-2-yI)p he nyl)-3-(4-(4 methylpiperazin-1 -yI)phenyl)urea; 15 (R)-1 -(4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)- 1, 3,5-triazi n-2-yI)p he nyl)-3-(4 (piperazin-1 -yI)phenyl)urea; 1 -(4-(4-((R)-3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(4 ((S)-3-methylpiperazin-1 -yI)phenyl)urea; 1 -(4-(4-((R)-3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(4 20 ((R)-3-methylpiperazin-1 -yI)phenyl)urea; 1 -(4-((3R,5S)-3,5-dimethylpiperazin-1 -yI) ph enyl)-3-(4-(4-((R)-3-m ethyl mo rpholIi no)-6-(tetra hyd ro 2H-pyran-4-y)-1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(2-(d im ethyla m ino)ethoxy)p he nyl)-3-(4-(4- (3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 25 (R)- 1 -(4-(4-ethylpiperazin-1 -yI)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4 yI)-l ,3,5-triazin-2-yI)phenyl)urea; (R)- 1 -(4-(4-isopropylpiperazin-1 -yI)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(4-(dimethylamino)piperidin-1 -yI)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro 30 2H-pyran-4-y)-1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; (R)-1 -(4-(4-isopropylpiperazine-1 -ca rbo nyl)p he nyl)-3- (4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro 2H-pyran-4-y)-1 ,3,5-triazin-2-yI)phenyl)urea; 35 (R)-1 -(4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(6-(4 methylpiperazin- 1 -yI)pyridin-3-yI)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-ethylpiperazin-1 yI)phenyl)urea; 261 WO 2009/143313 PCT/US2009/044774 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-isopropylpiperazin-1 yI)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4 (dimethylamino)piperidin-1 -yI)phenyl)urea; 5 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-methylpiperazine-1 carbonyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-isopropylpiperazine-1 carbonyl)phenyl)urea; 4- (3-(4-(4,6- bis((R)-3-m ethyl mo rphoIi no)- 1, 3,5-tri azi n-2-yI)p he nyl)u re ido)-N, N 10 dimethylbenzamide; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(pyrrolidin-1 ylmethyl)ph enyl)u rea; 4-({[4-(4-{4-[(methylcarbamoyl)amino]phenyl}-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 15 1 -{4-[4-(3,5-dimethylmorpholin-4-yI)-6-{4-[(methylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 yI]phenyl}-3-pyridin-3-ylu rea; 3-({[4-(4-{4-[(methylcarbamoyl)amino]phenyl}-6-morpholin-4-y- 1,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 1 -methyl-3-[4-(4-morpholin-4-yI-6-{4-[(pyridin-3-ylcarbamoyl)amino]phenyl- 1,3,5-triazin-2 20 yI)phenyl]urea; 1 -methyl-3-[4-(4-morpholin-4-yI-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl- 1,3,5-triazin-2 yI)phenyl] urea; 3-[({4-[4-(3,5-dimethylmorpholin-4-yI)-6-{4-[(methylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 25 4-[({4-[4-(3,5-dimethylmorpholin-4-yI)-6-{4-[(methylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[4-(3,5-dimethylmorpholin-4-yI)-6-{4-[(methylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 yI]phenyl}-3-pyridin-4-ylu rea; 1 -[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-methylurea; 30 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-{4-[4-morpholin-4-yI-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI]phenyllurea; 1 -{4-[(4-methylpiperazin-1 -yI)carbonyl]phenyl}-3-(4-{4-morpholin-4-yI-6-[(3S)-tetrahyd rofuran-3 yloxy]- 1,3,5-triazin-2-yIlphenyl)urea; 1 -[4-(4,6-dimorpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-pyridazin-4-ylurea; 35 1 -{4-[(4-methylpiperazin-1 -yI)carbonyl]phenyl}-3-{4-[4-morpholin-4-yI-6-(oxetan-3-yloxy)-1,3,5 triazin-2-yI]phenyllurea; 1 -(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yI]carbonyllphenyl)-3-[4-(4,6-dimorpholin-4-y- 1,3,5 triazin-2-yI)phenyl]urea; 262 WO 2009/143313 PCT/US2009/044774 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea; 1-[4-(4-isopropyl-6-morpholin-4-yl-1,3,5-triazin-2-yI)phenyl]-3-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}urea; 5 1 -{4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(4-pyrimidin-5-ylphenyl)urea; 1-(4-{4-[(2,2-dimethoxyethyl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-3 ylurea; 1 -{4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(4-pyridin-4-ylphenyl)urea; 1-(4-iodophenyl)-3-{4-[4-(1 -methylethyl)-6-morpholin-4-yl- 1,3,5-triazin-2-yl]phenyl}urea; 10 1 -{4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(4-{[4-( 1 methylethyl)piperazin-1 -yl]carbonyl}phenyl)urea; 1-[4-(4-azetidin-1 -yl-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-{[4-(1 -methylethyl)piperazin 1 -yl]carbonyl}phenyl)urea; 1 -{4-[2-(dimethylamino)pyrimidin-5-yl]phenyl}-3-{4-[4-(1 -methylethyl)-6-morpholin-4-yl-1,3,5 15 triazin-2-yl]phenyl}urea; tert-butyl 3-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)oxy]azetidine-1-carboxylate; 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 20 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-nitrophenyl)urea; 1-(4-aminophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea; N-[4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)phenyl]-4 methylpiperazine-1-carboxamide; 4-(dimethylamino)-N-[4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 25 yl)phenyl]carbamoyl}amino)phenyl]piperidine-1-carboxamide; 1-[2-(dimethylamino)ethyl]-3-[4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)phenyl]-1 -methylurea; 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-{[(2-piperidin-1 ylethyl)carbamoyl]amino}phenyl)urea; 30 N-[4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)phenyl]-4-methyl-1,4 diazepane-1 -carboxamide; N-[4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)phenyl]-4 ethylpiperazine-1 -carboxamide; 1 -{4-[(dimethylcarbamoyl)amino]phenyl}-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2 35 yl)phenyl]urea; 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(4-{[4 (dimethylamino)piperidin-1 -yl]carbonyl}phenyl)urea; 263 WO 2009/143313 PCT/US2009/044774 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]-N-[2-(dimethylamino)ethyl]-N-methylbenzamide; 1 -{4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yI]phenyl}-3-{4-[(4 methylpiperazin-1 -yl)carbonyl]phenyl}urea; 5 4-[({4-[4-(3,6-dihydro-2H-pyran-4-yl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]-N-[2-(dimethylamino)ethyl]benzamide; 1-(4-{[4-(dimethylamino)piperidin-1 -yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2 10 yl]phenyl}carbamoyl)amino]benzamide; 4-[({4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino] N-(2-pyrrolidin-1 -ylethyl)benzamide; 4-[({4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino] N-(2-piperidin-1 -ylethyl)benzamide; 15 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-{[4-(1 -methylethyl)piperazin- 1 yl]carbonyl}phenyl)urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3-yloxy] 1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; 4-{[(4-{4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3-yloxy]-1,3,5-triazin-2 20 yl}phenyl)carbamoyl]amino}-N-(2-piperidin-1 -ylethyl)benzamide; 4-{[(4-{4-morpholin-4-yl-6-[(3S)-tetrahydrofuran-3-yloxy]-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}-N-(2-pyrrolidin-1 -ylethyl)benzamide; 1-(4-{[4-(1 -methylethyl)piperazin-1 -yl]carbonyl}phenyl)-3-(4-{4-morpholin-4-yl-6-[(3S) tetrahydrofuran-3-yloxy]- 1,3,5-triazin-2-yl}phenyl)urea; 25 1-(4-{[4-(1 -methylethyl)piperazin-1 -yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5 triazin-2-yl]phenyl}carbamoyl)amino]benzamide; 4-[({4-[4-(2-methylpropyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoic 30 acid; 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-yl- 1,3,5-triazin-2-yl]phenyl}-3-[4-(4-methylpiperazin-1 yl)phenyl]urea; 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}carbamoyl)amino]benzoic acid; 35 methyl 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate; 1-{4-[4-(dimethylamino)piperidin-1-yl]phenyl}-3-[4-(4-ethyl-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]urea; 264 WO 2009/143313 PCT/US2009/044774 1 -{4-[4- (4-m ethyl ph enyl)-6-mo rphoi n-4-y- 1, 3,5-triazi n-2-yI] ph enyl}-3-pyrid in-4-yl urea; 1 -{4-[4-(dimethylamino)piperid in-i -yI]phenyl}-3-{4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5 triazin-2-yI]phenyllurea; N- [2-(d im ethyla m ino)ethyl]- N-m ethyl-4- [({4- [4-(4-m ethyl ph enyl)-6- mo rphoi n-4-y- 1, 3,5-tri azi n-2 5 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[4- (4-m ethyl ph enyl)-6-mo rphoIi n-4-y- 1, 3,5-triazi n-2-yI] ph enyl}-3-{4-[(4-m ethyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 1 -[4-(4-ethyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]-3-{4-[(4-pyridin-2-ylpiperazin- 1 yI)carbonyl]phenyllurea; 10 1 -{4-[4-(dimethylamino)piperidin- 1 -yI]phenyl}-3-[4-(4-morpholin-4-yI-6-phenyl- 1,3,5-triazin-2 yI)phenyl] urea; 1 -[4-(4-ethyl-6-mo rphoi n-4-y- 1, ,3,5-tri azi n-2-yI)p he nyl]-3-{4- [(4-m ethyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 1 -[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2-yI)phenyl]-3-pyridin-4-ylurea; 15 methyl 4-({[4-(4-morpholin-4-yI-6-phenyl- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)benzoate; N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; methyl 4-{[(4-{4,6-b is[(3 S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-triazi n-2 yIlphenyl)carbamoyl]aminolbenzoate; 20 4-({[4-(4-morpholin-4-yI-6-phenyl- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)benzoic acid; N-[2-(dimethylamino)ethyl]-4-[({4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[(4-methylpiperazin-1 -yI)carbonyl]phenyl}-3-[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2 yI)phenyl] urea; 25 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-[4-(4-morpholin-4-yI-6-phenyl-1,3,5 triazin-2-yI)phenyl]urea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 4-{[(4-{4,6-b is [(3S)-3- methyl morp hoi n-4-y]-1, ,3,5-triazi n-2-yIl ph enyl)ca rba moyl] am ino}-N- [2 30 (dimethylamino)ethyl]benzamide; 1 -{4-[(4-isopropylpiperazin- 1 -yI)carbonyl]phenyl}-3-{4-[4-(4-methylphenyl)-6-morpholin-4-y 1 ,3,5-triazin-2-yI]phenyllurea; 4-[({4-[4-(4-methylphenyl)-6-morpholin-4-y-1 3, 5-triazin-2-yI]phenyllcarbamoy)amino]-N-(2 pyrrolidin- 1 -ylethyl)benzamide; 35 4-{[(4-{4,6-b is [(3S)-3- methyl morp hoi n-4-y]-1, ,3,5-triazi n-2-yIlp he nyl)ca rba moyl] am inolbe nzoi c acid; 265 WO 2009/143313 PCT/US2009/044774 N-(2-methoxyethyl)-4-[({4-[4-(4-methylphenyl)-6-morpholin-4-y-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; N-(2-methoxyethyl)-4-({[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 5 4-({[4-(4-morpholin-4-yI-6-phenyl- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(2-pyrrolidin-1 ylethyl)benzamide; 1 -{4-[4- (4-m ethyl ph enyl)-6-mo rphoIi n-4-y- 1, 3,5-triazi n-2-y] ph enyl}-3-[4-(pyrroIid in- 1 ylcarbonyl)phenyl]urea; N-[3-(dimethylamino)propyl]-4-[({4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5-triazin-2 10 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5-triazin-2-yI]phenyl}-3-[4-(piperidin-1 ylcarbonyl)phenyl]urea; N-[3-(dimethylamino)propyl]-4-({[4-(4-morpholin-4-yI-6-phenyl-1 ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 15 1 -{4-[4-morpholin-4-yI-6-(2-thienyl)-1 ,3,5-triazin-2-yI]phenyl}-3-pyrid in-4-ylurea; 4-[({4-[4-morpholin-4-yI-6-(2-thienyl)-1 ,3,5-triazin-2-yI]phenyllcarbamoyl)amino]benzoic acid; 1 -{4-[(4-m ethyl p iperazi n- 1 -yI)ca rbo nyl] ph enyl}-3-{4-[4-mo rphoIi n-4-y-6-(2-th ie nyl)-1, 3,5-triazi n 2-yI]phenyllurea; methyl 4-[({4-[4-morpholin-4-yI-6-(2-thienyl)-1 ,3,5-triazin-2-yI]phenyllcarbamoyl)amino]benzoate; 20 N-(2-methoxyethyl)-4-[({4-[4-morpholin-4-y-6-(2-thienyl)-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-y-6-(2-thienyl)-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-y-6-(2-thienyl)-1 ,3,5-triazin-2 25 yI]phenyllcarbamoyl)amino]benzamide; 4-{[(4-{4,6-b is [(3S)-3- methyl mo rphoi n-4-y]-1, ,3,5-triazi n-2-yIl ph enyl)ca rba moyl] am ino}-N- [2 (dimethylamino)ethyl]-N-methylbenzamide; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-{4-[(4-m ethyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 30 1 -{4-[4-morpholin-4-yI-6-( 1,4-oxazepan-4-y)-1,3, 5-triazin-2-yI]phenyl}-3-pyridin-4-ylurea; methyl 4-[({4-[4-morpholin-4-yI-6-( 1,4-oxazepan-4-y)- 1,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzoate; 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-{4-[4-morpholin-4-yI-6-(2-thienyl) 1 ,3,5-triazin-2-yI]phenyllurea; 35 4-[({4-[4-morpholin-4-yI-6-( 1,4-oxazepan-4-yI)- 1,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzoic acid; 266 WO 2009/143313 PCT/US2009/044774 N- [3-(d im ethyl am ino) pro pyl]-4- [({4-[4-mo rphoi n-4-y-6-(2-th ie nyl)-1, ,3,5-triazi n-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-[4- (pyrroIid in- 1 ylcarbonyl)phenyl]urea; 5 N-[2-(dimethylamino)ethyl]-4-[({4-[4-morpholin-4-y-6-( 1,4-oxazepan-4-y)-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[(4-m ethyl p iperazi n- 1 -yI)carbonyl]phenyl}-3-{4-[4-morpholin-4-y-6-( 1,4-oxazepan-4-y) 1 ,3,5-triazin-2-yI]phenyllurea; N-(2-methoxyethyl)-4-[({4-[4-morpholin-4-y-6-( 1,4-oxazepan-4-y)-1 ,3,5-triazin-2 10 yI]phenyllcarbamoyl)amino]benzamide; 1 -{4-[4-ethylpiperazin-1 -yI)carbonyl]phenyl}-3-{4-[4-morpholin-4-y-6-(2-thienyl)-1 ,3,5-triazin-2 yI] phenyllu rea; 1 -{4-[4- (4-m ethyl ph enyl)-6-mo rphoIi n-4-y- 1, 3,5-triazi n-2-yI] ph enyl}-3-{3-[(4-m ethyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 15 3-[({4-[4-(4-methylphenyl)-6-morpholin-4-y-1,3, 5-triazin-2-yI]phenyllcarbamoyl)amino]benzoic acid; methyl 3-[({4-[4-(4-methylphenyl)-6-morpholin-4-y-1 ,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzoate; 1 -(3-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-{4-[4-(4-methylphenyl)-6-morpholin-4 20 yI-l ,3,5-triazin-2-yI]phenyllurea; N-[2-(dimethylamino)ethyl]-N-methyl-3-[({4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; methyl 3-({[4-(4-ethyl-6-morpholin-4-y- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)benzoate; methyl 3-({[4-(4-morpholin-4-yI-6-thiophen-2-y-1 ,3,5-triazin-2 25 yI)phenyl]carbamoyllamino)benzoate; N-[2-(dimethylamino)ethyl]-3-[({4-[4-(4-methylphenyl)-6-morpholin-4-y- 1,3,5-triazin-2 yI]phenyllcarbamoyl)amino]benzamide; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-y-6-( 1,4-oxazepan-4-y)-1,3,5-triazin 2-yI]phenyllcarbamoyl)amino]benzamide; 30 3-({[4-(4-ethyl-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)benzoic acid; methyl 3-({[4-(4-morpholin-4-yl-6-phenyl- 1,3,5-triazin-2-yl)phenyl]carbamoyllamino)benzoate; 1 -[4-(4-ethyl-6-morpholin-4-yl-1 ,3,5-triazin-2-yl)phenyl]-3-{3-[(4-pyridin-2-ylpiperazin- 1 yl)carbonyl]phenyllurea; N-[2-(dimethylamino)ethyl]-3-({[4-(4-ethyl-6-morpholin-4-yl- 1,3,5-triazin-2 35 yl)phenyl]carbamoyllamino)-N-methylbenzamide; 1 -[4-(4-ethyl-6-mo rphoIi n-4-yl-1, ,3,5-tri azi n-2-yl)p he nyl]-3-{3- [(4-m ethyl p ipe razi n- 1 yl)carbonyl]phenyllurea; 267 WO 2009/143313 PCT/US2009/044774 3-({[4-(4-morpholin-4-yI-6-phenyl- 1,3,5-triazin-2-yI)phenyl]carbamoyllamino)benzoic acid; methyl 4-({[4-(4-morpholin-4-yI-6-piperidin-1 -yI-l ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzoate; 1 -[4-(4-morpholin-4-yI-6-piperid in-i -yI-l ,3,5-triazin-2-yI)phenyl]-3-pyrid in-4-ylurea; 5 4-({[4-(4-morpholin-4-yI-6-piperidin- l-yI-l ,3,5-triazin-2-yI)phenyl]carbamoyllamino)benzoic acid; methyl 4-({[4-(4-morpholin-4-yI-6-pyrrolidin-1 -yI-l ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzoate; 1 -(4-{[4-(l1 -methylethyl)piperazin-1 -yI]carbonyllphenyl)-3-[4-(4-morpholin-4-y-6-piperidin-1 -yI 1, 3,5-tri azi n-2-yI) ph enyl] urea; 10 1 -{4-[4-ethylpiperazin-1 -yI)carbonyl]phenyl}-3-[4-(4-morpholin-4-y-6-piperidin-1 -yI-l 3,5-triazin 2-yI)phenyl]urea; 1 -{4-[(4-m ethyl p iperazi n- 1 -yI)carbonyl]phenyl}-3-[4-(4-morpholin-4-y-6-piperidin-1 -yI-l 3,5 triazi n-2-yI)p he nyl] urea; 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-[4-(4-morpholin-4-y-6-piperidin-1 -yI 15 1 ,3,5-triazin-2-yI)phenyl]urea; 4-({[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI-l ,3,5-triazin-2-yI)phenyl]carbamoyllamino)benzoic acid; 1 -[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI-l 3, 5-triazin-2-yI)phenyl]-3-pyridin-4-ylurea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-morpholin-4-y-6-piperidin-1 -yI-l ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 20 1 -(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)-3-[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI 1 ,3,5-triazin-2-yI)phenyl]urea; 1 -(4-{[4-(l1 -methylethyl)piperazin-1 -yI]carbonyllphenyl)-3-[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI 1 ,3,5-triazin-2-yI)phenyl]urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI-l ,3,5-triazin-2 25 yI)phenyl]carbamoyllamino)benzamide; N-[2-(dimethylamino)ethyl]-N-methyl-4-({[4-(4-morpholin-4-y-6-piperidin-1 -yI-l ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 1 -{4-[4-ethylpiperazin-1 -yI)carbonyl]phenyl}-3-[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI-l 3,5-triazin 2-yI)phenyl]urea; 30 1 -{4-[(4-methylpiperazin-1 -yI)carbonyl]phenyl}-3-[4-(4-morpholin-4-y-6-pyrrolid in-I -yI-I 3,5 triazin-2-yI)phenyl]urea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI-l ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-pyrid in-4-yl urea; 35 N-[3-(dimethylamino)propyl]-4-({[4-(4-morpholin-4-y-6-piperidin-1 -yI-l 3, 5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 268 WO 2009/143313 PCT/US2009/044774 N-(2-methoxyethyl)-4-({[4-(4-morpholin-4-yI-6-piperidin-1 -yI-l ,3,5-triazin-2 yI)phenyl]carbamoyllamino)benzamide; 1 -[4-(4-morpholin-4-y-6-pyrrolidin-1 -yI-l 3,5-triazin-2-yI)phenyl]-3-[4-(pyrrolidin- 1 ylcarbonyl)phenyl]urea; 5 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-{4-[(4-ethyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-ylp he nyl)-3-(4-{[4-(1 1 methylethyl)piperazin- 1 -yI]carbonyllphenyl)urea; methyl 4-{[(4-{4- [(3S)-3- methyl mo rphoIi n-4-yI]-6-mo rphoi n-4-y- 1, 3,5-tri azi n-2 10 yIlphenyl)carbamoyl]aminolbenzoate; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-(4-{[4 (dimethylamino)piperidin-1 -yI]carbonyllphenyl)urea; 1 -(4-{4-[(3S)-3-m ethyl mo rphoIi n-4-yI]-6-mo rphoIi n-4-y- 1, 3,5-triazi n-2-yIlp he nyl)-3-{4-[(4 methylpiperazin-1 -yI)carbonyl]phenyllurea; 15 1 -(4-{[4-(l1 -methylethyl)piperazin-1 -yI] ca rbo nyllp he nyl)-3- (4-{4-[(3S)-3- methyl mo rphoIi n-4-y]-6 morpholin-4-yI- 1,3,5-triazin-2-yIlphenyl)urea; 4-{[(4-{4-[(3S)-3-m ethyl mo rphoIi n-4-y]-6-mo rphoi n-4-y- 1, ,3,5-tri azi n-2 yIlphenyl)carbamoyl]aminolbenzoic acid; 1 -{4-[4-ethylpiperazin-1 -yI)ca rbo nyl] ph enyl}-3-(4-{4-[(3S)-3-m ethyl mo rphol in-4-yI]-6-mo rphoIi n 20 4-yI-l ,3,5-triazin-2-yIlphenyl)urea; N- [3-(d im ethyla m ino)p ro pyl]-4-{[(4-{4-[(3S)-3-m ethyl mo rphoIi n-4-y]-6- mo rphoIi n-4-y- 1, 3,5 triazin-2-yIlphenyl)carbamoyl]aminolbenzamide; 4-{[(4-{4-[(3S)-3-m ethyl mo rphoIi n-4-y]-6-mo rphoi n-4-y- 1, ,3,5-tri azi n-2 yIlphenyl)carbamoyl]amino}-N-(2-pyrrolid in-i -ylethyl)benzamide; 25 1 -(4-{4-[(3 R)-3- methyl mo rphoIi n-4-y]-6-[(3S)-3- methyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIl ph enyl) 3-{4-[(4-methylpiperazin- 1 -yI)carbonyl]phenyllurea; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-(4-{[4 (dipropylamino)piperidin-1 -yI]carbonyllphenyl)urea; 1 -{4-[4-ethylpiperazin-1 -yI)ca rbo nyl] ph enyl}-3-(4-{4-[(3 R)-3-m ethyl mo rphoIi n-4-yI]-6-[(3S)-3 30 methylmorpholin-4-y]- 1,3,5-triazin-2-yIlphenyl)urea; 4-{[(4-{4-[(3 R)-3- methyl mo rpholIi n-4-yI]-6- [(3S)-3- methyl mo rphoi n-4-y]- 1, 3,5-tri azi n-2 yIlphenyl)carbamoyl]aminolbenzoic acid; 1 -{4-[(4-butylpiperazin-1 -yI)ca rbo nyl] ph enyl}-3-(4-{4-[(3 R)-3-m ethyl mo rphoIi n-4-yI]-6-[(3S)-3 methylmorpholin-4-y]- 1,3,5-triazin-2-yIlphenyl)urea; 35 methyl 4-{[(4-{4- [(3 R)-3-m ethyl mo rpholIi n-4-yI]-6- [(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2 yIlphenyl)carbamoyl]aminolbenzoate; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-{4-[(4-b utyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 269 WO 2009/143313 PCT/US2009/044774 1 -(4-{[4-(l1 -methylethyl)piperazin-1 -yI]carbonyllphenyl)-3-(4-{4-[(3R)-3-methylmorpholin-4-y]-6 [(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-tri azi n-2-yIlp he nyl) urea; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-(4-{[4- (2 methylpropyl)piperazin-1 -yI]carbonyllphenyl)urea; 5 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-ylp he nyl)-3-(4-{[4-(1 1 methylpropyl)piperazin-1 -yI]carbonyllphenyl)urea; 4-{[(4-{4,6-b is[(3S)-3- methyl morp hoi n-4-y]- 1, 3,5-triazi n-2-yIl ph enyl)ca rba moyl] am ino}-N-[2- (4 methylpiperazin-1 -yI)ethyl]benzamide; N- [2-(d im ethyla m ino)ethyl]-4-{[(4-{4-[(3 R)-3- methyl mo rpholIi n-4-yI]-6-[(3S)-3- methyl mo rphoi n-4 10 yI]-l ,3,5-triazin-2-yIlphenyl)carbamoyl]aminolbenzamide; 4-{[(4-{4,6-b is [(3S)-3- methyl morp hoi n-4-y]-1, ,3,5-triazi n-2-yIl ph enyl)ca rba moyl] am ino}-N- (2 pyrrolidin- 1 -ylethyl)benzamide; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-{4-[(4-p ro pyl p ipe rid in- 1 yI)carbonyl]phenyllurea; 15 1- (4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]-1, ,3,5-tri azi n-2-yIlp he nyl)-3-[4- (p ipe rid in- 1 ylcarbonyl)phenyl]urea; 1 -(4-{4,6-b is[(3S)-3-m ethyl mo rphoi n-4-y]- 1, 3,5-triazi n-2-yIlp he nyl)-3-{4- [(4-p ro pyl p ipe razi n- 1 yI)carbonyl]phenyllurea; 4-{[(4-{4,6-b is [(3S)-3- methyl morp hoi n-4-y]-1, ,3,5-triazi n-2-yIl ph enyl)ca rba moyl] am ino}-N- (2 20 methoxyethyl)benzamide; 1 -{4-[4-morpholin-4-yI-6-(4-tricyclo[3.3. 1.1 3,7]dec-1 -ylpiperazin-1 -yI)-l ,3,5-triazin-2-yI]phenyl}-3 pyridin-4-ylurea; methyl 4-{[(4-{4-[4-(dimethylcarbamoyl)piperazin-1 -yI]-6-morpholin-4-yI- 1,3,5-triazin-2 yIlphenyl)carbamoyl]aminolbenzoate; 25 N, N-dimethyl-4-(4-morpholin-4-y-6-{4-[(pyrid in-4-ylcarbamoyl)amino]phenyl}-1 ,3,5-triazin-2 yI)piperazine-1 -carboxamide; N, N-d im ethyl-4-(4-{4-[({4- [(4-m ethyl p ipe razi n- 1 -yI)carbonyl]phenyllcarbamoyl)amino]phenyl}-6 morpholin-4-y-1 ,3,5-triazin-2-yI)piperazine- 1 -carboxamide; N, N-dimethyl-4-{4-morpholin-4-yI-6-[4-({[4-(pyridazin-4 30 ylcarbamoyl)phenyl]carbamoyllamino)phenyl]-1 ,3,5-triazin-2-yIlpiperazine-1 -carboxamide; N, N-dimethyl-4-(4-morpholin-4-y-6-{4-[({4-[(4-propylpiperidin-1 yI)carbonyl]phenyllcarbamoyl)amino]phenyl-1 ,3,5-triazin-2-yI)piperazine- 1 -carboxamide; 4-{[(4-{4-[4-(dimethylcarbamoyl)piperazin- 1 -yI]-6-morpholin-4-yI- 1,3,5-triazin-2 yIlphenyl)carbamoyl]aminolbenzoic acid; 35 4-(4-{4-[({4-[(2-methoxyethyl)carbamoyl]phenyllcarbamoyl)amino]phenyl-6-morpholin-4-y 1 ,3,5-triazin-2-yI)-N,N-dimethylpiperazine-1 -carboxamide; 4-[4-(4-{[(4-{[2-(dimethylamino)ethyl](methyl)carbamoyllphenyl)carbamoyl]aminolphenyl)-6 morpholin-4-yI- 1,3,5-triazin-2-y]-N ,N-dimethylpiperazine-l1-carboxamide; 270 WO 2009/143313 PCT/US2009/044774 4-(4-{4-[({4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}carbamoyl)amino]phenyl}-6-morpholin-4-yl 1,3,5-triazin-2-yl)-N,N-dimethylpiperazine-1 -carboxamide; 1-(4-{4-[4-(ethylsulfonyl)piperazin-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4 ylurea; 5 methyl 4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoate; 4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoic acid; N-[3-(dimethylamino)propyl]-4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5 10 triazin-2-yl}phenyl)carbamoyl]amino}benzamide; N-[2-(dimethylamino)ethyl]-4-{[(4-{4-[4-(ethylsulfonyl)piperazin-1-yl]-6-morpholin-4-yl-1,3,5 triazin-2-yl}phenyl)carbamoyl]amino}benzamide; 4-{[(4-{4-[4-(1 -methylethyl)- 1,4-diazepan-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoic acid; 15 methyl 4-{[(4-{4-[4-(acetylamino)piperidin-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoate; 1 -(4-{4-[4-(1 -methylethyl)- 1,4-diazepan-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-{4-[(4 methylpiperazin-1-yl)carbonyl]phenyl}urea; N-[1-(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2-yl)piperidin-4 20 yl]acetamide; 4-{[(4-{4-[4-(acetylamino)piperidin-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}benzoic acid; N-[2-(dimethylamino)ethyl]-4-{[(4-{4-[4- (1 -methylethyl)-1,4-d iazepan-1 -yl]-6-morpholin-4-yl 1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; 25 N-{1-[(4-{[(4-{4-[4-(1-methylethyl)-1,4-diazepan-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2 yl}phenyl)carbamoyl]amino}phenyl)carbonyl]piperidin-4-yl}acetamide; 1-{4-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}-3-(4-{4-[4-(1-methylethyl)-1,4-diazepan-1-yl]-6 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)urea; 1 -(4-{4-[4-(1 -methylethyl)- 1,4-diazepan-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-(4-{[4 30 (1 -methylethyl)piperazin-1 -yl]carbonyl}phenyl)urea; 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-(4-{[(3S)-3 methylmorpholin-4-yl]carbonyl}phenyl)urea; 1 -{4-[(4-butylpiperazin-1 -yl)carbonyl]phenyl}-3-(4-{4-[4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)urea; 35 1-(4-{4-[(4-methylpiperazin-1 -yl)amino]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-phenylurea; 1-(4-{4-[(1 -methylpiperidin-4-yl)oxy]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4 ylurea; 1 -{4-[4-morpholin-4-yl-6-(piperidin-4-yloxy)-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 271 WO 2009/143313 PCT/US2009/044774 ethyl 4-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)oxy]piperidine-1 -carboxylate; N-ethyl-4-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)oxy]piperidine-1 -carboxamide; 5 tert-butyl 4-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin-2 yl)oxy]piperidine-1 -carboxylate; 4-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}- 1,3,5-triazin-2-yl)oxy]piperidine 1-sulfonamide; 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin 10 4-ylurea; 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin 3-ylurea; 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3 phenylurea; 15 1-[4-(dimethylamino)phenyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}urea; 1-(4-cyanophenyl)-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}urea; 1 -{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-(2 20 methylpyridin-4-yl)urea; 1-[2-(dimethylamino)ethyl]-3-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-morpholin-4-yl-1,3,5 triazin-2-yl]phenyl}urea; 1-[4-(4-morpholin-4-yl-6-quinolin-3-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea; 1 -{4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; 25 methyl 4-[({4-[4-(2-methoxyethoxy)-6-morpholin-4-yl-1,3,5-triazin-2 yl]phenyl}carbamoyl)amino]benzoate; 1-(4-{4-morpholin-4-yl-6-[2-(pyridin-4-ylamino)ethyl]-1,3,5-triazin-2-yl}phenyl)-3-pyridin-4-ylurea; N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)-N-methylbenzamide; 30 N-[2-(dimethylamino)ethyl]-4-({[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2 yl)phenyl]carbamoyl}amino)benzamide; 4-({[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)-N-methyl-N-[2 (methylamino)ethyl]benzamide; 1-[4-(4-methoxy-6-morpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-{4-[(4-methylpiperazin-1 35 yl)carbonyl]phenyl}urea; 1-{4-[(3,3-dimethylpiperazin-1-yl)carbonyl]phenyl}-3-[4-(4-methoxy-6-morpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea; 272 WO 2009/143313 PCT/US2009/044774 4-({[4-(4-methoxy-6-morpholin-4-y-1 ,3,5-triazin-2-yI)phenyl]carbamoyllamino)-N-(2-piperidin- 1 ylethyl)benzamide; 1 -(4-{4-[2,5-bis(hydroxymethyl)pyrrolidin-1 -yI]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3 pyridin-4-ylurea; 5 1 -(4-{4-[2-( 1,3-dioxan-2-yI)ethyl]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3-pyridin-4-ylurea; 1 -(4-{4-[3-(dimethylamino)propyl]-6-morpholin-4-y-1 ,3,5-triazin-2-yIlphenyl)-3-pyrid in-4-ylurea; 1 -[4-(4-{3-[(lI -methylethyl)amino]propyl}-6-morpholin-4-y-1I,3,5-triazin-2-yI)phenyl]-3-pyridin-4 ylu rea; 1 -{4-[4-morpholin-4-yI-6-(3-pyrrolidin-1 -ylpropyl)- 1,3,5-triazin-2-yI]phenyl}-3-pyrid in-4-ylurea; 10 1 -(4-{4-[3-(4-methylpiperazin-1 -yI)propyl]-6-morpholin-4-yI- 1,3,5-triazin-2-yIlphenyl)-3-pyridin-4 ylu rea; 1 -{4-[4-(3-{[2-(dimethylamino)ethyl]aminolpropyl)-6-morpholin-4-y-1 ,3,5-triazin-2-yI]phenyl}-3 pyridin-4-ylurea; 1 -{4-[4-(3-hydroxypropyl)-6-morpholin-4-y-1 ,3,5-triazin-2-yI]phenyl}-3-pyridin-4-ylurea; 15 1 -{4-[4-morpholin-4-yI-6-(3-oxopropyl)- 1,3,5-triazin-2-yI]phenyl}-3-pyridin-4-ylurea; N-(4-morpholin-4-yI-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl-1 ,3,5-triazin-2 yI)benzenesulfonamide; N-{4-[4-({[4-(4-methylpiperazin- I -yI)phenyl]carbamoyllamino)phenyl]-6-morpholin-4-y-1,3,5 triazin-2-yIlbenzenesu Ifonamide; 20 N-(4-{4-[({4-[2-(dimethylamino)ethoxy]phenyllcarbamoyl)amino]phenyl-6-morpholin-4-y-1,3,5 triazin-2-yI)benzenesulfonamide; N-(4-{4-[({4-[(4-methylpiperazin- 1 -yI)carbonyl]phenyllcarbamoyl)amino]phenyl}-6-morpholin-4 yI-l ,3,5-triazin-2-yI)benzenesulfonamide; N-{4-morpholin-4-yI-6-[4-({[4-(piperazin- 1 -ylcarbonyl)phenyl]carbamoyllamino)phenyl]-1,3,5 25 triazin-2-yIlbenzenesu Ifonamide; N-[4-(4-{[(4-{[4-(dimethylamino)piperidin-1 -yI]carbonyllphenyl)carbamoyl]aminolphenyl)-6 morpholin-4-y-1 ,3,5-triazin-2-yI]benzenesulfonamide; N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4-morpholin-4-yI-6-[(phenylsulfony)amino]-1,3,5 triazin-2-yIlphenyl)carbamoyl]aminolbenzamide; 30 N-[2-(dimethylamino)ethyl]-4-{[(4-{4-morpholin-4-yI-6-[(phenylsulfonyl)amino]-1 ,3,5-triazin-2 yIlphenyl)carbamoyl]aminolbenzamide; methyl 4-{[(4-{4-morpholin-4-yI-6-[(phenylsu Ifonyl)amino]- 1,3,5-triazin-2 yIlphenyl)carbamoyl]aminolbenzoate; 4-{[(4-{4-morpholin-4-yI-6-[(phenylsulfonyl)amino]-1 ,3,5-triazin-2 35 yIlphenyl)carbamoyl]aminolbenzoic acid; 1 -{4-[(4-methylpiperazin-1 -yI)carbonyl]phenyl}-3-[4-(6-morpholin-4-yI-4-oxo-4,5-dihyd ro-1,3,5 triazin-2-yI)phenyl]urea; 273 WO 2009/143313 PCT/US2009/044774 1 -(4-(2,4-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-isopropyl-2-methylpiperazine- 1 carbonyl)phenyl)urea; 5 1 -(4-(4-cyclobutyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4-isopropyl-3-methylpiperazine- 1 carbonyl)phenyl)urea; 1 -(4-(3,4-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 10 yI)phenyl)urea; 1 -(4-(4-cyclobutyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 1 -(4-(4-cyclobutylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino- 1,3,5-triazin-2 yI)phenyl)urea; 15 1 -(4-(2,4-dimethylpiperazine- 1 -ca rbo nyl)p he nyl)-3- (4-(4-mo rpholIi no-6- (tetra hyd ro-2 H-pyra n-4 yI)-l ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-isopropyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-cyclobutyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H 20 pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-isopropyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(3,4-dimethylpiperazine- 1 -ca rbo nyl)p he nyl)-3- (4-(4-mo rpholIi no-6- (tetra hyd ro-2 H-pyra n-4 yI)-l ,3,5-triazin-2-yI)phenyl)urea; 25 1 -(4-(4-cyclobutyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-cyclobutylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4 yI)-l ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4-y) 30 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H-pyran-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(3-methylpiperazine-1 carbonyl)phenyl)urea; 35 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2-methylpiperazine-1 carbonyl)phenyl)urea; 1 -(4-(3,3-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 274 WO 2009/143313 PCT/US2009/044774 1 -(4-(3,3-dimethylpiperazine- 1 -ca rbo nyl)p he nyl)-3- (4-(4-mo rpholIi no-6- (tetra hyd ro-2 H-pyra n-4 yI)-l ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-mo rpholIi no-6- (tetra hyd ro-2 H-pyra n-4-y)- 1, 3,5-tri azi n-2-yI)p he nyl)-3-(4-(3,3,4 trimethylpiperazine-1 -carbonyl)phenyl)urea; 5 1 -(4-(4,6-dimorpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(3,3,4-trimethylpiperazine-1 carbonyl)phenyl)urea; 1 -(4-(2,4-dimethylpiperazine- 1 -ca rbo nyl)p he nyl)-3- (4-(4-mo rpholIi no-6- (tetra hyd ro-2 H-pyra n-4 yI)-l ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4- (3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H-pyra n-4-y)- 1, 3,5-triazi n-2-yI)p he nyl)-3-(4-(2 10 methylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-isopropyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6 (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2-yI)p he nyl) urea; 1 -(4-(4-cyclobutyl-2-methylpiperazine-1 -ca rbo nyl)p he nyl)-3-(4- (4-(3-m ethyl mo rphoIi no)-6 (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2-yI)p he nyl) urea; 15 1 -(4-(4-isopropyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6 (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2-yI)p he nyl) urea; 1 -(4-(3,4-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-cyclobutyl-3-methylpiperazine-1 -ca rbo nyl)p he nyl)-3-(4- (4-(3-m ethyl mo rphoIi no)-6 20 (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2-yI)p he nyl) urea; 1 -(4-(4-cyclobutylpiperazine-1 -ca rbo nyl)p he nyl)-3- (4-(4-(3- methyl mo rpholIi no)-6- (tetrahyd ro-2 H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-(3- methyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4-y)- 1, 3,5-tri azi n-2-yI)p he nyl)-3-(4-(3,3,4 trimethylpiperazine-1 -carbonyl)phenyl)urea; 25 1 -(4-(3,3-dimethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; N- (2-(d im ethyla m ino)ethyl)- N-m ethyl-4- (3- (4-(4-(3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H-pyra n-4 yI)-l ,3,5-triazin-2-yI)phenyl)ureido)benzamide; N- (2-(d im ethyla m ino)ethyl)-4-(3-(4- (4-(3-m ethyl mo rphoIi no)-6- (tetra hyd ro-2 H-pyra n-4-y)-1, 3,5 30 triazin-2-yI)phenyl)ureido)benzamide; 1 -(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6 (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2-yI)p he nyl) urea; 1 -(4-(2,4-dimethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 1 ,3,5-triazin-2-yI)phenyl)urea; 35 1 -(4-(2,4-dimethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-isopropyl-2-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 275 WO 2009/143313 PCT/US2009/044774 1 -(4-(4-cyclobutyl-2-methylpiperazine-1 -ca rbo nyl)p he nyl)-3-(4-(4-(2-m ethyl mo rphoIi no)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(4-(2-methylmorpholino)-6-morpholino-1,3,5 triazin-2-yI)phenyl)u reido)benzamide; 5 1 -(4-(4-isopropyl-3-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-(2-methylmorpholino)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(3-methylpiperazine- 1 carbonyl)phenyl)urea; 1 -(4-(3,4-dimethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 10 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-cyclobutyl-3-methylpiperazine-1 -ca rbo nyl)p he nyl)-3-(4- (4-(2-m ethyl mo rphoIi no)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(3,3-dimethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 1 ,3,5-triazin-2-yI)phenyl)urea; 15 1 -(4-(4- (2-m ethyl mo rpholIi no)-6- mo rphoIi no-1, ,3,5-triazi n-2-yI)p he nyl)-3-(4-(3,3,4 trimethylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-cyclobutylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6-morpholino 1 ,3,5-triazin-2-yI)phenyl)urea; N-(2-(dimethylamino)ethyl)-4-(3-(4-(4-(2-methylmorpholino)-6-morpholino-1 ,3,5-triazin-2 20 yI)phenyl)ureido)benzamide; 1 -(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(2-methylmorpholino)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 25 1 -(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydro-2H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6 (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2-yI)p he nyl) urea; 1 -(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6- ((R)-3-m ethyl mo rphoIino)-1, ,3,5-triazi n-2 30 yI)phenyl)-3-(4-(4-methylpiperazin-1 -yI)phenyl)urea; 1 -(4-(4-(dimethylamino)piperid in-i -yI)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6 ((R)-3-m ethyl mo rphoIi no)-1, ,3,5-triazi n-2-yI) ph enyl)u rea; 1 -(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6- ((R)-3-m ethyl mo rphoIino)-1, ,3,5-triazi n-2 yI)phenyl)-3-(4-(quinuclidin-4-yI)phenyl)urea; 35 1 -(4-(4-cyclopropylpiperazin- 1 -yI)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin- 1 -yI)-6-((R)-3 methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-(cyclopropylmethyl)piperazin- 1 -yI)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6 ((R)-3-m ethyl mo rphoIi no)-1, ,3,5-triazi n-2-yI) ph enyl)u rea; 276 WO 2009/143313 PCT/US2009/044774 1 -(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6- ((R)-3-m ethyl mo rphoIino)-1, ,3,5-triazi n-2 yI)phenyl)-3-(4-(4-ethylpiperazin- 1 -yI)phenyl)urea; 1 -(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6- ((R)-3-m ethyl mo rphoIino)-1, ,3,5-triazi n-2 yI)phenyl)-3-(4-(4-isopropylpiperazin-1 -yI)phenyl)urea; 5 1 -(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6- ((R)-3-m ethyl mo rphoIino)-1, ,3,5-triazi n-2 yI)phenyl)-3-(4-(4-methylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6- ((R)-3-m ethyl mo rphoIino)-1, ,3,5-triazi n-2 yI)phenyl)-3-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 10 yI)-6-((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6- ((R)-3-m ethyl mo rphoIino)-1, ,3,5-triazi n-2 yI)phenyl)-3-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-cyclopropylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-((2R,5S)-2,5-dimethylpyrrolidin-1 -yI)-6 ((R)-3-m ethyl mo rphoIi no)-1, ,3,5-triazi n-2-yI) ph enyl)u rea; 15 1 -(4-(4-(cyclopropylmethyl)piperazine- 1 -carbonyl)phenyl)-3-(4-(4-((2R,5S)-2,5 dimethylpyrrolidin-1 -yI)-6-((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rphoIi no)-1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-methylpiperazin-1 -yI)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rphoIi no)-1, 3,5-triazi n 20 2-yI)phenyl)-3-(4-(4-(dimethylamino)piperidin-1 -yI)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rphoIi no)-1, 3,5-triazi n 2-yI)phenyl)-3-(4-(quinuclidin-4-yI)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rphoIi no)-1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-cyclopropylpiperazin-1 -yI)phenyl)urea; 25 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rphoIi no)-1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-(cyclopropylmethyl)piperazin-1 -yI)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rphoIi no)-1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-ethylpiperazin-1 -yI)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rpholIi no)-i1 3,5-triazi n 30 2-yI)phenyl)-3-(4-(4-isopropylpiperazin-i -yI)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rpholIi no)-i1 3,5-triazi n 2-yI)phenyl)-3-(4-(4-methylpiperazine-i -carbonyl)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rpholIi no)-i1 3,5-triazi n 2-yI)phenyl)-3-(4-(4-isopropylpiperazine-i -carbonyl)phenyl)urea; 35 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rpholIi no)-i1 3,5-triazi n 2-yI)phenyl)-3-(4-(4-(dimethylamino)piperidine-i -carbonyl)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rpholIi no)-i1 3,5-triazi n 2-yI)phenyl)-3-(4-(4-ethylpiperazine-i -carbonyl)phenyl)urea; 277 WO 2009/143313 PCT/US2009/044774 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rphoIi no)-1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-cyclopropylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-((2S, 5R)-2,5-bis(hyd roxymethyl)pyrro lid i n-i1 -yI)-6-((R)-3-m ethyl mo rphoIi no)-1, 3,5-triazi n 2-yI)phenyl)-3-(4-(4-(cyclopropylmethyl)piperazine- 1 -carbonyl)phenyl)urea; 5 1 -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 1 -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-3-yI)urea; I -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1I,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4-yI)urea; 1 -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)- 1,3,5-triazin-2-yI)phenyl)-3-(pyrimid in-5-yI)urea; 4-(3-(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yI)phenyl)ureido)benzamide; 10 N- (2- (d im ethyla m ino)ethyl)-4- (3-(4- (4- mo rpholIi no-6- (tetra hyd rofu ra n-3-yloxy)-1, ,3,5-triazi n-2 yI)phenyl)ureido)benzamide; N- (2-(d im ethyla m ino)ethyl)-N-m ethyl-4- (3-(4- (4- mo rpholIi no-6- (tetra hyd rofu ra n-3-yloxy)- 1, 3,5 triazin-2-yI)phenyl)ureido)benzamide; N- (2-(m ethyl am ino)eth yl)-4-(3- (4-(4-mo rpholIi no-6- (tetra hyd rofu ra n-3-yloxy)-1, ,3,5-triazi n-2 15 yI)phenyl)ureido)benzamide; N- methyl-N- (2-(m ethyla m ino)eth yl)-4- (3-(4-(4- mo rpholIi no-6- (tetra hyd rofu ra n-3-yloxy)-1, 3,5 triazin-2-yI)phenyl)ureido)benzamide; I -(4-((R)-3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6 (tetra hyd rofu ra n-3-yloxy)- 1, 3,5-tri azi n-2-yI) ph enyl) urea; 20 1 -(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 1 -(4-(4-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy) 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-ethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)- 1,3,5 25 triazin-2-yI)phenyl)urea; 1 -(4-(4-isopropylpiperazine-1 -ca rbo nyl)p he nyl)-3- (4-(4- mo rphoIi no-6- (tetra hyd rofu ra n-3-yloxy) 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-((S)-3- methyl mo rpholIi no)-6- (tetra hyd rofu ra n-3-yloxy)-1, ,3,5-triazi n-2-yI)p hen yl)-3 (pyridin-4-yI)urea; 30 1 -(4-(4-((S)-3- methyl mo rpholIi no)-6- (tetra hyd rofu ra n-3-yloxy)-1, ,3,5-triazi n-2-yI)p hen yl)-3 (pyridin-3-yI)urea ; 1 -(4-(4-((S)-3- methyl mo rpholIi no)-6- (tetra hyd rofu ra n-3-yloxy)-1, ,3,5-triazi n-2-yI)p hen yl)-3 (pyridazin-4-yI)urea; 1 -(4-(4-((S)-3- methyl mo rpholIi no)-6- (tetra hyd rofu ra n-3-yloxy)-1, ,3,5-triazi n-2-yI)p hen yl)-3 35 (pyrimidin-5-yI)urea; 4- (3-(4-(4- ((S)-3-m ethyl mo rpholIi no)-6- (tetra hyd rofu ra n-3-yloxy)- 1, 3,5-triazi n-2 yI)phenyl)ureido)benzamide; 278 WO 2009/143313 PCT/US2009/044774 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-((S)-3-methylmorpholino)-6 (tetrahydrofuran-3-yloxy)- 1,3,5-triazin-2-yl)phenyl)urea; 1 -(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran-3-yloxy)-1,3,5-triazin-2-yl)phenyl)-3-(4 (piperazine-1 -carbonyl)phenyl)urea; 5 1 -(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran-3-yloxy)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-((S)-3-methylmorpholino)-6-(tetrahydrofuran 3-yloxy)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-((S)-3-methylmorpholino)-6 10 (tetrahydrofuran-3-yloxy)- 1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4-yl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5-yl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 15 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-chlorophenyl)urea; 1-(4-(4-(1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-fluorophenyl)urea; methyl4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2yl)phenyl)ureido) benzoate; 4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)benzoic acid; 20 4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N-(2 (dimethylamino)ethyl)benzamide; 4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)-N-(2 (dimethylamino)ethyl)-N-methylbenzamide; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(3 25 (dimethylamino)pyrrolidine-1-carbonyl)phenyl)urea; 4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)benzamide; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-ethylpiperazine-1 30 carbonyl)phenyl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-isopropylpiperazine-1 carbonyl)phenyl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 (dimethylamino)piperidine-1 -carbonyl)phenyl)urea; 279 WO 2009/143313 PCT/US2009/044774 1-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 5 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 ethylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-n 10 propylpiperazine-1-carbonyl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 isopropylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 15 N-(2-(dimethylamino)ethyl)-4-(3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino 1,3,5-triazin-2-yl)phenyl)ureido)benzamide; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 20 1-(4-chlorophenyl)-3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 1-(4-fluorophenyl)-3-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 25 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4 yl)urea; 1-(4-(4-(4-methyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5 yl)urea; 30 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine- 1 carbonyl)phenyl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 35 ethylpiperazine-1-carbonyl)phenyl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-n propylpiperazine-1 -carbonyl)phenyl)urea; 280 WO 2009/143313 PCT/US2009/044774 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 isopropylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(4-ethyl-1,4-diazepan- 1-yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 5 N-(2-(dimethylamino)ethyl)-4-(3-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5 triazin-2-yl)phenyl)ureido)benzamide; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 10 1-(4-chlorophenyl)-3-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 1-(4-fluorophenyl)-3-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 15 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4-yl)urea; 1-(4-(4-(4-ethyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5-yl)urea; 1-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 20 1-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 ethylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-n 25 propylpiperazine-1-carbonyl)phenyl)urea; 1-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 isopropylpiperazine-1 -carbonyl)phenyl)urea; 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 30 N-(2-(dimethylamino)ethyl)-4-(3-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5 triazin-2-yl)phenyl)ureido)benzamide; 1-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 35 1-(4-chlorophenyl)-3-(4-(4-(4-propyl-1,4-diazepan-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 281 WO 2009/143313 PCT/US2009/044774 1 -(4-fluorophenyl)-3-(4-(4-(4-propyl- 1,4-diazepan- 1 -yI)-6-morpholino- 1,3,5-triazin-2 yI)phenyl)urea; 1 -(4-(4-(4-propyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-3-yI)urea; 1 -(4-(4-(4-propyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 5 1 -(4-(4-(4-propyl-1 ,4-d iazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4 yI)u rea; I -(4-(4-(4-propyl-1 ,4-d iazepan-1 -yI)-6-morpholino-1I,3,5-triazin-2-yI)phenyl)-3-(pyrimidin-5 yI)u rea; 1 -(4-(4-(4-isopropyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-3 10 yI)urea; 1 -(4-(4-(4-isopropyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4 yI)u rea; 1 -(4-(4-(4-isopropyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4 yI)u rea; 15 1 -(4-(4-(4-isopropyl- 1,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyrimidin-5 yI)u rea; 1 -(4-(4-(4-acetyl- 1,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridin-3-yI)urea; 1 -(4-(4-(4-acetyl- 1,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4 20 yI)urea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyrimidin-5 yI)urea; 1 -(4-(4-(4-acetyl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-phenylurea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4 25 chlorophenyl)urea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4 fi uorophenyl)u rea; Methyl-4-(3-(4-(4-(4-acetyl- 1,4-diazepan- 1-yI)-6-morpholino-1 ,3,5-triazin-2 yI)phenyl)ureido)benzoate; 30 4-(3-(4-(4-(4-acetyl-1 ,4-d iazepan-1I-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)ureido)benzoic acid; 4-(3-(4-(4-(4-acetyl-1 ,4-d iazepan- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)ureido)-N-(2 (dimethylamino)ethyl)benzamide; 4-(3-(4-(4-(4-acetyl-1 ,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)ureido)-N-(2 35 (dimethylamino)ethyl)-N-methylbenzamide; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(3 (dimethylamino)pyrrolidine-1 -carbonyl)phenyl)urea; 282 WO 2009/143313 PCT/US2009/044774 4-(3-(4-(4-(4-acetyl-1 ,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)ureido)benzamide; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4 5 ethylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-(4-acetyl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(4-(4-n propylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4 isopropylpiperazine-1 -carbonyl)phenyl)urea; 10 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 1 -(4-(4-(4-acetyl- 1,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4 (dimethylamino)piperidine-1 -carbonyl)phenyl)urea; 1 -(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-(4-isobutyryl-1 ,4-diazepan-1 -yI)-6 15 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-(4-isobutyryl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(4-(piperazine 1 -carbonyl)phenyl)urea; 1 -(4-(4-(4-isobutyryl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(4-(4 methylpiperazine-1 -carbonyl)phenyl)urea; 20 1 -(4-(4-ethylpiperazine- 1 -carbonyl)phenyl)-3-(4-(4-(4-isobutyryl- 1,4-diazepan-1 -yI)-6 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-(4-isobutyryl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(4-(4 isopropylpiperazine-1 -carbonyl)phenyl)urea; 1 -(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(4-isobutyryl-1 ,4-diazepan-1 -yI)-6 25 morpholino-1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(4-(4-isobutyryl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-phenylurea; 1 -(4-chlorophenyl)-3-(4-(4-(4-isobutyryl-1 ,4-diazepan-1 -yI)-6-morpholino-1 ,3,5-triazin-2 yI)phenyl)urea; 1 -(4-fluorophenyl)-3-(4-(4-(4-isobutyryl- 1,4-diazepan- 1 -yI)-6-morpholino- 1,3,5-triazin-2 30 yI)phenyl)urea; 1 -(4-(4-(4-isobutyryl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridin-4 yI)u rea; 1 -(4-(4-(4-isobutyryl-1 ,4-diazepan- 1 -yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4 yI)u rea; 35 1 -(4-(4-(4-isobutyryl-1 ,4-diazepan-1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyridin-3 yI)u rea; 1 -(4-(4-(4-isobutyryl-1 ,4-diazepan- 1 -yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-(pyrimidin-5 yI)u rea; 283 WO 2009/143313 PCT/US2009/044774 tert-butyl 4-(4-(4-(3-(4-(methoxycarbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2-yl) 1,4-diazepane-1-carboxylate; methyl4-(3-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl) ureido)benzoate; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 5 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-chlorophenyl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yI)phenyl)-3-(4-fluorophenyl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4-yl)urea; 10 1-(4-(4-(1,4-diazepan-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5-yl)urea; N-methyl-4-(4-morpholino-6-(4-(3-phenylureido)phenyl)-1,3,5-triazin-2-yl)-1,4-diazepane-1 carboxamide (M+H) 532.2; 4-(4-(4-(3-(4-chlorophenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2-yl)-N-methyl-1,4 diazepane-1 -carboxamide; 15 4-(4-(4-(3-(4-fluorophenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2-yl)-N-methyl-1,4 diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(2-(dimethylamino)ethylcarbamoyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5 triazin-2-yl)-N-methyl-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-((2-(dimethylamino)ethyl)(methyl)carbamoyl)phenyl)ureido)phenyl)-6-morpholino 20 1,3,5-triazin-2-yl)-N-methyl-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-carbamoylphenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2-yl)-N-methyl-1,4 diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino 1,3,5-triazin-2-yl)-N-methyl-1,4-diazepane-1 -carboxamide; 25 N-methyl-4-(4-morpholino-6-(4-(3-(4-(piperazine-1 -carbonyl)phenyl)ureido)phenyl)-1,3,5-triazin 2-yl)-1,4-diazepane-1-carboxamide; N-methyl-4-(4-(4-(3-(4-(4-methylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino 1,3,5-triazin-2-yl)-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2 30 yl)-N-methyl-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5 triazin-2-yl)-N-methyl-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5 triazin-2-yl)-N-methyl-1,4-diazepane-1 -carboxamide; 35 4-(4-(4-(3-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5 triazin-2-yl)-N-isopropyl-1,4-diazepane-1 -carboxamide; 284 WO 2009/143313 PCT/US2009/044774 N-isopropyl-4-(4-(4-(3-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino 1,3,5-triazin-2-yl)-1,4-diazepane-1 -carboxamide; 4-(4-(4-(3-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino-1,3,5-triazin-2 yl)-N-isopropyl-1,4-diazepane-1-carboxamide; 5 N-isopropyl-4-(4-(4-(3-(4-(4-methylpiperazine-1 -carbonyl)phenyl)ureido)phenyl)-6-morpholino 1,3,5-triazin-2-yl)-1,4-diazepane-1 -carboxamide; N-isopropyl-4-(4-morpholino-6-(4-(3-(4-(piperazine-1 -carbonyl)phenyl)ureido)phenyl)-1,3,5 triazin-2-yl)-1,4-diazepane-1 -carboxamide; N-isopropyl-4-(4-morpholino-6-(4-(3-pyridin-4-ylureido)phenyl)-1,3,5-triazin-2-yl)-1,4-diazepane 10 1-carboxamide; N-isopropyl-4-(4-morpholino-6-(4-(3-pyridazin-4-ylureido)phenyl)-1,3,5-triazin-2-yl)-1,4 diazepane-1 -carboxamide; N-isopropyl-4-(4-morpholino-6-(4-(3-pyrimidin-5-ylureido)phenyl)-1,3,5-triazin-2-yl)-1,4 diazepane-1 -carboxamide; 15 N-isopropyl-4-(4-morpholino-6-(4-(3-pyridin-3-ylureido)phenyl)-1,3,5-triazin-2-yl)-1,4-diazepane 1-carboxamide; 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-3-yl)urea; 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4-yl)urea; 20 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5-yl)urea; 1-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 1-(4-chlorophenyl)-3-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-fluorophenyl)-3-(4-(4-morpholino-6-(1 H-pyrazol-1 -yl)-1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(2-methyl-1 H-imidazol-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-phenylurea; 25 1-(4-chlorophenyl)-3-(4-(4-(2-methyl-1 H-imidazol-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 1-(4-fluorophenyl)-3-(4-(4-(2-methyl-1 H-imidazol-1 -yl)-6-morpholino-1,3,5-triazin-2 yl)phenyl)urea; 1-(4-(4-(2-methyl-1 H-imidazol-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea; 30 1 -(4-(4-(2-methyl-1 H-imidazol-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridazin-4 yl)urea; 1-(4-(4-(2-methyl-1 H-imidazol-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyrimidin-5 yl)urea; 1 -(4-acetylphenyl)-3-(4-(4,6-bis((R)-3-methylmorpholino)- 1,3,5-triazin-2-yl)phenyl)urea; 35 1-(4-(4,6-bis((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazin-1 -yl)phenyl)urea; 285 WO 2009/143313 PCT/US2009/044774 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 (dimethylamino)acetyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 morpholinoacetyl)phenyl)urea; 5 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 hydroxyacetyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4 (methoxymethyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 10 methoxyethyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(1 hydroxyethyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2-hydroxypropan-2 yI)phenyl)urea; 15 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2 hydroxypropyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(2-hydroxy-2 methylpropyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-(4 20 (dimethylamino)piperidine-1 -carbonyl)phenyl)urea; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(4-cyanophenyl)urea; 4-(3-(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)ureido)-N-methylbenzamide; 4- (3-(4-(4,6- bis((R)-3-m ethyl mo rphoIi no)- 1, 3,5-tri azi n-2-yI)p he nyl)u re ido)-N, N dimethylbenzamide; 25 4-(3-(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)ureido)benzamide; 1 -(4-(4,6-bis((R)-3-methylmorpholino)-1 ,3,5-triazin-2-yI)phenyl)-3-(6-(4-methylpiperazine-1 carbonyl)pyridin-3-yI)urea; (R)-1 -(4-((dimethylamino)methyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran 4-yI)-l ,3,5-triazin-2-yI)phenyl)urea; 30 (R)-1 -(4-(4-(3- methyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3 (pyridin-4-yI)urea; (R)-1 -(4-acetyl ph enyl)-3- (4- (4-(3-m ethyl mo rphoIi no)-6- (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2 yI)phenyl)urea; (R)- 1 -(4-(2-(dimethylamino)acetyl)phenyl)-3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran 35 4-yI)-l ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4- (4-(3-m ethyl mo rpholIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)- 1, 3,5-triazi n-2-yI)p he nyl)-3-(4-(2 morpholinoacetyl)phenyl)urea; 286 WO 2009/143313 PCT/US2009/044774 (R)-1 -(4-(2-hyd roxyacetyl) ph enyl)-3-(4- (4-(3-m ethyl mo rphoi no)-6- (tetra hyd ro-2 H- pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(m ethoxym ethyl)p he nyl)-3-(4- (4-(3-m ethyl mo rphoi no)-6-(tetrahyd ro-2 H-pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; 5 (R)-1 -(4-(2- methoxyeth yl) ph enyl)-3- (4-(4-(3- methyl mo rphoi no)-6-(tetra hyd ro-2 H- pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(l1 -hyd roxyethyl)p he nyl)-3-(4- (4- ((R)-3- methyl mo rpholIi no)-6-(tetra hyd ro-2 H-pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(2-hyd roxyp ro pa n-2-yI)p he nyl)-3- (4-(4-(3-m ethyl mo rphoIi no)-6-(tetra hyd ro-2 H- pyra n-4 10 yI)-l ,3,5-triazin-2-yI)phenyl)urea; 1 -(4-(2-hyd roxyp ro pyl) ph enyl)-3-(4- (4-((R)-3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H-pyra n-4-y) 1 ,3,5-triazin-2-yI)phenyl)urea; (R)-1 -(4-(2-hyd roxy-2- methyl pro pyl)p he nyl)-3-(4- (4-(3-m ethyl mo rphoIi no)-6-(tetra hyd ro-2 H pyran-4-yI)- 1,3,5-triazin-2-yI)phenyl)urea; 15 (R)-1 -(4-(4-(dimethylamino)piperidine-i -ca rbo nyl)p he nyl)-3-(4-(4-(3-m ethyl mo rphoIi no)-6 (tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-tri azi n-2-yI)p he nyl) urea; (R)-1 -(4-cya no ph enyl)-3- (4-(4-(3- methyl mo rphoin o)-6-(tetra hyd ro-2 H-pyra n-4-y)-1, ,3,5-triazi n-2 yI)phenyl)urea; (R)- N-m ethyl-4-(3-(4- (4-(3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H-pyra n-4-y)- 1, 3,5-tri azi n-2 20 yI)phenyl)ureido)benzamide; (R)-N, N-d im ethyl-4-(3- (4- (4-(3-m ethyl mo rpholIi no)-6- (tetra hyd ro-2 H-pyra n-4-y)-1, ,3,5-triazi n-2 yI)phenyl)ureido)benzamide; (R)-4-(3-(4-(4-(3-methylmorpholino)-6-(tetrahydro-2H-pyran-4-y)- 1,3,5-triazin-2 yI)phenyl)ureido)benzamide; 25 (R)-1 -(4- (4-(3-m ethyl mo rphoIi no)-6-(tetra hyd ro-2 H- pyra n-4-y)-1, ,3,5-triazi n-2-yI)p he nyl)-3-(6-(4 methylpiperazine-1 -carbonyl)pyridin-3-yI)urea; 1 -(4-(4-(3-methyl-1 H-pyrazol- 1 -yI)-6-morpholi no-1, ,3,5-triazi n-2-yI)phenyl)-3-(pyri mid in-5-yI)u rea; 1 -(4-(4-(3-methyl-1 H-pyrazol- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-3-yI)urea; 1 -(4-(4-(3-methyl-1 H-pyrazol- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridin-4-yI)urea; 30 1 -(4-(4-(3-methyl-1 H-pyrazol- 1-yI)-6-morpholino-1 ,3,5-triazin-2-yI)phenyl)-3-(pyridazin-4-yI)urea; 1 -(4-(4-(3-methyl- 1 H-pyrazol- 1-yI)-6-morpholino- 1,3,5-triazin-2-yI)phenyl)-3-phenylurea; 1 -(4-chlorophenyl)-3-(4-(4-(3-methyl-1 H-pyrazol-1 -yI)-6-morpholino- 1,3,5-triazin-2 yI)phenyl)urea; 1 -(4-fluorophenyl)-3-(4-(4-(3-methyl- 1 H-pyrazol-1 -yI)-6-morpholino- 1,3,5-triazin-2 35 yI)phenyl)urea; methyl 4-(3- (4-(4- (3-m ethyl- 1 H-pyrazol-1 -yI)-6-morpholino- 1,3,5-triazin-2 yI)phenyl)ureido)benzoate; 287 WO 2009/143313 PCT/US2009/044774 4-(3-(4-(4-(3-methyl-1 H-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)benzoic acid; 4-(3-(4-(4-(3-methyl-1 H-pyrazol-1 -yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)ureido)benzamide; 1-(4-(3-(dimethylamino)pyrrolidine-1 -carbonyl)phenyl)-3-(4-(4-(3-methyl-1 H-pyrazol-1 -yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 5 1-(4-(4-(3-methyl-1 H-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(piperazine-1 carbonyl)phenyl)urea; 1-(4-(4-(3-methyl-1 H-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4 methylpiperazine-1-carbonyl)phenyl)urea; 1-(4-(4-ethylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methyl-1 H-pyrazol-1 -yl)-6-morpholino 10 1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-isopropylpiperazine-1 -carbonyl)phenyl)-3-(4-(4-(3-methyl-1 H-pyrazol-1 -yl)-6-morpholino 1,3,5-triazin-2-yl)phenyl)urea; 1-(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(4-(3-methyl-1 H-pyrazol-1 -yl)-6 morpholino-1,3,5-triazin-2-yl)phenyl)urea; 15 1-{4-[(4-butylpiperazin-1-yl)carbonyl]phenyl}-3-(4-{4-[4-(1-methylethyl)-1,4-diazepan-1-yl]-6 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)urea; 1 -(4-{4-[4-(1 -methylethyl)- 1,4-diazepan-1 -yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)-3-(4-{[4 (1 -methylethyl)piperazin-1 -yl]carbonyl}phenyl)urea; 1 -{4-[(4-ethylpiperazin-1 -yl)carbonyl]phenyl}-3-(4-{4-[4-(1 -methylethyl)-1,4-diazepan-1 -yl]-6 20 morpholin-4-yl-1,3,5-triazin-2-yl}phenyl)urea; 1 -{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4 yl)-1,3,5-triazin-2-yl]phenyl}urea; 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea; 25 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5 triazin-2-yl)phenyl]urea; 1-(4-{[4-(1 -methylethyl)piperazin-1 -yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6-(tetrahydro-2H pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-[({4-[4-morpholin-4-yl-6-(tetrahydro-2H-pyran-4-yl)-1,3,5 30 triazin-2-yl]phenyl}carbamoyl)amino]benzamide; 1 -{4-[4-(azetidin-3-yloxy)-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl}-3-pyridin-4-ylurea; N-(1 -methylethyl)-3-[(4-morpholin-4-yl-6-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-1,3,5-triazin 2-yl)oxy]azetidine-1 -carboxamide; N-{1 -[(4-{[(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]-1,3,5-triazin-2 35 yl}phenyl)carbamoyl]amino}phenyl)carbonyl]piperidin-4-yl}acetamide; 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-(4-{[4-(1 -methylethyl)-1,4 diazepan-1 -yl]carbonyl}phenyl)urea; 288 WO 2009/143313 PCT/US2009/044774 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-[4-(3-oxa-8 azabicyclo[3.2. 1 ]oct-8-ylcarbonyl)phenyl]urea; 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-{4-[(4-cyanopiperidin-1 yl)carbonyl]phenyl}urea; 5 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-(4-{[(3S)-3 (dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)urea; 1 -(4-{4,6-bis[(3S)-3-methylmorpholin-4-yl]- 1,3,5-triazin-2-yl}phenyl)-3-(4-{[(3R)-3 (dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)urea; 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-(4-{4-(morpholin-4-yl)-6-[4 10 (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-(4-{4-(morpholin-4-yl)-6-[4 (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-{4-[(2-methylpiperazin-1 yl)carbonyl]phenyl}urea; 15 1-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)-3-[4 (piperazin-1 -ylcarbonyl)phenyl]urea; 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-(4-{4-(morpholin-4-yl)-6-[4 (propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-{4-[(3,3,4-trimethylpiperazin-1 20 yl)carbonyl]phenyl}urea; 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-(4-{[(3R)-3-methylpiperazin- 1 yl]carbonyl}phenyl)urea; 1-(4-{[(3R)-3,4-dimethylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin 2-yl]phenyl}urea; 25 1 -(4-{[(3R)-4-cyclobutyl-3-methylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl) 1,3,5-triazin-2-yl]phenyl}urea; 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-(4-{[(3R)-3-methyl-4-(propan-2 yl)piperazin-1 -yl]carbonyl}phenyl)urea; 1 -{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-(4-{[(3S)-3-methylpiperazin-1 30 yl]carbonyl}phenyl)urea; N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-[4-(propan-2-yl) 1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; 1 -(4-{4-[(3S)-3-methylmorpholin-4-yl]-6-[4-(propan-2-yl)- 1,4-diazepan-1 -yl]-1,3,5-triazin-2 yl}phenyl)-3-{4-[(4-methylpiperazin-1 -yl)carbonyl]phenyl}urea; 35 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-(4-{4-[(3S)-3-methylmorpholin-4 yl]-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; N-[3-(dimethylamino)propyl]-4-{[(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl] 1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; 289 WO 2009/143313 PCT/US2009/044774 N-[2-(dimethylamino)ethyl]-N-methyl-4-{[(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan 1-yl]-1,3,5-triazin-2-yl}phenyl)carbamoyl]amino}benzamide; 1-[4-(morpholin-4-ylcarbonyl)phenyl]-3-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 yl]-1,3,5-triazin-2-yl}phenyl)urea; 5 N-(2-methoxyethyl)-4-{[(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin 2-yl}phenyl)carbamoyl]amino}benzamide; 1-[4-(1,4-diazepan-1 -ylcarbonyl)phenyl]-3-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4 diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)urea; 1-(4-{4-(morpholin-4-yl)-6-[4-(propan-2-yl)-1,4-diazepan-1 -yl]-1,3,5-triazin-2-yl}phenyl)-3-(4-{[4 10 (propan-2-yl)-1,4-diazepan-1 -yl]carbonyl}phenyl)urea; 1-(4-{[(3S)-4-cyclobutyl-3-methylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl) 1,3,5-triazin-2-yl]phenyl}urea; 1-(4-{[(3S)-3,4-dimethylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4,6-di(morpholin-4-yl)-1,3,5-triazin 2-yl]phenyl}urea; 15 1 -{4-[4-(morpholin-4-yl)-6-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}-3-{4-[(3,3,4 trimethylpiperazin-1 -yl)carbonyl]phenyl}urea; 1-(4-{[(3S)-3,4-dimethylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4-(morpholin-4-yl)-6-(tetrahydro 2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; 1-(4-{[(3S)-3-methylpiperazin-1 -yl]carbonyl}phenyl)-3-{4-[4-(morpholin-4-yl)-6-(tetrahydro-2H 20 pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; 1-(4-{[(3R)-3-(dimethylamino)pyrrolidin-1 -yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea; and 1-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-3-{4-[4-morpholin-4-yl-6 (tetrahydro-2H-pyran-4-yl)-1,3,5-triazin-2-yl]phenyl}urea. 25
13. The compound of claim 12, which is 1-(4-{[4-(dimethylamino)piperidin-1 yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea.
14. A composition comprising a compound of any one of claims 1-13 and a pharmaceutically acceptable carrier.
15. The composition of claim 14, wherein the pharmaceutically acceptable carrier 30 suitable for oral administration and the composition comprises an oral dosage form. 290 WO 2009/143313 PCT/US2009/044774
16. A composition comprising a compound of any one of claims 1-13; a second compound selected from the group consisting of a topoisomerase I inhibitor, a MEK 1/2 inhibitor, a HSP90 inhibitor, procarbazine, dacarbazine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, 5 hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epirubicin, 5-fluorouracil, docetaxel, paclitaxel, leucovorin, levamisole, irinotecan, estramustine, etoposide, 10 nitrogen mustards, BCNU, carmustine, lomustine, vinblastine, vincristine, vinorelbine, cisplatin, carboplatin, oxaliplatin, imatinib mesylate, Avastin (bevacizumab), hexamethylmelamine, topotecan, tyrosine kinase inhibitors, tyrphostins, herbimycin A, genistein, erbstatin, hydroxyzine, glatiramer acetate, interferon beta-1a, interferon beta-1b, natalizumab and lavendustin A; and a 15 pharmaceutically acceptable carrier.
17. The composition of claim 16, wherein the second compound is Avastin.
18. A method of treating a P13K-related disorder or an mTOR-related disorder, comprising administering to a mammal in need thereof a compound of any one of claims 1-13 in an amount effective to treat a P13K-related disorder. 20
19. The method of claim 18, wherein the P13K-related disorder or the mTOR-related disorder is selected from restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, and cancer. 25
20. The method of claim 19, wherein the P13K-related disorder or the an mTOR related disorder is cancer.
21. The method of claim 20, wherein the cancer is selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal 30 cancer, gastric cancer, and brain cancer. 291 WO 2009/143313 PCT/US2009/044774
22. A method of treating advanced renal cell carcinoma, acute lymphoblastic leukemia, acute malignant melanoma, or soft-tissue or bone sarcoma, comprising administering to a mammal in need thereof a compound of any one of claims 1-13 in an amount effective to treat advanced renal cell carcinoma, acute 5 lymphoblastic leukemia, acute malignant melanoma, or soft-tissue or bone sarcoma.
23. A method of treating a cancer selected from the group consisting of leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric 10 cancer, and brain cancer comprising administering to a mammal in need thereof the composition of claim 17 in an amount effective to treat the cancer.
24. A method of inhibiting mTOR, P13K, and hSMG-1 together in a subject, comprising administering to a subject in need thereof a compound of any one of claims 1-13 in an amount effective to inhibit mTOR, P13K, and hSMG-1. 15
25. A method of making a compound of claim 1 having the formula R 7 0 R 8 R6 N R 9 N N said method comprising: a) reacting 2,4,6-trichloro[1,3,5]triazine with R 7 0 R 8 R6 N R 9 H 292 WO 2009/143313 PCT/US2009/044774 to form the intermediate dichlorotriazine compound R 7 0 R 8 R N R 9 N N Cl N Cl b) reacting the intermediate dichlorotriazine compound from step a) with R 7 0 R 8 R6 N R 9 H 5 to form the intermediate compound R 7 0 R 8 R N R 9 N N R Cl N N) 0 R 9 R 8 c) reacting the intermediate from step b) with: i) a compound of formula R 2 -B(OH) 2 or ester thereof wherein R 2 is as defined in claim 1 to give a compound of formula 1, or 293 WO 2009/143313 PCT/US2009/044774 ii) an aminoaryl or aminoheteroaryl boronic acid or ester thereof and converting the amino group to a urea of formula 1.
26. The method of claim 25 wherein the reacting moiety R 7 0 R 8 R6 N R 9 H 5 is N 294
AU2009248993A 2008-05-23 2009-05-21 Triazine compounds as PI3 kinase and mTOR inhibitors Active AU2009248993C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5566108P 2008-05-23 2008-05-23
US61/055,661 2008-05-23
PCT/US2009/044774 WO2009143313A1 (en) 2008-05-23 2009-05-21 Triazine compounds as p13 kinase and mtor inhibitors

Publications (3)

Publication Number Publication Date
AU2009248993A1 true AU2009248993A1 (en) 2009-11-26
AU2009248993B2 AU2009248993B2 (en) 2011-07-07
AU2009248993C1 AU2009248993C1 (en) 2013-10-03

Family

ID=40911929

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009248993A Active AU2009248993C1 (en) 2008-05-23 2009-05-21 Triazine compounds as PI3 kinase and mTOR inhibitors
AU2009248997A Abandoned AU2009248997A1 (en) 2008-05-23 2009-05-21 Triazine compounds as PI3 kinase and mTOR inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009248997A Abandoned AU2009248997A1 (en) 2008-05-23 2009-05-21 Triazine compounds as PI3 kinase and mTOR inhibitors

Country Status (44)

Country Link
US (8) US20090304692A1 (en)
EP (3) EP2300483A1 (en)
JP (2) JP4948677B2 (en)
KR (1) KR101331341B1 (en)
CN (2) CN104230831B (en)
AP (2) AP2010005452A0 (en)
AR (2) AR071908A1 (en)
AU (2) AU2009248993C1 (en)
BR (1) BRPI0912294B8 (en)
CA (2) CA2721692C (en)
CL (2) CL2009001273A1 (en)
CO (1) CO6311070A2 (en)
CR (1) CR11757A (en)
CU (1) CU23887B1 (en)
CY (2) CY1118879T1 (en)
DK (2) DK2294072T3 (en)
DO (1) DOP2010000315A (en)
EA (1) EA020317B1 (en)
EC (2) ECSP10010624A (en)
ES (2) ES2625467T3 (en)
GE (1) GEP20125589B (en)
HK (2) HK1157328A1 (en)
HR (2) HRP20170637T1 (en)
HU (1) HUE043331T2 (en)
IL (2) IL209061A0 (en)
LT (2) LT3216793T (en)
MA (1) MA32319B1 (en)
ME (1) ME01111B (en)
MX (1) MX2010012808A (en)
MY (1) MY155653A (en)
NI (1) NI201000198A (en)
NZ (1) NZ588526A (en)
PA (2) PA8828101A1 (en)
PE (2) PE20091957A1 (en)
PL (1) PL3216793T3 (en)
PT (2) PT3216793T (en)
RS (2) RS55960B1 (en)
SA (1) SA109300314B1 (en)
SI (2) SI3216793T1 (en)
TR (1) TR201906123T4 (en)
TW (2) TW201008949A (en)
UA (1) UA99361C2 (en)
WO (2) WO2009143313A1 (en)
ZA (1) ZA201007204B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036963B (en) 2008-05-23 2013-08-21 诺瓦提斯公司 Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
ME01111B (en) * 2008-05-23 2013-03-20 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
US10022381B2 (en) * 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
TW201038567A (en) 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
UY32582A (en) 2009-04-28 2010-11-30 Amgen Inc 3 KINASE PHOSPHINOSITI INHIBITORS AND / OR MAMMAL OBJECTIVE
EP3072890B1 (en) 2009-07-07 2018-10-17 MEI Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
MX2012001974A (en) * 2009-08-19 2012-04-11 Ambit Biosciences Corp Biaryl compounds and methods of use thereof.
US8697691B2 (en) * 2009-12-21 2014-04-15 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
EA201290876A1 (en) 2010-03-05 2013-03-29 Президент Энд Феллоуз Оф Гарвард Колледж COMPOSITIONS OF INDUCED DENDRITIC CELLS AND THEIR USE
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
WO2012101654A2 (en) * 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds
EA201300867A1 (en) * 2011-01-27 2014-03-31 Дзе Трастиз Оф Принстон Юнивесити MTOR KINASE INHIBITORS AS ANTI-VIRUS AGENTS
BR112013020329A2 (en) * 2011-02-09 2016-08-02 Hoffmann La Roche heterocyclic compounds as pi3 kinase inhibitors
ES2608967T3 (en) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralkylamino substituted in alpha and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in the treatment of proliferative diseases
CN102250065B (en) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 Substituted triazine phenyl urea derivatives and application thereof
CN102887867B (en) * 2011-07-21 2015-04-15 中国科学院上海药物研究所 Triazine compound and preparation method and application of triazine compound
US9175011B2 (en) 2011-09-21 2015-11-03 Cellzone Limited Morpholino substituted urea or carbamate derivatives as MTOR inhibitors
KR20140084130A (en) 2011-10-07 2014-07-04 셀좀 리미티드 Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors
CN102659765B (en) * 2011-12-31 2014-09-10 沈阳药科大学 Pyrimidine and triazine compound preparation method and application
BR112014028881A2 (en) 2012-05-23 2017-06-27 Hoffmann La Roche cell populations, cell bank, methods of obtaining a cell population, methods of identifying a factor, selection methods, methods of providing therapy, hepatocyte populations, and method of obtaining cells.
WO2014005182A1 (en) * 2012-07-04 2014-01-09 Monash University Phosphoinositide 3-kinase (pi3k) inhibitors
IN2015DN01408A (en) * 2012-07-23 2015-07-03 Sphaera Pharma Pte Ltd
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
MX2016012009A (en) 2014-03-14 2016-12-05 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same.
WO2016049774A1 (en) * 2014-10-03 2016-04-07 The Royal Institution For The Advancement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
CN107106685A (en) 2014-10-10 2017-08-29 辉瑞公司 Cooperate with the auspicious statin combination of Australia
JP6695875B2 (en) 2014-11-20 2020-05-20 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ Novel 1,3,5-triazine PI3K inhibitor as anticancer agent and method for producing the same
SG11201703826TA (en) * 2014-12-17 2017-07-28 Pfizer Formulations of a pi3k/mtor-inhibitor for intravenous administration
CN104725361B (en) * 2015-04-09 2017-05-31 江苏富比亚化学品有限公司 A kind of preparation method of hindered amine light stabilizer 3346
RU2737085C2 (en) 2016-05-12 2020-11-24 Наньцзин Шици Фармасьютикал Ко. Лтд. Novel 2,4,6-trisubstituted s-triazine compound, a method for production thereof and use thereof
KR102472461B1 (en) 2016-05-18 2022-11-30 토르쿠르 아게 treatment of neurological disorders
JOP20190254A1 (en) 2017-04-27 2019-10-27 Pharma Mar Sa Antitumoral compounds
IT201700047189A1 (en) * 2017-05-02 2018-11-02 Fondazione St Italiano Tecnologia COMPOUNDS AND COMPOSITIONS FOR CANCER TREATMENT, RETINAL DISORDERS AND CARDIOMYOPATHIES
CN117860758A (en) 2017-05-23 2024-04-12 梅制药公司 Combination therapy
CA3072476A1 (en) 2017-08-14 2019-02-21 Mei Pharma, Inc. Combination therapy
HRP20211985T1 (en) * 2017-08-25 2022-04-01 Pfizer Inc. Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN108191837A (en) * 2018-01-10 2018-06-22 贵州医科大学 PI3K α/mTOR bidifly enzyme inhibitors and its pharmaceutical composition and application
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
KR102022323B1 (en) * 2018-03-30 2019-09-18 정하윤 Triazine Compound And Use Thereof
SG11202011256RA (en) 2018-06-07 2020-12-30 Pfizer Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
JPWO2020130125A1 (en) 2018-12-21 2021-11-04 第一三共株式会社 Combination of antibody-drug conjugate and kinase inhibitor
CN109942562B (en) * 2019-02-27 2022-02-08 江西科技师范大学 Five-membered heterocyclic diazine compound containing aryl structure and preparation method and application thereof
CA3163680A1 (en) 2019-12-05 2021-06-10 David John O'neill Rapamycin analogs and uses thereof
WO2021207024A1 (en) * 2020-04-07 2021-10-14 Mei Pharma, Inc. Preparation of a 1,3,5-triazinyl benzimidazole
KR20220138575A (en) 2021-04-06 2022-10-13 부산대학교병원 Method for screening drugs for the treatment or prevention of translocation Renal Cell Carcinoma
CN113200969B (en) * 2021-05-19 2022-11-25 中国药科大学 PI3K alpha selective inhibitor and preparation method and application thereof
CA3227191A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
CN115109049B (en) * 2022-08-12 2023-08-15 江西科技师范大学 Triazine compound containing aryl urea structure and application thereof
CN115557908A (en) * 2022-09-28 2023-01-03 九江学院 Triazine derivative containing sulfur connecting bond and synthesis method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1129597C (en) * 1997-07-24 2003-12-03 全药工业株式会社 Heterocyclic compounds and antitumor agent containing the same as active ingredient
CN1290264A (en) * 1997-12-12 2001-04-04 艾博特公司 Triazine angiogenesis inhibitors
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP1877388A2 (en) * 2005-02-25 2008-01-16 Kudos Pharmaceuticals Ltd Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
JP5534811B2 (en) * 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ Morpholinopyrimidine derivatives useful for the treatment of proliferative diseases
ME01111B (en) * 2008-05-23 2013-03-20 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors

Also Published As

Publication number Publication date
HK1157328A1 (en) 2012-06-29
JP4948677B2 (en) 2012-06-06
CN102036995A (en) 2011-04-27
MY155653A (en) 2015-11-13
MX2010012808A (en) 2010-12-21
MA32319B1 (en) 2011-05-02
SI2294072T1 (en) 2017-05-31
CA2721692C (en) 2014-01-14
GEP20125589B (en) 2012-07-25
TR201906123T4 (en) 2019-05-21
KR20110002485A (en) 2011-01-07
TWI389906B (en) 2013-03-21
PA8828201A1 (en) 2009-12-16
DK2294072T3 (en) 2017-05-15
DK3216793T3 (en) 2019-05-06
CN104230831A (en) 2014-12-24
CU23887B1 (en) 2013-04-19
TW201011010A (en) 2010-03-16
BRPI0912294B1 (en) 2019-11-12
JP2011522802A (en) 2011-08-04
PE20091943A1 (en) 2009-12-19
US8217036B2 (en) 2012-07-10
PA8828101A1 (en) 2009-12-16
CU20100229A7 (en) 2011-11-15
RS55960B1 (en) 2017-09-29
CY1121699T1 (en) 2020-07-31
AU2009248997A1 (en) 2009-11-26
US20090304692A1 (en) 2009-12-10
EP3216793A1 (en) 2017-09-13
EA201071232A1 (en) 2011-06-30
IL209060A0 (en) 2011-01-31
US20090291079A1 (en) 2009-11-26
EP2294072A1 (en) 2011-03-16
AU2009248993B2 (en) 2011-07-07
WO2009143317A1 (en) 2009-11-26
EP2300483A1 (en) 2011-03-30
PT3216793T (en) 2019-05-30
ECSP10010623A (en) 2010-12-30
US8445486B2 (en) 2013-05-21
US20130315865A1 (en) 2013-11-28
AP2010005453A0 (en) 2010-12-31
CL2009001274A1 (en) 2009-10-16
ECSP10010624A (en) 2010-12-30
US20150011752A1 (en) 2015-01-08
CO6311070A2 (en) 2011-08-22
US8859542B2 (en) 2014-10-14
US8575159B2 (en) 2013-11-05
EP3216793B1 (en) 2019-03-27
UA99361C2 (en) 2012-08-10
CR11757A (en) 2010-11-30
HRP20190680T1 (en) 2019-06-14
ES2625467T3 (en) 2017-07-19
TW201008949A (en) 2010-03-01
CN104230831B (en) 2016-08-24
AP2010005452A0 (en) 2010-12-31
US20110312955A1 (en) 2011-12-22
JP2011520979A (en) 2011-07-21
CL2009001273A1 (en) 2009-11-27
BRPI0912294A2 (en) 2015-10-20
LT3216793T (en) 2019-05-10
HRP20170637T1 (en) 2017-06-30
NI201000198A (en) 2011-05-09
ES2728163T3 (en) 2019-10-22
SA109300314B1 (en) 2012-09-26
HK1203199A1 (en) 2015-10-23
HUE043331T2 (en) 2019-08-28
WO2009143313A1 (en) 2009-11-26
RS58724B1 (en) 2019-06-28
EP2294072B1 (en) 2017-03-29
IL209060A (en) 2014-05-28
AP2775A (en) 2013-09-30
SI3216793T1 (en) 2019-06-28
LT2294072T (en) 2017-06-12
KR101331341B1 (en) 2013-11-19
AU2009248993C1 (en) 2013-10-03
AR071909A1 (en) 2010-07-21
DOP2010000315A (en) 2010-12-15
US20140248239A1 (en) 2014-09-04
US20130005723A1 (en) 2013-01-03
CN102036995B (en) 2014-09-17
CY1118879T1 (en) 2018-01-10
US20130109670A1 (en) 2013-05-02
CA2721692A1 (en) 2009-11-26
US8039469B2 (en) 2011-10-18
PT2294072T (en) 2017-05-29
US8748421B2 (en) 2014-06-10
CA2721710A1 (en) 2009-11-26
IL209061A0 (en) 2011-01-31
BRPI0912294B8 (en) 2021-05-25
PL3216793T3 (en) 2019-09-30
AR071908A1 (en) 2010-07-21
EA020317B1 (en) 2014-10-30
ME01111B (en) 2013-03-20
PE20091957A1 (en) 2009-12-30
US9174963B2 (en) 2015-11-03
ZA201007204B (en) 2011-12-28
NZ588526A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
AU2009248993C1 (en) Triazine compounds as PI3 kinase and mTOR inhibitors
CA2755554A1 (en) Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US10022381B2 (en) Triazine compounds as PI3 kinase and mTOR inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 JUN 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 JUN 2013